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 Abstract  
Background 
The impact of locally recurrent rectal cancer (LRRC) on health-related quality of life (HrQoL) is 
poorly understood. The overall aim of the project was to develop and validate a patient reported 
outcome measure (PROM) to assess HrQoL in LRRC in patients in the UK and Australia. This thesis 
reports on the initial development of the LRRC-QoL and the results from the interim psychometric 
analysis from the UK cohort.  
Methods 
An international, three phase, mixed methodological study was conducted. Phase I consisted of two 
systematic reviews and a qualitative study consisting of a series of focus groups. Phase II consisted of 
the development and pre-testing of the provisional PROM; The Locally Recurrent Rectal Cancer 
Quality of Life Measure (The LRRC-QoL). Phase III assessed the psychometric properties of the 
LRRC-QoL including scale structure, reliability and validity.  
Results 
Phase I: Relevant HrQoL themes were identified; symptoms, sexual function, psychological impact, 
role functioning, healthcare services, future perspective.  These themes were operationalised into a 
conceptual framework and reviewed by an expert panel prior to the development of a provisional 
version of the LRRC-QoL.  
Phase II: A total of 27 cognitive interviews were undertaken to pre-test the LRRC-QoL. The measure 
underwent three revisions in both population cohorts. The final version of the LRRC-QoL ready for 
psychometric testing consisted of 32 questions organised into 5 scales. 
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Phase III:  Eighty patients participated in the UK validation study. The final scale structure consisted 
of healthcare services, psychological impact, sexual function, pain, urostomy-related symptoms, lower 
limb symptoms, stoma related issues, sexual interest and urinary symptoms.   
The reliability of the LRRC-QoL was good, with Cronbach’s Alpha and Intraclass correlation values 
of >0.7 for the majority of the scales. The LRRC-QoL was unable to demonstrate the properties of 
convergent validity and known-groups comparison sufficiently. 
Conclusions 
The LRRC-QoL is the first measure to be developed exclusively in patients with LRRC. The scale 
structure of the LRRC-QoL is robust. Further work is required including the completion of the 
psychometric validation in Australia and the confirmation of reliability and validity in an independent 
sample.  
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1 Chapter One – Introduction  
 
1.1 Introduction 
 
The period between the 1980s and the early 2000s witnessed improvements in the surgical technique 
and the use of multimodal treatments in the management of primary rectal cancer. The success of 
these advances translated clinically as a reduction in the incidence of local (pelvic) recurrence of 
rectal cancer from 30-40% to 5-10%[1-4].  Unsurprisingly, attention has since been directed towards 
advancing the surgical management of locally recurrent rectal cancer (LRRC). It is estimated that 
approximately 700 patients present each year within the UK with LRRC, of which 50% of patients 
will be suitable for surgical resection [5]. These small but significant numbers of patients represent a 
significant challenge to the National Health Service (NHS) with regards to optimal treatment and 
management strategies. As a consequence a number of international bodies have pooled together their 
expertise to develop international guidelines to inform the clinical decision-making in this cohort of 
patients [6, 7].  
 
1.2 Locally Recurrent Rectal Cancer 
 
Local recurrence following previous ‘curative’ resection of primary rectal cancer is defined as 
‘tumour recurrence in the previous operative field within the pelvis’ [8, 9]. The majority of local 
recurrences present within the first 3 years of the primary surgery [10]. A third of recurrences are 
asymptomatic and are detected during routine post-operative follow up examination. Pelvic pain, 
rectal bleeding, discharge, change in bowel habit and non-healing perineal wounds may all be 
symptoms of recurrent disease.  It is estimated up to 50% of patients with local recurrence present 
with synchronous metastatic disease. 
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1.2.1 Classification 
 
Pelvic recurrences following rectal cancer have been categorised according to their anatomical 
location by a number of authors. The Leeds group defined pelvic recurrences as central (confined to 
pelvic organs without bony involvement), sidewall (involving pelvic sidewall structures), sacral 
(abutting onto or involving the sacrum), or composite (involving sacral and sidewall structures) [8]. 
The Mayo Clinic described recurrence in terms of degree of fixation both in terms of site (anterior, 
sacral, right or left) and number of points of fixation (F0-3) [11]. The Memorial Sloan Kettering 
group classified recurrences as axial (anastomotic recurrence after low anterior resection, perineal 
recurrence following APR and local recurrence following transanal excision), anterior (involving 
urological and/or gynaecological structures), posterior (involving the sacrum and/or coccyx) and 
lateral (involving pelvic sidewall structures) [12]. Wanebo et al based their classification of local 
recurrence upon the UICC TNM system; with TR1 and TR2 tumours corresponding to intraluminal 
recurrences following local excision or at the anastomosis, TR3 corresponding to recurrence at or 
around the level of the anastomosis with limited extramural spread and without pelvic fixation; TR4 
corresponds to invasion into either adjacent urogenital structures or presacral tissues with tethering 
but no fixation and TR5 corresponding to invasion into the sacrum or pelvic sidewall [13]. For the 
purposes of this thesis all patients will be classified in accordance with the anatomical location of 
their disease recurrence; anterior (involving the urogenital organs), posterior (involving the sacrum 
and/or coccyx), central (involving the neo-rectum or rectal stump) and lateral (involving the pelvic 
sidewall structures).  
 
1.2.2 Treatment  
 
Treatment strategies are complex in LRRC, with treatment decisions often following on from the 
treatment strategy received during the treatment of the primary rectal cancer. A multimodal approach, 
including surgery, chemotherapy and radiotherapy, is often incorporated in the management of LRRC 
following multidisciplinary team meeting. Although, there are no formal guidelines on the 
16 
management of LRRC, The Beyond TME collaborative group, consisting of surgeons, oncologists, 
radiologists and pathologists, published a consensus statement on best clinical practice in this cohort 
of patients. This consensus statement included algorithms to help guide management (Figures 1.1 and 
1.2). 
The treatment decisions in this cohort of patients are often complex, and require a multidisciplinary 
approach, with appropriate input from surgeons (colorectal, urologists, gynaecologists and plastics), 
radiologists, oncologists and palliative care medicine physicians. Current National Institute of Health 
and Care Excellence only outline the role of MDTs in the management of patients with metastatic 
colorectal cancer, with no specific recommendations for the discussion of LRRC within this forum 
[14]. Previous works on the role of the MDT in recurrent disease for oesophageal cancer identified 
that a smaller than expected number of patients were being referred for further discussion. However, 
of those who were referred for further discussion active management in the form of palliative 
chemotherapy +/- radiotherapy, oesophageal stenting or surgery was offered to over fifty per cent of 
patients. The role and importance of MDTS is amplified in difficult disease settings, such as LRRC, 
where treatment decisions can be complex, with a variety of potential options available and where 
treatment goals can range from cure to best supportive care. There is limited research on the role of 
MDTs specifically in LRRC, however, Kontovounisios et al reported improved patient selection for 
surgery and consequently improved clinical and surgical outcomes for locally advanced and recurrent 
rectal cancer, when patients were discussed in a dedicated specialist MDT at a tertiary referral centre. 
The importance of MDT discussion for locally advanced and recurrent colorectal cancer has recently 
been acknowledged by the Association of Coloproctology of Great Britain and Ireland, and has 
identified this as a key area for improvement, with a view to developing an advanced cancer MDT.  
 
Surgery 
The aims of operative intervention are primarily to achieve cure, with a curative R0 resection 
achieved in 40-50% of patients undergoing surgery [15]. In select circumstances operative 
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intervention may be reserved to achieve palliation with treatment aims based on symptom control, 
prolongation of life and improvement of health-related quality of life (HrQoL).  
Curative Surgery  
The main aim of curative surgery in LRRC is to obtain a negative (R0) resection margin. A R0 
resection margin confers optimal survival benefit in this cohort of patients when compared to a 
microscopically (R1) or macroscopically (R2) positive margin [15].  
Traditionally, there have been a number of absolute and relative contraindications to surgery. The 
absolute contraindications include the presence of unresectable metastatic disease and frailty 
precluding general anaesthesia. Relative contraindications include high sacral involvement above the 
level of S3, extensive lateral pelvic sidewall involvement, extension through the greater sciatic notch 
and 360 degree encasement of the iliac vessels [8]. Being guided by these recommendations, a 
number of authors have reported 5-year survival rates of 25-50% in patients undergoing surgical 
resection of LRRC combined with multimodal treatments [16-18]. This survival benefit must be offset 
against the high risks carried with surgical intervention with 30-day morbidity and mortality quoted at 
15-68%. In a bid to further improve clinical outcomes in this cohort of patients combined with 
affording cure to a greater proportion of patients, an emphasis has been placed on ultra-radical 
resection, thus rendering these relative contraindications obsolete [19]. This has been accelerated due 
to vast improvements in surgical techniques and critical care services combined with an emphasis on 
the surgical multidisciplinary team within the operating theatre. The preliminary evidence in this 
cohort of patients is encouraging with 5 year survival rates of 17-31% in high sacrectomy [13, 20-22], 
62% in external hemipelvectomy[23] and upto 52% in lateral pelvic sidewall resection[24-26], 
however, the rates of morbidity have been documented to be 31-70%. 
 
Palliative Surgery  
Palliative surgery for LRRC is controversial with no additional survival benefit conferred by surgery 
when compared to palliative oncological treatments [15]. In the complex scenario of advanced pelvic 
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recurrence not amenable to curative resection surgical intervention is reserved for palliation and 
control of symptoms in selected cases.  Palliative surgical resection offers the most benefit in patients 
with bleeding, obstruction, pelvic sepsis and intractable pelvic pain [27, 28]. 
 
Post-operative Outcomes  
Irrespective of the intent of surgery, i.e. curative or palliative, surgery in this cohort of patients is 
associated with high post-operative burden. Due to the extensive nature of operative intervention post-
operative recovery is often long and associated with a high rate of complications. Thirty day post-
operative morbidity is estimated between 15-68%, with pelvic sepsis and post-operative wound 
complications being the most common [18]. Further intervention, either radiological or surgical is 
often required to adequately and effectively deal with post-operative complications [29]. Thirty-day 
post-operative mortality is high, with an estimated rate of 1-15% [18]. These risks are significantly 
higher than that conferred by operative management in primary rectal cancer, with the National Bowel 
Cancer Audit reporting a 90-day mortality rate of 3.2% in patients undergoing a major resection for 
rectal cancer [30]. These short-term burdens of post-operative recovery must be balanced against the 
goals of surgery, any potential benefit conferred by survival and the risk of re-recurrent disease.  
 
Multimodal Treatments  
It is desirable to incorporate a multimodal approach in combination with operative intervention, with 
the emphasis being on the incorporation of chemotherapy +/- radiotherapy within the treatment 
algorithm.  However, the use of multimodal treatments in LRRC is often dictated by the treatments 
received during the management of primary rectal cancer and on the goals of treatment (i.e. curative 
or palliative).  
 In the curative setting, patients with LRRC who are radiotherapy naive are usually treated with pre-
operative chemoradiation.  However, it is the management of the cohort of patients, who have 
previously received radiotherapy that is contentious due to the concerns of potential higher rates of 
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morbidity encountered secondary to the high cumulative radiation doses to normal structures with 
further radiation. As a result, there have been a number of radiotherapy techniques that have been 
developed to circumvent the potential hazards of additional delivery of external beam radiation, 
including, intra-operative radiotherapy, brachytherapy and image-guided radiotherapy.  
Re-irradiation  
The role of re-irradiation with external beam radiotherapy (EBRT) in combination with surgery has 
been explored by some authors, with re-irradiation doses of 30Gy associated with a reported 5-year 
survival of 19-25% [31-33]. However, there are concerns with use of re-irradiation due to the 
cumulative effects of radiation toxicity, with initial rates of acute and late toxicity reported to be 25-
32% and 36-38% respectively[32, 33]. To circumvent the relatively high rates of radiation toxicity 
observed with the use of EBRT in the reirradiation of LRRC, a group of authors have explored the use 
of reirradiation with hyperfractionated chemoradiation with encouraging results. Valentini et al 
reported a grade 3 acute toxicity rates of 5.1% with no grade 4 toxicity observed in 51 patients 
completing a hyperfractionated radiotherapy schedule of 1.2Gy twice daily, with a cumulative dose of 
40Gy, with concurrent infusion of 5-fluorouracil [34]. Similarly, Das et al treated 50 patients with a 
hyperfractionated accelerated regimen of 1.5Gy, with a cumulative dose of 39Gy, with concurrent 
capecitabine [35]. This group reported a 4% rate of grade 3/4 acute toxicity. In combination with a 
lower rate of radiotherapy related toxicity, this group of authors reported a statistically significant link 
between response to re-irradiation and the ability to perform a radical resection (p=0.009).   
In the palliative setting, the use of reirradiation with EBRT has been found to effectively palliate and 
control symptoms, with Mohiuddin et al reporting effective palliation of symptoms of bleeding in 
100% of patients for a median period of 10 months, pain in 55% and tumour mass in 25% for a 
median period of 9 and 8 months respectively [31]. Lingareddy presented similar rates of palliation of 
symptoms in 52 patients undergoing palliative reirradiation, with effective palliation of symptoms in 
80% of patients, using a regimen of 1.2Gy fractions twice a day or 1.8Gy once daily, up to a median 
dose of 30Gy, with selective boost doses of 6-20Gy [36].  
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Intraoperative Radiotherapy 
Intraoperative radiotherapy (IORT) is a specialist technique of delivering irradiation at the time of 
surgery. Over the past three decades, two alternative but complementary IORT methods; 
intraoperative electron radiation therapy and high-dose rate brachytherapy, have evolved into 
technically sophisticated treatments with the central philosophy of achieving higher effective doses of 
irradiation whilst limiting radiation to surrounding normal tissues. The advantage of incorporating 
IORT into the radiotherapy treatment algorithm for LRRC is the precise application and delivery of 
radiation to ‘at risk areas’ for further disease relapse.   
The use of IORT was first reported by Gunderson et al in the 1980s, this group reported the combined 
used of ERBT and IORT in 51 patients with locally advanced or recurrent colorectal cancer, reporting 
an overall 5 year survival of 23% in the recurrent disease group [37]. Local failure rate within the 
IORT field was 2% and within the external beam field was 18% [37]. This study provided 
encouraging data for the incorporation of IORT into the multimodal strategy for LRRC, leading to a 
number of investigators to explore the addition of IORT to surgery +/- chemoradiation [38-53], with 
reported 5 year local control rates of 26-74% and 5 year survival rates of 11-49.5% [54-70].  The 
largest series of IORT in combination with EBRT +/- chemotherapy was reported by Haddock et al in 
607 patients, with 5 year central relapse rate of 14% within the IORT field, a local relapse rate of 28% 
and overall 5 year survival of 30% [70].  
Local control rates observed in the IORT series are 26-81% which are comparable, if not slightly 
superior to the rates observed in the non-IORT series at 41- 67% [71-74]. A number of authors have 
demonstrated good rates of disease control within the actual IORT field, with reported rates of central 
control of 53-93% [61, 65, 67, 70]. Nuyttens et al observed a greater number of out of IORT field 
recurrences than in field recurrences (7 versus 5), with out of field recurrences occurring earlier at a 
median time of 16 months compared to 31 months with in field recurrences (p=0.077) [67]. This 
observation has been echoed by a number of other authors, which adds to the evidence base, that 
IORT provides high rates of local control. To reduce the rate of out of field recurrences, further 
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studies are required to investigate the role of expanding the IORT field and/or increasing the dose of 
IORT delivered.  
IORT is most commonly reserved for use in the curative surgical setting with limited reports in the 
palliative surgical setting. Suzuki et al exclusively reported outcomes in patients undergoing palliative 
resection of LRRC in combination with IORT, with improved rates of 3 year overall survival and 
local disease relapse rates in the IORT group versus the non-IORT group[51].   
It is difficult to elicit the true IORT related complication rates in the majority of studies, due to the 
differences in reporting complication rates, with some studies reporting IORT related complication 
separately, whilst others combine surgical and IORT related complications. Peripheral neuropathy and 
ureteral stenosis have emerged as IORT-related complications from the literature, with rates of 7-
34%[56, 75] [48, 54, 55, 60] and 6.4-36% [44, 46, 56, 60] respectively.  
 
Brachytherapy  
Brachytherapy is the implantation of radioactive sources within or close to malignant lesions, which 
enable the delivery of radiation directly to the site of the tumour. In the treatment of LRRC, temporary 
iridium-192 or permanent implantable iodine-125 is used as the radiation source. In temporary 
implantation applicators are implanted intraoperatively, with delivery of radiation in the post-
operative period. The advantages of interstitial implantation include the higher delivery of radiation, 
combined with limitation of damage to surrounding normal tissue structures due to the sharp dose fall 
off outside the implanted volume.  
The evidence base for brachytherapy in LRRC is mainly limited to the treatment with palliative intent 
following surgical debulking in the presence of microscopic or macroscopic residual disease. This is 
not a common modality of treatment for this cohort of patients. The documented local control rates 
with brachytherapy are variable, with reported rates of 8 – 64%, with an associated complication rate 
of 10-45% [76-82].  
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Highly Conformal Stereotactic Radiotherapy 
Emerging radiotherapy techniques such as image-guided radiotherapy (IGRT) combined with 
improvements in radiotherapy software and hardware have led to the development of Cyberknife, 
tomotherapy and linear accelerator based stereotactic body radiation therapy (SBRT). These 
techniques permit precise radiotherapy planning and the delivery of highly conformed radiation 
beams to the target volume along with real time visualisation of target volumes and normal tissues 
during treatment delivery. This precise visualisation of anatomical structures combined with reduced 
treatment volumes allows for the precise delivery of radiotherapy, thus limiting radiotherapy induced 
damage to normal anatomical structures. However, this technology is in its infancy with only a few 
reports in the palliative setting with regards to LRRC.  
Kim et al investigated the use of Cyberknife in inoperable nodal recurrences in 23 patients [83]. Five 
patients were treated with a combination of EBRT (45Gy in 1.8Gy fraction) followed by a stereotactic 
single fraction radiotherapy boost (16Gy). 18 patients were treated with SBRT alone, with a median 
dose of 39Gy (IQR 36-51) delivered in 3 fractions.  This group reported an overall 5 year survival rate 
of 23.3%, with a 4 year actuarial local progression free survival rate of 74.3%. Grade 4 toxicity was 
observed in 1 (4.3%) patient. No complications were observed in 4 patients who underwent 
reirradiation.  
Dewas et al reported their experience of reirradiation using Cyberknife in 16 patients with recurrent 
inoperable pelvic malignancy, 4 of whom had recurrent rectal cancer[84]. The median dose of the 
previous radiotherapy treatment was 45Gy (IQR 20-96). Patients were treated with a total dose of 
36Gy in six fractions over a three week period. No grade 3 or 4 acute toxicity was observed in this 
group. One year local control rate was 51.4% with a one year survival rate of 46%.  
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Figure 1-1 Guidance for the use of chemoradiotherapy in LRRC – BeyondTME guidance [6] 
 
 
 
* Boxes in red represent areas of controversy. IMRT – intensity modulated radiotherapy.  
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Figure 1-2 Management options for pelvic resectable pelvic disease – BeyondTME guidance [6] 
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1.2.3 Locally Recurrent Rectal Cancer – Future Directions? 
 
LRRC represents a heterogeneous group of patients who are extremely complex to manage, often 
requiring a tailored management approach. The management options available to these patients are 
often dependent on local referral pathways alongside local expertise and resources available [5].    
The current evidence base comprises of level 2 and 3 grade evidence, consisting of single centre case 
studies and cohort studies. Given the heterogeneous nature of LRRC, conducting a large-scale, multi-
centre randomised controlled trial to inform clinical practice has been acknowledged to be extremely 
difficult [7]. To circumvent this and in an attempt to standardise the management of patients with 
LRRC two expert panels have developed a set of guidelines to aid management decisions in this 
cohort [6, 7]. These two comprehensive reviews of the current evidence base identified a number of 
key areas to focus on to improve outcomes including the standardisation of outcome measures, 
measuring the cost-effectiveness of interventions and reporting on HrQoL.  
As the management strategy for LRRC continues to evolve, with an increasing emphasis placed on 
achieving cure for a greater proportion of patients through the use of extended surgical resection 
combined with aggressive multimodal therapies [19, 85], it is essential the impact on patients is 
reported. The traditional markers of success such as morbidity, mortality, survival and re-recurrence 
need to be extended to include patient-reported outcomes (PROs), specifically HrQoL [6, 7] to 
provide a more broad and robust perspective in this cohort of patients.  
1.3 Measurement of Health Status and Health Outcomes 
 
The traditional model of measuring health status relied on the presence or absence of disease, with 
traditional health outcomes based on clinical markers of morbidity, mortality and survival. The steady 
evolution of health outcomes measurement has led to significant attention and consideration being 
given to PROs to include quality of life (QoL) and HrQoL in the reporting of outcomes in oncology 
and chronic diseases [86-88]. The US Food and Drug Agency (FDA) define a PRO as ‘a measurement 
based on a report that comes directly from the patient about their health condition without amendment 
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or interpretation of the patients response by a clinician or anyone else’ [89]. The term QoL was 
developed by the World Health Organisation and is defined as an ‘individual’s perception of their 
position in life in the context of the culture and value systems in which they live and in relation to 
their goals, expectations, standards and concerns’. It is a broad concept affected by an individual’s 
physical health, psychological state, level of independence and social relationships. HrQoL is defined 
as the extent to which one’s physical, emotional and social well being are affected by a medical 
condition or its treatment [90]. HrQoL is a complex, multi-dimensional construct which includes 
dimensions of physical functioning, social functioning, role functioning, mental health and general 
health perceptions, with additional dimensions, including symptom status, functional status and 
characteristics of the individual and environment [91-93]. PRO and HrQoL data is best interpreted 
within its clinical context alongside clinical and oncological outcomes [88]. This is reflected in a 
number of conceptual models for HrQoL, including the Wilson and Cleary model, which incorporates 
biological and psychological aspects of health outcomes (Figure 1.3) [93]. The Wilson and Cleary 
model consists of five core levels, which includes biological and physiological factors, symptoms, 
functioning, general health perceptions and quality of life.  In addition to these levels, this model 
proposes a number of causal relationships between these levels, thus linking traditional clinical 
variables and measures of HrQoL and switching the emphasis of measuring health status from a 
biomedical model to a patient-centred model. Utilising this conceptual model to measure health status 
and its outcome provides clinicians and policy-makers a unique insight into the patient perspective of 
disease impact and its outcome. 
Figure 1-3 The Wilson and Clearly Model of HrQoL 
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1.3.1 PROMS Measurement in the NHS  
 
Patient Reported Outcome Measures (PROMS) were initially highlighted within the NHS by Lord 
Darzi in the NHS Next Stage Review Report in 2008 [94]. This review acknowledged the role of 
PROMS data in the evaluation of healthcare and the potential to use this data to guide regulatory 
decision-making. Following this review, the NHS PROMS programme was introduced in 2009 as 
commissioned by the Department of Health [94]. PROMS data were given further impetus within the 
NHS in 2010 through the White Paper document ‘Equity and Excellence: Liberating the NHS’, which 
placed an emphasis on shared decision-making between patients and clinicians, with PROMS data 
being central to this process [95].  
The political emphasis on PROMS data combined with a desire to improve patient outcomes has led 
to a fundamental shift in the measurement of outputs within the NHS, extending traditional outputs of 
clinically defined variables to include the patient perspective through the routine collection of 
PROMS data. Initially, piloted in four elective surgical procedures, to include hip and knee 
replacement, hernia surgery and varicose vein surgery, there are plans underway to expand the NHS 
PROMS programme to include a number of chronic diseases and selected cancers including colorectal 
cancer.  
The publication and dissemination of routinely collected mandatory standardised PROMS data within 
the NHS has a number of advantages and can help inform patients, clinicians and health-care 
commissioners when evaluating the quality and equity of current healthcare services. From a patient 
perspective, PROMS data can help guide patients to appropriately identify their care provider under 
the remit of the 2008 NHS initiative of open choice [96-100], with clinician-level PROMS data 
further contributing to this choice of service provider. There is emerging evidence from the dataset 
collected through the PROMS programme for elective orthopaedic procedures that this data may be a 
more sensitive indicator of consultant outcomes when compared to elective post-operative mortality 
[101]. Furthermore, PROMS data can provide supplementary information to clinical outcomes when 
guiding patients with regards to treatment options [102, 103], with this being of the most importance 
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when considering treatments where the survival benefit is modest or symptom control is the primary 
outcome [104-106].   
Using PROMS to inform and guide clinical decision-making provides clinicians with a broader 
perspective on patients overall health status. PROMS can be used to screen diseases, monitor response 
to treatments, evaluate disease progression/regression by comparing baseline PROMS data to serial 
measurements, highlight unique issues engendered by treatments and improves communication 
between patients and health-care providers [107, 108].  
The recent landmark Montgomery ruling will potentially impact on the way in which PROMS will be 
used to help inform and guide clinical decision making when informing and consenting patients 
regarding potential treatment options. The new ruling requires healthcare professionals to consider 
whether “a reasonable person in the patient’s position would be likely to attach significance to the 
risk, or the doctor is or should reasonably be aware that the particular patient would be likely to attach 
significance to” [109]. This ruling emphasises the individual nature of the consent process, focussing 
on patient autonomy and emphasising the importance of patient centred approach.  When considering 
major surgery patients value PROMS data including QoL over other aspects of care [110] [111]. In 
view of patients needs to be informed about HrQoL data in combination with the Montgomery ruling 
makes it an opportune time to integrate PROMs data with clinical and oncological data, and present 
this data in tandem when discussing treatment options with patients. 
From a health care commissioning perspective PROMS can provide a unique and insightful 
perspective into the delivery and outputs of health services. PROMS can be used to monitor 
performance from healthcare providers, incentivise providers to improve patient health by linking 
payment to performance in PROMS, benchmark performance of different healthcare providers using 
PROMS data and may be helpful in identifying inequitable variations in patient health outcomes [112, 
113]. Furthermore, PROMS data can be used to assess cost-effectiveness by combining this data with 
provider-level costs to quantify the health gain and associated costs for interventions [113]. 
Employing this approach with data from the NHS PROMS Programme cost-effectiveness has been 
determined for elective laparoscopic inguinal hernia repair [114] and elective hip replacements [115].  
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PROMS measurement within the NHS has great potential to enhance patient experience and outcome, 
guide clinical decision-making, benchmark performance and influence policy. The initial success of 
the NHS PROMS Programme and its subsequent plans for expansion suggests PROMS are a valuable 
and credible source of information in the quest for improving patient outcomes at a local and national 
level.  
1.3.2 PROMS Measurement in Clinical Research  
 
There is a steady movement towards measuring PROMS in clinical research, most notably within the 
remit of randomised clinical trials [116-118]. Oncology trials most commonly employ PROMS data 
to examine differences between treatment arms [118-121]. QoL and PRO outcomes are of increasing 
importance in advanced and palliative oncology trials where large survival benefits are unlikely to be 
realised. Randomised controlled trials represent the gold standard of treatment efficacy, representing 
Level I evidence for guiding evidence-based medicine. Therefore, the increased use of PROMS data 
in clinical trials has the potential to provide high quality data to guide patients and clinicians, by 
providing scientific rigour necessary for valid outcome interpretation. This has been recognised and 
encouraged by a number of international bodies including The Radiation Therapy Oncology Group 
[122], National Cancer Institute Clinical Trials Cooperative [123, 124], The US Food and Drug 
Agency [125] and the European Organisation for Research and Treatment of Cancer [126]. 
Alongside measuring PROMS in clinical trials there is much work being dedicated to using 
population-based registries in collecting this data [127-131], which would be ideally placed for the 
measuring of PROMS outcomes in LRRC. Using population-based cancer registries to document 
PROs is associated with a number of advantages including a large sample size, high external validity, 
ability to compare the clinical demographics of responders and non-responders, explore PROs in rare 
cancers and monitoring changes to PRO data before and after diagnosis [132].  In current practice, 
these registries are being used as sampling frameworks to assess PROs in long-term cancer survivors, 
thus providing a cross-sectional, ‘snap-shot’ perspective of outcome [127]. These disease registries 
have already been established to measure clinical outcomes, with the measurement of PROs being a 
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secondary endpoint once the registry is successfully established. This has important implications on 
the results obtained with variable response rates, lack of baseline data and potentially important 
differences between responders and non-responders missed. However, despite these shortcomings the 
use of population based registries has the potential to amass a large wealth of PRO data alongside 
clinical data over a relatively short period of time whilst reflecting the needs of the population and 
enabling comparisons between different service providers. To be successful in collecting PROMs data 
within the framework of a registry consensus is required from all key stakeholders, including patients 
and clinicians, on the type of PROM included, its linkage with registry data, standardisation of data 
collection and on-going evaluation of data collection to improve compliance [133].   
Given this rise in the inclusion of PROMS data in clinical trials and population registries, there has 
been much work targeted at standardising the reporting of PROMS outcome data, specifically HrQoL 
[134]. Current practice of reporting PROMS in clinical trials is highly variable with regards to the 
quality of data analysis and reporting [135-138]. This variation in reporting of PROMS outcome data 
produces inconsistencies in data interpretation and therefore potentially leads to the lack of 
application of this data to clinical practice. To improve the scientific rigour of reporting HrQoL data 
in oncology trials a minimum set of criteria was proposed as a checklist in 2003 [139].  Using this 
checklist as guide a higher proportion of methodologically robust randomised controlled trials 
reporting HrQoL were identified following the guidelines inception [140]. However, despite these 
recommendations, the reporting of PROMS within the context of clinical trials remains suboptimal, 
with Brundage et al reporting the failure to report on the rationale for inclusion of PROM, on HrQoL 
hypothesis, missing data and appropriate sample size in 794 randomised controlled trials across a 
range of clinical conditions [135]. Furthermore, this review identified inconsistencies in data reporting 
and presentation. These systematic errors in trials incorporating and reporting on PROMS data are due 
to insufficient detail included in the trial protocols, with inadequate detail provided on relevant 
existing PRO research, a rationale of collecting PRO data, provision of a PRO specific hypothesis, 
justification of PROM timings, PRO sample size calculations, justification of PROM used, lack of 
data on the clinical significance of PRO data, lack of detail on handling of missing data and PROM 
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specific data monitoring [141].  The acknowledgement of these inadequacies in current reporting 
methods of PROMS data within the context of clinical trials has led to the extension of the 
Consolidated Standards of Reporting Trials (CONSORT) to include PROs as the CONSORT-PRO. 
This guideline aims to improve the methodological rigour of assessing and reporting PROMS data, by 
making five key recommendations which include: 
1. that PROs are identified as a primary or secondary outcome in the abstract, 
2. that a description of the hypothesis and relevant domains be provided (if a multidimensional 
PRO tool has been used), 
3. that evidence of instrument validity and reliability be provided or cited, 
4. that the statistical approaches for dealing with missing data be explicitly stated, 
5. that PRO-specific limitations of study findings and generalizability of results to other 
populations and clinical practice to be discussed. 
 
To ensure the continued use of PROMS to identify key differences between treatments in clinical 
research requires complete transparency and disclosure of results. Adopting a robust, methodological 
approach under the guidance of the CONSORT-PRO statement will allow for accurate and valid 
PROs to be obtained through well-designed research studies [142]. This will enable clinicians to 
critically appraise PROMS data prior to utilising this data to inform clinical decision-making.  
 
1.3.3 PROMS Measurement in Colorectal Surgery 
  
There is a strong heritage of PROs across the speciality of colorectal surgery, given its sensitive and 
personal nature, combined with its reliance on the subjective reporting of symptoms to aid diagnosis 
and treatment. Generic and disease-specific measures are available to assess PROs in all subspecialty 
areas of colorectal surgery including colorectal cancer [143-145], inflammatory bowel disease [146], 
pelvic floor disorders [147, 148] and functional bowel disease [149, 150]. There has been an 
acknowledgement in recent times by the colorectal fraternity of the role played by PROMS in clinical 
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practice, audit and research. With this there has been a concomitant rise in the use of PROMS in 
clinical colorectal trials and comparative effectiveness research [151-162], with an increasing number 
of studies using PROMS as the primary endpoint [161, 163-166], thus providing a patient-centred 
approach to evidence-based medicine in this field of surgery. However, despite, this increase in the 
use of PROMS in colorectal research the standard of reporting PROMS data remains suboptimal with 
only a third of colorectal cancer trials reporting high quality PROMS data [136]. The underreporting 
of good quality, robust PROMS data detracts from its importance and application in the clinical 
setting and therefore prevents its use in clinical practice. 
A range of disease-specific measures currently exist for measuring PROMS outcomes in colorectal 
disease, which reflects the steady movement away from the use of generic PROMS in evaluating 
HRQoL outcomes in patients with specific diseases[167]. Disease-specific measures have the ability 
to detect and evaluate subtle changes between patient and treatment groups, which may potentially be 
missed by generic measures [168-171]. It is therefore essential to use validated, disease- specific 
measures to produce clinically meaningful and relevant data [172]. A number of disease-specific 
PROMS have been developed and validated for use in colorectal cancer [143, 144], these measures 
have been found to be more sensitive and responsive in detecting clinical changes when compared to 
generic measures [171]. Building on from this there has been much work in developing validated 
PROMS in patients with metastatic colorectal cancer, most notably, in those with liver metastases 
[173, 174]. The development of a disease-specific measure for patients with colorectal liver 
metastases acknowledges this cohort of patients have a unique set of issues which differ from patients 
with primary colorectal cancer [174].  It can be hypothesised the same principles apply to patients 
with LRRC, with these patients being affected by a unique set of issues, which may not be captured 
by existing PROMS developed for use in primary colorectal cancer. Just as patients with colorectal 
liver metastases have been defined as a clinically significant group with a dedicated PROM, it is 
important we acknowledge the LRRC group in a similar fashion. This is further justified by the 
differences observed in clinical outcomes between primary advanced rectal and recurrent rectal 
cancer, with a higher proportion of curative resections and prolonged survival in the locally advanced 
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group compared to the recurrent group [17, 175-177].  Whilst traditional clinical outcomes have been 
examined between these two clinically distinct groups, HrQoL and PRO outcomes have only been 
examined in the primary rectal cohort using validated PRO measures [178-180].  Acknowledging 
these differences in clinical outcomes between primary rectal cancer and recurrent rectal cancer 
further reinforces the hypothesis that similar differences may exist between these two groups with 
regards to HrQoL. This is an opportune time to examine and develop a disease-specific PROM in 
patients with LRRC with endorsement from two international collaboratives [6, 7].  
 
1.4 Conclusion 
 
LRRC is a complex disease entity, with a number of treatment options available. The surgical and 
oncological outcomes associated with LRRC are well documented, however, little is known about the 
impact of LRRC and its treatments on HrQoL. There is growing interest within the surgical fraternity 
in documenting these important outcomes in patients with LRRC and integrating these outcomes with 
traditional clinical and oncological outcomes, in a bid to provide a more balanced perspective. The 
current landscape for PROMS measurement is changing, with recognition and endorsement from a 
number of key stakeholders including politicians, policy-makers and clinicians. PROMS data can be 
used for a variety of reasons including service improvement, national benchmarking, clinical 
monitoring and decision-making.  This is reflected in the upward trend of including PROMS data in 
clinical trials and population registries and the increasing guidance available on the incorporation of 
PROMS in such studies. There is a paradigm shift in surgical oncology with a focus on integrating 
clinical and patient-reported outcomes. This makes it an opportune time to acknowledge the 
complexities of managing patients with LRRC, to employ a patient-centric approach and investigate 
HRQoL in this cohort.  
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2 Chapter 2 - Systematic Review of Health-Related Quality of Life in Locally 
Recurrent Rectal Cancer 
 
2.1 Background 
 
Traditionally, surgical endpoints, such as morbidity, mortality and overall survival are used as 
markers of success of an operative intervention. In the complex scenario of LRRC operative 
intervention is not always performed with curative intent, but to palliate symptoms and improve 
HrQoL. There is a steady movement away from the traditionally paternalistic model of healthcare 
delivery, with a greater emphasis on PROs, which include HrQoL [88]. Such outcome measures are 
gaining increasing momentum in assessing efficacy of new treatments and the effectiveness of 
existing treatments as well as obtaining information on patient perceived benefits and risks of 
treatments. There has much been much interest in PROs, namely HrQoL outcomes in patients with 
LRRC in recent times [181]. It is believed that assessment of HrQoL of patients with LRRC may help 
inform the current on going debate of the management of this cohort of patients, especially with 
regards to further radicalisation of curative surgery and palliative surgery and the cost-effectiveness of 
these interventions.  
 
2.2 Aims 
 
The aims of this review were: 
• to identify and assess the current literature on HrQoL outcomes in LRRC 
• to identify tools used to assess HrQoL in patients with LRRC 
• to identify common HrQoL themes in patients with LRRC. 
 
 
35 
2.3 Methodology 
 
2.3.1 Search Strategy 
 
Literature searches were performed in three databases: MEDLINE (1966-January 2013), EMBASE 
and CINAHL. The searches were limited to the English language. The major subject heading, LRRC, 
was combined with HrQoL, QoL, symptom control, questionnaires, physical distress, psychological 
distress and psychosocial distress. The search was designed to identify qualitative research that 
explored patients’ subjective experience and quantitative studies that measured HrQoL using 
standardised measures. 
To identify on going and unpublished research, hand searches of specialist journals and relevant 
conference proceedings were carried out. An Internet search of web content relating to LRRC self-
help and focus group websites was also undertaken (Appendix 1).  
 
2.3.2 Study Inclusion Criteria 
 
Studies were included if they fulfilled the following criteria; they reported outcomes of patients with 
LRRC, including symptom control, HrQoL outcomes and impact on function. Patients undergoing 
surgery and palliative treatments were included. Studies were excluded if LRRC HrQoL outcomes 
were not measured. Case reports, reviews and letters were excluded. 
 
2.3.3 Selection of Studies  
 
Abstracts from studies retrieved were screened for relevance; studies that did not meet inclusion 
criteria at this stage were excluded at this stage. Studies assessed as potentially relevant, or where 
relevance was ambiguous, were obtained in full, for further scrutiny. 
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2.3.4 Data Extraction  
 
Data extraction was conducted independently by two reviewers (Deena Harji, DH and Ben Griffiths, 
BG). The following information was extracted from each study; first author, year of publication, study 
population characteristics, study design (prospective, retrospective, or other), number of patients in 
each group (total number of patients assessed and number of patients with LRRC), comparative 
groups, HrQoL assessment tool used, median time interval between diagnosis/treatment and 
assessment, main findings and quality of study.  
 
2.3.5 Data Quality 
 
The methodological issues surrounding the quality of the studies assessing and measuring HrQoL in 
LRRC were considered A pragmatic approach was undertaken to include all studies reporting HrQoL 
outcomes and patient testimony irrespective of the quality of the study, due to the sparsely available 
literature on this topic. However, a quality analysis was undertaken of all published studies included 
in accordance with the Newcastle-Ottawa Scale (NOS) for assessment of non-randomised 
studies[182]. There are two separate scoring systems incorporated into the NOS dependent on study 
type; case-control study or cohort study. There are three general areas in which each study is marked, 
which includes selection, comparability and exposure for case-control studies and outcome in cohort 
studies. Studies are marked against pre-defined criteria using a star system, with a maximum of 10 
stars available for case-control studies and 13 stars for cohort studies. Studies were deemed as good 
quality if a minimum of 7 stars are scored.  
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2.3.6 Data Analysis 
 
All studies were evaluated for the following criteria; a definition of HrQoL, use of a valid and reliable 
instrument, compliance issues, handling of missing HrQoL data, reporting of statistical methods 
employed, examination of clinical significance and reporting in detail the presentation of results. 
A combined synthesis of qualitative and quantitative research was performed. This process involved 
the generation of a priori distribution of factors and their relative importance using the principles of 
content analysis to generate common categories and themes from the study findings. The principles of 
triangulation for integrating mixed methods data were used to determining consistency between 
findings from each data set [183] [184]. A meta-synthesis of the qualitative data was carried out, with 
all relevant findings grouped together. Common categories and themes were identified from the study 
findings. A category was determined by grouping similar findings reflecting similar underlying 
constructs. In turn categories were synthesised into themes, if they were sufficiently similar, this 
enabled the summary of all evidence for a particular domain. The same process was carried out for the 
quantitative data, with findings from the quantitative data set encoded to the categories identified from 
the meta-synthesis if appropriate, or to new categories. This process enabled comparison between 
findings from the two types of data sets (qualitative and quantitative), thus enabling the review of all 
emerging categories and assessing for consistency, discrepancy and complementarity between two the 
data sets. The combined categories and themes were reviewed and synthesised into a working 
conceptual framework for HrQoL specific LRRC. 
 
2.4 Results 
 
The search strategy identified a total of 73 references. Five duplicates and 51 inappropriate references 
were identified through examining the abstracts and were excluded (Figure 2.1). The remaining 17 
abstracts were retrieved for further evaluation, of which 14 were included in this review. This 
identified a total of 946 patients with locally advanced rectal cancer (LARC), LRRC and recurrent 
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gynaecological malignancy, of which 501 (52.9%) patients had LRRC. A total of 676 (71.4%) 
patients completed the full complement of assessment tools, with assessments carried out at a median 
age of 64. This included 330 (48.8%) male and 278 (41.1%) female patients. The gender is unknown 
in 68 (10.1%) patients. Operative intervention, curative or palliative, was the commonest mode of 
treatment, with 403 (80.4%) of patients with LRRC undergoing surgery alone or in combination with 
chemotherapy +/- radiotherapy. Forty-five (8.9%) patients underwent palliative chemotherapy +/- 
radiotherapy or best supportive treatment for LRRC. The treatment modality is unclear in 53 (10.5%) 
patients with LRRC.  
 
Figure 2-1 Flowchart of Studies Retrieved From Literature Search 
 
 
 
 
 
 
 
 
 
 
 
Twelve published studies [27, 185-195] and two abstracts[196, 197] were identified, of which 12 
studies were quantitative, 1 qualitative study and 1 study employed mixed methodology, reporting 
Studies identified from literature search 
- 73 
Studies Excluded – 56 
Reviews – 3 
Case Reports – 2 
Primary Rectal Cancer Outcomes – 13 
LRRC Surgical Outcomes – 30 
Other diseases - 3 
Duplicates - 5 Studies selected after reading abstracts - 
17 
Studies included in the present review - 
14 
Studies Excluded – 3 
Qualitative experiences in primary rectal 
cancer – 1 
Cost-effectiveness outcomes only for 
LRRC -1 
Surgical strategy reported for restoration 
of functional outcomes in LRRC only - 
1 
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qualitative and quantitative data.  No randomised controlled trials were identified. The number of 
patients with LRRC participating in each study ranged from 2-105. Study design included 5 
retrospective cohort studies, 3 retrospective case control studies, 4 prospective longitudinal studies, 1 
prospective cross-sectional study and 1 qualitative interview. A summary of the main points of each 
study is highlighted in Table 2.1, with quality analysis of all studies outlined in Table 2.2.  The quality 
of the studies included were generally poor according to the NOS scoring system, with only one high 
scoring study included (Table 2.2).  A total of 28 patient forums were identified on LRRC from three 
public cancer websites, including Beating Bowel Cancer, Macmillan and Cancer Research UK. These 
patient forums were analysed to identify relevant patient testimony. 
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Table 2-1 Summary Findings of the Studies Included Outlining HrQoL in LRRC 
Author and Year Study Population Study Design 
Total 
No 
Patients  
Total 
No of 
Patient
s with 
LRRC 
Comparativ
e Group 
Treatment 
of Patients 
Median Time 
Interval Between 
Diagnosis/Treatment 
and Assessment 
Number of 
Assessments HrQoL 
Assessment 
Tool 
Main Findings 
Camilleri-
Brennan[185] 
2001 
LRRC and 
DM* 
Retrospective 
Cohort Study 25 13 
Age and sex 
matched 
disease free 
patients 
- 24 months 
 
 
1 
EORTC 
QLQ-
C30/QLQ-
CR38 
SF36 II 
QoL scores were lower in 
patients with tumour 
recurrence compared to 
matched controls with no 
recurrence. 
 
Guren [193] 
2001 
 
 
 
LRRC and 
LARC 
 
Retrospective 
Case-control 
cross-sectional 
study 
 
12 
 
2 
Patients with 
LRRC/LARC 
without 
urinary 
diversion and 
reference 
Norwegian 
population 
 
Surgery and 
RT+ - 2 
 
- 
 
 
1 
 
EORTC 
QLQ-CR38 
EORTC 
QLQ-
BLM30 
 
Comparable QoL scores 
between patients with and 
without urinary diversion. 
Mannaerts [189] 
2001 
LRRC and 
LARC 
Retrospective 
Cohort Cross-
sectional study 
76 39 LARC 
patients 
Surgery, 
RT and 
IORT++ – 
39 
14 months 
 
1 
 
Symptom 
scales 
Significant post-operative 
urogenital dysfunction in 
both LARC and LRRC, with 
higher rates observed in the 
female population. 
Esnaola [188] 
2002 
LRRC 
Prospective 
Longitudinal 
Study 
45 45 
LRRC 
patients 
treated with 
non-surgical 
palliation 
Surgery  - 9 
Palliative 
alone -8 
Surgery and 
CRT+++ - 3 
Surgery, 
CRT and 
IORT - 10 
 
1 month*** or 15.2 
months**** 
 
 
 
 3 monthly 
 
BPI 
 
FACT-C 
Worse pain scores in patients 
undergoing non-surgical 
palliation compared to those 
undergoing curative surgery. 
Pain affected QoL. QoL is 
impaired initially for patients 
undergoing surgery however 
returns to baseline within 3 
years.  
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Surgery and 
CT - 4 
Palliative 
CRT - 8 
Supportive 
Care - 3 
Mannaerts [190] 
2002 
LRRC and 
LARC 
Retrospective 
cohort cross-
sectional study 
76 39 LARC patients 
Surgery, 
RT and 
IORT – 39 
14 months 
 
2 
 
Symptoms 
scales 
LRRC patients had a higher 
degree of post-operative 
morbidity, social handicap 
and functional impairment 
when compared to LARC. 
Miner [27] 
2002 
LRRC Retrospective Cohort Study 105 105 
LRRC treated 
with surgical 
palliation 
 
Curative 
surgery - 81 
Palliative 
Surgery - 
24 
- 
 
 
2 
 
Symptom 
scales 
Clinical improvement was 
observed in 42% of patients 
following palliative surgery 
and in 78% of patients 
undergoing non-palliative 
surgery. 
Wright [194] 
2006 
LRRC and 
LARC 
Qualitative 
Interview 10 3 None 
Surgery and 
RT - 1 
Surgery and 
CRT -7 
Surgery and 
CT - 1 
11 months 
 
 
1 
Qualitative 
Face to Face 
Interview 
Patient experiences reflected 
a highly focused desire to 
seek cure, however revealed 
a misunderstanding of 
disease biology, probability 
of cure, therapeutic options 
and treatment morbidity.  
 
Palmer [192] 
2008 
LRRC, LARC 
and LASC** 
Retrospective 
Case-control 
cross-sectional 
study 
43 13 
Age-sex 
matched 
patients with 
operable 
primary 
rectal cancer 
and reference 
Swedish 
Surgery - 
43 
 
9-149 months 
 
 
1 
 
EORTC 
QLQ-
C30/QLQ-
CR38 
 
Lower global, physical, role, 
social functioning and body 
image scores in the study 
group. No differences were 
observed in colorectal cancer 
symptoms between the two 
groups.  
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population 
Austin [191] 
2010 
LRRC and 
LARC 
Retrospective 
case-control 
cross-sectional 
study 
37 20 
Primary 
rectal cancer 
patients and 
reference 
Australian 
population 
Surgery - 
20 47 months 
 
 
1 
FACT-C 
SF36 II 
Comparable QoL scores 
between study group and 
primary rectal cancer 
patients.  
Zoucas [186] 
2010 
LRRC/LARC/ 
Gynaecological 
malignancy 
Prospective 
Longitudinal 
study 
85 20 None 
 
- 
4 and 16 months 
 
2 
EORTC 
QLQ-C30 
HrQoL improved at 16 
months post-operatively.  
You [187] 
2011 
LRRC 
Prospective 
Longitudinal 
study 
105 105 
LRRC treated 
with non-
curative 
surgery and 
non-surgical 
palliation. 
 
Curative 
surgery - 12 
Curative 
surgery and 
CRT - 50 
Non-
curative 
surgery - 13 
Palliative 
CRT - 21 
Palliative 
brachythera
py - 2 
Supportive 
treatment - 
7 
- 
 
 
 
3 monthly 
FACT-C 
BPI 
Physical well-being was 
better in patients undergoing 
curative surgery compared to 
non-curative or non-surgical 
treatments. QoL scores were 
largely preserved in all three 
groups.  
 
Vaughan [198] 
2012 
LRRC and 
LARC 
Prospective 
cross-sectional 
study 
45 20 - - - 
 
 
1 
EORTC 
QLQ-CR30 
EORTC 
QLQ-CR29 
Global health status and pain 
were better in patients 
undergoing surgery compared 
to non-surgical palliation 
(p<0.001). Greater buttock 
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pain was the only difference 
between LRRC and LARC 
patients.  
Thaysen [196] 
2012 
LRRC and 
LARC 
Prospective 
Longitudinal 
Study 
126 59 
Primary 
rectal cancer 
patients and 
reference 
Danish 
population 
- - 
 
 
 
 
4 
EORTC 
QLQ-C30 
EORTC 
QLQ-CR29 
SF36 II 
No differences were found in 
HrQoL compared to patients 
with primary rectal cancer. 
Global quality of life was 
comparable to the general 
population. Clinically 
signiﬁcant lower HrQoL was 
found in relation to role 
function, bodily pain and 
emotional role. 
Holman [195] 
2013 
LRRC and 
LARC 
Retrospective 
Cohort Cross-
sectional Study 
 
51 18 LARC 
patients 
Surgery and 
CRT – 49 
Surgery – 2 
Additional 
IORT -44 
3 years 
 
 
1 
EORTC 
QLQ-C30 
EORTC 
QLQ-CR38 
Qualitative 
Interview 
After vaginal reconstruction, 
women reported equal or 
higher scores on global health 
status, emotional functioning 
and body image. Following 
reconstruction, 40% of 
women were unable to 
engage in sexual intercourse 
due to technical reasons.  
* DM = distant metastases, ** LASC – Locally advanced sigmoid cancer, + RT – Radiotherapy, ++ IORT – Intraoperative radiotherapy, +++ CRT – Chemoradiation, ^CT – 
Chemotherapy ***Non-surgical palliation only ****Surgical treatment 
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Table 2-2 Quality Assessment of All Published Studies Included According to the Newcastle-
Ottawa Scale 
 
CASE-CONTROL STUDIES 
 SELECTION COMPARABILITY EXPOSURE OVERALL 
SCORE 
Guren [193] *** * * 5 
Palmer [192] *** - * 4 
Austin [191] *** ** ** 7 
 
COHORT STUDIES 
 SELECTION COMPARABILITY OUTCOME OVERALL 
SCORE 
Camilleri-Brennan 
[185] 
** ** - 4 
Mannaerts [189]  * ** ** 5 
Esnaola [188] ** * ** 5 
Mannaerts [190] * ** ** 5 
Miner [27] ** ** ** 6 
Zoucas [186] ** * ** 5 
You [187] ** * ** 5 
Holman[195] ** - ** 4 
 
Table 2.3 highlights the methodological and statistical design issues associated with each identified study. 
HrQoL was the main primary endpoint in 9 studies[185, 187, 188, 191, 192, 194, 196, 197], with clinically 
significant differences determined prior to study commencement in 7 studies. Compliance with completion of 
HrQoL assessments were reported by 12 studies, with reported compliance ranging from 60-100%. Baseline 
assessments of HrQoL prior to the initiation of treatment were available in five studies alone [27, 187-190], with 
the majority of assessments being carried out at a median time frame of 4-149 months following diagnosis 
and/or treatment of LRRC [186, 189-192, 194, 195].  Handling of missing data was reported by 3 studies alone 
[188-190]. 
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Table 2-3 Statistical and Design Issues Assessing HrQoL in LRRC 
Author Definition of HrQoL 
Primary 
Outcome 
Use of Valid and 
Reliable Instrument 
for LRRC 
Compliance 
Handling 
of Missing 
Data 
Baseline 
Characteristics 
Reported 
Method of 
Analysis 
Reported 
Follow-Up 
Data 
Reported 
HrQoL 
significance 
addressed 
HrQoL 
significant 
Camilleri- Brennan[185] No HrQoL No 83% Not reported No Yes Yes Yes Yes 
Zoucas [186] No Clinical No Not reported Not reported No Yes Yes Yes Yes 
You [187] No HrQoL No Not reported Not reported Yes Yes Yes Yes Yes 
Esnaola [188] No HrQoL No 88% Yes Yes Yes Yes No Yes 
Mannaerts [189] No Clinical No 96% Yes Yes Yes Yes No Yes 
Mannaerts [190] No Functional Outcome No 96% Yes Yes Yes Yes No Yes 
Austin [191] No HrQoL No 84% Not reported No Yes N/A Yes No 
Palmer [192] Yes HrQoL No 89% Not reported No Yes N/A Yes Yes 
 Guren [193] No HrQoL No 97% Not reported No Yes Yes Yes Limited 
Wright [194] No HrQoL Qualitative Interview 100% N/A N/A Yes N/A No No 
Miner [27] No Clinical No 60% Not reported Yes Yes Yes No No 
Holman [195] No Clinical and HrQoL No 85% 
Not 
reported No Yes Yes Yes Yes 
Thaysen [196] No HrQoL No 74% Not reported No No Yes No Yes 
Vaughan-Shaw [198] No HrQoL No 91% Not reported No No Yes No No 
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2.4.1 HrQoL Assessment Tools 
 
Nine studies utilised HrQoL tools used to assess outcomes in primary rectal cancer, this included the 
Functional Assessment of Cancer Therapy-Colorectal Specific Questionnaire (FACT-C) [187, 188, 
191], European Organisation for Research and Treatment of Cancer QLQ-C30 (EORTC QLQ-C30) 
[186] combined with the colorectal specific modules EORTC QLQ-CR38 [185, 192, 193, 195] and 
EORTC QLQ-CR29 [196, 197]. Five studies incorporated the Short-Form 36 Version II (SF36-II) 
[185, 191, 196] and/or the Brief Pain Inventory [187, 188, 199] to assess generic outcomes.  One 
study used the European Organisation for Research and Treatment of Cancer Bladder Cancer 
questionnaire (EORTC QLQ-BLM30) [193]. Three studies utilised ad hoc symptom scales, 
specifically designed for the individual study [27, 189, 190]. No disease-specific tools were identified 
to measure HrQoL outcomes in LRRC.  
 
2.4.2 Identified HrQoL Themes     
                                                                                                                                                                                       
Using the principles of content analysis one hundred and eighty four findings, thirty categories and 
eight themes were identified (Table 2.4). 
Table 2-4 Synthesised Categories and Themes Identified 
 
 
Theme 
 
Category 
Physical impact  Physical restrictions due to LRRC symptoms and treatment 
interventions 
Adaptation of physical environment to facilitate impact of LRRC 
Psychological impact Impact on mental health and psychological well being 
Employment of coping mechanisms 
Future perspective 
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Anxiety  
Anger  
Acceptance and health bargaining 
Social Impact Social life restricted due to physical restrictions 
Adaptation of social circumstances to facilitate impact of LRRC 
Affect on personal life and relationships 
Symptoms General Health 
Stoma issues 
Gastrointestinal Symptoms 
Genitourinary Symptoms 
Musculoskeletal Symptoms 
Pain Descriptors 
Financial Impact Financial Difficulties 
Delayed Return to Work  
Change of occupation to accommodate restrictions imposed by LRRC 
Relationships With Others Paternalistic relationship with healthcare professionals 
Dependence on others 
Communication Need for information  
Delay between referral from GP to specialist services 
Difficulty seeking second opinions 
Frustration regarding miscommunication and delayed communication 
between specialist services and primary consultant 
Misunderstanding of disease biology and treatment options due to lack 
of communication  
Sexual Function Emotional aspects of sex 
Technical aspects of engaging in sexual activities 
Sexual enjoyment 
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2.4.2.1 Physical Impact 
 
Physical function is defined as the ‘ability to carry out various activities that require physical 
capability, ranging from self-care, including basic activities of daily living, to more vigorous activities 
that require increasing degrees of mobility, strength or endurance’. 
Eleven studies reported the impact of LRRC on physical well being and functional outcomes with 
conflicting outcomes [185-188, 190-192, 194-197]. Camilleri-Brennan et al reported lower scores of 
physical well being using the EORTC QLQ-CR38 in patients with locoregional recurrence compared 
to disease free patients [185]. Conversely, Austin et al failed to detect any clinically significant 
differences in physical well being scores using the FACT-C between patients undergoing surgery for 
LARC or LRRC cancer requiring extended resection compared to primary rectal cancer [191], unlike 
Palmer et al who reported lower physical functioning scores on the EORTC QLQ-CR38 in LRRC and 
LARC patients when compared with a similar comparative group [192]. You et al reported lower 
physical well being scores using the FACT-C questionnaire combined with higher scores of pain 
interference with activities of daily living in patients undergoing non-curative surgery compared to 
patients undergoing curative surgery [187].  
Mannaerts et al reported the functional impact on patients undergoing surgery for LRRC, with 
patients experiencing post-operative walking difficulties and requiring help with basic activities [190]. 
Wright et al reported patient experiences following surgery for LARC or LRRC with patients 
reporting adverse effects on mobility, activities of daily living and leisure activities [194]. 
Two longitudinal studies from the same unit, both reported long term return of physical functioning to 
baseline levels in the patients treated surgically with curative intent at 3 and 7 years respectively [187, 
188], However, in the non-curative patients treated surgically and in the palliatively treated patients, 
physical functioning scores deteriorated with time [187].   
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2.4.2.2 Psychological Impact 
 
Psychological impact is defined as the impact on one’s mental and emotional well being. Seven 
studies commented on psychological impact following surgery for LRRC [185, 187, 188, 191, 193-
195] using the emotional well being and emotional function domains of the FACT-C and the EORTC 
QLQ-C30 questionnaires respectively.  
Patients undergo a range of emotions during the diagnosis and treatment of LRRC, according to the 
qualitative experiences reported by Wright et al [194], these range from desperation, despair and 
helplessness when seeking a diagnosis of LRRC followed by a more motivated outlook during the 
post-operative recovery period, due to the employment of coping mechanisms and health-bargaining. 
The psychological impact of LRRC has a considerable effect on the future perspectives on this cohort 
of patients, however this is partially dependent on the experience during the management of the 
LRRC, as Camilleri-Brennan reported lower scores of future perspective in patients with LRRC [185]. 
However, Palmer et al reported equivalent scores between patients with LRRC/LARC and patients 
with primary rectal cancer [192]. Similarly, Austin et al reported higher mental well being scores in 
patients undergoing exentarative surgery for LARC/LRRC compared to the general Australian 
population despite having lower physical well being scores [191].  
Patient experiences reported on internet cancer support forums suggest a great deal of anxiety in the 
initial diagnostic and investigative phases of LRRC treatment, with occasional anger expressed at the 
prospect of disease recurrence and the ‘failure’ of primary treatment. Once the diagnosis and 
treatment pathway is established, a more positive and accepting attitude is adopted.  
 
2.4.2.3 Social Impact 
 
Social function is defined as the ability of one to participate and engage in social and recreational 
activities. LRRC had an impact on social functioning as reported by five studies [185, 190, 193, 194].  
The impact on social function was assessed using qualitative interviews [194] or through quantitative 
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measures including EORTC QLQ-C30 [185, 193], EORTC QLQ CR38 [185, 193] and ad hoc 
questionnaires designed specifically for the study [190]. Camilleri-Brennan reported a greater impact 
on role functioning in patients with LRRC compared to disease-free patients [185]. The negative 
impact on social functioning is multifactorial with contributing factors including invasive diagnostic 
investigations, pre-operative treatments including chemoradiation and the operative burden with its 
high associated morbidity rate. Interestingly, the resumption of normal social activities is described to 
be a motivating factor to get better by patients [194].  
 
2.4.2.4 Symptoms 
 
Given the heterogeneous nature of LRRC with its variable disease pattern and the range of operative 
interventions available, patients present with and experience a multitude of symptoms affecting a 
range of systems, including the gastrointestinal, genitourinary and musculoskeletal systems. Such 
symptoms are a source of anxiety for patients in the pre-operative and post-operative periods. 
Furthermore, symptoms can be attributable to a number of factors including post-operative 
complications and disease re-recurrence.  A total of 9 studies commented on a variety of symptoms in 
patients with LRRC, with pain and gastrointestinal symptoms being the most commonly reported [27, 
185, 187, 188, 190, 193-195, 197]. 
 
• Pain 
Pain is a common presenting symptom in patients with LRRC, with this being the chief complaint 
in up to 40% of patients [27]. Pain is typically described to be pelvic, perineal or sciatic in nature. 
Mannaerts et al used an adhoc scale to report differences in post-operative pain based on initial 
subsite of pain, with worsening post-operative pain scores [190]. Esnaola et al reported the 
presence of pelvic or sciatic pain at presentation was a strong predictor of poor overall outcome 
[188]. 
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Two studies used the generic pain scale, the Brief Pain Inventory [199] to assess pain in this 
cohort of patients. You et al observed no differences in pain scores between patients treated 
curatively or palliatively over the length of their study [187]. However, this group demonstrated 
the prognostic significance of pain on overall survival, with patients reporting a pre-treatment 
pain intensity score of less than 4 surviving for a median of 3.8 years compared to 2 years in 
patients with scores of more than 4 (p=0.001). Conversely, Esnaola et al observed worsening pain 
scores in patients treated with non-surgical palliation over a 3 year period compared to those 
treated surgically, with median pain scores of 8 and 3 at 12 months (p=0.2), with long term 
survivors (> 3 years) of surgical resection reporting a median pain score of 0 [188]. Pain had a 
significant impact on QoL, with patients with low pain scores reporting better QOL scores 
compared to those with higher pain scores (p=0.001).  
 
• Gastrointestinal symptoms 
As expected patients with LRRC experience a greater degree of gastrointestinal (GI) symptoms 
compared to disease-free patients [185]. However, patients undergoing surgery for LRRC 
experience a considerable number of GI symptoms in the post-operative period related to 
incontinence and stoma-related problems, Mannaerts et al observed a 25% higher post-operative 
complaint rate in patients with LRRC compared to LARC [190].  
 
• Genitourinary symptoms 
Given the anatomical proximity of the neural plexus supplying the urogenital organs and the 
potential of disease invasion of these organs, a significant proportion of patients with LRRC will 
have a degree of urogenital dysfunction. This can be as a consequence of the primary surgery, 
radiotherapy, disease recurrence or recurrent surgery itself. Mannaerts et al reported significant 
post-operative urinary and sexual dysfunction in patients treated in a multimodal fashion 
(radiotherapy, surgery and intra-operative radiotherapy) for both LARC and LRRC, with these 
differences most pronounced in the female sex [189]. According to this group of authors, 56% of 
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patients with LRRC reported post-operative voiding dysfunction compared to 22% pre-
operatively (p=0.001). 
 
A proportion of patients will need a total pelvic exenteration to achieve complete disease 
clearance, leaving them with two stomas, typically a colostomy and a urostomy. Guren et al 
compared QoL outcomes between patients requiring urinary diversion in the form of a urostomy 
and those who had the urogenital system preserved, with no significant differences observed 
between the two groups and the reference group, which consisted of the Norwegian general 
population [193].  
 
• Musculoskeletal Symptoms 
The commonest musculoskeletal complaint in patients with LRRC is mainly that of lower limb 
weakness and pain leading onto subsequent difficulties with mobility. Mannaerts et al reported 
post-operative lower limb pain in 42% of patients compared to 21% pre-operatively, with 56% 
complaining of reduced lower limb strength in the post-operative period compared to 13% in the 
pre-operative phase, and walking difficulties reported by over half of all patients with LRRC 
[190]. Wright et al reported the qualitative comments of two patients, one of whom complained of 
intermittent foot swelling and difficulties walking and the second who complained of no lower 
limb control [194].    
 
2.4.2.5 Financial and Occupational Impact 
 
Impact upon financial and occupational status is defined as a change in economic status due to a 
change in the financial and occupational status following treatment of LRRC. This was commented 
upon in 3 studies through the use of the EORTC QLQ C30, EORTC QLQ CR38 and ad hoc 
questionnaires [185, 190, 193].  
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Guren et al reported higher scores of financial difficulty in patients undergoing surgery for LRRC and 
LARC with urinary diversion compared to patients without urinary diversion [193]. A similar 
observation was reported in patients with LRRC compared to disease-free patients following 
treatment of primary rectal cancer [185].  
Undergoing treatment for LRRC has significant impact upon occupational recovery. Mannaerts et al 
reported 50% of patients returned back to their former lifestyle following surgery for LRRC, with 
18% of patients returning to their former occupation and a further 13% of patients returning to lighter 
occupational duties [190]. 
 
2.4.2.6 Relationships with others 
 
An impact on relationships was defined as a change in the role and interactions in personal and 
professional relationships. This was commented on in two studies using the EORTC QLQ-BM30 
questionnaire and through the use of semi-structured qualitative interviews [192-194].  
Post-operatively, patients with urinary diversion for LRRC and LARC reported a greater dependence 
on others with regards to urostomy care and urostomy-related problems [193]. Wright et al, reported 
on the qualitative experiences of patients undergoing surgery for LARC or LRRC with health-care 
professionals, with a frustration expressed at the difficulties in obtaining a diagnosis of LRRC, and 
this impacting upon the doctor-patient relationship [194]. Similar experiences are expressed on 
Internet forums, whereby patients perceive some healthcare professionals delivering a pessimistic 
outlook following the diagnosis of LRRC with this having a subsequent negative effect on the doctor-
patient relationship.  Other opinions expressed on the Internet forums include the impact of LRRC on 
personal relationships including spousal and family relations, with an emphasis on these roles 
changing towards more of a carer status.  
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2.4.2.7 Communication 
 
Wright et al reported patient experiences following treatment for LARC or LRRC, with a number of 
patients reporting difficulties in communication with healthcare professionals, with regards to 
investigating new symptoms and referral to specialist services [194]. This is echoed across a number 
of cancer support group forums, on which the majority of the discussion revolves around the lack of 
communication between specialist services and primary care or referring consultant, leading to 
inappropriately long periods of waiting, perceived delays in treatment and subsequent anxiety. The 
general lack of communication leads to misperceptions regarding treatment intent, disease biology 
and prognosis amongst patients. 
 
2.4.2.8 Sexual Function 
 
Sexual function is defined as the ability to enjoy and engage in sexual activity. The impact on sexual 
function was reported by four studies using a combination of qualitative and quantitative measures, 
including the use of EORTC QLQ-CR38 and ad hoc questionnaires [185, 189, 193, 195]. 
Holman et al investigated the post-operative sexual function in 10 women who had undergone vaginal 
reconstruction following surgery for LRRC or LARC through the use of qualitative interviews and 
established quantitative assessment tools [195]. Two women in this group reported sexual function as 
satisfactory, describing intercourse as ‘pleasant’. In 40% of women sexual intercourse was difficult 
due to technical reasons, with the neovagina being too small or suffering complications of surgery 
leading to sexual difficulties [195]. There is significant anxiety experienced prior to embarking upon a 
sexual relationship following surgery and vaginal reconstruction, this is due to a combination of fear 
of using the neovagina and potential changes in sexual relationships [195].  This group of authors also 
explored sexual function in 5 men, reporting poor sexual functioning in men undergoing perineal 
reconstruction using a vertical rectus abdominis myocutaneous flap for LARC or LRRC compared to 
no reconstruction for LARC [195]. Mannaerts et al reported an adverse effect on sexual function 
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following surgery for LRRC, reporting a reduction in sexual activity from 68% pre-operatively to 
32% post-operatively (p=0.000) [190]. Similarly, Guren et al reported significant post-operative 
sexual dysfunction in patients with LARC/LRRC involving the genitourinary system, with 8 out of 9 
males in the treatment group reporting erectile dysfunction [193].  
 
2.5 Discussion 
 
This is the first systematic review to focus exclusively on HrQoL outcomes in patients with LRRC. 
The current literature reports the impact of LRRC on a wide range of HrQoL domains, including 
physical, psychological and social aspects. The complex management of LRRC including surgery 
(curative or palliative), the use of re-irradiation, intra-operative radiotherapy and chemotherapy has a 
detrimental effect on a wide range of HrQoL domains as well as having an impact upon financial 
circumstances, relationships with others and communication with health care professionals.  
 
There are only three studies in the current literature which focus exclusively on HrQoL and symptom 
control in patients with LRRC [27, 187, 188].  All the other studies report mixed outcomes on patients 
with LRRC, LARC and recurrent gynaecological malignancies. Although LARC and LRRC share 
some similarities in terms of diagnostic pathway and operative management, LRRC is a distinct 
clinical entity. LRRC has a distinct clinical course, with a tailored management strategy utilising a 
range of interventions including surgery, radiotherapy, intraoperative radiotherapy and chemotherapy 
dependent on treatment goals which may include cure, palliation of symptoms or improvement of 
HrQoL. LRRC is associated with poor clinical outcomes compared to LARC, with fewer radical 
resections, greater morbidity and poor overall survival [17, 177, 200, 201].  Due to the inherent 
differences in the disease biology and clinical course and outcomes of these two distinct clinical 
entities, it can be inferred that HrQoL outcomes may be different between the two groups, thus 
making it difficult to correctly interpret current literature. Differences between the two have been 
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illustrated in the current literature, with Mannearts et al demonstrating a higher degree of post-
operative morbidity, social handicap and functional impairment in LRRC patients compared to LARC 
patients [190]. 
 
The assessment of HrQoL is not uniform across the different studies reviewed, with baseline 
assessments being taken at a variable time periods following diagnosis or treatment of LRRC, with a 
median time interval of 1-149 months to initial assessment. Seven of the reported studies were 
retrospective in nature, with initial assessments taken at a median time interval of 11-149 months, as a 
result of this long lapse in time, assessments may have been subject to recall bias, with the potential of 
positive experiences reported by the survivors of LRRC participating in these studies. In the three 
published prospective studies and two abstracts, only three studies provided pre-treatment baseline 
HrQoL scores, with only 5 patients out of 45 with pre-treatment scores reported by Esnaola et al [188] 
and 54 out of 105 patients with similar scores in the study by You et al [187]. The lack of baseline 
data makes it difficult to assess the impact of different interventions on overall HrQoL and to assess 
the patient perceived risk-benefit ratio.  
 
Twelve of the studies included in the review were quantitative, basing HrQoL scores on a range of 
assessment tools, which included FACT-C, EORTC QLQ-CR29 and CR38, EORTC QLQ-BLM30, 
SF36 II and BPI. SF36 II is a generic measure of HrQoL, which is most commonly used in a wide 
variety of diseases [202].  The BPI is a similar generic tool used to assess clinical pain in a variety of 
disease scenarios, including cancer, and has been proven to be psychometrically proficient in 
producing valid and reliable findings [203, 204].  However, the disease-specific measures used by the 
studies including FACT-C, EORTC QLQ-CR38 and QLQ-CR29 are validated for primary colorectal 
cancer, across a range of cancer stages (Stage I – IV) and languages [143, 145, 205-211]. The EORTC 
QLQ-BLM30 was developed to measure HrQoL in bladder cancer [212]. It has not previously been 
used to measure urological outcomes in patients with LRRC or LARC, and therefore the results from 
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this study must be interpreted cautiously. Generic HrQoL assessment tools are designed to assess 
HrQoL in a broad range of populations. Disease-specific HrQoL are used to measure outcomes in 
specific disease populations. As a result, disease specific HrQoL measures have enhanced capability 
of detecting and evaluating subtle changes and differences between patient and treatment groups [170, 
213]. There are currently no disease-specific measures available to measure HrQoL in LRRC. The use 
of disease-specific HrQoL tools for primary rectal cancer is an inappropriate measure to assess 
outcomes in patients with LRRC. Data is of little value unless it has been obtained by the use of a 
validated questionnaire of proven applicability in the context concerned. 
 
There is little qualitative data available on the experiences of patients with LRRC. The only 
qualitative study identified was by Wright et al, which involved three out of ten patients with LRRC 
[194]. The study identified six themes, which included; 1. All that is important is your health, 2. 
Limited options, 3. Believe in your own intuitive sense of body, 4. Unanticipated morbidity, 5. 
Mistaken perception of cure and 6. Appropriately and timely information needed. These themes are 
not echoed in the current quantitative HrQoL assessment tools, suggesting LRRC has a different 
impact upon patients HrQoL compared to primary rectal cancer. On consultation of Internet support 
group forums, the emphasis tends to be on communication, the need for information and relationships 
between patients and healthcare professionals. This suggests further qualitative work is required to 
identify relevant HrQoL and PROs in this group of patients, prior to the development of a disease-
specific assessment tool, which will generate meaningful and relevant data. Holman et al used mixed 
methods to explore outcomes in patients undergoing vaginal and perineal reconstruction following 
surgery for LRRC and LARC [195]. This group used qualitative interviews exclusively in 10 women, 
focusing on sexual function and related outcomes. This is the first study to explore this theme in detail 
and therefore makes a significant contribution to current literature. However, the lack of similar 
qualitative data in men makes it difficult to draw any conclusions regarding gender differences in 
sexual function and overall impact on HrQoL following surgery for LRRC.  
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There are a number of limitations to the current literature, some of which are common throughout all 
the studies (Table 2.3). No disease specific measures were used, with only one study defining HrQoL 
[192].  The quality of the studies included in this review are generally poor, with the majority of 
studies scoring 5 on the Newcastle-Ottawa Scale, with only one study deemed to be of ‘good’ quality, 
with a score of 7 [191]. This combined with the majority of the studies being retrospective in nature 
has inherent bias associated with it. Furthermore, the use of non-validated HrQoL tools used to assess 
outcomes in mixed populations makes it difficult to draw any firm conclusions regarding the impact 
of LRRC and its treatments on HrQoL.  
 
Despite, the high compliance to HrQoL measures of over 64% in the identified studies, which is a 
crucial methodological requirement to avoid bias in results, the small numbers of patients involved in 
these studies mean they are usually underpowered to detect statistical and clinically significant 
differences.  Twelve studies reported the method of analysis, with only 3 studies outlining the 
handling of missing data and only half of the studies taking into account the clinical significance of 
HrQoL scores. These issues are essential to understanding whether there are any systematic 
differences between groups in HrQoL scores. The use of clinical significance in these studies helps 
the interpretation of results on a more meaningful basis and from a patient perspective, rather than 
simply from the position of statistical significance. 
 
2.6 Conclusion 
 
Current literature on HrQoL in LRRC provides an insight into the wide-ranging impact of this disease 
process and its subsequent management, despite the limitations in study methodology. To overcome 
these limitations, a disease-specific, validated and reliable outcome measure is required to provide 
robust data outcomes in this cohort of patients. This tool must then be used in a study incorporating a 
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large sample size of patients in a dedicated study measuring HrQoL outcomes across a range of 
centres and management strategies to truly elucidate the impact of LRRC on HrQoL. Measuring 
HrQoL using robust methodology will inform healthcare policy and current treatment guidelines and 
will provide information and understanding of patient specific needs. This will allow for a 
multidimensional emphasis to be placed on the management on LRRC, taking into account patients 
needs as well as disease specific goals i.e. cure or palliation, which will in turn improve patient 
outcomes and HrQoL. In the complex management of LRRC, PROs including HrQoL will inform the 
role of further radicalisation in the continuing evolution of the management of this disease process.  
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3 Chapter 3 - Systematic Review of Health-Related Quality of Life in Patients 
undergoing Pelvic Exenteration 
3.1 Background 
 
Pelvic exenteration (PE) whereby there is complete or partial removal of all of the pelvic viscera, 
vasculature, musculature and ligaments and part of the pelvic bony ring, is the second commonest 
operation carried out to ensure cure in patients with LRRC [15].  This radical operative procedure is 
not only reserved to achieve cure in LRRC, but is also used in a number of other advanced pelvic 
malignancies, including primary rectal cancer, gynaecological malignancies including ovarian, vulval, 
cervical cancer and urological malignancies including bladder and prostate cancer.  PE can be divided 
into total pelvic exenteration (TPE) or partial pelvic exenteration (PPE). TPE involves the removal of 
all pelvic organs, which necessitates the construction of two stomas. PPE can be further subdivided 
into anterior or posterior exenteration; the uterus, adnexa and bladder are removed during anterior PE, 
while the uterus and rectum alone are removed during a posterior PE.  
 
The differing tumour biology between different pelvic malignancies requiring a pelvic exenteration is 
reflected in the survival outcomes observed, with 5 year survival of 46-66% in primary rectal cancer 
[177, 200, 214, 215], 8-42% in LRRC [17, 200, 216, 217] and 45-56% in cervical cancer [200, 218]. 
However, it can be assumed the HrQoL issues posed by undergoing this operative intervention are 
common to all groups of patients, irrespective of underlying disease pathology due to the impact of 
the operation itself.   
 
In recent times, there has been an improvement in the overall survival in patients undergoing PE. This 
is attributed to improvements in radiological staging, better patient selection, greater use of 
neoadjuvant chemoradiation and advances in surgical technique. This has obvious implications on 
cancer survivorship with a greater proportion of patients presenting post-operatively to healthcare 
professionals with a range of physical and psychological issues. It is therefore essential to document 
and understand HrQoL issues relevant to this cohort of patients.  
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3.2 Aims 
 
The aims of this review were to undertake a comprehensive and systematic review of the current 
literature on HrQoL in patients undergoing a PE, to identify the key HrQoL issues in this population 
and which instruments were used to measure these outcomes. 
 
3.3 Methodology 
 
This systematic review was conducted according to a pre-specified protocol based on guidance from 
the Centre for Reviews and Dissemination [219]  and the Cochrane Handbook [220]. The review is 
reported in line with the PRISMA statement[221]. 
 
3.3.1 Search Strategy 
 
Literature searches were performed in three databases: MEDLINE (1975 - January 2013), EMBASE 
and CINAHL. The searches were limited to the English language. The major subject heading, PE, was 
combined with ‘health-related quality of life’ or ‘quality of life’ or ‘body image’ or ‘physical distress’ 
or ‘psychological distress’ or ‘physical function’ or ‘psychosexual’ or ‘questionnaires’.  
The search was designed to identify qualitative research that explored patients’ subjective experience 
and quantitative studies that measured HrQoL using standardised measures. 
 
Study Inclusion Criteria 
Studies were included if they fulfilled the following criteria; they reported outcomes of patients 
undergoing PE, including symptom control, HrQoL outcomes and impact on function. Patients 
undergoing surgery and palliative treatments were included. Studies were excluded if HrQoL or 
functional outcomes were not measured. Case reports, reviews and letters were excluded. 
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Selection of Studies 
Abstracts from studies retrieved were screened for relevance; studies that did not meet inclusion 
criteria at this stage were excluded. Studies assessed as potentially relevant, or where relevance was 
ambiguous, were obtained in full, for further scrutiny. 
 
3.3.2 Data Extraction  
 
Data extraction was conducted independently by two reviewers (Deena Harji, DH and Ben Griffiths, 
BG) into a pre-specified data sheet. Any discrepancies in data extraction were resolved through 
discussion and consultation with an independent reviewer. The following information was extracted 
from each study; first author, year of publication, study population characteristics, number of patients, 
study design, HrQoL assessment tool used, median time interval between diagnosis/treatment and 
assessment, main findings and quality of study.  
 
3.3.3 Data Quality 
 
The methodological issues surrounding the quality of the studies assessing and measuring HrQoL and 
functional outcomes in PE were considered A pragmatic approach was undertaken to include all 
studies reporting HrQoL outcomes and patient testimony irrespective of the quality of the study, due 
to the sparsely available literature on this topic. However, a quality analysis was undertaken of all 
published quantitative and qualitative studies. 
Qualitative analyses were carried out in accordance with the Critical Appraisal Skills Programme 
Checklist (CAPS) for qualitative data[222, 223].  This is a checklist consisting of 10 questions which 
assesses the rigour, credibility and relevance of the qualitative data.  Quantitative data was assessed 
against the Newcastle-Ottawa Scale (NOS) for assessment of non-randomised studies [182]. The NOS 
contains eight items, categorised into three dimensions including selection, comparability and 
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outcome for cohort studies or exposure for case control studies. A star system is used to allow a semi-
quantitative assessment of study quality; the NOS star ratings range from 0-9, with a rating of 7 or 
more indicating a high quality study.  
 
 
3.3.4 Data Analysis 
 
All studies were evaluated for the following criteria; a definition of HrQoL, use of a valid and reliable 
instrument, compliance issues, handling of missing HrQoL data, reporting of statistical methods, 
examination of clinical significance and detailed reporting of results. 
A combined synthesis of qualitative and quantitative research was performed. This involves 
generation of a priori distribution of factors and their relative importance using the principles of 
content analysis to generate common categories and themes from the study findings [224, 225]. The 
principles of triangulation for integrating mixed methods data were used to determining consistency 
between findings from each data set [183, 184]. A meta-synthesis of the qualitative data was carried 
out, with all relevant findings grouped together. Common categories and themes were identified from 
the study findings. A category was determined by grouping similar findings reflecting similar 
underlying constructs. In turn categories were synthesised into themes, if they were sufficiently 
similar, this enabled the summary of all evidence for a particular domain. The same process was 
carried out for the quantitative data, with findings from the quantitative data set encoded to the 
categories identified from the meta-synthesis if appropriate, or to new categories. This process 
enabled comparison between findings from the two types of data sets (qualitative and quantitative), 
thus enabling the review of all emerging categories and assessing for consistency, discrepancy and 
complementarity between two the data sets.  
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3.4 Results 
 
The search strategy identified a total of 194 references. Thirty-six duplicates and 138 inappropriate 
references were identified through examining the abstracts and were excluded (Figure 3.1). The 
remaining 20 abstracts were retrieved for further evaluation, of which 19 were included in the review. 
Studies were excluded if they did not have sufficient details regarding PROs in this cohort. This 
identified a total of 585 patients who had undergone a PE for a variety of advanced pelvic 
malignancies. Four hundred and seventy three (80.8%) patients underwent surgery for gynaecological 
cancer, 21 (3.6%) patients for colorectal cancer, 20 (3.4%) patients for LRRC, 15 patients for a 
primary rectal cancer or LRRC (2.5%), 15 (2.5%) patients for urological cancer and 8 (1.4%) for anal 
cancer. The origin of the pelvic malignancy is unknown in 33 (5.6%) patients. A total of 27 (4.6%) 
men and 427 (72.9%) women participated in the studies.  The gender of participants is unknown in 
131 (22.3%). Overall median age at the time of completing questionnaires or participating interviews 
was 54 years.  
 
 
Figure 3-1 Flowchart of Studies Retrieved From Literature Search 
 
Studies identified from literature search 
- 194 
Studies Excluded – 174 
Inappropriate –138  
Duplicates - 36 
Studies selected after reading abstracts - 
20 
Studies included in the present review - 
19 
Studies Excluded - 1 
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Of the 19 studies identified, 5 were qualitative studies [226-230] and 14 were quantitative studies 
[186, 191, 231-242]. Study design included 12 retrospective cohort studies, 1 retrospective case-
control study, 5 prospective longitudinal studies and 1 prospective cohort study. A summary of the 
main points of each study is highlighted in Table 3.1, with quality analysis of all studies outlined in 
Table 3.2 and Table 3.3.  Overall, the quality of the qualitative studies included in this review were of 
good quality with 50-90% compliance with the CASP checklist. The quality of the quantitative studies 
was variable, with the majority of studies scoring over 4 on the NOS scoring system; only one study 
was identified to be of poor quality with a score of 3 [233] and two studies identified to be of good 
quality [235, 237]. 
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Table 3-1: Summary Findings of Studies Included Assessing HrQoL in PE 
 
                  
             
Author and 
Year 
 
 
Cancer Type 
 
 
No of 
Patients 
 
 
Median 
Age 
 
 
Sex 
M:F 
 
 
Study 
Design 
 
 
HrQoL 
Assessment 
Median Time 
Interval 
Between 
Diagnosis/ 
Treatment 
and 
Assessment 
 
 
Assessment 
Intervals 
 
 
Main Findings 
Dempsey[226] 
1975 
Gynaecological 
malignancy 
16 50 0:16 Prospective 
Longitudinal 
Study 
Qualitative 
Interview 
Pre-operative 
Assessment 
No comment Post-operatively patients were able to 
resume their pre-operative 
occupational, recreational and social 
status.  
Vera [227] 
1981 
Gynaecological 
malignancy 
19 51 0:19 Retrospective 
Cohort Study 
Qualitative 
Interview 
6 months - 9 
years 
One off 
assessment 
Women reported long term impact on 
sexual function and on occupational 
and social activities. However, 
despite that all patients stated their 
lives had improved following surgery 
and believed they would continue 
improving.  
Corney [228] 
1993 
Gynaecological 
malignancy 
8 55 0:8 Retrospective 
Cohort Study 
Qualitative 
Interview 
30 One off 
assessment 
66% of women complained of sexual 
dysfunction post-operatively with 
lack of sexual desire being the 
commonest issue.  
Mirhashemi 
[229] 
Gynaecological 
malignancy 
9 41 0:9 Retrospective 
Cohort Study 
Symptom scales No comment One off 
assessment 
78% of women undergoing PE and 
vaginal reconstruction had resumed 
sexual intercourse in the post-
operative period and were satisfied 
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2002 with overall sexual function.  
Carter [230] 
2004 
Gynaecological 
malignancy 
6 57 0:6 Retrospective 
Cohort Study 
Qualitative 
Interview 
4 - 44 months One off 
assessment 
Patients reported a decrease in sexual 
activity and interest combined with 
difficulties in body image. However, 
an improvement in mood, an increase 
in activities and adaptation to stomas 
was noted over time.  
Love  [231] 
2013 
Primary rectal 
cancer and 
locally recurrent 
rectal cancer 
(15) / Anal (8)/ 
Gynaecological 
(2) 
26 62 0:26 Retrospective 
Cohort Study 
Sexual Function 
Vaginal 
Changes 
Questionnaire 
(SVQ) 
26 months One off 
assessment 
14% of patients were sexually active 
in the post-operative period.  
Rezk [232] 
2012 
Gynaecological 
malignancy 
16 58 0:16 Prospective 
Longitudinal 
Study 
EORTC QLQ-
C30/ EORTC-
QLQ CR38/ 
EORTC QLQ-
BLM30/ BFI/ 
BPI-SF IADL/ 
CES-D/ IES-R 
Pre-operative 
Assessment 
3 monthly QoL declined at 3 months but 
returned to baseline at 12 months, 
including the ability to perform 
instrumental daily activities, sexual 
function and role function.  
Guimaraes 
[233] 
2011 
Gynaecological 
malignancy 
13 58 0:13 Retrospective 
Cohort Study 
Symptom 
Scales 
8 months One off 
assessment 
All patients achieved pain control, 
with a reduction in the use of opioid 
analgesia and control of malodorous 
discharge.  
Forner [234]  
2011 
Gynaecological 
malignancy 
100 56 0:10
0 
Retrospective 
Cohort Study 
SF12 37 months One off 
assessment 
Comparable QoL scores between 
patients undergoing an ileal conduit 
and ileocaecal pouch for a PE 
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Zoucas [186] 
2010 
Colorectal/ 
Anal/ Ovarian/ 
Cervical/ 
Uterine/Sacral/ 
Prostatic 
 
 
22 
 
 
- 
 
 
- 
 
Prospective 
Longitudinal 
Study 
 
EORTC QLQ-
C30 
 
 
4 months 
 
 
4 and 16 
months 
 
HrQoL improved at 16 months post-
operatively.  
Austin[191] 
2010 
Primary rectal 
cancer and 
locally recurrent 
rectal cancer 
37 62 16:2
1 
Retrospective 
case-control 
cross-
sectional 
study 
FACT-C/SF36 
II 
47 months One off 
assessment 
Patients undergoing PE had similar 
QoL scores compared to patients 
undergoing anterior resection or 
abdominoperineal excision.  
Hawighorst 
[236] 
2004 
Gynaecological 
malignancy 
129 47 0:12
9 
Prospective 
Cohort Study 
Cancer 
Rehabilitation 
Evaluation 
System 
(CARES)/Preop
erative Anxiety 
(STAI) 
Pre-operative 
Assessment 
One off 
assessment 
Women due to undergo PE had poor 
preoperative QoL compared to 
women due to undergo a Wertheim 
procedure. Patients with high 
preoperative levels of anxiety had 
significantly poorer physical and 
psychosocial functioning, and 
reported poor medical interaction.  
Hawighorst-
Knapstein 
[235] 
2004 
Gynaecological 
malignancy 
64 47 0:64 Prospective 
Longitudinal 
Cohort Study 
Cancer 
Rehabilitation 
Evaluation 
System 
(CARES)/ 
Strauss-Appelt 
Body Image 
Pre-operative 
Assessment 
4 and 12 
months 
Patients undergoing PE requiring two 
stomas had poorer quality of life and 
body image compared to those with 
one stoma or those undergoing 
Wertheims hysterectomy.  
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Hawighorst-
Knapstein 
[237] 
1997 
Gynaecological 
malignancy 
28 49 0:28 Prospective 
Longitudinal 
Study 
Cancer 
Rehabilitation 
Evaluation 
System 
(CARES)/ 
Strauss-Appelt 
Body Image 
Pre-operative 
Assessment 
4 and 12 
months 
Patients with two stomas had poor 
quality of life one year post-
operatively, compared to patients 
with one stoma or no stomas.  
Roos[238] 
2004 
Gynaecological/
Urological 
malignancy 
25 60 0:25 Retrospective 
Cohort Study 
EORTC QLQ-
C30/       
EORTC QLQ-
OV28/ 
Symptom scales 
59 months One off 
assessment 
Women undergoing PE had poor 
physical, social and role functioning 
with a greater degree of financial 
difficulty compared to healthy 
Danish controls and women with 
cervical cancer. Total exenteration 
had a greater impact on role and 
social functioning, on body image 
and attitude towards the disease 
compared to partial exenteration.   
Woodhouse 
[239] 
1995 
 10   Retrospective 
Cohort Study 
Symptom 
Scales 
No comment One off 
assessment 
80% of patients achieved excellent 
palliation of symptoms following PE. 
Brophy [240] 
1994 
Colorectal(21)/ 
Urinary (9)/ 
Gynaecological 
malignancy  (5) 
 
35 
 
60 
 
11:2
4 
 
Retrospective 
Cohort Study 
 
Symptom 
Scales 
 
Pre-operative 
Assessment 
 
One off post-
operative 
assessment 
88% of patients reported an 
improvement in QoL. 60% achieved 
control of pain and 50% of patients 
achieved control of symptoms of 
bleeding and fistulae.  
Gleeson [241] 
1994 
Gynaecological 
malignancy 
8  0:8 Retrospective 
Cohort Study 
Symptom 
Scales 
15.5 months One off 
assessment 
87.5% of women reported long term 
sexual dysfunction, with 37.5% 
complaining of long term symptoms 
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of vulval pain.  
Andersen[242] 
1983 
Gynaecological 
malignancy 
15 54 0:15 Retrospective 
Cohort Study 
Symptom 
Checklist-90/ 
Beck 
Depression 
Inventory /Katz 
Social 
Adjustment 
Scales/ Marital 
Adjustment/ 
Derogatis 
Sexual 
Functioning 
Inventory/ 
Heterosexual 
Behaviour 
Hierarchy/ 
Sexual Arousal 
Inventory 
5 years and 6 
months 
One off 
assessment 
Women report long term sexual 
dysfunction, with symptoms of mild 
depression however were well 
adjusted socially, reporting active 
social lives.  
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Table 3-2 Quality Assessment of Qualitative Studies 
Author 
Clear 
Statement of 
Aims 
Is 
Qualitative 
Methodology 
Appropriate 
Was the 
research 
design 
appropriate 
to address 
the aims of 
the 
research? 
Was the 
recruitment 
strategy 
appropriate 
to the aims of 
the research? 
Was the 
data 
collected in 
a way that 
addressed 
the 
research 
issue? 
Has the 
relationship 
between 
researcher 
and 
participant 
been 
adequately 
considered?  
Have ethical 
considerations 
been taken into 
consideration? 
Was the 
data 
analysis 
sufficiently 
rigorous? 
Is there a 
clear 
statement 
of 
findings? 
How 
valuable is 
the 
research? 
Dempsey [226]            
Vera [227]            
Corney [228]           
Mirhashemi [229]           
Carter [230]           
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Table 3-3 Quality Assessment of All Quantitative Studies 
 
CASE-CONTROL STUDIES 
 SELECTION COMPARABILITY EXPOSURE OVERALL 
SCORE 
Forner [234] ** * *** 6 
Austin [191] *** ** ** 7 
Roos [238] ** * ** 5 
 
COHORT STUDIES/CASE SERIES 
 SELECTION COMPARABILITY OUTCOME OVERALL 
SCORE 
Love [231] ***  * 4 
Rezk [232] *** * ** 6 
Guimaraes [233]  *  ** 3 
Zoucas [186] ** * ** 5 
Hawighorst 
[236] 
*** * ** 6 
Hawighorst-
Knapstein [235] 
**** * ** 7 
Mirhashemi 
[229]  
**  ** 4 
Hawighorst-
Knapstein [237] 
**** * ** 7 
Woodhouse 
[239] 
**  ** 4 
Brophy [240] **  ** 4 
Gleeson   **  ** 4 
Andersen  **  ** 4 
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HrQoL was the main primary endpoint in 12 studies [191, 226-228, 230-232, 235-238, 242], however 
only one study defined the meaning of HrQoL [235] (Table 3.4). Compliance with completion of 
HrQoL assessments was reported in 73% of studies included in this review, with reported compliance 
ranging from 46-100%. Baseline assessments of HrQoL assessments prior to the initiation of 
treatment were available in six studies [231, 232, 235-237] [226], with the majority of assessments 
being carried out at a median timeframe of 4-59 months. Two studies had a long lag period between 
treatment and assessment of HrQoL undertaking assessments at 5.5 and 9 years respectively [227, 
242].   
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Table 3-4 Statistical and Design Issues in Studies Assessing HrQoL 
Author 
Definition 
of HrQoL 
Primary 
Outcome 
Compliance 
Handling of 
Missing Data 
Baseline 
Characteristics 
Reported 
Method of 
Analysis 
Reported 
Follow-Up 
Data 
Reported 
HrQoL 
significance 
addressed 
HrQoL 
significant 
Dempsey [226] No HrQoL 69% Not reported Yes No N/A No No 
Vera [227] No HrQoL 76% Not reported No No N/A No No 
Corney [228] No HrQoL 76% Not reported No No N/A No No 
Mirhashemi [229] No Clinical Not reported Not reported No No N/A No No 
Carter [230] No HrQoL 55% Not reported No Yes N/A No No 
Love [231] No HrQoL 87% Not reported Yes Yes Yes Yes Yes 
Rezk [232] No HrQoL 80% Not reported Yes Yes Yes Yes Yes 
Guimaraes [233] No Clinical 100% N/A No No No No No 
Forner [234] No Clinical Not reported Not reported No No No No No 
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Zoucas [186] No Clinical Not reported Not reported No Yes Yes Yes Yes 
Austin [191]  No HrQoL 84% Not reported No Yes N/A Yes No 
Hawighorst-
Knapstein [235]  No HrQoL 52% Not reported Yes Yes Yes Yes 
Yes 
Hawighorst-
Knapstein [237] Yes HrQoL 46% Not reported Yes Yes Yes Yes 
Yes 
Hawighorst [236] No HrQoL Not reported Not reported Yes Yes Yes Yes Yes 
Roos [238] No HrQoL 86% Not reported No Yes No Yes Yes 
Woodhouse [239] No Clinical 100% N/A No No Yes No No 
Brophy [240] No 
Symptom 
Control Not reported Not reported Yes No Yes Yes 
Yes 
Gleeson [241] No Functional 50% Not reported No No Yes No No 
Andersen [242] No HrQoL 100% Not reported N/A Yes N/A No No 
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Quality of Life Trajectory 
Four prospective longitudinal studies were identified which highlighted the HrQoL trajectories 
experienced by patients undergoing PE [186, 232, 235, 237], of these 4 studies, 3 studies had pre-
operative baseline data [232, 235, 237]. All four studies reported similar patterns of recovery of 
HrQoL domains, with an initial deterioration in HrQoL scores in the immediate post-operative period 
of 3-4 months, followed by a gradual improvement or a return to baseline scores at 12-16 months 
post-operatively. Rezk et al reported poor scores of emotional function, insomnia, future perspectives 
and stress-related ideation at baseline, with continuing improvement in these scores at 3 months and 
12 months, with the worse scores observed at baseline [232].  
 
Total versus Partial Pelvic Exenteration 
Patients undergoing a TPE experience a greater degree of post-operative morbidity due to the greater 
radicality the operative approach necessitates which in turn has an adverse effect on HrQoL outcomes, 
compared to patients undergoing a PPE. Supporting evidence for this comes from Hawighorst-
Knapstein et al, who reported poor overall HrQoL outcomes in patients with two stomas compared to 
patients with one stoma, with deteriorating HrQoL scores in the this group during the first 12 months 
post-operatively, compared to improvement in these scores in the latter group [235, 237]. Similarly, 
Roos et al reported lower HrQoL scores observed in patients who underwent a TPE compared to a 
PPE, with the greatest differences observed in the domains of role functioning, social functioning, 
body image and attitude towards disease [238].  
 
3.4.1 Identified HrQoL Themes 
 
One hundred and eighty four findings, 33 categories and 9 themes were identified through scrutiny of 
the literature (Table 3.5). 
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Table 3-5 Synthesised Categories and Themes Identified 
Theme Category 
 
 
Body Image 
Adjustment to bodily changes 
Attractiveness 
Self-image 
Self-confidence 
 
Social Impact 
Disruption of activities of daily living 
Reduction in social and recreational activities 
 
 
Sexual Function 
Interest in sex and sexual activities 
Sexual satisfaction 
Physical difficulties with sexual intercourse 
Psychological difficulties with sexual intercourse 
Sexual difficulties affecting relationships 
 
 
Treatment Expectations 
Length of recovery 
Pain expectations 
Complications 
Treatment intent 
Cure and disease recurrence 
 
 
Symptoms 
General Health 
Gastrointestinal Symptoms 
Stoma issues and complications 
Pain 
 
Communication 
Communication with partner 
Communication with medical professionals 
Need for medical information 
 
Psychological Impact 
Impact on mental and emotional well being 
Future Perspective 
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Anxiety 
 
Relationships 
Change of role 
Dependence on others 
Adjustment of relationships 
Relationship with medical professionals 
 
Work and Finance 
Occupational recovery 
Financial difficulties 
Adaptation of work environment to accommodate restrictions imposed 
upon by surgery 
 
 
3.4.1.1 Body Image 
 
Four studies, consisting of 133 (22.7%) female patients undergoing PE for gynaecological (95.5%) or 
urological (4.5%) malignancy, reported the impact of PE on body image [232, 235, 237, 238].  Two of 
these studies used the Stauss and Appelt Body Image questionnaire to evaluate the impact on body 
image [235, 237]. The remaining two studies reported the impact on body image using items from the 
European Organisation for Research and Treatment of Cancer colorectal cancer specific module 
QLQ-CR38 and the EORTC QLQ-OV28 ovarian cancer specific module [238]. 
Two prospective, longitudinal studies, reported an initial deterioration in body image scores, with 
improvement towards baseline scores at 12 months [232, 237].  A third prospective, longitudinal 
study of 64 women with gynaecological malignancy reported deteriorating scores of attractiveness 
and self-confidence in the first post-operative year, with baseline scores of 11.4 compared to 12 
month scores of 9.96 on the Stauss and Appelt Body Image questionnaire, p=0.000 [235].  Patients 
with two stomas had higher scores concerning body uncertainty/discomfort and less 
attractiveness/self-confidence 12 months post-operatively compared to the pre-operative period [235, 
237]. Furthermore, these scores were statistically significantly higher in this cohort of patients 
compared to patients with one or no stomas (p<0.05) [235, 237, 238]. Age did not have an impact 
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upon perceptions of body image [238]. Patients undergoing surgery for primary gynaecological or 
urological malignancy had lower scores for negative body image compared to patients undergoing 
surgery for recurrent malignancy [238].  
 
3.4.1.2 Social Impact 
 
Seven studies, four quantitative [24, 232, 238] and two qualitative [226, 227], commented upon the 
impact of PE on social function. Rezk et al documented an initial decline in social functioning scores, 
with gradual improvement over time and a return to baseline scores at 12 months post-operatively 
[232]. Austin et al reported no differences in post-operative social well being between patients 
undergoing PE and surgery for primary rectal cancer [191].   
The earliest qualitative studies on patients undergoing PE was carried out in the 1970s by Dempsey et 
al [226]. This group conducted qualitative interviews with 17 women who had undergone PE for 
gynaecological malignancy. All women in this study reported resumption of previous hobbies and 
social activities in the post-operative period, however it took a prolonged period of time to resume 
slightly more vigorous activities such as bowling, and an adaptation to other activities such as 
swimming [226]. Furthermore, this group of patients reported no change in social interactions and 
relationships [226]. Andersen et al reported similar findings, with the majority of patients resuming 
social activities, however did comment upon a subset of patients adapting their social activities to 
accommodate their post-operative functional status [242].  Furthermore, women who were able to 
maintain social activities post-operatively displayed lower levels of psychological distress [242].  
 
3.4.1.3 Sexual Function 
 
Twelve studies reported the impact of PE on sexual function using a variety of questionnaires and 
semi-structured interviews, with conflicting results. These 12 studies reported the findings of 240 
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women who underwent PE for gynaecological (87.5%), primary rectal or LRRC (6.7%), bladder 
(2.5%) or anal canal (3.3%) malignancy. Studies reported between 50-100% of women were sexually 
active pre-operatively, this deteriorated to 12.5-18% in the post-operative period [226-228, 231], with 
only one study reporting higher rates of post-operative sexual activity [229].  
Two of the ten studies reported satisfactory post-operative sexual function following PE [229, 232], 
with Rezk et al reported the return of sexual function scores to baseline at 12 months following an 
initial dip in scores at 3 months in 16 women undergoing PE for gynaecological malignancy [232].  
Mirhashemi et al reported satisfactory post-operative sexual function in 9 women who had undergone 
PE with vaginal reconstruction, with 78% of women reporting successful sexual intercourse [229].  
Six studies reported significant post-operative disruption in sexual function using a range of 
quantitative measures [231, 235, 237, 238, 241, 242]. These studies documented deteriorating post-
operative sexual function scores in the first post-operative year [235, 237], with poor scores observed 
in women with two stomas [237, 238]. Furthermore, women undergoing PE had poor sexual function 
scores when compared to women undergoing Wertheim’s hysterectomy [235] and reported a 
reduction in sexual activity far below the norms provided for sexually dysfunctional women [242]. 
Four studies explored reasons behind sexual dysfunction following PE using qualitative interviews 
[226-228, 230], reasons cited for lack of sexual activity, included lack of sexual desire [226-228, 
231], vaginal pain, bleeding and dryness [228], difficulties in engaging in intercourse with a 
neovagina [227, 230] and stomas affecting sexual intercourse [227] . Corney et al reported 46% of 
women felt moderate-severe mental and emotional distress as a result of their sexual problems [228].  
 
3.4.1.4 Treatment Expectations 
 
Patient treatment expectations are dependent on operative intent i.e. curative or palliative. Patients 
often view exenterative surgery as the only alternative to death from advanced pelvic malignancy, 
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viewing this as the only option of potential cure and are therefore willing to accept the risks involved 
[230].  
In appropriately selected patients, PE can be undertaken to achieve appropriate palliation of 
distressing symptoms [233, 239, 240].  Brophy et al reported an improvement in quality of life in 88% 
of patients following palliative PE, with 60% reporting improvements in pain control and 50% 
reporting improvement in bleeding or fistulae [240].  
Carter et al reported the qualitative experiences of patients treatment experiences regarding PE 
surgery, they reported all 6 women were surprised and distressed by the length of recovery and 
despite adequate pre-operative information felt unprepared regarding complications [230]. Vera et al 
reported 36.8% of patients reported the general recovery following PE to be the most difficult thing to 
contend with [227]. Rezk et al reported patients had high expectations of pain pre-operatively, 
however found pain scores remained static throughout a 12 month post-operative period [232].  The 
majority of patients in this study also reported their actual recovery time to match up to their 
expectations, with only 25% of patients reporting a longer than expected recovery time [232].  
 
3.4.1.5 Symptoms 
 
Given the advanced nature of the range of malignancies requiring a PE and the radical nature of the 
surgery, patients present with and experience a range of symptoms, affecting general health as well as 
a variety of systems. 
• General Health 
Overall, general health deteriorates in the initial post-operative period, with patients experiencing 
greater fatigue and lethargy, however with recovery and time, this returns to normal [232]. Roos 
et al demonstrated patients undergoing PE reported high scores of fatigue, insomnia and poor 
appetite, compared to the healthy population and women undergoing surgery for cervical cancer 
[238].  It is this general deterioration in health which has far reaching effects, with women 
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reporting this deterioration to be a key factor in the delayed return to normal daily activities 
including work [226].  
 
• Gastrointestinal Symptoms 
Gastrointestinal symptoms, such as abdominal pain and distension are commonly reported in the 
post-operative period [232, 238]. Rezk et al reported a higher incidence of gastrointestinal 
symptoms, including flatulence, at 12 months post-operatively [232].  
 
• Pain 
Pain is a common complaint amongst patients undergoing PE, with patients typically describing 
abdominal or pelvic pain. Patients have high expectations of pain in the pre-operative period 
[232], however pain scores are static in the post-operative period and are comparable to scores in 
the healthy population [232, 238].  
 
The distressing symptoms of pain and its wide ranging impact on overall HrQoL, is one of the 
most common indications for palliative PE [233, 239, 240]. Guimaraes et al reported resolution 
on pain with a reduction in opioid analgesia use in 13 patients undergoing palliative PE, with 
reports of an overall 2 year survival of 15.4% [233].  
 
• Stoma Issues and Complications 
Overall, the permanence of the stoma in patients undergoing PE is a source of physical and 
psychological distress, contributing to issues concerning body image and sexual function, 
engagement in social activities, combined with the practicalities of managing a stoma [226, 
227, 230]. Vera et al reported a third of patients undergoing PE found the adaptation of life to 
accommodate a stoma was the most disruptive aspect of undergoing surgery [227].  However, 
following a period of adjustment the majority of patients accepted the stoma with resolution 
of any previous issues [226, 227, 230].   
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There is conflicting evidence regarding the impact of one permanent stoma as per PPE and 
two permanent stomas as per TPE.  Hawighorst-Knapstein et al reported women undergoing 
TPE had poor scores of physical, psychosocial, sexual and marital function compared to 
women undergoing PPE with one stoma (p=0.003) and no stomas (p=0.008) 12 months post-
operatively [237]. Similar findings were reported by Roos et al, with poor scores of emotional 
functioning, social functioning, body image and attitude towards disease documented in 
patients undergoing TPE compared to PPE (p <0.05) [238]. Conversely, Austin et al reported 
comparable HrQoL scores between patients undergoing TPE and PPE [191]. 
 
To avoid the creation of a second permanent stoma, occasionally a continent pouch can be 
created as an alternative. Forner et al reported their findings of 59 patients undergoing TPE, 
of which 22 patients had an ileocaecal pouch constructed as opposed to a traditional ileal 
conduit, HrQoL scores were higher in the pouch group compared to the stoma group (81 
versus 56, p=0.10) [234].  However, operating times were longer in the pouch group, with a 
greater number of post-operative complications observed.  
 
3.4.1.6 Communication 
 
Corney et al reported 105 women undergoing PE would have liked more information on their disease, 
operation and recovery [228]. Furthermore, 28% of women would’ve like more information regarding 
sexual matters and a further 26% of women felt their partner had received inadequate information 
[228]. Similarly, Carter et al, reported despite women receiving information pre-operatively, they felt 
it was inadequate in preparing them for their post-operative recovery and potential complications 
[230].  
Dempsey et al and Vera et al reported upon the communication with and impact upon partners; 
reporting a range of reactions, from shock and grief to hope [226, 227]. All patients in a relationship 
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found the communication between themselves and their partner to be a great source of support [226, 
227].  Conversely, Carter et al reported women found it difficult and uncomfortable discussing 
surgery and the subsequent body changes with their families and wider social circle due to feelings of 
embarrassment, shame, stigma and fear of rejection [230].  
Hawighorst et al explored the patient-physician relationship pre-operatively in women undergoing 
surgery for gynaecological malignancy [236]. They found no differences in medical interaction 
between women due to undergo a PE compared to a Wertheim hysterectomy [236]. However, they did 
report women expressing higher levels of anxiety stated a significant lack of medical explanation, 
expressed more difficulties in understanding medical information, asked doctors more questions and 
felt helpless in the medical setting [236].  
 
3.4.1.7  Psychological Impact 
 
The psychological impact of PE and the emotions expressed by patients is a dynamic process, with 
different emotions expressed at different stages of treatment. Qualitative research in this field reports 
initial emotions of shock and fear, followed by an acceptance and a hope for cure, with occasional 
symptoms of sadness and depression in the preoperative period [226, 227]. Motivating factors cited 
during this period are based on watching families growing up and the resolution of symptoms. 
Immediate postoperative feelings and emotions are generally negative, with feelings of depression 
regarding the future and bodily changes, feelings of frustration and loss of independence and worries 
regarding the impact upon others [226, 227, 230]. Vera et al explored the long term psychological 
impact following PE surgery, and found patients generally felt their lives had improved following 
surgery and would continue to improve, with a great deal of hope expressed [227]. 
A number of authors have used quantitative measures to assess psychological impact, with similar 
results to qualitative data. Rezk et al reported stress-related ideation and patients perspective for the 
future were at there worst during the pre-operative period and improved significantly during the first 
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12 months post-operatively [232]. Furthermore, the same authors observed a decline in post-operative 
depression levels over the same time frame [232]. Similar findings were reported by Hawighorst-
Knapstein et al, who reported a reduction in psychosocial scores over 12 months in patients 
undergoing PPE, however in patients undergoing TPE, these scores deteriorated much more 
significantly [235, 237]. The same group of authors examined the effects of pre-operative anxiety of 
HrQoL, and found women expressing higher levels of anxiety had poor scores in HrQoL domains 
compared to women with moderate levels of anxiety, irrespective of the operative procedure [236].  
 
3.4.1.8 Relationships 
 
Personal and marital relationships are most affected by exenterative surgery, with a range of 
outcomes. Early reports from Vera et al suggested a small proportion of patients were abandoned by 
their spouses following diagnosis and impending surgery, however the majority of partners expressed 
initial support and were hopeful of cure [227]. Dempsey et al reported similar reactions by both the 
patients’ and their husbands’ to the initial diagnosis, with all husbands going on to play a supportive 
role subsequently [226]. Corney et al explored the impact of PE on marital status and sexual function, 
reporting all 8 women undergoing PE felt their marital satisfaction had improved or stayed the same, 
however 47% of women indicated a deterioration in their sexual relationship [228].  Andersen et al 
reported post-operative marital adjustment scores similar to average non-distressed couples at a 
median of 5 years post-operatively [242].  
PE surgery can have an adverse effect on personal relationships, due to potential changes in roles, 
bodily changes and sexual function.  Roos et al reported higher scores of disruption within 
relationships in younger women undergoing PE surgery [238], with similar reports from Corney et al 
who reported the end of 5 marriages in women aged 32-45 following surgery [228].  The presence of 
two stomas can have a greater impact on marital status, with greater marital disruption in this group 
compared to patients with one stoma [237]. These adverse effects extend beyond personal 
relationships and can effect family life and the wider social network, due to changes in role and need 
86 
for dependence on others [230]. Carter et al reported the qualitative experiences of 11 women 
undergoing PE surgery, of which the majority of women were unwilling to share their body image for 
fear of shame, embarrassment and rejection [230]. The majority of patients in this study felt feelings 
of guilt and were worried about being a burden upon their families.  Similar qualitative research has 
revealed immediate post-operative concerns involve families and children and the impact of surgery 
upon them [227].   
Patients with high levels of preoperative anxiety have poor relationships with healthcare 
professionals, with an increased need for medical information [235]. Hawighorst-Knapstein et al 
documented poor scores of medical interaction pre-operatively, however these improved and 
remained static at 3 and 12 months post-operatively [235, 237]. The majority patients had a good 
relationship with their doctor however one qualitative study reported feelings of hatred and anger 
expressed towards the doctor who made the initial diagnosis [226].  
 
3.4.1.9 Work and Finances 
 
The impact of PE on general health, combined with a potentially lengthy recovery has obvious 
implications on return to work, occupational recovery and overall financial status.  Vera et al reported 
only 1 patient out of 11 having undergone PE was able to return to her pre-operative employment, 
with this leading to a decline in overall income in 53% of patients [227]. The most common reason for 
unemployment was physical illness or disability, followed by limitations imposed by the surgery 
[227]. Dempsey et al reported 80% of full time workers had been able to return to work, with a 100% 
of part time workers returning to lighter duties [226]. The documented return to work was staged, 
with a return to part time duties 2 months post-operatively, followed by return to full time 
employment in the following months [226].  
Concerns regarding financial impact of PE surgery were most prominent pre-operatively, with 
patients citing this as a source of stress and worry [226, 227].  This is illustrated by Rezk et al, who 
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documented higher scores of financial difficulties pre-operatively, followed by improvement and 
stabilisation of these scores in the post-operative period [232].  
 
3.4.2 HrQoL Assessment Tools 
 
Four studies utilised qualitative interviews to determine the impact of PE on HrQoL [226-228, 230]. 
Of the 15 quantitative studies, a number of different assessment tools were utilised to assess the 
impact of PE on HrQoL (Table 3.1).  Of the 10 quantitative studies utilising existing HrQoL 
assessment tools 16 generic tools were used. Five studies utilised ad hoc symptom scales, designed 
specifically for the individual study [229, 233, 239-241]. The EORTC QLQ-C30 questionnaire was 
used in 3 studies [186, 232, 238] and was combined with the colorectal cancer module, EORTC-CR38 
[232], the muscle invasive bladder cancer module, EORTC QLQ-BLM30 [232] and the ovarian 
cancer module, EORTC OV28 [238].   The Cancer Rehabilitation Evaluation System was used in 3 
studies [235-237].  Body image was assessed using the Strauss and Appelt Body Image questionnaire 
[235, 237].  A range of other assessment tools were used including, the Sexual Function Vaginal 
Changes Questionnaire [231], Pre-operative Anxiety (STAI) questionnaire [236], Symptom Checklist-
90 [242], Beck Depression Inventory [242], Katz-Social Adjustment Scale [242], Dyadic Adjustment 
Scale [242], Derogatis Sexual Functioning Inventory [242], Heterosexual Behaviour Hierarchy [242], 
Sexual Arousal Inventory [242], SF36-II [191], FACT-C[191], Short-Form 12 (SF-12) [234], 
Instrumental Activities of Daily Living (IADL) [232], Centre for Epidemiologic Studies Depression 
Scale (CES-D) [232], Brief Fatigue Inventory (BF1) [232], Brief Pain Inventory – Short Form (BPI-
SF) [232] and the Impact of Events Scale-Revised (IES-R) [232].   
 
3.5 Discussion 
 
This systematic review reveals that PE surgery has a wide ranging impact upon a number of HrQoL 
domains including physical, psychological and social domains as well as upon body image, sexual 
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function, communication, relationships, work and finance. The reporting of these domains is variable 
and is often reported using a variety of different PROMs. Furthermore the study design is often of 
poor quality, which makes it difficult to interpret the impact of PE surgery on each of these domains. 
PE is the only available option in a range of advanced pelvic malignancies, including gynaecological 
malignancy, urological malignancy and primary and recurrent rectal cancer. This review identified 
585 patients of which 80.8% of patients underwent PE for a gynaecological malignancy. This has 
obvious implications of the findings of this review, given the majority of the findings were reported 
by women.  It is well documented within the literature that women utilise health services and report 
symptoms more frequently than men [243-245]. The disproportionately high number of women 
included in the review may impact the themes identified. There were no reports of the impact of body 
image in men undergoing PE in this review, as the study population of the two studies looking 
exclusively at body image were made up entirely of women [235, 237]. This has potentially important 
implications, as healthy women are documented to have poor body image compared to men [246, 
247], with these differences potentially exacerbated by surgery.  Sexual function was also not reported 
in the male population, as the majority of studies exploring this theme included female patients alone 
[228, 229, 231, 241, 242].  Furthermore, the majority of the qualitative work undertaken in patients 
undergoing PE was carried out in women [226, 227, 230], as a result, little is known about the HrQoL 
issues, specifically, body image and sexual function, which effect men, and therefore the results of 
current literature should be interpreted cautiously.  
The majority of the qualitative work carried on the impact of PE was undertaken in the 1970s [226] 
and 1980s [227], with little modern data available. There has only been one study carried out in the 
2000s, which identified a different set of HrQoL issues [230] compared to the earlier works of Vera et 
al [227] and Dempsey et al [226].  In 2004 Carter et al reported 7 themes of recovery, complications, 
social support, stoma issues, sexuality, disclosure and fear of recurrence [230]. Earlier reports 
commented on themes of husbands reactions to need for surgery, pre-operative reactions, mood and 
method of coping prior to surgery, short-term post-operative reactions, occupational recovery, sexual 
activity and marriage, psychiatric disorders, adjustment to stomas, hobbies and recreation and post-
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operative appraisal of life [226, 227].  This suggests modern day qualitative work is required to 
potentially confirm themes identified by previous works and to establish up to date current HrQoL 
issues which may effect patients.  
 
 Stratifying patients according to the number of stomas created provides important HrQoL data, with 
poor HrQoL scores observed in patients with two stomas compared to one [235, 237, 238]. However, 
HrQoL is also dependent on the type stoma, as demonstrated by Forner et al, who reported higher 
HrQoL scores in patients undergoing continent urinary diversion compared to an incontinent urinary 
diversion, although these differences were not statistically significant, they may be clinically relevant 
[234]. More accurate and targeted HrQoL data can be obtained if these patients are stratified 
according to the type of stoma created. This would lead to five clinically distinct groups; a continent 
urinary diversion with and without a colostomy, an incontinent urinary diversion with and without a 
colostomy and a colostomy alone. Being able to provide good quality, prospectively collected HrQoL 
data on this group of patients will enable and empower patients and inform clinicians during pre-
operative decision-making.  
 
The current reporting of HrQoL in patients undergoing PE is variable, with a number of limitations in 
the study methodology; with the majority of studies being retrospective in nature, little baseline data 
and long lapses in time between treatment and assessment of HrQoL leading to potential for recall 
bias. This is reflected in the variable quality of the studies as assessed by the CASP checklist for 
qualitative studies and NOS for quantitative studies, with only a handful of studies being deemed of 
good or high quality. The use of a multitude of generic and disease-specific measures makes it very 
difficult to compare HrQoL outcomes between studies. Furthermore, the majority of disease-specific 
measures have been used inappropriately in this cohort of patients, as these measures were not 
originally validated for use in this group of patients. Austin et al were the only group of authors to use 
an appropriate disease-specific measure, utilising the FACT-C assessment tool in patients undergoing 
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PE for primary and recurrent rectal cancer [191]. However, FACT-C is only validated for primary 
rectal cancer [205] and therefore the data obtained for patients with LRRC must be interpreted 
cautiously as it has not been obtained through validated, reliable means. The use of disease specific 
measures ensures a sensitive method of detecting changes and differences between patients and 
treatment groups [170, 213].  Two studies used between 6 [242] and 8 [232] different HrQoL 
assessment tools. In one study patients were expected to complete this volume of questionnaires at 3 
monthly intervals [232], this is associated with significant responder burden, which may potentially  
have an adverse impact on the results obtained due to potential compliance issues. The use of multiple 
HrQoL assessment tools is currently used to encompass all the potential issues faced by this cohort of 
patients, as there is currently no specific assessment tool for patients undergoing PE.  
Overall compliance with HrQoL assessments is good with reported rates of 46-100%. However 
despite this there is a lack of detail regarding statistical analysis of data, with only 10 studies reporting 
this information [186, 191, 231, 232, 235-238, 240, 242]. Furthermore, no studies reporting the 
handling of missing of data and only 8 studies addressed the clinical significance of HrQoL prior to 
study commencement [186, 232, 235, 236] [231, 237, 238, 240]. This is an essential requirement for 
interpreting data in a meaningful and clinically relevant manner and not just from a statistical 
perspective.  
Overall, the different methodology employed in these studies, combined with the variety of 
assessment tools used and the variable reporting make it very difficult to compare the results obtained 
from these studies, and consequently, interpret them in a clinically meaningful manner.  The variable 
reporting of PROs has been highlighted as a consistent issue in clinical research [248, 249], with 
much work being carried out on standardising reporting outcomes within the context of clinical 
trials[142]. However, similar work is required to establish a minimum data set which must be adhered 
to in the reporting of PROs in observational research. This will help standardise PRO reporting and 
thus potentially enable meaningful comparisons.  
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3.6 Conclusions 
 
This review consolidates the current literature on the impact of PE, identifying a number of relevant 
HrQoL issues. However, it highlights a number of shortcomings in the current literature, with the 
majority of the literature being retrospective in nature, with a long lag time between treatment and 
assessment. This is combined with the use of inappropriate disease-specific measures to assess 
different populations of interest. Currently, there is no one specific assessment tool that encompasses 
all the HrQoL issues which effect patients following PE. More work is required in this field to update 
the current literature, including qualitative work in men undergoing PE surgery to supplement current 
data and potentially aid in the development of a disease specific measures for patients with advanced 
malignancy requiring a PE. Future studies need to be methodologically robust in design and reporting 
as this is the only way meaningful data can be generated to be used and applied in the clinical setting 
for this complex cohort of patients.  
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4 Chapter 4 - Development of a LRRC Specific Conceptual Framework 
 
4.1 Background 
 
PROMs extend patient outcome assessment beyond traditional clinical outcomes, such as survival, 
adverse effects and treatment efficacy. PRO measures are designed to capture concepts related to the 
health experience of the individual, in relation to their disease and treatments. HrQoL is a specific 
type of PRO, and is the commonest type of PRO measure used in clinical practice. This is an area of 
growing interest in the field of surgical oncology, with an emphasis on the integration of the 
combined reporting of PRO outcomes and clinical outcomes [88]. PROs in surgery, and specifically, 
in LRRC, can provide valuable data to inform clinical decision making, improve patient care, improve 
provision of information and influence health care policy and decision making [250-252].    
The documentation of PROs in LRRC is poor; a systematic review of HrQoL in LRRC identified a 
small number of studies documenting the impact of LRRC on HrQoL, with little integration of 
clinical and PRO outcomes (Chapter 2).  
For a PRO measure to be valid it must be developed in a systematic and scientifically rigorous manner 
[89, 253, 254].  To be able to capture meaningful and appropriate data, PRO measures must possess 
content validity. Content validity assesses whether items are comprehensive, understandable and 
acceptable, and reflect the perspective of the population of interest.  
Qualitative data is essential for establishing content validity of a PRO measure. Content validity must 
be based on direct input from an adequate sample of patients from the target clinical population. To 
this end, the use of conceptual frameworks have been recommended by a number of regulatory 
agencies including the Food and Drug Agency [89], The Medical Outcomes Trust [255], International 
Society for Pharmacoeconomics and Outcomes Research (ISPOR) [256] and the European 
Organisation for Research and Treatment of Cancer [257, 258]. The development of a new PRO 
measure is a multi-step process, with the first step being that of identification of concepts and themes 
relevant to patients with LRRC and the development of a conceptual framework. The conceptual 
93 
framework outlines the structure of the concept that a PRO aims to measure and is often depicted 
diagrammatically, representing the relationships between the overarching concept (HrQoL in LRRC), 
the identified domains (HrQoL themes) and the items.  Establishing content validity is essential in 
providing evidence that the conceptual framework, content of items and overall measure is consistent 
with the perspective, experiences and words of the population of interest. Developing a conceptual 
framework is a two stage process, with the first stage consisting of a systematic review of current 
literature to identify key themes relevant to the population of interest followed by supplementary 
qualitative studies. This can be done through the use of focus groups or individual interviews [259]. 
This approach has been used in developing a conceptual framework for LRRC, two previously 
conducted literature searches identified 10 key themes relevant to this cohort of patients (Chapters 2 
and 3).  These searches were supplemented by patient perspective. The development of a robust and 
accurate conceptual framework is key to the PRO measure, as inadequacies in the framework may 
lead to inappropriate and incorrect outcome measurements [260].  
 
4.2 Aims and Objectives 
 
The objectives of this study were to: 
• Identify HrQoL themes relevant to patients who have undergone surgery for LRRC 
• Identify the impact of clinical factors (subsite location, concurrent metastatic disease, 
adjuvant treatments) on HrQoL 
• To develop a conceptual framework for LRRC-specific HrQoL 
 
4.3 Methods 
4.3.1 Qualitative Study – Focus Groups 
 
To identify HrQoL themes relevant to patients with LRRC, gender-specific teleconference focus 
groups were held. All focus groups were held by the same facilitator and were informed by a topic 
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guide (Appendix 2) based on the previous systematic reviews (Chapter 2 and 3). All focus groups 
were recorded and transcribed verbatim. Notes were taken throughout each focus group. All patients 
were offered a debriefing service at the end of the focus group.  
A purposive sampling method was devised to aid recruitment, with sampling of patients targeted to 
key factors to reflect the range and diversity of the target population, including sex, LRRC subsite 
(anterior, central, lateral or posterior), presence of concurrent metastatic disease and use of 
multimodal treatments (chemotherapy +/- radiotherapy). A minimum of four patients per key factor 
were consecutively sought (Table 4.1). 
Table 4-1 Purposive Sampling Strategy 
 
Factors 
 
 
Number of Patients 
 
Gender 
Male 
Female 
 
 
12 
9 
 
 
Subsite Location 
Central 
Anterior 
Posterior 
Lateral 
 
 
 
7 
5 
5 
4 
 
Concurrent Metastatic Disease 
Yes 
No 
 
 
5 
16 
 
Pre-operative Treatments 
None 
Chemotherapy 
Chemoradiation 
 
 
 
6 
4 
11 
 
 
4.3.2 Data Analysis 
 
The transcripts were imported into NVivo 10 and coded line by line. NVivo 10 is designed to 
facilitate the storage, coding and retrieval of qualitative data using Boolean operators.  
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The principles of thematic content analysis were employed to aid data analysis. This process involves 
interpreting data and creating codes, categories and themes [225, 261].  This method of analysis was 
chosen as it enables structured data collection combined with an explicit analytical procedure 
informed by a priori reasoning based on existing theory and literature [225, 262]. This methodology is 
in keeping with the objectives of this study, which extended a preliminary conceptual framework 
based on current literature with new patient reported data.  
Concepts that pertain to the same phenomenon are grouped to form categories. Categories are further 
developed into themes. Using thematic content analysis HrQoL issues were identified from the 
transcripts and coded in accordance to a provisional coding framework. Identifying a series of codes 
and then grouping them into similar categories and themes was the systematic approach employed in 
this study. Analysis was an iterative process during the data collection process, with data from each 
focus group being analysed immediately. This enabled future focus groups to be informed by the 
preceding focus group, thus ensuring confirmation of identified codes. Following the first focus 
group, all subsequent coding was undertaken with the preceding focus group and emerging theory in 
mind. This continuous analysis ensured that the emerging coding schema was complete and saturated. 
Saturation is the point in data analysis process where no further information is elicited. To ensure 
sufficient data was collected to reach conceptual saturation, a saturation grid was devised to track 
emerging concepts. All coding was reviewed iteratively by a second coder, who was a dedicated 
qualitative researcher. Any discrepancies in coding were resolved through discussion.  
 
Comparative Analysis 
On completion of coding, a comparative analysis was conducted across all identified themes and the 
patient sample to explore any emerging differences. Any patterns and associations were identified 
unique to each patient factor i.e. disease subsite, margin status, presence of metastatic disease, use of 
multi-modal treatments pre and post-operatively and to each study location (Leeds or Sydney).   
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Expert Review 
Following all data analysis, a multidisciplinary expert panel consisting of six surgeons (3 British, 3 
Australian), two oncologists, two colorectal nurse specialists, a clinical psychologist and a public 
health epidemiologist reviewed the proposed conceptual framework. Distinctions were made by the 
panel regarding HrQoL issues and issues relating to service delivery and provision of healthcare 
resources. All expert panel interviews were guided by an interview topic guide (Appendix 3).  
 
4.3.3 Development of a Conceptual Framework 
 
A LRRC-specific conceptual framework of HrQoL was developed by combining inductive (top-
down) approach and deductive (bottom up) approaches [225, 262].  
• Inductive Content Analysis 
An inductive or top down approach was utilised to develop a conceptual framework based upon a 
systematic review of HrQoL issues in LRRC (Chapter 2). This review identified a number of HrQoL 
issues associated with LRRC and its management. A second review identified HrQoL issues 
pertaining to patients undergoing pelvic exenteration. The themes extracted from these two reviews 
were combined to produce a provisional working conceptual framework consisting of ten broad based 
domains which included physical impact, psychological impact, social impact, symptoms, finance and 
occupational impact, relationship with other, communication, body image, sexual function and 
treatment expectations. The provisional working conceptual framework informed the development of 
the topic guide for the focus groups. 
 
• Deductive Content Analysis 
The provisional conceptual framework informed the subsequent qualitative work. Focus groups were 
conducted to elicit information pertaining to the impact of LRRC on HrQoL, to define specific 
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domain components and to clarify and confirm the importance of the identified provisional themes in 
a group of patients with LRRC. Data obtained from the qualitative focus groups were used to refine 
and revise the working conceptual framework. This framework was reviewed by an expert panel prior 
to finalisation.  
 
4.4 Recruitment 
 
4.4.1 Eligibility 
 
Inclusion Criteria 
Identified patients were included in the study if the following criteria were fulfilled: 
• aged ≥ 18 years 
• with an existing resectable LRRC or 
•  surgically treated for a LRRC within the last two years and  
• able to provide informed written consent to participate and 
• able to read and write in English 
Exclusion Criteria  
Patients were excluded from the study in any of the following criteria applied. They: 
• have undergone non-surgical palliative treatment of their LRRC 
• have cognitive impairment 
• are unable to speak/read and/or write English 
• are unable to provide informed consent 
4.4.2 Patient Recruitment 
 
Patients were identified from a prospectively kept disease register at St James University Hospital, 
Leeds and The Royal Prince Alfred Hospital, Sydney. Ethical approval was gained from both UK and 
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Australian sites prior to the commencement of this study. Patients that met the eligibility criteria were 
approached, informed about the study, and provided with a project information leaflet which included 
details about the rationale, design and personal implications of the study, and an agreement form to be 
contacted by the researcher. Following the receipt of the signed agreement form, the researcher 
contacted the patient, informing them of the time of the focus group.  
4.4.3 Baseline Data Collection:  
 
The following data were collected:  
• Patients initials and date of birth 
• Gender 
• Primary Cancer Details (location, neoadjuvant/adjuvant treatments, date of operation, 
operative and histological detail) 
• Mode of detection of LRRC (symptomatic or surveillance) 
• Treatment plan of LRRC (pre-operative treatment, operative detail and histological detail, 
post-operative treatment) 
• Current disease status. 
4.5 Results 
 
4.5.1 Patient Demographics 
 
Twenty-three patients with operatively managed LRRC between January 2010 and January 2012 
consented to participate. Gender specific patient teleconference focus groups were undertaken over a 
four week period, with a total of 6 focus groups undertaken to achieve saturation. A total of 21 
patients participated, 12 male and 9 female patients with a median age at time of interview of 63 years 
(IQR 50-75). All 3 male focus groups consisted of 4 patients each and all 3 female focus groups 
consisted of 3 patients each. Median time elapsed between the operation for LRRC and the interview 
date was 11.7 months (IQR 3.1 -24).  Patient demographics are outlined in Table 4.2. Patients were 
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selected to ensure equal representation of disease subsite, the presence of concurrent metastatic 
disease and the use of multimodal preoperative treatments (Table 4.2). Median length of the 
teleconference focus group was 72 minutes (IQR 61-85).  
Table 4-2 Patient Demographics 
 
Factor 
 
Number of Patients 
 
Median Age 
63 
(50-75) 
Gender 
Male 
Female 
 
12 
9 
 
Primary Operation Type 
Anterior Resection 
Abdominoperineal Excision of Rectum 
Hartmaans Procedure 
Proctocolectomy 
 
 
15 
2 
3 
1 
Neoadjuvant Treatment – Primary Cancer 
None 
Chemoradiation 
Radiotherapy 
 
13 
6 
2 
Adjuvant Treatment – Primary Cancer 
None 
Chemotherapy 
Chemoradiation 
 
8 
12 
1 
Reason for Detection of Recurrence 
Surveillance 
 
14 
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Symptoms 7 
Neoadjuvant Treatment – Recurrent Cancer 
None 
Chemoradiation 
Chemotherapy 
 
6 
11 
4 
Adjuvant Treatment – Recurrent Cancer 
None 
Chemotherapy 
 
17 
4 
Subsite Location 
Central 
Anterior 
Posterior 
Lateral 
 
 
7 
5 
5 
4 
Operative Procedure for LRRC 
Total Pelvic Exenteration  
Anterior Pelvic Exenteration 
Posterior Pelvic Exenteration 
Excision of recurrent tumour mass 
Completion proctectomy 
Ultralow Hartmaans 
Composite abdominosacral resection 
 
4 
2 
1 
4 
5 
1 
4 
LRRC and Metastatic Disease 
Liver 
Lung 
None 
 
3 
2 
16 
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4.5.2 Identified Themes and Conceptual Framework 
 
On scrutiny of the data and the emerging themes, two distinct patterns emerged, the majority of the themes and 
categories identified addressed the issue of HrQoL, however, a minority, addressed issues relating to healthcare 
service delivery and utilisation. Saturation of all emerging issues was achieved by the 5th consecutive focus 
group, with no further issues identified in the final focus group (Table 4.3).  Table 4.4 presents a list of 
quotation relevant  to each subdomain.  
Table 4-3 Saturation Grid 
 
DOMAINS 
 
 
FOCUS GROUP 1 
 
FOCUS GROUP 
2 
 
FOCUS GROUP 
3 
 
FOCUS 
GROUP 4 
 
FOCUS 
GROUP 5 
 
FOCUS 
GROUP 6 
 
Symptoms 
 
Vaginal symptoms 
Gastrointestinal 
symptoms 
Pain 
Fatigue 
Urological 
symptoms 
Stoma Issues 
Adaptation of life to 
symptoms 
  Locomotor 
symptoms 
  
Sexual Function 
Practical Issues 
Gynaecological 
symptoms 
Erectile 
dysfunction 
Sexual desire 
Stomas interfering 
with sex 
   
Psychological 
Impact 
Shock 
Surprise 
Anger 
Self-confidence 
Self-consciousness 
Hope 
Relief 
Change in 
perceptions 
Embarrassment 
Attractiveness and 
body image 
   
Role Functioning 
Work 
Housework/General 
activities 
Dependence on 
others 
 
Change in 
occupational 
status 
Finance 
Leisure activities 
Hobbies 
Communication 
with partner 
    
Healthcare 
Services 
Utilisation and 
Delivery 
Convincing 
healthcare 
professionals  
Hope of Cure 
Limited Options 
Intensity of 
diagnostic 
imaging, 
delays, concerns 
regarding 
progression  
Prolongation of 
life 
 
Professional 
communication 
and support 
Length of 
Recovery 
 Travel  
Future 
Perspective 
Morbidity 
Restriction 
Short term plans 
Hope Adjuvant 
therapies 
Anxiety regarding 
appointments and 
symptoms  
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Table 4-4 Illustrative quotes highlighting identified themes  
 
Theme Illustrative Quote 
Symptoms 
Pain ‘I had this deadly pain, at the bottom end’ 
‘I’ve had a pain in my hip’ 
Lethargy ‘I’m tired, I don’t have the energy I use to.’ 
‘I haven’t got the energy anymore’ 
‘I just can’t summon the strength to do something on a regular basis’ 
Gynaecological symptoms ‘my vagina sits flat, everything isn’t as it use to be and I’ve had a few 
small bleeds’ 
 
Urological symptoms ‘I’m not able to pass water as energetically as before, if you like, it was 
starting to get a bit of dribble’ 
‘Its pretty embarrassing when you start to dribble and you can’t direct 
that as well as a stream, and I’ve wet my legs on more than one 
occasion’ 
‘I have the symptoms of bladder infections all the time with burning 
when I pass urine’ 
Gastrointestinal symptoms ‘The rectum still produces lubrication fluid, and if you don’t empty that 
regularly it can be uncomfortable’ 
‘I get discharge from my back passage, it’s damp and messy’ 
Locomotor symptoms ‘Well with the wound in my back, i have no mobility its not handy’ 
‘ Its the lack of mobility, that can be depressing’ 
‘ I can’t walk on my crutches, I’ve got no feeling in my feet’ 
Sexual Function 
Sexual Intercourse ‘I had bleeding and pain during sex. I couldn’t have sex because it was 
just too sore.’  
‘Other than the fact they took everything out and the sex life is now 
down the drain’ 
‘The physical side of the marriage, the sex side of things, has ceased... 
was the second time, more nerves were damaged and obviously I had 
some more chemotherapy and that was the end of it really.’ 
Psychological Impact 
Mood 
 
‘It was pretty depressing and like i say i’ve got it again’ 
‘The second time my cancer returned I felt very frustrated, angry, 
mainly because I thought I’d done all the right things’ 
Self-efficacy and 
Dependence 
 
‘I find it difficult from my point of view of relying on others and 
whether you are a burden to them’ 
‘I feel my self-confidence is gone.’ 
‘I do get frustrated at times that i’m not as independent as I use to be’ 
Appearance and Body 
Image 
 
‘I don’t like my body. I don’t like all the scars, i don’t like having a 
bag’ 
‘I felt like  a body devoid of organs’ 
Role Functioning 
Work ‘I don’t get up onto the scaffolding, I get up on the planks and on the 
ground, I can reach up, so its affected me a little bit, and I’m a little 
slower than I was’ 
‘I think with the stress of the finances...it makes things worse’ 
Household Activities ‘I use to go to the Saturday market for food shopping, and I can’t do 
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that anymore.’ 
‘Tasks that need to be done, such as washing the car, cutting the grass 
or trimming the hedge or whatever it is, you’re gasping for breath, for 
something which you use to take in your stride before, so fatigue, is a 
major element' 
 
Social ‘We still go out to nightclubs and see bands, i don’t get up and dance 
much, 
socially, its negative now. There is very little social activity now.’ 
‘My activities have changed, I use to go for long walks and kayaking, I 
don’t do that as much, I don’t go out as much now.’ 
Relationships ‘That’s what kept me going too, talking to neighbours and mates’ 
‘Obviously, it has an impact on my wife, she gets very stressed at 
times... but, we talk about it very openly.’ 
‘be open about your problem and talk to your family and your mates, 
otherwise you’ll go downhill’ 
‘it’s awful for my family, that’s the most upsetting thing, that’s the 
impact it has on your family and how they feel.’ 
Future Perspective 
Disease Re-recurrence ‘Lately I’ve had a pain in my hip, and that concerns me because it could 
be the cancer coming back, and so I’m in the process of dealing with 
that’ 
‘Any little ache or pain I think the cancer is coming back, it not there all 
the time, it’s just when I get a pain or symptom that when I think about 
it’ 
Further Treatments ‘I was having chemo and I wasn’t expecting it and everything was 
going wrong’ 
‘Apart from having my hernia fixed I thought that’s all I would need, I 
didn’t think I would need any more surgery than that and I could get on 
with my life’ 
Future Plans ‘I don’t think mine will come back,  I’m pretty positive’  
‘I’ve been very unconfident that I’ll still be alive in 18 months time and 
we’ll see...because things are going wrong’ 
‘Short term; take every day as it comes.’ 
Healthcare Services Utilisation and Delivery 
Disease Management ‘It took a long time, about 6 months for them to figure out what to do, 
where I’m from they are not equipped to do that sort of surgery.’ 
‘I felt like I kept getting left behind, I ended up having to get the 
doctors here to push the doctors in Adelaide to get things going.’ 
‘It took a bit of pushing to get it checked out just took a long time to 
sort it out.’ 
‘The recurrence was detected after several scans; again, it didn’t just 
come in, one single dose as it were.’ 
Treatment Expectations ‘There were difficulties, I ended up with a urostomy and colostomy 
bag, there were some difficulties in that operation too, and I spent a 
total of 6 months in hospital.’ 
‘It cured what need to be cured at the time.’ 
‘I viewed and expected my surgery to be curative and that it is absolute 
cure, 
I’m just hoping they have fixed me and it doesn’t come back and I can 
have  a bit longer before I have to worry about it’ 
‘It took me a long time to recover but in that recovery period I was 
determined’ 
Healthcare Professionals ‘I chased the information.’ 
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‘As far as information before the operation was concerned that was 
adequate, my concern was far more the lack of information afterwards.’ 
‘We had trouble in waiting, almost as though they weren’t in 
communication with the hospital that had initially done the scans and 
scopes, and we were waiting for quite a long time between having the 
scans done and getting through to Leeds and working on it, it’s quite a 
delay’ 
 
 
4.5.2.1 Health Related Quality of Life Themes 
 4.5.2.1.1 Symptoms 
 
Pain  
Patients with LRRC reported some form of pain and discomfort. Common sites of reported pain were 
abdominal, perineal, back and leg pain. Perineal, back and leg pain was typically, described to be ‘a 
numb and dead pain’, ‘shooting pain’ or ‘a nerve pain’; these descriptors are commonly associated 
with neuropathic pain. Abdominal pain was more commonly described to be ‘crampy’ or a ‘dull 
ache’. Pain is typically described to get worse throughout the day ‘Worse of an evening... My best 
time is the morning, so I try and do everything I possibly can in the morning’. 
Pain caused significant discomfort and interference with activities of daily living ‘I’m careful about 
lifting, working hard with vacuum cleaner because it makes my muscles ache’ and the ability to 
assume comfortable positions ‘I still can’t sit comfortably I can’t sit on a sofa or a soft seat’.  
Fatigue 
Patients complained of feelings of lethargy, malaise and a general lack of energy. This generally led 
to an inability to carry out tasks, requiring a break or abandonment of the task in the hand. ‘When I 
would get tired I would sit down and catch my breath’. 
Gynaecological Symptoms 
Fifty five percent of women reported vaginal symptoms, this included vaginal pain and numbness, 
bleeding and discharge. These symptoms interfered with daily life, intimacy, body image and social 
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activities. Women felt they were unable to embark upon sexual and intimate relationships as a 
consequence of these symptoms, with this causing emotional distress such as anxiety and feelings of 
self-consciousness. ‘...because my anatomy is a bit messed up the very thought of having an intimate 
relationship would bother me and also the thing is having a colostomy, it’s something, that I just 
couldn’t envisage myself getting into a relationship’. 
Urological Symptoms 
Urological symptoms were reported both by men and women. Patients described a range of urological 
symptoms including urgency, incontinence, dribbling and poor flow with these symptoms causing a 
significant amount of discomfort. This caused a significant amount of emotional distress and 
embarrassment, with the avoidance of social situations where a toilet was not easily accessible. 
Patients stated they had to adapt their lifestyles to accommodate these symptoms with the use and 
carriage of incontinence pads, the need for urinary catheterisation and the avoidance of public urinals. 
‘If I sit for too long and I stand up I just pass water. I wet myself quite a lot and I find that 
embarrassing’. 
Gastrointestinal Symptoms 
Patients complained of few gastrointestinal symptoms, with the two main symptoms being that of 
flatulence and rectal discharge. Rectal discharge caused discomfort, embarrassment and required the 
use of incontinence pads to manage these symptoms; ‘Its uncomfortable, it’s not huge volume or 
anything, but it’s damp and messy’. The symptoms of flatulence were more easily managed socially 
through the use of humour; ‘if I make a bit of a smell, well that’s the price they pay for my company’.  
Stoma Related Issues 
Approximately 70% of patients included in this study had a stoma (colostomy or urostomy). Patients 
complained of stoma related issues in the immediate post-operative period, with stomal leakage being 
the main complaint, however following a period of adjustment, patients adapted to this. Longer term 
issues related to the stoma, including difficulties engaging in sexual relationships and social activities 
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due to feelings of embarrassment and emotional distress. Patients described the stoma to be a 
permanent reminder of their cancer journey. Overall, there was an acceptance of the stoma(s) as all 
patients felt there was no other alternative ‘I don’t mind the bag – its either a bag or the box’.  
 
 
Locomotor Symptoms 
Patients with posterior recurrences involving sacral resection reported symptoms of lower limb pain 
and paraesthesia, which led to impairment in mobility and a restriction in movement, leading to 
disruption of daily and social activities.  ‘I have tingling in the bottom of my feet, its like throwing a 
couple of handfuls of sand in your shoes and then walking around’, ‘I can’t walk on my crutches, I’ve 
got no feeling in my feet’, ‘ My wife puts my shoes and socks on because where they cut my legs I 
can’t bend them, I can get them off but I can’t get them on’. 
 
4.5.2.1.2 Sexual Function  
 
Sexual function was significantly impaired following operative management of LRRC, with the 
majority of patients citing a reduction or complete abstinence from sexual intercourse. Reasons cited 
for this included gynaecological symptoms of vaginal numbness, pain and bleeding, erectile and 
ejaculatory dysfunction, issues with self-confidence and body image and the practical issues of having 
a stoma. ‘...my anatomy is all different and I still have bleeding and that now I guess my body is all 
different’. 
Male patients continued to express feelings of sexual desire, however female patients experiencing 
gynaecological symptoms had no such feelings. Patients substituted the lack of sexual intercourse for 
other activities such as kissing and cuddling ‘we have a cuddle but there’s nothing sexual’. Feelings of 
guilt and sympathy towards partners were expressed for the lack of a sexual relationship, however, 
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overall patients felt little adverse impact on their marital relationships. ‘I’ve surprised myself, I 
thought it would affect me, it’s one of those things you put a lot of importance on, whilst you share 
that part of a relationship, now it’s been taken away, yes it was a shock at the time, but when you’ve 
got a relationship as strong as we have’. 
 
4.5.2.1.3 Psychological Impact 
 
Mood 
The diagnosis and treatment of LRRC had a significant impact on psychological wellbeing. Patients 
expressed a range of emotions to their initial diagnosis of LRRC, including surprise, shock, anger and 
disappointment. Feelings of shock and surprise were more commonly expressed by patients who had 
their recurrence detected during routine surveillance investigations ‘I was surprised because I was 
feeling so well and everyone said I looked well. So I was shocked’. Feelings of disappointment and 
anger were expressed at disease recurrence following the recovery and perceptions of cure after the 
first operation; ‘I was pretty much devastated....you think you’ve beaten it you see, you’ve had the 
cancer at first and I had the operation and the chemo, and you just felt so well, and I did everything I 
could, it was just a massive shock’. 
Frustration and feelings of anxiety were commonly expressed during the investigative period when 
trying to obtain a definitive diagnosis, however this changed to feelings of hope and relief when 
potentially curative treatment in the form of surgery was offered ‘so, obviously I was really down at 
that point, but later on my initial surgeon, said he knew a colleague in Leeds, that was Mr Sagar, who 
said he could operate, so at that point I was elated’. 
Patients adopted a positive and hopeful attitude in the peri-operative period, with an emphasis on 
achieving cure and early recovery. Feelings of frustration were greater when recovery was felt to be 
prolonged due to on going treatments and when restrictions on daily activity were imposed as a result 
of recovery; ‘Personally I was fed up because I was having to have dressings all the time, and I was 
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thinking just hurry up and heal up, and it still hasn’t healed up, and we’re a year down the line’. 
Despite these feelings of frustrations during the management of complications patients were grateful 
for the chance of undergoing potentially curative surgery. 
 
Self-efficacy and Dependence 
The loss of independence and the dependence on others due to the impact of disease recurrence and 
surgery had a huge adverse impact of patients, as the majority of patients had felt they had only just 
regained their independence and restored their lives to normality prior to being diagnosed with 
recurrent disease. This often led to feelings of anger, frustration and isolation, and was further 
exacerbated by societal changes in perception of identity and role functioning. ‘I think people regard 
me with a lot more pity and I don’t like that, I don’t like people feeling sorry for me’. ‘One of the 
difficult things was at work when the second time, when the cancer came back and I had to go off, 
they sat me down, and said now in employment law you’re classed as disabled....  when someone 
classifies you as disabled that’s a really hard thing to take’. ‘They were people in the office looking 
the other way, or not looking you in the eye and you sort of feel alienated’. Patients felt frustrated that 
they had to rely on others to carry out normal daily activities such as getting dressed, shopping and 
socialising, which led to a loss of independence and feelings of being a burden ‘I find it difficult from 
my point of view of relying on others and whether you are a burden to them’.  
 
Appearance and Body Image 
Changes in patient perception of body image and appearance were related to physical and 
psychological aspects of their LRRC treatment. The physical components consisted of the presence of 
a permanent stoma, multiple wounds with delayed healing, abdominal wall fistulae, abdominal wall 
hernias, weight loss and loss of sexual organs and sexual function. These physical factors had a 
significant psychological impact leading to feelings of self-consciousness, lack of self-confidence and 
embarrassment which often led to social isolation due to voluntary lack of participation in certain 
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social settings and the non-engagement in potentially new relationships. ‘it’s not very nice to look at 
is it, when there are that many scars’. 
 
4.5.2.1.4 Role Functioning 
 
Work 
Due to the significant physical constraints of re-operative surgery, a number of patients stated a 
change in occupational status, taking a ‘lesser’ job on with fewer responsibilities and where applicable 
lighter duties. In some instances, patients have been unable to go back to work and have had to resign 
or take early retirement. ‘I have renegotiated my contract with my employer, where I’ll work a little 
bit each week, each day, but I’ll be honest I’m doing very very little at the moment’. These changes 
are to accommodate symptoms of the disease recurrence or recovery period combined with general 
symptoms of lethargy and malaise, as well as to accommodate on going adjuvant treatment. There is 
an obvious financial implication in making such adaptations, which goes onto cause anxiety about the 
future and long term plans to provide for the family. 
The change in occupational identity can have a significant psychological impact, with patients feeling 
a loss of sense of self when occupational activity ceases or feeling the constant need to prove oneself 
upon return to work following recovery. ‘I resent my identity been taken away from me, I’ve had to 
give up work, I worked in a pub, I loved it, but I can’t work now, as I don’t know whether I’m going 
to need chemo or how I’m going to feel’, ‘I had to make a lot of adjustments but I felt that now, 
because I’ve had two bouts of this, I constantly have to prove myself that I’m still capable of doing 
the job and that if I lose that I’ll lose a bit of me really and if I sort of forget something, or I make a 
mistake, or I make a wrong judgement,  I feel very much that the directorship of the company will 
think she’s had cancer twice, and the whole stigma of it’. 
 
Household Activities 
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Alongside, changes in occupational activity there is a shift in the type and pattern of household chores 
and general activities undertaken by patients, with a dependence on spouses and family members in 
the initial post-operative phases to undertake all household chores, however this reduced with gradual 
recovery and improvement in post-operative function. Despite, a slow return in undertaking daily 
chores, patients were reluctant to undertake ‘heavier duty’ chores such as gardening, heavy lifting or 
vacuuming for fear of symptoms of pain. The inability to perform such tasks combined with the 
dependence on others leads to feelings of guilt, frustration and a lack of self-confidence. ‘I haven’t 
been able to do everything I wanted to do, and it knocks your confidence, you feel as if, not useless 
exactly, you feel like you’re letting the family and the side down by not doing what you’re suppose to 
do’. 
 
Social 
Patients reported a reduction in social and leisure activities following operative intervention, with a 
very slow and gradual recovery of these activities. The return to participation in these activities is 
often cited as a positive motivating factor for recovery. Although there is a restoration of leisure 
activities and hobbies in the post-operative phase, patients tend to adapt these activities a little to 
match new and lower energy levels. ‘I still get onto my motorbike, to ride it, I just don’t race much 
because my reflexes aren’t that quick’. 
Patients report variable social participation, with certain social situations causing anxiety and 
embarrassment. This was most relevant when going abroad on holiday and having to potentially 
expose parts of their bodies and when in public places without easy access to public toilets; these 
situations caused a great deal of anxiety and made patients feel self-conscious. Patients generally 
adapted their lifestyles to accommodate social activities to minimise embarrassment and discomfort. 
‘I’m going on holiday this year, and I’m really frightened to go on holiday’, ‘I have plenty of pads, I 
have my little colostomy sets for changing that and I always keep an extra set of pads and panty 
liners.’ 
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Relationships 
Overall, patients felt personal relationships (marital, family, close friends) strengthened during the 
diagnosis and treatments of their LRRC, with a great emphasis placed on communication, especially, 
with regards to decision making regarding treatment strategy. The communication between couples 
helped overcome other changes engendered by their LRRC in their relationships such as intimate and 
sexual relationships. When patients weren’t able to communicate with their partners this caused 
feelings of sadness and anxiety. However, patients did not disclose all their feelings to their partners 
or family members for fear of upsetting them and being perceived to having a negative outlook. 
Feelings of guilt were also expressed by patients when discussing their partners for having put them 
through cancer a second time round, as well as for adopting a more dependent role and not being able 
to contribute equally to the household or family. The feeling of dependence extended to all members 
of the family who helped in the patients care, with associated feelings of guilt and a loss of the sense 
of self. ‘I felt that I had to rely on hubby for everything and so you feel a bit guilty that you’re relying 
on one person’. 
 
4.5.2.1.5 Future Perspective  
 
Disease Re-recurrence 
Despite patients undergoing a curative resection for their LRRC, they all expressed anxieties and 
concerns regarding the potential for disease re-recurrence in the future. Symptoms of complications 
were often misinterpreted as evidence of disease re-recurrence and therefore, all such symptoms were 
over-reported to all healthcare professionals and caused a great deal of anxiety. In symptom-free 
patients, the period of time leading up to follow up appointments and investigations were deemed too 
anxious and nerve-racking. ‘...it’s still in the back of your mind that it might come back again I try 
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and put it to the back of my mind, I try and put it out of my mind but it is there but I do get quite 
wound up when I go for scans and appointments’. 
Further Treatments 
Patients expressed surprise at the need for further adjuvant treatment in the form of chemotherapy 
following surgery, however understood, the reasoning behind this and therefore accepted it as part of 
their treatment package. The need for further adjuvant chemotherapy was deemed to cause social 
interference and prolonged overall recovery time.  
The morbidity associated with LRRC surgery was often underestimated by patients, with expectations 
expressed of a short post-operative recovery similar to their primary rectal cancer surgery, with 
frustration expressed at the on going treatments required for slow healing wounds, fistula 
management, abdominal wall hernias and recurrent episodes of intestinal obstruction. ‘I’ve been in 
about 8 times, with various problems, the colostomy bag since 2004, is permanent obviously, it has 
had 4 different locations, 2 different operations for hernias’, ‘I’m nowhere near recovered, I’m 50% 
there but I’ve been having my wound dressed for the last 12 months’. 
Most patients learnt to adapt and accommodate symptoms arising as a result of post-operative 
morbidity, despite some restrictions imposed upon social and daily activities, especially, with regards 
to regular wound management.  
 
Future Plans 
All patients regarded surgery as a prolongation of their lives, irrespective of whether the surgery was 
curative or palliative, and viewed the future to be hopeful and optimistic, However, despite, this 
overall, positive attitude, patients made very short term plans, adopting an attitude of living on a day-
to-day basis as opposed to making any committed long term future plans. This was due to the 
potential fear of failure, and as they had experienced this once before with their primary rectal cancer. 
‘One day at a time, I don’t know, if I’ll have a long future or not’. 
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4.5.2.2 Themes Identified Related to Health Services Delivery and Utilisation  
 4.5.2.2.1 Healthcare Services 
 
Disease Management 
Patients reported difficulties in obtaining a definitive diagnosis of their LRRC, especially, when they 
were experiencing symptoms, as they felt an intuitive sense of disease recurrence, ‘the illness had 
come back, it had taken me quite a few months for me to persuade the surgeon here that something 
was wrong; I kept telling him that something wasn’t right’, ‘think when you find you’ve got it again, 
it’s almost like you know you’ve got it and you dread it again’, ‘really getting some discomfort, when 
to see my chemo specialist, who said, no, no its not related to that, it’s probably just a trapped nerve, 
but I insisted on having some bloods taken which revealed there was a problem and I was scanned and 
it proved the tumour had returned in the sacral area’. Where there was an insistence on the patients’ 
part to have these symptoms further investigated by their healthcare professional, this occasionally led 
to the breakdown of the doctor-patient relationship and feelings of frustration.  
The investigative pathway for the detection of LRRC was felt to be intense and often induced feelings 
of anxiety and ‘not knowing’, which led to considerable emotional distress both for the patient and 
their partners. This was exacerbated by perceived delays in obtaining the diagnosis and potential 
referral delays between general and specialist services, which led to anxiety and concerns regarding 
disease progression and spread. This led to a significant degree of interference with social activities, 
with the cancellation of holidays and avoidance of certain social situations in case further 
investigations or appointments were made at short notice.  ‘The recurrence was detected after several 
scans; again, it didn’t just come in one single dose as it were.... It was basically, the lead up of several 
scans and x-rays, it was becoming obvious, so by the time, they’d announced the recurrence, you 
already knew that by the sheer volume of the intensity of the scanning that was going on.’, ‘I then had 
another CT scan and another MRI scan, and then went to Nottingham and had the PET scan and still 
no-one knew what was going on’, ‘We felt that there was a long delay in finding out that there might 
be something and actually deciding that there was something, we were a long while, in no man’s land, 
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not knowing one way or the other’, ‘It’s that delay, the month without any treatment you don’t know 
whether things might be growing or spreading’. 
Patients reported difficulties in travelling to the specialist centres for diagnostic purposes, treatment 
and follow up, as if the local and specialist hospitals were over a great distance the physical act of 
travelling was often uncomfortable due to symptoms of pain. However despite this patients preferred 
to have their on going post-operative follow up and the management of complications at the specialist 
centre, irrespective of the distance required to travel as they had more confidence in the expertise of 
the specialist centres. ‘If there was a problem the doctors here (Adelaide) weren’t quite sure because it 
wasn’t their expertise’, ‘I’m just glad I went back to Sydney for my check up and nowhere else 
because it (third recurrence) might not have been picked up earlier’. 
 
Treatment Expectations 
 
Patients expressed feelings of’ ‘hope’ and ‘relief’ upon being offered operative management of their 
LRRC, with a view that this would ‘prolong’ their lives, irrespective of the success of the surgery; ‘I 
thought great, I’m not looking forward to the operation but here’s hope again’, ‘it was cutting edge 
surgery, but my view was that it was going to improve my longevity I’ll buy into that and I have done 
and I wouldn’t change it’, ‘400 people diagnosed with similar to me, with half a dozen operated on 
and I was one of the lucky ones to be operated on but in the past there just wasn’t the technology. I 
was getting desperate let’s put it that way, if there’s an opportunity to increase ones longevity’.  
Patients stated they had limited treatment options, with surgery being the only curative option, with 
chemotherapy being reserved for palliative treatment only, ‘I just thought that palliative care, was just 
a slow way of going, if you like, or whatever, but at least with an operation there was a chance we 
could still beat it’. Patients expressed feelings of having ‘no other alternative’, ‘as one said earlier on 
its the op or the box, you don’t have a real choice in the matter’.  
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Patients’ treatment expectations were intrinsically linked with their future goals in life and their 
psychological well being. When given the option of potential life saving surgery patients outlook on 
life improved and gave them hope for a prolonged future, thus minimising some of the psychological 
distress associated with the recurrent cancer. This shifted their psychological outlook from being 
negative to positive, and thus impacted on their overall wellbeing.  
Patients envisaged a quicker post-operative recovery and did not expect potentially long hospital 
stays.  The process of recovery impacted upon physical function, restricting daily activities and 
prolonging the return to work, this was associated with a greater dependence others, which often led 
to feelings of ‘frustration’. 
 
Healthcare Professionals 
Patients expressed variable confidence in the decision-making and disease management of their 
surgeon, with less confidence in their primary surgeon compared to their specialist surgeon, this was 
most pronounced when patients had difficulty in obtaining a definitive diagnosis of their recurrent 
disease. However, all patients expressed complete confidence in their specialist surgeon and were 
guided by their expertise in the management of their LRRC.  
Patients felt occasionally there was ineffective communication between healthcare professionals 
regarding management decisions and this impacted adversely upon their care, which led to feelings of 
anxiety and worry. Despite this perception, patients felt their own communication with healthcare 
professionals was good, with an adequate amount of information given regarding the management 
strategy combined with all associated risks. This exchange of communication led to an alleviation of 
anxieties and put patients at ease; ‘I was made very comfortable and I was very confident with his 
capabilities and I knew I was in a safe pair of hands’.  
Patients felt upon discharge there was a lack of psychological support available from British and 
Australian healthcare services, as a result, patient sought such support from external services, such as 
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‘The Colostomy Association’ and ‘The Holistic Centre’.  Patients valued this support as it meant the 
disclosure of thoughts and feelings they could not share with their family, with this disclosure leading 
to the alleviation of some emotional and psychological distress. Furthermore, patients felt they could 
not make such disclosures with their doctors, preferring to discuss physical issues alone. ‘I like people 
in a professional way to talk really’, ‘I think should it be part and parcel of the recurrence of my 
cancer.’, ‘I went for quite a few months, and there were things I could say to them that I couldn’t tell 
my family’. 
4.5.3 Patterns of Association  
 
A cross analysis of the data was undertaken to identify any association between patient and disease 
factors (age, gender, method of detection of recurrent disease, pre-operative and post-operative 
treatments, subsite location of disease recurrence, margin status and current disease status) and 
HrQoL issues.  For all the factors, the reported HrQoL issues were the largely the same for all patient 
types. Patients with posterior and lateral recurrences complained of pain and locomotor symptoms 
more frequently than patients with central and anterior disease. Conversely, patients with central and 
anterior recurrences complained of gastrointestinal, urological and gynaecological symptoms more 
frequently than patients with posterior or lateral disease. There were no differences in the HrQoL 
issues expressed between patients in the UK and Australia, with both sites being similar in terms of 
health services infrastructure, with patients being referred from generic to specialist services. These 
similarities in infrastructure led to similar issues being reported by both population groups such as 
lack of referral services, frustration at seeking diagnosis and treatment and long travel in both  
geographical regions. 
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4.5.4 Expert Panel Review 
 
The expert panel group consisted of a clinical team of 6 surgeons (3 British, 3 Australian), 2 clinical 
oncologists and 2 colorectal nurse specialists. In addition to this, the executive and deputy executive 
directors of the Surgical Outcomes Research Centre, Sydney, with backgrounds in public health and 
epidemiology and clinical psychology participated in the expert panel interviews.  
The panel generally agreed that clinically relevant themes had been identified through the patient 
focus groups, with complete agreement on the inclusion of the first 5 domains (symptoms, sexual 
function, psychological impact, role functioning and future perspective). The expert panel suggested 
the identified subdomain of Stoma Related Issues should be divided into a gastrointestinal stoma and a 
urostomy and be incorporated into the subdomains of gastrointestinal symptoms and urological 
symptoms, as this will help distinguish patients based on their stoma type and may potentially provide 
discriminatory HrQoL data in these subgroups of patients. 
Opinion was divided amongst the expert panel regarding the final domain of healthcare services, as 
some experts felt this domain concentrated on the provision of healthcare resources and therefore 
would provide information on the infrastructure and delivery of health services and not HrQoL. 
Conversely, other experts felt that this domain addressed an important issue regarding the delivery of 
health services and its potential impact on patients overall well being and HrQoL, and therefore will 
be useful in informing future healthcare policy. All the experts agreed this domain addresses 
important issues relevant to patients with LRRC, however opinion was divided on its incorporation 
into a conceptual framework addressing HrQoL. There was some discussion of the using this domain 
as a module to assess current health services and to monitor changes in healthcare services as an 
exercise to inform future healthcare policies.  
4.5.5 Finalised Conceptual Framework 
 
The themes extracted from the two systematic reviews n HrQoL in LRRC and PE were integrated 
with the analysis. The final LRRC-specific HrQoL framework includes six domains and 21 sub-
domains (Figure 4.1.)
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SEXUAL FUNCTION Sexual Intercourse  
Pain Location, Pain severity, frequency and interference 
Lack of energy and lethargy.  
Bleeding, discharge, pain, interference and bother 
Incontinence, urgency and interference. Urological stoma 
Fatigue 
Gynaecological symptoms  
Urological symptoms  
Gastrointestinal symptoms  
SYMPTOMS 
 Locomotor symptoms   Mobility, Lower limb paraesthesia and lower limb pain 
Flatulence, rectal discharge, interference. Gastrointestinal stoma 
Surprise/Shock/Anger, Depression, Frustration, Anxiety, Hope, 
Self confidence, reliance on others, change in perception  
Self-consciousness, Embarrassment 
 Mood 
Self-efficacy and 
Appearance and Body Image 
PSYCHOLOGICAL 
IMPACT 
Work  Change in occupational status, Finance 
General activities, Housework 
Social activities, Leisure activities and hobbies 
Change in roles, dependence on partner, communication with 
partner 
Household Activities 
Social  
Relationships  
ROLE FUNCTIONING 
 
Future Plans Short term, Hope  
Anxiety regarding appointments and symptoms Disease Rerecurrence  
Further Treatments  Adjuvant therapies, Morbidity and restriction  
FUTURE PERSPECTIVE 
Obtaining a diagnosis, intensity of diagnostic imaging, progression of 
disease, follow up intensity, travel 
Hope of cure, prolongation of life, limited options, length of 
Confidence in decision-making and disease management, 
communication and support 
Disease Management 
Treatment Expectation 
Healthcare Professionals 
HEALTHCARE SERVICES 
UTILISATION AND 
DELIVERY 
LRRC- QoL  
Figure 4-1 Conceptual Framework of HrQoL for LRRC  
Sexual desire, practical issues, gynaecological symptoms, 
erectile dysfunction, self confidence 
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4.6 Discussion  
 
This is the first qualitative study undertaken in patients with LRRC to examine HrQoL issues relevant 
to this cohort of patients. The findings of this study have been used to devise a conceptual framework 
which will inform the overall development of a PROM of HrQoL in this patient population. This 
study identified two patterns of issues relevant to patients with LRRC, the first being relevant to 
overall HrQoL and the second relevant to healthcare service delivery and utilisation.  A total of six 
domains or constructs were identified by this study. A number of constructs identified in this study are 
similar to HrQoL domains in established PRO measures for primary rectal cancer, however a number 
of LRRC-specific components were also identified. The symptoms experienced by this cohort were 
wide ranging and affected a range of systems and were not only gastrointestinal specific as seen in 
primary rectal cancer patients. In addition, several other components emerged that have not been 
previously identified, including that of ‘future perspective’ including ‘disease re-recurrence’, ‘further 
treatments’ and ‘future plans’.   
 
Previous research has used established quantitative measures for primary rectal cancer to ascertain the 
impact of LRRC on HrQoL. These studies have reported negative impacts on HrQoL in terms of 
physical functioning [185, 187, 190, 192], psychological and emotional function [185], social function 
[185, 190, 193], occupational role [190, 193], as well as a variety of symptoms. Consistent with the 
findings of these studies, our study identifies these constructs. Previous qualitative work in advanced 
rectal cancer requiring an extended pelvic resection identified themes beyond those identified through 
quantitative measures. These themes included ‘the life changing impact of surgery [263], ‘patient 
satisfaction with immediate care in hospital [263], ‘significant chronic pain related to sacrectomy 
[263], ‘patients need for additional information regarding long-term recovery [263], ‘patient gratitude 
to be alive [263]. ‘all that is important is your health [194], ‘limited options [194], ‘believe in your 
own intuitive sense of self [194], ‘unanticipated morbidity [194], ‘mistaken perception of cure [194] 
and ‘appropriate and timely information needed [264]. Our study reflects these themes, and 
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incorporates the themes identified by previous quantitative and qualitative work, which has been 
further supplemented by the perceptions of patients who have undergone surgery for LRRC. Thus 
ensuring the final conceptual framework is reflective of patient opinion with regards to important and 
relevant issues 
 
Differences were explored between patients in terms of patient and disease factors as well as location 
(UK versus Australia). No major differences were observed between the subgroups apart from in 
terms of symptoms, with patients with anterior and central recurrences complaining of more 
gastrointestinal, urological and gynaecological symptoms than patients with lateral and posterior 
recurrences. This latter group of patients complained more of pain and locomotor symptoms. These 
findings are in keeping with previous work [8, 69] and can be explained due to the pattern of organ 
invasion by the disease recurrence, with anterior and central recurrences more likely to invade the 
neorectum/rectal stump and urogenital organs leading to a variety of symptoms including rectal 
bleeding and discharge, vaginal symptoms and urinary symptoms. Similarly, posterior and lateral 
recurrences are more likely to invade the bony pelvis and the pelvic neural plexus leading to 
symptoms of neuropathic pain and lower limb dysfunction including paraesthesia and a reduction in 
mobility. However, despite these observed differences there were no differences between subsite 
location of LRRC and sexual function, healthcare services, psychological impact, role functioning and 
future perspective. More importantly, no differences were observed between patients in the UK and 
the Australia, thus confirming that the issues identified by this study are universal to all patients 
irrespective of the geographical location where their LRRC disease is managed. 
  
This is the first time issues regarding the provision of healthcare services have been examined from a 
patient perspective in this cohort of patients, as previous works have concentrated on the provision of 
services from a healthcare providers perspective alone [265]. Due to the lack of healthcare providers 
offering a dedicated service in the surgical management of LRRC, there are often potential delays in 
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referrals and appropriate radiological staging of disease to ascertain suitability for surgical resection, 
coupled with occasional ineffective communication between primary and specialist teams. These 
patient perceptions can have a negative impact on HrQoL, especially psychologically, with feelings of 
frustration, anxiety and worry expressed. Similar themes revolving around the provision of health 
services have been previously identified through qualitative methodology by Davidge [263] and 
Wright et al [194] in patients with advanced primary rectal cancer requiring an extended pelvic 
resection. The themes identified by these authors revolve around the need for adequate 
communication and information from healthcare professionals in a timely and appropriate manner and 
the satisfaction with post-operative management.  
 
HrQoL instruments are used in a variety of ways including monitoring an individual patients clinical 
response to a treatment or intervention, as primary or secondary endpoints in Phase I-III trials and as 
an outcome measure in health services research [266-268]. The modular system utilised by the 
EORTC and FACIT groups enables the use of questionnaires in their entirety or partially using only 
the relevant subscales of interest [267]. A similar approach could be incorporated into the LRRC-
QoL, utilising each subdomain as required dependent on the study outcomes and measurement points. 
This will be most relevant to the domain of ‘Healthcare Services’ as the expert panel could not agree 
on its inclusion into the main body of the conceptual framework due to disagreements on the 
measurement properties of this domain as a measure of HrQoL or provision of adequate health 
services. However, the qualitative data obtained from patients suggests the provision of health 
services had an impact on psychological well being, and therefore the inclusion of this domain may 
provide important information and may potentially impact other aspects of HrQoL measured by the 
LRRC-QoL. Despite the disagreements on inclusion of this domain all members of the expert panel 
acknowledged this domain was important, therefore a pragmatic decision was made to incorporate it 
into the main conceptual framework. The LRRC-QoL should be used in a modular fashion and 
therefore this domain could be included/excluded in future studies as deemed relevant.  
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Qualitative data can be generated and collected using two types of methods; through the use of 
interviews or through focus groups. Both have pros and cons, with focus groups identifying ‘a range 
of experiences and perspectives’, whilst individual interviews offer in-depth exploration. Focus 
groups enable participants to react to and build on the comments made by other members of the 
group, yielding opinions and experiences that may not surface during individual interviews [269]. For 
the purposes of our study, given the scattered geographical location of patients and the practical 
constraints of assembling a group together, a pragmatic decision was taken to undertake a series of 
teleconference focus groups consisting of 3-4 patients each. Our focus groups were single sex, this 
was to promote patient comfort when discussing sensitive issues such as sexual function and body 
image, thus providing data which was rich and robust and therefore able to support content validity. 
Criticisms of teleconference focus groups include the lack of nonverbal communication, which might 
reduce the richness of the qualitative data and the difficultly in managing group interaction [270]. 
Despite, these criticisms, teleconference focus group participants appear to be more willing to discuss 
experiences of a sensitive or personal nature due to the visual anonymity afforded by this medium 
[271, 272].  Furthermore, recent evidence has found there is little difference in the type of data 
obtained from face-to-face focus groups and telephone focus groups [272].  
One of the potential difficulties in conducting qualitative research is the ‘researcher effect’[273]. The 
role and position of the researcher can potentially have an impact on the behaviour of the participants. 
It is well known that participants can behave differently with different researchers. Furthermore, there 
is the additional issue of researcher bias, with researchers potentially observing behaviours and 
interpreting findings in view of their own bias. With regards to this study, it is possible that patients 
may have over reported issues regarding symptoms and under reported more personal and sensitive 
issues such as sexual function and psychological function. It is possible patients may have placed 
more emphasis on surgical treatments and reported the consequences of surgery in a more positive 
light given my clinical role as a surgical trainee. This may have had an impact on themes extracted 
within this study. To overcome this, it would’ve been ideal to have additional focus groups facilitated 
by a qualitative researcher with a non-clinical background. This may have potentially lead to some 
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differences in the themes reported and may have potentially provided a ‘richer’ data set. However, 
this was not feasible due to logistical and practical issues. With regards to reporting and observing 
behaviours and issues in accordance with my own bias, all the teleconferences were recorded and 
transcribed verbatim and coded by myself and a qualitative researcher. This minimised the potential 
of researcher bias as all reported issues were appropriately recorded, transcribed and reviewed.  
 
4.7  Conclusion 
 
This study provides qualitative evidence for HrQoL outcomes that are important for patients with 
LRRC across two geographical regions. Themes extracted from this study have been combined with 
themes extracted from the current evidence base in this cohort of patients, and have been 
operationalisation into a conceptual framework. This framework will provide the basis for the 
development of a new LRRC-specific PROM of HrQoL.  
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5 Chapter 5 - Systematic Review of Patient Reported Outcome Instruments for 
Rectal Cancer 
 
5.1 Introduction  
 
The growing emphasis on the integration of patient reported outcomes with clinical outcomes has led 
to the development and availability of a number of PROMs [88]. To draw valid and robust 
conclusions from PROs, they must be captured and measured in a standardised manner using 
measures that demonstrate sufficiently robust measurement properties. PROMs must adhere to a set of 
minimum standards prior to their use in patient-centred outcomes research and comparative 
effectiveness research. A number of guidelines exist to guide these standards including guidance from 
Food and Drug Agency [89], the 2002 Medical Outcomes Trust guidelines [255], the COnsensus-
based Standards for the selection of health Measurement Instruments [274-276], the European 
Organisation for Research and Treatment of Cancer [277] guidelines, the Functional Assessment of 
Chronic Illness Therapy (FACIT) approach [278] and the International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR) task force recommendation documents [256, 
279-281]. These guidelines were recently incorporated with expert opinion by International Society 
for Quality of Life Research (ISOQOL) to establish a minimum measurement standard to promote the 
appropriate use of PROMS [282].  
Data obtained from PROMs is only valid and meaningful if it has been obtained in an appropriate 
manner in the intended population in which the PROM has been developed. A review of HrQoL 
outcomes in LRRC revealed a number of PROMs which had been used to capture this data (Chapter 
2). However, the majority of PROMs used to measure HrQoL in this cohort were developed 
specifically for the study as an ad hoc measure or were developed to measure HrQoL in primary 
colorectal cancer. The aim of this study was to identify and assess PROMs developed and validated 
for use in primary rectal cancer and to assess their applicability to measuring PROMs data in LRRC 
by conducting a domain and subdomain level analysis to identify overlapping constructs.   
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5.2  Aims 
 
The aims of this review were:  
• To identify HrQoL PROMs developed and validated for primary rectal cancer 
• To assess identified PROMs against ISOQOL minimum measurement standards 
recommendations 
• To assess the existing PROMs content against the LRRC-specific HrQoL conceptual 
framework 
 
5.3 Methodology 
 
This systematic review was conducted according to a pre-specified protocol based on guidance from 
the Centre for Reviews and Dissemination [219]  and the Cochrane Handbook [220]. The review is 
reported in line with the PRISMA statement [221]. 
 
5.3.1 Literature Search  
 
Systematic searches of the literature were conducted in Medline, EMbase, Science Citation Index, 
Ovid Evidence-Based Medicine databases, PychoINFO and Health and Psychosocial Instruments 
using the following search string ‘rectal cancer’ or ‘rectal neoplasm’ and ‘patient reported outcome’ 
or ‘questionnaire’ or ‘instrument’ or ‘measure’ or ‘scale’ or ‘index’. For the appraisal of psychometric 
and operational performance of the measures identified a second search strategy was devised using 
the following search string ‘validation’ or ‘validity’ or ‘reliable’ or ‘reliability’ or ‘responsiveness’ or 
‘responsive’ or ‘internal consistency’ or ‘psychometric properties’.  
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5.3.2 Study Inclusion Criteria  
 
All instruments included in the review were PROMs which measured rectal cancer related quality of 
life and/or bowel function that had undergone development and validation in colorectal oncology 
patients; measures which did not undergo validation i.e. ad hoc instruments were excluded. The 
following studies were excluded: studies of health-related quality of life instruments, studies of 
instruments related to colonic cancer alone; studies of instruments that are used in the paediatric 
population.  
 
5.3.3 Data Extraction and Analysis 
 
Extraction of data for all selected studies was conducted by one reviewer (D.P.H). The accuracy of the 
extracted data was verified by a second reviewer (B.G). Data were analysed for three broad categories 
including instrument development and content validity, domain and subdomain level content analysis. 
• Instrument Development and Content Validity 
The following data were extracted for the evaluation of instrument development and content validity: 
objectives of each questionnaire, characteristics of intended patient population and patient population 
involved in the questionnaire development, method of item generation, process used for conducting 
patient qualitative data and methods used to evaluate the draft questionnaire.  
Psychometric properties of all identified PROMs were evaluated including reliability (the extent to 
which the instrument is free from random error), validity (the extent to which the instrument measures 
what it purports to measure) and responsiveness (the ability of the instrument to detect changes over a 
period of time) (Table 5.1).  
The ISOQOL recommendations on the minimum standards for the design of a PROM for use in 
clinical research is the most up to date guidance in this field and incorporates the guidance from a 
number of previously established guidelines [283]. The ISOQOL guideline outlines 6 desirable 
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standards PROMS should adhere to including 1) A conceptual and measurement model, 2) Reliability, 
3) Validity, 4) Interpretability of Scores, 5) Translation of the PRO measure and 6) Patient and 
Investigator Burden (Table 5.2). It was therefore deemed appropriate that adherence to these 
guidelines should be determined for each of the identified PROMs to assess whether the PROM was 
developed in a sufficiently robust methodological manner. 
 
• Domain and Subdomain Level Content Analysis 
To identify the extent to which identified PROMs covered the LRRC-specific framework a domain 
and sub-domain level content analysis was undertaken. This identified the number of PROM domains 
and sub-domains that mapped onto the LRRC-specific conceptual framework. Where names differed 
from those in the LRRC-specific conceptual framework item content was analysed for relevance and 
compared against the LRRC-specific domain and sub-domain content to determine consistency 
irrespective of different labelling.  
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Table 5-1 Assessment of Psychometric Properties of PROMS 
Measure Definition Assessment Measure Interpretation of Scores 
 
Convergent Validity 
 
 
Measures of constructs that are 
theoretically related. 
 
Pearson’s Product Moment Correlation 
(r). 
 
 
>0.60 strong correlation, 0.30-0.60 
moderate correlation, <0.30 low 
correlation 
 
 
Divergent Validity 
 
 
Measures of constructs that are 
theoretically unrelated.  
 
 
Pearson’s Product Moment Correlation 
(r). 
 
 
>0.60 strong correlation, 0.30-0.60 
moderate correlation, <0.30 low 
correlation 
 
 
Internal Consistency 
 
 
Measure of inter-relational properties of 
all items within a domain.  
 
 
Cronbach’s α 
 
>0.70 supports internal consistency 
 
 
Test-Retest Reliability 
 
 
Stability of scores over time when no 
change is expected in the concept of 
interest. 
  
 
 
Intraclass Correlation Coefficient  
 
 
>0.70 supports test-retest reliability 
 
 
 
Known Groups Validity 
 
 
Extent to which the instrument can 
discriminate between groups that are 
known to differ on the variables being 
measured. 
 
 
Effect size 
 
>0.80 large change, 0.50-0.79 moderate 
change, 0.2-0.49 small change 
 
 
Score change statistics 
 
 
Statistically significant differences in 
score 
 
 
 
 
Responsiveness Ability to detect change over time 
 
Effect size 
 
>0.80 large change, 0.50-0.79 moderate 
change, 0.2-0.49 small change 
 
 
Score change statistics 
 
 
Statistically significant differences in 
score 
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Table 5-2 ISOQOL Recommendations for Minimum Standards for PROMS 
 
Recommendation 
 
 
Definition 
Conceptual and Measurement Model A PRO measure should have documentation defining and describing the 
concept(s) included and the intended population(s) for use. In addition, there 
should be documentation of how the concept(s) are organised into a measurement 
model, including evidence for the dimensionality of the measure, how items 
relate to each measured concept, and the relationship among concepts included in 
the PRO measure.  
Reliability The reliability of a PRO measure should preferably be at or above 0.70 for group 
level comparisons, but may be lower if appropriately justified. Reliability can be 
estimated using a variety of methods including internal consistency reliability, 
test-retest reliability, or item-response theory. Each method should be justified.   
Validity  
Content Validity A PRO measure should have evidence supporting its content validity, including 
evidence that patients and experts consider the content of the PRO measure 
relevant and comprehensive for the concept, population and the aim of the 
measurement application. This includes documentation of as follows: (1) 
qualitative and/or quantitative methods used to solicit and confirm attributes in 
the evaluation (e.g. race/ethnicity, culture, age, gender, socio-economic status, 
literacy level) with an emphasis on similarities or differences with respect to the 
target population; and (3) justification for the recall period for the measurement 
application. 
Construct Validity A PRO measure should have evidence supporting its construct validity, including 
documentation of empirical evidence of changes in scores consistent with 
predefined hypotheses regarding changes in the measured PRO in the target 
population for the research application.  
Responsiveness A PRO measure for use in a longitudinal research study should have evidence of 
responsiveness, including empirical evidence of changes in scores consistent with 
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predefined hypotheses regarding changes in the measured PRO in the target 
population for the research application.  
Interpretability of Scores A PRO measure should have documentation to support interpretation of scores 
including what low and high scores represent for the measured concept.  
Translation of the PRO A PRO measure translated to one or more languages should have documentation 
of the methods used to translate and evaluate the PRO measure in each language. 
Studies should at least include evidence from qualitative methods (e.g. cognitive 
testing) to evaluate the translations.  
Patient and Investigator Burden A PRO measure must not be overly burdensome for patients or investigators. The 
length of the PRO measure should be considered in the context of other PRO 
measures included in the assessment, the frequency of the PRO data collection 
and the characteristics of the study population. The literacy demand of the items 
in the PRO measure should usually be at a 6th grade education level or lower (i.e. 
12 year old or lower); however, it should be appropriately justified for the context 
of the proposed application.  
 
 
5.4 Results 
 
A total of 135 articles were identified, which identified 114 PROMs. On application of the inclusion 
and exclusion criteria, 105 PROMs were eliminated, of which 39 were generic measures, 30 were ad 
hoc questionnaires, 7 questionnaires were validated for urological conditions, 13 were for 
psychological well-being, 7 were for assessment of sexual function and 9 were for the assessment of 
faecal incontinence. Nine measures fulfilled the eligibility criteria, including two core measures with 
colorectal specific supplementary measures; European Organisation for Research and Treatment of 
Cancer QLQ-C30 (EORCT QLQ-C30) and the Functional Assessment of Cancer Therapy – General 
(FACT-G) and 7 disease specific measures. All of the identified measures were developed and 
validated for use in primary rectal cancer. There were no identified measures which were developed 
specifically for patients with LRRC 
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5.4.1 Identified PROMS 
 
EORTC QLQ-C30, EORTC CR38 and EORTC CR29 
The EORTC has adopted a modular measurement approach to the assessment of QoL in cancer 
patients. The EORTC QLQ-C30 is a second generation core questionnaire following the modification 
of the original EORTC QLQ-C36 [284]. This core measure encompasses a number of QoL issues 
relevant to a broad range of oncology patients. The QLQ-C30 has demonstrable psychometric 
properties, with adequate reliability, validity and responsiveness [284]. A number of modules exist to 
supplement this core measure to assess specific QoL issues relevant to subset cancer populations. The 
EORTC QLQ-CR38 was designed to supplement the EORTC QLQ-C30 for colorectal cancer patients 
receiving a range of treatments, including surgery, radiotherapy and chemotherapy [145]. It consists 
of 38 items measuring body image, sexuality, micturition problems, symptoms in the gastrointestinal 
tract, chemotherapy-related side effects, problems with defaecation, stoma-related problems, and male 
and female sexual problems. To reflect the evolving management of primary colorectal cancer, this 
module was updated in 2007, which led to the development of the EORTC QLQ-CR29 [144, 285]. 
This consists of 29 items making up 6 domains of micturition problems, abdominal and pelvic pain, 
defaecation problems, faecal incontinence, anxiety and body image and 11 single items. Both the 
EORTC QLQ-CR38 and QLQ-CR29 display acceptable psychometric properties[145] [285].  
 
FACT-G and FACT-C 
The Functional Assessment of Chronic Illness Therapy Measurement measures QoL in patients with 
cancer and chronic illness. There is a general version of the questionnaire, the FACT-G, which is 
administered to all patients and provides a common framework. In addition to this a number of 
modules exist, which are disease, symptom or treatment specific, including one for primary colorectal 
cancer (FACT-C). The FACT-G consists of 5 Domains; Physical Well-Being, Social Well-Being, 
Emotional Well-Being, Functional Well-Being and Relationship with Doctor [286]. This measure has 
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been validated in a large sample size of patients with breast, lung and colorectal cancer, with 
acceptable psychometric properties [286]. The FACT-C retains four of the five subscales of the 
FACT-G questionnaire (Physical Well-Being, Social Well-Being, Emotional Well-Being, Functional 
Well-Being) with 9 additional items comprising the Colorectal Cancer Subscale, it has been widely 
validated and demonstrates acceptable psychometric properties [143].  
 
City of Hope Quality of Life-Ostomy Questionnaire 
The City of Hope Quality of Life-Ostomy questionnaire is a disease-specific measure to assess 
HrQoL in patients with a stoma, irrespective of the pathology. This PROM was developed using 
patients with a stoma as a result of a wide variety of diseases including colorectal malignancy, 
gynaecological malignancy, diverticulitis and other diagnoses [287]. It consists of a total of 90 items 
across 4 domains of Physical Well-Being, Social Well-Being, Psychological Well-Being and Spiritual 
Well-Being,  
 
Stoma-QoL Questionnaire 
The Stoma-QoL questionnaire is a disease-specific measure used to assess HrQoL in patients with a 
colostomy or ileostomy due to a variety of benign and malignant diseases [288]. It consists of 4 
domains of sleep, sexual activity, relations to family and close friends and social relations to others 
than family and friends. The questionnaire is available in English, French, German, Spanish and 
Danish, with confirmation of cross-cultural validity. The questionnaire demonstrates good internal 
consistency reliability with a calculated Crombachs α of 0.92 and a high test-retest reliability with a 
Spearman’s correlation coefficient of >0.88 [288].  
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Stoma Quality of Life Scale (SQOLS) 
 
The SQOLS questionnaire was developed to assess HrQoL in patients with a colostomy or ileostomy, 
irrespective of the permanence of the stoma and underlying disease pathology. The questionnaire 
consists of 21 items covering three domains of work/social function, sexuality/body image and stoma 
function [289]. The SQOLS demonstrated adequate test-retest reproducibility with intraclass 
coefficients of 0.75-0.93 and acceptable internal consistency reliability with Cronbachs coefficient of 
0.72-0.89 [289]. The scales were capable of discriminating between patients with worse and better 
QoL after stoma formation and appropriately correlated with the Physical and Mental Health scales of 
the SF-12 questionnaire [289].  
 
MSKCC Bowel Function Instrument 
 
The MSKCC Bowel Function Instrument is a disease-specific and surgery-specific questionnaire for 
patients undergoing sphincter-preserving surgery for Stage I-III rectal cancer[290]. The questionnaire 
consists of 3 domains Frequency, Dietary, Urgency/Soiling and 4 individual items. The questionnaire 
demonstrates adequate test-retest reliability with Pearson correlation coefficients of 0.62-0.87[290]. 
The domains correlated appropriately with EORTC QLQ-C30, EORTC QLQ CR38 and Faecal 
Incontinence Quality of Life (FIQL) scores[290]. The scales were able to significantly discriminate 
between radiation treatment groups, type of surgery and type of anastomosis and quality of life.  
 
5.4.2 Development of PROMs 
 
All 9 PROMs included in this review documented the operational and psychometric processes of the 
PROM in question, with clear objectives of the purpose of the questionnaire and its target population 
(Table 5.3 and 5.4). The use of qualitative data from patients for item generation, either through focus 
groups or interviews is documented in 7 studies [143-145, 285-290].  This is supplemented by further 
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data from literature reviews and an expert clinical panel in 6 studies [143, 144, 285-287, 289, 290]. 
Prior to psychometric testing a draft questionnaire was evaluated by patients and/or an expert clinical 
panel in 7 studies [143-145, 285, 287, 288, 290].  
Eight studies employed the Classical Test Theory in assessing the psychometric properties of the 
PROM in question[143, 145, 284-287, 289, 290]. Prieto et al utilised the Classical Test Theory and 
Rasch analysis when assessing the psychometric properties of the Stoma-QoL [288]. All studies 
commented on the population in which the validation study was conducted.  
Adherence to the ISOQOL minimum standards recommendations were between 50-100%, with 4 
PROMS (EORTC QLQ-CR38, EORTC QLQ-CR29, FACT-G and FACT-C) fulfilling all the 
requirements (Table 5.5). The areas of the ISOQOL recommendations which demonstrated a lack of 
compliance included measuring responsiveness, translation of PROMs and documentation of patient 
and investigator burden. 
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Table 5-3 Psychometric and Operational Properties of Identified PROMS 
Instrument Author Year Objective Domains Scale 
No of 
Items 
Intended 
Patient 
Population 
Patient 
population used 
in questionnaire 
development 
Item 
Generation 
Patient 
Qualitative 
Interviews and 
Focus Groups 
Draft 
Questionnaire 
Evaluation 
Patient 
Cognitive 
Interviews 
City of Hope 
Quality of 
Life -Ostomy 
Questionnaire 
Grant/ 
2004 
Development 
and validation 
of an 
instrument to 
assess QoL in 
patients with a 
stoma. 
4 Domains: 
Physical Well-
Being, Social 
Well-Being, 
Psychological 
Well-Being, 
Spiritual Well-
Being 
10 point 
Likert 
Scale 
90 Patients with a stoma 
Patients with a 
stoma with 
colorectal cancer, 
gynaecological 
cancer, 
diverticular 
disease or other 
diagnoses.  
Literature 
review with 
input from 
patients and a 
clinical panel 
Interviews and 
focus groups 
Assessed by a 
clinical panel. NR 
EORTC 
QLQ-C30 
Aaronson 
/1993[284] 
Development 
of a cancer-
specific 
questionnaire 
to measure 
QoL.  
9 Domains: 
Physical, Role, 
Cognitive, 
Emotional, 
Social, Fatigue, 
Pain, Nausea 
and Vomiting, 
Global Health 
Status and 
Quality of Life 
4 point 
Likert 
Scale 
30 Cancer patients NR NR NR NR NR 
EORTC 
QLQ-CR29 
Gujral/ 
2007 [144] 
and 
Whistance/
2009 [285] 
Update and 
improve the 
QLQ-CR38 
module and 
prepare a 
module that 
could be 
validated 
internationally 
for use in 
clinical trials 
in colorectal 
cancer 
6 Domains: 
Micturition 
problems, 
Abdominal and 
pelvic pain, 
Defaecation 
problems, 
Faecal 
incontinence, 
Anxiety, Body 
Image 
4 point 
Likert 
Scale 
29 
Colorectal 
cancer patients 
Stage I-IV 
Colorectal cancer 
patients Stage I-
IV 
Literature 
review 
combined with 
patient 
interviews. 
Semi-structured 
interviews 
Patients and 
clinical panel 
Cognitive 
interviews 
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EORTC 
QLQ-CR38 
Sprangers/
1999[145] 
Construction 
of a colorectal 
cancer-
specific 
questionnaire 
module to be 
used in 
conjunction 
with EORTC 
QLQ-C30 for 
assessing 
QoL.  
9 Domains: 
Body Image, 
Sexuality, 
Micturition 
problems, 
Symptoms in 
the 
gastrointestinal 
tract, 
chemotherapy-
related side 
effects, 
problems with 
defaecation, 
stoma-related 
problems, male 
and female 
sexual 
problems.  
4 point 
Likert 
Scale 
38 
Colorectal 
cancer patients 
Stage I-IV 
Colorectal cancer 
patients Stage I-
IV 
Literature 
review with 
input from a 
clinical panel 
NR Patients Cognitive interviews 
FACT-C Ward/1999[143] 
Development 
of a measure 
of specific 
concerns or 
problems 
related to 
quality of life 
in colorectal 
cancer 
patients. 
5 Domains: 
Physical, 
Functional, 
Social/Family, 
Emotional, 
Colorectal 
Cancer 
Subscale 
5 point 
Likert 
Scale 
36 
Patients with 
colorectal 
cancer in 
clinical 
practice or 
clinical trials  
Patients with 
Stage I-IV 
colorectal cancer 
Literature 
review with 
input from 
patients and a 
clinical panel 
Structured 
Interviews 
Assessed by 30 
colorectal 
cancer patients 
for relevance 
and importance 
NR 
FACT-G Cella/1993 [286] 
Development 
and validation 
of a core 
measure of 
QoL in cancer 
patients.  
5 Domains: 
Physical Well-
Being, Social 
Well-Being, 
Emotional 
Well-Being, 
Functional 
Well-Being, 
Relationship 
with Doctor 
5 point 
Likert 
Scale 
28 Cancer patients 
Breast, lung and 
colorectal cancer 
patients 
Interviews with 
patients and 
clinicians 
Semi-structured 
interviews 
Patients and 
clinical panel NR 
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MSKCC 
Bowel 
Function 
Instrument 
Temple/ 
2005 [290] 
Development 
and validation 
of an 
instrument to 
assess bowel 
function in 
patients who 
had 
undergone 
sphincter-
preserving 
surgery for 
rectal cancer.  
3 Domains: 
Frequency, 
Dietary, 
Urgency/Soiling 
and 4 individual 
items 
5 point 
Likert 
Scale 
18 
Patients 
following 
sphincter 
preserving 
surgery for 
rectal cancer 
Patients with 
Stage I-III Rectal 
cancer undergoing 
sphincter 
preserving 
surgery 
Literature 
review with 
input from 
patients and a 
clinical panel 
Semi-structured 
interviews 
Assessed by 
patients for 
relevance, 
importance and 
wording.  
NR 
Stoma 
Quality of 
Life Scale 
(SQOLS) 
Baxter/ 
2006 [289] 
Development 
of an 
instrument to 
measure QoL 
in patients 
with a stoma. 
3 Domains: 
Work/Social 
Function, 
Sexuality/Body 
Image, Stoma 
Function 
5 point 
Likert 
Scale 
21 Patients with a stoma 
Patients with 
colostomies or 
ileostomies with 
benign and 
malignant disease.  
Expert panel 
and patient 
focus groups 
Focus Groups None None 
Stoma-QoL Prieto/ 2005 [288] 
Development 
of an 
instrument to 
measure QoL 
in patients 
with an 
ileostomy or 
colostomy 
4 Domains: 
Sleep, sexual 
activity, 
relations to 
family and close 
friends, and 
social relations 
to other than 
family and 
friends 
4 point 
Likert 
Scale 
20 Patients with a stoma 
Patients with a 
stoma 
Generated based 
on patient 
interviews 
Semi-structured 
interviews 
Assessed by a 
panel of lay 
people for 
linguistic 
clarity, 
understanding 
and ease of 
completion.   
Cognitive 
interviews 
with stoma 
patients to 
assess for 
clarity.  
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Table 5-4 Psychometric and Operational Properties of Identified PROMS 
Instrument Validation Study Population 
Convergent 
validity 
Discriminant 
Validity 
Internal 
consistency 
Test-retest 
reliability 
Known groups 
validity 
Responsiveness 
to change 
Non English 
language 
translations 
City of Hope Quality of 
Life -Ostomy 
Questionnaire 
Members of the United 
Ostomy Association for the 
state of California.  
Pearson 
Correlation of 
each scale with 
single overall QoL 
item, r=0.24-0.76. 
NR Cronbachs α  0.95 NR 
Significant association 
between new sexual 
concerns, social 
adjustment, general 
physical QoL, specific 
physical QoL, specific 
psychological QoL and 
gender. 
NR - 
EORTC QLQ-C30 Non-resectable lung cancer - - Cronbachs α 0.65-0.86 
Pearson 
correlation 
coefficient: 
0.82-0.92 
Statistically significant 
differences between 
emotional functioning 
and pattern of 
malignant disease 
(p<0.05). 
Statistically 
significant 
between group 
differences over 
time were 
observed for 
physical 
functioning 
(p<0.001), role 
functioning 
(p<0.001), 
fatigue 
(p<0.01), nausea 
and vomiting 
(p<0.05) and 
global quality of 
life (p<0.01).  
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EORTC QLQ-CR29 
Colorectal Cancer patients 
Stage I-IV (UK, France, 
Taiwan, Italy, Germany, 
Spain, USA) 
- 
Pearson 
correlation 
with the 
QLQ-C30 
r<0.40 
Cronbachs α  
0.69-0.84 
ICC >0.68 for 
all scales and 
>0.55 for 
single items.  
Differences between 
known groups were 
observed in 16 of the 
23 scales and items.   
Statistically 
significant 
differences were 
observed over 
time for pain 
(p=0.045) and 
physical 
function 
(p=0.045) 
 
EORTC QLQ-CR38 Colorectal cancer Dutch patients Stage I-IV - - 
Cronbachs α  
0.38-0.91 
ICC : 0.53-
0.92 Effect size: 0.40-0.94 
Statistically 
significant 
between group 
differences over 
time were 
observed in the 
expected 
direction 
(p=0.0001). 
 
FACT-C Colorectal cancer patients Stage I-IV 
Pearson 
Correlation of 
Colorectal Cancer 
Subscale with The 
Functional Living 
Index-Cancer 0.54 
and with the Brief 
Profile of Mood 
States (BPOMS)  -
0.46 
Correlation of 
Colorectal 
Cancer 
Subscale with 
the Marlowe-
Crowne 
Social 
Desirability 
Scale - 0.22 
Cronbachs α  
0.47-0.91 NR 
Significant differences 
between three 
performance status 
ratings groups and the 
5 subscales of FACT-c 
(p=0.0011) 
Mean change in 
symptom 
improvement 
5.59 (p<0.001). 
Spanish 
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FACT-G 
Breast, lung, colorectal, 
leukaemia/lymphoma, head 
and neck, prostate, ovarian, 
other primary cancers 
Pearson 
Correlation with 
The Functional 
Living Index-
Cancer 0.79 
Pearson 
Correlation 
with the 
Marlowe-
Crowne 
Social 
Desirability 
Scale - 0.22 
NR 
Pearson 
correlation 
coefficient: 
0.82-0.92 
Significant differences 
between stage of 
disease (p<0.01), 
performance status 
rating (<0.001) and 
location of 
questionnaire 
administration (p<. 
0001) 
Overall 
sensitivity to 
change 
demonstrated by 
all subscales 
p<0.001 
- 
MSKCC Bowel Function 
Instrument 
Stage I-III Rectal cancer 
patients who had undergone 
sphincter preserving surgery 
Pearson 
Correlation with 
EORTC QLQ 30: 
-0.53 - 0.36, with 
EORTC CRC-38 -
0.45 - 0.38 and 
FIQL 0.50 - 0.68 
NR NR 
Pearson 
correlation 
coefficient: 
0.62-0.87 
Significant differences 
radiation treatment 
groups (p=0.005), type 
of surgery (p=0.002) 
and type of 
anastomosis (<0.0001). 
NR - 
Stoma Quality of Life 
Scale (SQOLS) 
70 consecutive ostomy 
patients (34 colostomy; 36 
ileostomy) 
Spearman's 
Correlation with 
SF-12 Physical 
Health and Mental 
Health Score 0.54-
0.75  
NR Cronbachs α  0.72-0.89 
ICC: 0.75-
0.93 NR NR - 
Stoma-QoL 
182 patients from 4 
European countries with 
stomas due to malignant and 
benign diseases 
  
Cronbachs α  
0.92 
Spearman's 
Correlation 
coefficient 
>0.88 
NR NR 
German, 
Spanish, 
French 
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Table 5-5 PROMS adherence to ISOQOL recommendations 
ISOQOL 
Recommendations  
EORTC 
QLQ-C30 
EORTC 
QLQ-
CR38 
EORTC 
QLQ-
CR29 
City of Hope 
Quality of 
Life-Ostomy 
Questionnaire 
MSKCC 
Bowel 
Function 
Instrument 
Stoma 
Quality 
of Life 
Scale 
(SQOL
S) 
FACT-
C 
FACT-
G 
Stoma-
QoL 
Conceptual and 
measurement model • • • • • • • • • 
Reliability • • • • • • • • • 
Validity                   
Content Validity   • • • • • • • • 
Construct Validity • • • • • • • • • 
Responsiveness • • •       • •   
Interpretability of 
Scores • • • •   • • • • 
Translation of PRO 
measure 
• • • 
      
• 
  
• 
Patient and 
Investigator Burden • • •       • • • 
% of ISOQOL 
recommendations 
covered  87.5 100 100 62.5 50 
 
62.5 100 100 87.5 
 
5.4.3 Domain and Subdomain Level Analysis  
 
The nine identified measures covered between 16.6-50% of LRRC-specific domains and 5.5-38.8% of 
the LRRC-specific subdomains (Table 5.6). The LRRC-QoL domain of symptoms was covered by all 
the identified PROMS. None of the identified PROMs covered the domain of Healthcare Services. 
The subdomain of gastrointestinal symptoms was most commonly covered by the identified PROMS, 
with 77.7% of instruments covering this subdomain. The subdomains of disease management, 
treatment expectations and healthcare professionals were poorly covered. The FACT-G and FACT-C 
instruments covered the highest number of subdomains on the LRRC-specific conceptual framework, 
with each instrument covering 7 out of 18 subdomains.  
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Table 5-6 PROMS for Primary Rectal Cancer and LRRC-Specific Conceptual Framework: Content Analysis 
LRRC specific subdomains EORTC QLQ-C30 
EORTC 
QLQ-CR38 
EORTC 
QLQ-CR29 
City of Hope 
Quality of Life-
Ostomy 
Questionnaire 
MSKCC 
Bowel 
Function 
Instrument 
Stoma Quality 
of Life Scale 
(SQOLS) 
FACT-C FACT-G Stoma-QoL 
Symptoms * * *   * * * * * 
Pain and discomfort •   •       • •   
Gynaecological Symptoms                   
Urological Symptoms   • •             
Gastrointestinal Symptoms   • • • • • •   • 
Locomotor Symptoms                   
Sexual Function   * *     *     * 
Sexual Intercourse   • •     •     • 
Healthcare Services                    
Disease Management                   
Treatment Expectation                   
Healthcare Professionals               •   
Psychological Impact *   * *   * * *   
Mood •   • •     • •   
Self-efficacy and dependence                   
Appearance and Body Image     •     •       
Role Functioning *     *   * * * * 
Work •     •   • • •   
Social •     •   • • • • 
Relationships •           • • • 
Future Perspective   *         * *   
Disease Rerecurrence                   
Further Treatments   •         • •   
Future Plans                   
Number (%) of LRRC-specific 
domains covered 3 (50%) 3 (50%) 3 (50%) 2 (33.3%) 1 (16.6%) 4 (66.6%) 4 (66.6%) 4 (66.6%) 3 (50%) 
Number (%) of LRRC-specific 
subdomains covered 5 (27.7%) 4 (22.2%) 6 (33.3%) 4 (22.2%) 1 (5.5%) 5 (27.7%) 7 (38.8%) 7 (38.3%) 4 (22.2%) 
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5.5 Discussion 
 
This review identified 9 PROMs that were developed and validated in primary rectal cancer 
for use in clinical practice and research. This review identified two core measures of HrQoL 
in cancer patients (FACT-G and EORTC QLQ-C30), three primary colorectal cancer specific 
measures (FACT-C, EORTC QLQ-CR38 and EORTC QLQ-CR29), three stoma specific 
measures (City of Hope Quality of Life-Ostomy Questionnaire, SQOLS and Stoma-QoL) and 
one disease specific, surgery specific measure (MSKCC Bowel Function Instrument). No 
disease specific measures were identified for LRRC.  
Overall, there was a lack of overlap between the domains of the identified PROMs and the 
LRRC-QoL conceptual framework. The majority of the identified PROMs failed to 
encapsulate appropriate themes at domain and sub-domain level that are relevant to patients 
with LRRC. The FACT-G and FACT-C instruments covered the greatest number of LRRC-
specific domains (66.6% each) and subdomains (38.8% each). Therefore, using existing 
PROMs, in their current format, to assess the HrQoL in LRRC is inappropriate as they do not 
provide a true reflection of the impact of LRRC, and thus lack content validity. There are a 
number of strategies which are available when existing PROMs fail to measure all relevant 
and identified domains [291] [281]. One strategy is to use multiple instruments to cover the 
relevant domains identified by the LRRC-QoL conceptual framework. The advantages of 
measuring PROs in this manner is the use of validated measures which lends credibility to the 
measurement strategy overall and allows for comparison between a number of studies. 
However, this was not a feasible option for measuring PROs in LRRC as combining domains 
from existing PROMs fails to capture all the domains identified by the LRRC-QoL 
conceptual framework, especially given that the domain of Healthcare Services was not 
covered by any of the identified measures. Furthermore, the use of different domains from a 
multitude of PROMs has a number of disadvantages include potentially increasing responder 
and administrative burden and cost. An alternative strategy to this is the modification of an 
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existing PROM [281]. Modifying the FACT-C questionnaire to reflect the needs of patients 
with LRRC is a possibility, as this instrument covered 66.6% of the LRRC-QoL. The FACT-
C is a well constructed, psychometrically robust PROM, with a 100% adherence to the 
ISOQOL recommendations, which makes it a potential candidate for modification for use in 
the LRRC cohort. However, the FACT-C questionnaire would require significant 
modification to be able to appropriately measure PROs in patients with LRRC. This is evident 
by the fact that despite coverage of 66.6% of the domains of the LRRC-QoL, the FACT-C 
only covers 38.8% of the subdomains of the LRRC-QoL conceptual framework. The existing 
instrument would require significant revision of its current domains and the addition of two 
new domains to reflect the themes of sexual function and healthcare services. An alternative 
questionnaire which could be modified or combined is the EORTC QLQ-C30 and its 
colorectal modules CR29 and CR38. Although, these questionnaires only covered 50% of the 
LRRC-QoL domains and between 22.2 – 33.3% of subdomains individually, when these 
questionnaires are combined, they cover five out of the six (83.3%) LRRC-QoL domains and 
fourteen (77.7%) out of the eighteen subdomains. The LRRC-QoL domains which the 
EORTC questionnaires failed to cover adequately were the healthcare services domain and 
the future perspectives domain. Therefore, despite the good overall coverage, further work 
would be required to modify the EORTC questionnaires to enable future use in patients with 
LRRC.   
 
Given the lack of overlap between existing measures and the LRRC-QoL conceptual 
framework, combined with the significant work required to revise existing PROMs to enable 
their use in LRRC, a pragmatic decision was made to develop a disease-specific PROM for 
LRRC. Using a combination of domains from a variety of instruments or modifying an 
existing PROM to measure PROs in LRRC to reflect the LRRC-QoL conceptual framework, 
although feasible options may not produce psychometrically robust and valid results in this 
complex cohort of patients without significant work. Given the degree of overlap between the 
EORTC questionnaires combined and the LRRC-QoL a pragmatic decision was made to 
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produce the LRRC-QoL, utilising guidance from the EORTC, including, using a similar 
design and identifying items from the EORTC item bank, with the end-user product made to 
be used as a supplementary module to the core EORTC QLQ-C30 module. Producing a 
disease-specific measure for use in LRRC would enable the measurement of HrQoL 
outcomes exclusively in this cohort of patients and allow for meaningful results to be 
obtained. Furthermore, disease specific measures are more sensitive in detecting changes due 
to the effects of the disease [170]. This would allow for detection of subtle differences 
between different subpopulation groups with LRRC when assessing treatment efficacy and 
impact, which would provide data in a more meaningful and clinically relevant manner.  
 
5.6 Conclusion  
 
This review has identified a number of PROMs for use in assessing outcomes in primary 
rectal cancer.  The identified measures failed to adequately correlate with the LRRC-QoL 
conceptual framework. Consequently, these measures are inappropriate for use to assess 
PROs in LRRC. As no LRRC-specific PROM currently exists, a new PROM is required in 
this group of patients for use in clinical practice and future research. 
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6 Chapter 6 -  Development and Pre-testing of the LRRC-QoL  
 
6.1 Background 
 
The process of designing and developing a new PROM is an exhaustive process, requiring a 
number of stages to be undertaken including 1) item generation, 2) pre-testing and 3) field 
testing to ensure a valid and psychometrically robust instrument is produced. The successful 
adoption of a newly developed instrument in clinical and academic practice is dependent on 
its content validity. Providing evidence for content validity demonstrates the link between the 
measurement concept and the score produced by the instrument in a specific context of 
measurement [89, 254, 292, 293]. Content validity is critical for determining how the results 
from future studies; including clinical trials and epidemiological studies, use the PROM to 
obtain meaningful clinical data.  
The early developmental phases of a new PROM provides evidence for content validity by 
documenting that the proposed instrument represents the concept it intends to measure. 
Establishing content validity during the later stages of development focuses on instrument 
construction and respondent understanding, ensuring the methods employed to develop the 
instrument maintain the scientific rigour and credibility of the earlier phases [292]. During 
Phase II of the development, construction and pre-testing of the LRRC-QoL the emphasis on 
maintaining on-going content validity was on ensuring that the provisional instrument reached 
consensus regarding the format and instruction of the questionnaire, that the items were clear, 
unambiguous, understandable and relevant, with an appropriate recall period [259] , in a bid 
to develop an end product which was suitable for psychometric testing.  
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6.2 Design and Construction of LRRC-QoL 
 
6.2.1 Item Generation  
 
The aim of the first phase of item generation was to compile a comprehensive list of relevant 
issues specific to patients with LRRC. A systematic approach was employed to generate an 
exhaustive and unbiased item list, utilising three sources: 1) existing literature including 
existing instruments 2) patients and 3) clinical experts.  
Existing literature 
Two systematic literature searches were conducted identifying HrQoL issues relevant to 
patients with LRRC (Chapter 2) and patients undergoing exenterative surgery (Chapter 3). 
Patient cancer forums searches were conducted to supplement the item list generated from the 
literature review.  
A further literature search was conducted identifying existing PROMs (Chapter 5). Items 
from these identified measures were mapped to the LRRC-specific conceptual framework to 
determine relevance to LRRC. Those considered relevant were included in the item pool.  
Patient Focus Groups 
Six focus groups were conducted; four in the UK and two in Australia, with a total of 23 
patients participating to generate items (Chapter 4). All content was grouped into HrQoL 
domains, with each domain comprising a number of items describing different components.  
Clinical Expert Panel 
The clinical expert panel consisted of 6 surgeons, 2 clinical oncologists, 2 colorectal nurse 
specialists, a clinical psychologist and a public health epidemiologist, all of whom have a vast 
range of experience treating patients with LRRC and therefore have significant insight into 
patients experiences. The clinical expert panel reviewed the conceptual framework generated 
from the existing literature and patient focus groups and commented upon the clinical 
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relevance of the identified items and domains (Chapter 4). No new items or domains were 
generated following interviews with the expert panel.  
 
6.2.2 Item Selection   
 
Using the above three sources, a pooled list of HrQoL issues was generated. This list of 
HrQoL issues was converted into a list of questions utilising existing questions from the 
EORTC item bank [294]. Questions were sought from the EORTC item bank, which pools 
questions from all validated instruments previously developed by the organisation. 
Advantages of using existing questions include using questions which have previously 
undergone psychometric testing and have been proven to be useful, as well as saving time and 
effort. 
 
 In cases where the item bank yielded more than one item option for a particular issue all the 
potential options for this item were incorporated into the provisional list for expert clinical 
panel and patient review. In cases, where a suitable item option was unavailable the 
PROQUOLID database was consulted [295]. The PROQUOLID database is a comprehensive 
record of QoL and PROMs. If a suitable alternative was found in the PROQUOLID database 
the format of the item was adapted to achieve consistency with the EORTC format. In 
keeping with the FDA guidelines for developing new PRO instruments, questions were 
picked from the EORTC item bank and the PROQUOLID database which reflected the 
domains in question, related to the instruments objectives and used words which were 
familiar and non-confrontational, upsetting or ambiguous.  
 
A total of 66 questions were mapped to the issues identified as a provisional item list 
(Appendix 4). This list of questions was administered to a group of clinical experts and 
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patients for review to ensure clarity, breadth of coverage and no overlap. A modified, online 
Delphi exercise was undertaken to determine item inclusion into the preliminary LRRC-QoL. 
An inclusion criteria of 75% agreement was set between all participants to include a question 
into the revised list. Multiple rounds of testing were conducted with removal of items which 
had reached the 75% level of agreement from subsequent rounds. A total of three rounds of 
testing were conducted. A total of 13 people participated in the modified Delphi, including 4 
colorectal surgeons (2 British, 2 Australian), 2 clinical oncologists, 1 colorectal nurse 
specialist and 6 patients (4 male, 2 female; 3 British, 3 Australian). Consensus was achieved 
at the end of the third round with 43 items included and 23 items rejected.  The revised item 
list consisting of the 43 questions is outlined in Appendix 5. Following this items were 
mapped onto the EORTC QLQ-C30 with any overlapping items removed from the LRRC-
QoL. The final provisional item list consisted of 39 questions.  
 
6.2.3 Construction of the LRRC-QoL 
 
Design and Layout 
The format of a questionnaire is central to its completion by its respondents [296-298]. A well 
designed questionnaire guides respondents through the instrument, motivating them to invest 
time and effort in ensuring completion [296]. Using existing guidelines careful consideration 
has been given to the design and format of the LRRC-QoL, including format and layout, scale 
construction, question ordering, response category format, time frame and administration 
[296, 298-301].  The general principles of questionnaire design dictate that a simple, clear and 
attractive format is employed, in keeping with these current recommendations [296, 302], the 
LRRC-QoL was designed as an A4 booklet, with size 12 Times New Roman font. A number 
of HrQoL questionnaires employ table grid lines to guide respondents through rows and 
columns, however, using the principles of cognitive design, these grid lines may represent 
barriers or stopping points and therefore may effect overall completion [296]. Consequently, 
it was decided to use dot leaders to guide responders horizontally across rows and upside 
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down triangles to guide respondents vertically. The LRRC-QoL design was broadly based on 
the design format of the EORTC questionnaires to ensure consistency between the core 
questionnaire (EORTC QLQ-C30) and our supplementary module. The use of a consistent 
design reduces the cognitive demands placed upon a respondent during questionnaire 
completion, enabling them to develop cognitive models for repetitive behaviours which are 
essential for navigating through the instrument and formulating responses [296, 298]. The 
main difference between the EORTC QLQ-C30 and the LRRC-QoL was the use of dot 
leaders and upside down triangles to guide responders horizontally and vertically.  
 
The ability of respondents to comprehend instructions and questions appropriately is 
dependent on the presentation of the contextual information in an appropriate location. In the 
context of the LRRC-QoL, a decision was made to include a title page, introducing the 
general topic of the LRRC-QoL and thanking the respondents in advance for their 
participation. This has the advantage of gauging the respondents’ interest and has implications 
on overall completion and data quality [298, 301, 303]. Instructions on completing the LRRC-
QoL were placed at the start of the questionnaire and within the context of the questions to 
ensure retention of the instructions and ensure the questionnaire is completed appropriately 
[296].  
 
Scale Construction   
The process of scale construction or operationalisation is the grouping together of logically 
related items. Multi item scales break down complex variables into their component parts, 
thus improving validity, responsiveness and precision in measurement, however, this must be 
offset against the risk of responder burden [304-306]. The 39 items identified were 
operationalised into 5 scales of Symptoms, Psychological Impact, Sexual Function, Future 
Perspective and Healthcare Services to reflect the conceptual framework of the LRRC-QoL. 
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In constructing the scales for the LRRC-QoL a balanced view was adopted ensuring each 
construct was adequately operationalised with an adequate number of items to measure the 
construct in question, whilst maintaining an acceptable overall length of the LRRC-QoL.  
Section headers were used to help guide respondents through the scales/topics of the LRRC-
QoL, this may help in completion of the overall questionnaire and potentially reduce 
responder bias [296].    
 
Ordering of Questions 
The ordering of questions can impact upon response bias [298, 304, 307].  Due consideration 
should be given to the ordering of items, with opening questions poised to be easy and non-
threatening. Opening questions should be relevant to respondents’ circumstances, thus 
highlighting the relevance and importance of the questionnaire and encouraging completion. 
Controversial, emotive and sensitive questions should be avoided early on in the 
questionnaire to encourage completion [298, 307]. Based on the qualitative work carried out 
in patients with LRRC a combination of symptoms were common to all patients, therefore the 
decision was made to open the LRRC-QoL with questions regarding symptoms. Sensitive 
items regarding sexual function, body image and psychological well-being were embedded in 
the middle of the questionnaire.  
A number of questions may not be relevant or applicable to all patients with LRRC, in these 
instances skip questions have been introduced within the format of the LRRC-QoL to guide 
respondents to the next appropriate question and to reduce overall responder burden. 
 
Response Category Format 
The response category format is largely dependent on the nature of the underlying question. A 
number of different scales exist, including frequency scales, Thurstone scales or Likert scales 
[304]. Frequency scales establish how often a target behaviour or event has occurred [307]. 
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Thurstone scales use empirical data derived from judges to measure attitudes along a 
continuum [304, 307].  Likert scales use fixed choice response formats, measuring attitudes 
and opinions on a linear scale. Likert scales are the commonest rating scales to be used in 
PROMs and therefore this was the method of choice for LRRC-QoL. This decision was 
partially influenced by the use of items from EORTC item bank as the response category 
format for these questions was a 4 point Likert scale. It was therefore decided to maintain this 
response format to maintain consistency with the core EORTC questionnaire.  
 
Time Frame  
An appropriate recall period must be selected to ensure that appropriate changes due to 
disease burden or impact are captured, whilst minimising the potential of response bias. 
Setting too long a time period may lead to the under reporting of events occurring, whilst a 
shorter time frame may not be appropriate as clinically relevant events may not yet have 
occurred. Furthermore, a standard, universal time frame may not be appropriate for all the 
scales being measured. With regards to the LRRC-QoL, it was decided two time frames 
would be used, a shorter time frame of 1 week to assess symptoms, psychological impact and 
role functioning and a longer time frame to assess sexual function, future perspective and 
healthcare services. This was based on clinical grounds, as changes in LRRC symptomology 
and severity can change over the course of a week and therefore a longer recall period would 
risk not capturing relevant changes to HrQoL, whereas sexual function, future perspective and 
healthcare services impact will have a prolonged impact and therefore will remain static over 
a longer period of time.   
Expert Appraisal 
Prior to the commencement of the pre-testing of the LRRC-QoL an expert panel comprised of 
5 colorectal surgeons (2 British, 3 Australian), 2 clinical oncologists and 3 colorectal nurse 
specialists reviewed the preliminary version with an emphasis on question wording, ordering, 
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format and relevance. Amendments were made to the LRRC-QoL format and ordering of 
questions which led to the production of a preliminary LRRC-QoL ready for pre-testing 
(Appendix 6).  
6.3 Pre-testing of the LRRC-QoL 
 
The pre-testing of a PROM is essential in establishing content validity to ensure responders in 
the target population find the questionnaire to be relevant, appropriate, comprehensible and 
understandable prior to final field testing [89, 254, 292, 293]. 
The principles of Cognitive Aspects of Survey Methodology (CASM) have been widely used 
in pre-testing questionnaires to investigate and understand the cognitive processes employed 
by respondents in reading, comprehending and interpreting questions and in formulating a 
response to a set questions [308, 309]. Cognitive interviewing aims to reduce measurement 
error in questionnaire design, with particular emphasis on response error. Underpinning this, 
is the four stage model proposed by Tourangeau, which consists of the cognitive processes of 
comprehension, retrieval, judgement and response whilst formulating a response to 
questionnaire items [310]. The four stages highlighted by this model are applicable in the 
context of assessing HrQoL as responders are expected to understand complex questions, deal 
with abstract concepts, effectively retrieve information from long term memory, aggregate 
that information, apply frequency judgements, magnitude estimations and decision heuristics 
in selecting which response category to endorse [309, 311].  
 
6.4 Aims and Objectives 
 
The aims of this study were:  
• To assess respondent comprehension of LRRC-QoL. This included evaluation of the 
wording and format of the questionnaire, instructions, item stems, recall period and 
response options. 
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• To evaluate the comprehensiveness and relevance of the LRRC-QoL to its target 
population. 
• To ensure the cross-cultural equivalence of the LRRC-QoL between British and 
Australian participants. 
 
6.5 Methods 
 
6.5.1 Cognitive Interviews 
 
Face-to-face cognitive interviews were undertaken to investigate the cognitive processes 
involved whilst completing the preliminary version of the LRRC-QoL (Appendix 6) in both 
population groups. The principles from Tourangeau four stage cognitive model were used to 
identify, understand and evaluate patients responses to the LRRC-QoL.  
There are two main types of cognitive interview; concurrent and retrospective [312]. 
Concurrent interviewing involves the respondent providing a verbal account of their thinking 
as they work through the questionnaire. Retrospective interviewing involves questioning the 
respondent upon completion of the questionnaire. In this study both methods were employed, 
with concurrent interviewing used to assess responder understanding with regards to item 
content, wording and format. Retrospective interviewing was used to evaluate questionnaire 
design with emphasis on overall format, completion time, recall period and response options.  
The interview techniques of ‘think-aloud’ and ‘verbal-probing’ were both incorporated when 
undertaking cognitive interviews. The think-aloud technique enables respondents to verbalise 
thoughts during the completion of the questionnaire, this is interpreted as a representation of 
the respondents memory, language, comprehension and problem-solving processes [312, 
313]. Verbal probing involves asking respondents to paraphrase questions, to clarify the 
definitions of wording within questions, explain the rationale behind responses and identify 
areas of the questionnaire that pose difficulty in understanding, interpretation or completion 
[312]. The key differences between the two interview techniques are highlighted below [314]: 
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Think Aloud Verbal Probing 
Respondent driven Interviewer driven 
Lower interviewer burden Lower respondent burden 
Potential for difficulty to be experienced by 
the respondent during the interview 
Easier interview for the respondent  
 
Cognitive Interviews Methodology 
Face-to-face cognitive interviews were undertaken to assess the processes of comprehension 
and response formulation during questionnaire completion. Participants completed the 
preliminary LRRC-QoL without assistance. Both interview techniques, of think-aloud and 
verbal probing, were employed during the interview. A standardised semi-structured 
cognitive interview guide informed all cognitive interviews (Appendix 7). Participants were 
guided through each item whilst encouraged to engage in the think-aloud process followed by 
verbal probing with questioning using prescribed interview scripts and standardised probes. 
The use of scripted questions and probes ensured standardisation across all interviews and 
ensured overall consistency and objectivity. Scripted probes were developed ensuring there 
was no bias in phrasing of words. All probes were developed based on the four stage 
Tourangeau cognitive model (Table 6.1). All interviews were recorded and transcribed 
verbatim.  
Table 6-1 Examples of Cognitive Probes 
Cognitive 
Component 
Definition of Cognitive Probe Interview Probe 
Comprehension Respondents’ interpretation of a 
question by determining what they 
believe the question is asking based on 
the meanings of specific words and 
What does the word x mean to you? 
What do you understand by x? 
156 
 
Due to the international nature of this study cognitive interviews and data analysis were 
undertaken individually within the two countries, this was done to ensure a multinational 
perspective was incorporated into the pretesting of the LRRC-QoL. The analyses from the 
two countries were synthesised and the recommendations from both countries were evaluated, 
with appropriate revisions made and analysed by the expert groups in both countries prior to 
finalisation of the LRRC-QoL. An overview of the data analysis plan is outlined in Figure 
6.1.  
 
 
 
 
 
phrases.  
Retrieval Relevant information retrieved from 
long-term memory to enable a response. 
Explores the strategies used to retrieve 
the relevant information.  
How did you remember that? 
Did you have a particular time period in 
mind? 
Judgement Retrieved information evaluated for its 
relevance to the question and is judged 
for its completeness 
How did you arrive at that answer? 
How well do you remember this? 
Response Initial response is considered for 
acceptability and consistency, which is 
mapped onto a response category. 
How did you feel answering this question? 
Were you able to find your first answer to 
the question from the response options 
shown? 
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Figure 6-6-1 Overview of Data Analysis Plan 
 
 
6.5.2 Data Analysis  
 
Data analysis was conducted in the same manner in both the UK and Australia, with review 
and analysis of all data from individual cognitive interviews conducted after a minimum of 3 
interviews, with subsequent review of any revisions to the LRRC-QoL by the expert panel 
Initial Development of 
preliminary LRRC-QoL 
Cognitive Interview Preparation 
Development of interview materials 
(e.g. recruitment letter, interview script, 
probes, data analysis schema) 
Local Principal Investigator 
• Participant selection 
• Securing sites and equipment 
• Interviewer training 
 
Conducting interviews 
Data Analysis and Expert Appraisal 
Item Revision   
Synthesis and analysis of 
data from UK and Australia 
Evaluate recommendations 
from UK and Australia 
Item revision 
Expert Appraisal  
Item finalisation  
Final LRRC-QoL 
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prior to further testing. This method of multiple rounds of pretesting enabled problems to be 
identified and rectified at an early stage and ensured no new problems had been introduced 
secondary to the revisions. This iterative process was continued up to the point of saturation 
in both population groups.  
The LRRC-QoL was analysed in a systematic manner using the Question Appraisal System 
(QAS-99) [315]. The QAS-99 is a coding tool, which categorises item problems identified 
during the cognitive interview process. It consists of eight major categories, which includes 
reading, instructions, clarity, assumptions, knowledge, sensitivity/bias, response and other 
problems. These categories focus on question characteristics that are likely to present 
problems when completing and forming responses to questionnaires.  
 
Expert Panel Analysis 
Following each round of cognitive testing, the expert panel reviewed all findings within and 
across the interviews. Each item was individually considered when deciding whether to 
retain, revise, eliminate or add further items to the LRRC-QoL. Decisions made to make 
revisions to the design and format of the LRRC-QoL were made by consensus. These 
decisions were made based on similar comments made by a number of participants or a single 
comment, if this was deemed sufficiently important. The clinical relevance of the LRRC-QoL 
was assessed with each revision and round of cognitive interviews.  
 
6.6 Results  
 
6.6.1 Patient Demographics 
 
A total of 27 patients participated in this study between November 2013 and June 2014, with 
16 participants from the UK and 11 from Australia, with a median age of 62.  Patient 
demographics, clinical and operative data are outlined in Table 6.2. Median time elapsed 
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between diagnosis or treatment of LRRC and interview date was 12 months (IQR 5-16). 
Patients were selected to ensure representation of disease subsite, the presence of concurrent 
metastatic disease and the use of multimodal preoperative treatments.  
Table 6-2 Patient and Clinical Demographics 
 
 
Factor 
 
Number of Patients 
 
Median Age 
 
62 (IQR 42 - 83) 
 
Gender 
Male 
Female 
 
 
18 
9 
 
Primary Operation Type 
Anterior Resection 
Abdominoperineal Excision of Rectum 
Hartmaans Procedure 
Proctocolectomy 
 
 
17 
4 
4 
2 
Neoadjuvant Treatment – Primary Cancer 
None 
Chemoradiation 
Radiotherapy 
 
16 
8 
3 
Adjuvant Treatment – Primary Cancer 
None 
Chemotherapy 
Chemoradiation 
Radiotherapy 
 
15 
9 
1 
2 
Reason for Detection of Recurrence 
Surveillance 
 
14 
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Symptoms 13 
Neoadjuvant Treatment – Recurrent Cancer 
None 
Chemoradiation 
Chemotherapy 
 
12 
12 
4 
Adjuvant Treatment – Recurrent Cancer 
None 
Chemotherapy 
 
24 
3 
Subsite Location 
Central 
Anterior 
Posterior 
Lateral 
 
10 
5 
7 
5 
Operative Procedure for LRRC 
Total Pelvic Exenteration  
Anterior Pelvic Exenteration 
Posterior Pelvic Exenteration 
Excision of recurrent tumour mass 
Completion proctectomy 
Composite abdominosacral resection 
 
8 
4 
4 
3 
5 
3 
Current Disease Status 
Disease Free 
Local Disease Re-recurrence 
Distant Metastatic Disease 
Local and Distant Disease  
 
18 
4 
2 
3 
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6.6.2 Cognitive Interview 
 
Median length of the interview was 85 minutes (IQR 40 – 100). In both the UK and 
Australian groups saturation was reached following the third round of pretesting. Cognitive 
interviews identified issues with the content of LRRC-QoL in both study populations.  
6.6.2.1 British Cohort 
 
The QAS-99 system was used to categorise all identified issues throughout all cognitive 
interviews (Table 6.3). In the British cohort a total of 16 items were identified as problematic 
using the QAS-99 tool. This led to the removal of 4 items, the merging of 7 items, the 
revision of 1 item and an addition of an extra item. The LRRC-QoL underwent revision on 
two occasions with the final version (British) in this cohort of patients consisting of 31 items 
(Appendix 8 and 9, Figure 2). The QAS-99 identified issues within the categories of clarity, 
assumptions and other problems in this cohort. Within the category of clarity, a total of 6 
items were identified. Ambiguities arose within this category when trying to understand the 
meaning of the word ‘perception’ in Question 20 ‘Do you think others perception of you has 
changed following your medical diagnosis and treatment?’ with all participants in the first 
round of cognitive testing requiring clarification of the meaning of ‘perception’ and deeming 
the question vague and irrelevant following explanation. Further areas of contention included 
items referring to future health perspectives, with participants stating Question 31 ‘Have you 
been worried about your health in the future?’ and Question 32 “Have you felt uncertain 
about the future?’ were sufficiently similar, with the former question being grammatically 
ambiguous as it referred to the past tense when asking about the future, as well as, pre-
empting the answer to the next question. The wording of question 32 was preferred and 
therefore this was retained. Similar observations were made regarding the items referring to 
patient satisfaction with healthcare professionals and services, with Questions 33 ‘Were you 
satisfied with the information the healthcare professionals gave you about your illness?’, 
Question 34 ‘Were you satisfied with the information the healthcare professionals gave you 
about your treatment?’ and Question 35 ‘Are you satisfied with the diagnosis, treatment and 
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medical follow up provided?’. The format and wording of Questions 33 and 34 were preferred 
and therefore these two questions were merged and Question 35 removed. 
Within the assumptions category, Question 36 ‘Are you satisfied with the length of your 
recovery?’ was categorised as assuming a constant behaviour by all participants in the first 
round of pre-testing. Participants felt that it was assumed that recovery occurred within a pre-
defined period of time, whereas in actual fact recovery was viewed as a continuum, which is 
difficult to measure quantitatively, with pre-morbid functional capacity not being truly 
achieved and a number of adaptations being made to accommodate post-operative functional 
status. 
Other identified issues related to the content, with participants stating there was no item 
focussing on wound related issues including pain and discharge, as a result the question ‘Have 
you had any pain or discharge from your wound?’ was added to the questionnaire. However, 
pre-testing in the second round of cognitive interviews revealed participants interpreted the 
word ‘wound’ as an open, healing surgical incision which would describe the initial post-
operative phase and preferred the addition of the word ‘scar’ to denote the incision during the 
latter phases.  Question 10 ‘Are you worried about your mobility’ which was part of the 
subscale symptoms was deemed to be out of keeping with the other questions in this subscale. 
Participants felt this question referred to the psychological component of the impact of 
reduced mobility on overall HrQoL and not its physical impact as per the other questions in 
this subscale. Furthermore, participants did not attribute issues related to mobility to their 
diagnosis or treatment of LRRC, consequently this question was removed.  
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Figure 6-2 Flow diagram demonstrating modifications and retentions using the 
Symptoms Subscale in the UK Cohort as an example 
 
 
 
 
 
 
 
 
 
 
 
ORIGINAL ITEM SET  
1. Have you had abdominal pain? 
2. Have you had pain in your lower back and/or pelvis? 
3. Have you had pain in your buttocks/anal area/rectum? 
4. Have you had any abnormal bleeding or discharge from 
your rectum? 
5. For women only: Have you had irritation or soreness in 
your vagina or vulva? 
6. For women only: Have you had any abnormal discharge 
or bleeding from your vagina? 
7. Have you had pain or a burning feeling when passing 
water/urinating? 
8. Have you had any unintentional release (leakage) of urine? 
9. Have you had any weakness of both legs? 
10. Have you worried about loss of mobility because of your 
illness? 
11.  Have you had any tingling or numbness in your feet or 
legs? 
12.  Do you have a urostomy? 
13. Did you have problems caring for your urostomy? 
14. Have you felt embarrassed because of your urostomy? 
15. Have you have been dependent on others for caring for 
your urostomy? 
16. Do you have a stoma? 
17. Have you felt embarrassed because of your stoma? 
18. Have you had any problems caring for your stoma? 
REVISED ITEM SET 
1. Have you had abdominal pain? 
2. Have you had pain in your lower back and/or pelvis? 
3. Have you had pain in your buttocks/anal area/rectum? 
4. Have you had any abnormal bleeding or discharge from 
your rectum? 
5. For women only: Have you had irritation or soreness in 
your vagina or vulva? 
6. For women only: Have you had any abnormal discharge 
or bleeding from your vagina? 
7. Have you had pain or a burning feeling when passing 
water/urinating? 
8. Have you had any unintentional release (leakage) of urine? 
9. Have you had any weakness of both legs? 
10. Have you worried about loss of mobility because of your 
illness? 
11.  Have you had any tingling or numbness in your feet or 
legs? 
12.  Have you had pain or discharge from your wound? 
13.  Do you have a urostomy? 
14. Did you have problems caring for your urostomy? 
15. Have you felt embarrassed because of your urostomy? 
16. Have you have been dependent on others for caring for 
your urostomy? 
16. Do you have a stoma? 
17. Have you felt embarrassed because of your stoma? 
18. Have you had any problems caring for your stoma? 
Interviews - 3 
Missing 
question on 
wound pain and 
discharge 
Expert Panel 
Incorporate question on 
wound pain and discharge 
into symptoms subscale.  
‘Have you had pain or 
discharge from your 
wound?’ 
Interviews - 3 
Q10. Not sure 
mobility is relevant. 
Being worried 
about mobility is 
not a symptom. 
Q12. Wound refers 
to an open wound 
and a healing 
wound. Better to 
use scar as well.  
Expert Panel 
Remove Q10 as mobility 
issues do not seem relevant 
to LRRC. 
Q12. Change wording to 
include wound and scar.  
 
REVISED ITEM SET FINAL  
1. Have you had abdominal pain? 
2. Have you had pain in your lower back and/or pelvis? 
3. Have you had pain in your buttocks/anal area/rectum? 
4. Have you had any abnormal bleeding or discharge from 
your rectum? 
5. For women only: Have you had irritation or soreness in 
your vagina or vulva? 
6. For women only: Have you had any abnormal discharge 
or bleeding from your vagina? 
7. Have you had pain or a burning feeling when passing 
water/urinating? 
8. Have you had any unintentional release (leakage) of urine? 
9. Have you had any weakness of both legs? 
10. Have you had any tingling or numbness in your feet or 
legs? 
11.  Have you had pain or discharge from your wound? 
12.  Do you have a urostomy? 
13. Did you have problems caring for your urostomy? 
14. Have you felt embarrassed because of your urostomy? 
15. Have you have been dependent on others for caring for 
your urostomy? 
16. Do you have a stoma? 
17. Have you felt embarrassed because of your stoma? 
18. Have you had any problems caring for your stoma? 
 
Interviews – 10 
No further changes 
or comments by 
patient and expert 
group  
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Table 6-3 Identification of Issues with LRRC-QoL using the QAS-99 System 
 
 
QAS-99 Coding Category 
 
Number of Items 
UK Cohort 
 
 
Number of Items 
Australian Cohort 
Reading 
What to read 
Missing Information 
How to read 
 
0 
0 
0 
 
0 
0 
0 
Instructions 
Conflicting or Inaccurate Instructions 
Complicated Instructions 
 
0 
0 
 
0 
0 
Clarity 
Wording 
Technical Terms 
Vague 
Reference Periods 
 
5 
0 
1 
0 
 
5 
1 
1 
0 
Assumptions 
Inappropriate assumptions  
Assumes constant behaviour 
Double –Barrelled 
 
0 
1 
0 
 
1 
0 
0 
Knowledge 
Knowledge 
Attitude 
Recall  
Computation 
 
0 
0 
0 
0 
 
0 
0 
0 
0 
Sensitivity/Bias 
Sensitive Content 
Sensitive Wording 
 
0 
0 
 
0 
0 
165 
Socially Acceptable 0 0 
Response 
Open-Ended 
Mismatch 
Technical Terms 
Vague 
Overlapping 
Missing 
Illogical Order 
 
0 
0 
0 
0 
0 
0 
0 
 
0 
0 
0 
0 
0 
0 
0 
Other Problems 
Recurring/Similar Question 
Missing Question/Content  
Irrelevant Question 
 
7 
1 
1 
 
6 
2 
0 
TOTAL No OF IDENTIFIED ITEMS 16 16 
  
6.6.2.2 Australian Cohort 
 
In the Australian cohort the QAS-99 system identified 16 items as problematic, which led to the 
revision of 8 items, the merging of 5 questions, the removal of 5 items and the addition of an extra 
item (Table 6.3). Problems were identified within the categories of clarity, assumptions and other 
problems. The LRRC-QoL underwent revision on two occasions with the final version (Australian) in 
this cohort of patients consisting of 32 items (Appendix 10 and 11).  
A number of items were revised to improve clarity, relevance and patient comprehension, this 
included Question 9, which was revised from ‘weakness in both legs’ to ‘either or both legs’ to reflect 
patients with unilateral symptoms. Question 10 ‘Are you worried about your mobility’ was revised 
with substitution of the ‘worried’ with ‘difficulty’ as patients felt it was the physical act of walking 
which was impacted upon and this was more in keeping with the rest of the questions within the 
symptoms subscale. Question 12 ‘Do you have a urostomy?’ was revised to include the word ‘urine 
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bag’ as this was the colloquial term used and better understood by patients. Similar issues were 
identified with Question 20 regarding perception of others as the British cohort with misinterpretation 
of the meaning of the word ‘perception’.    
Question 23. ‘Have you felt less interest in sex?’ was revised to ‘Have you felt interest in sex?’ as the 
former question suggested a baseline interest in sex which may not be applicable to all patients. 
Similarly, Questions 24 and 25 regarding difficulty gaining or maintaining an erection and ejaculation 
problems were rephrased from ‘Did you have difficulty gaining or maintaining an erection?’ to ‘How 
difficult is for you to gain/maintain an erection?’ and from ‘Did you have ejaculation problems (e.g. 
dry ejaculation)?’ to ‘Have you had ejaculation problems?’. Patients felt the use of the word ‘did’ 
referred to the past tense and did not reflect their current sexual status and therefore found the 
question confusing. 
Within the assumptions category Question 36 ‘Are you satisfied with your length of recovery?’ was 
removed as participants felt this question was not applicable in the pre-operative phase and therefore 
could be potentially confusing.  
Patients felt there was repetition in asking questions about future health status and satisfaction with 
healthcare professionals and services with Questions 31-32 and Questions 33-35, therefore these 
questions were amalgamated into two individual questions.  
Inclusions to questions were made to reflect the full spectrum of HrQoL issues related to patients with 
LRRC, this includes Question 4 which was revised to include faecal leakage as part of the 
complement of rectal symptoms. Question 37 ‘Were you satisfied with the knowledge and experience 
of your doctors?’  was revised to ‘your specialist team including doctors/nurses/specialist nurses’ as 
this reflected the multidisciplinary management of LRRC, thus enabling patients to comment on their 
complete experience. One new question was included regarding wound related issues including pain 
and discharge. 
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6.6.2.3 Questionnaire Format 
 
The self-complete mode of administration was acceptable to all patients, with all patients stating the 
instructions were clear, concise and easy to understand. The overall format of the questionnaire was 
acceptable to patients with easy to understand and follow response options. Patients commented on 
the different recall periods of 1 week and 4 weeks for the short-term issues of symptoms and 
psychological impact and sexual function, future perspective and healthcare services respectively, 
stating the recall period could be better highlighted. Consequently, the format of the recall period was 
changed to highlight the differences by using italics and underlining.  
 
6.6.2.4 Comparative Analysis 
 
On review of the final LRRC-QoL questionnaires from both population cohorts (Appendix 9 and 11), 
similar issues with the questionnaire were highlighted, such as, difficulties with understanding the 
word ‘perception’, repetition of questions on future health and satisfaction with healthcare services, 
irrelevance of the length of recovery and the inclusion of an item on wound related pain and 
discharge. Two items and one skip question were removed from both population groups due to 
overlap with the EORTC QLQ-C30 core module and one skip question was removed regarding sexual 
activity due to the loss of potentially important data. The main differences between the two final 
versions were the retention and revision of the question regarding mobility by the Australian cohort. 
There was consistency within the wording of the majority of items with differences observed in 7 
items alone. The inconsistencies were solved by consensus through discussion by the expert panel to 
produce a final overall version of the preliminary LRRC-QoL (Appendix 12, Table 6.4).   
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Table 6-4 Comparative Analysis of British and Australian versions of the LRRC-QoL  
 
British Version Australian Version Expert Panel Analysis 
Have you had any abnormal bleeding 
or discharge from your rectum? 
Have you had any abnormal bleeding, 
discharge or faecal leakage from your 
rectum? 
Include faecal leakage into 
question. 
Have you had any weakness of both 
legs? 
Have you had any weakness of either 
or both legs? 
 
Accept Australian version as 
accounts for unilateral and bilateral 
symptoms. 
Question removed Have you had any difficulty in 
walking? 
Include question – highlighted in 
Phase I of focus groups. Relevant to 
patients with high sacral resection 
and sciatic nerve involvement.  
Do you have a urostomy? 
 
Do you have a urostomy (urine bag)? 
 
Include urine bag as improves 
patient comprehension of the 
question. 
Have you felt less interest in sex? Have you felt interest in sex? Remove ‘less’ as suggests baseline 
level of interest. 
Did you have difficulty gaining or 
maintaining an erection? 
How difficult is it for you to gain or 
maintain an erection? 
Accept Australian version as 
assesses current status.  
Did you have ejaculation problems 
(e.g. dry ejaculation) 
Have you had ejaculation problems 
(e.g. dry ejaculation)? 
Accept Australian version.  
‘Were you satisfied with the 
knowledge and experience of your 
doctors? 
Were you satisfied with the knowledge 
and experience of your specialist team 
(Doctors/ Nurses/Specialist Nurses/ 
Physiotherapists)? 
Accept Australian version  
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6.6.3 The Final LRRC-QoL 
 
The final LRRC-QoL consists of 32 questions organised into 5 scales; Symptoms, Sexual Function, 
Psychological Impact, Future Perspective and Healthcare Services (Appendix 12).  This final version 
was used in the final field study to document the psychometric properties of the LRRC-QoL. 
 
6.7 Discussion  
 
This study uses a multinational approach in establishing the content validity of the LRRC-QoL by 
conducting cognitive interviews in both the UK and Australia prior to final psychometric validation. 
This enabled a truly multinational perspective to be gauged, identifying and rectifying issues specific 
to both population groups, thus minimising the potential for responder error across both population 
groups. This was a cross-national study incorporating two countries with a number of common social 
and political perspectives and a common language. In such studies, it is the cultural variance in 
HrQoL conceptualisation, validation and expression that is important [316].  
 
Ensuring cross-cultural equivalence is a prerequisite for conducting cross-national HrQoL research 
[317]. This encompasses four areas which include conceptual equivalence, operational equivalence, 
item equivalence and scalar equivalence [318]. Conceptual equivalence refers to the overlap in 
construct conceptualisation across different groups thus ensuring concepts hold similar meanings in 
all groups, this was demonstrated through Phase I of the development of the LRRC-QoL. Operational 
equivalence ensures no bias is introduced through the mode of administration of the questionnaire, 
item and response format [317]. This was demonstrated in this study with patients from both 
population groups stating the questionnaire format was acceptable, understandable and easy to follow. 
Item equivalence ensures items measure the same concepts in different cultures and nations, this has 
been demonstrated within this study. Finally, scalar equivalence is achieved when a construct is 
measured on the same metric, this will be tested in the final phase of development of the LRRC-QoL.  
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Item equivalence between the British and Australian populations was assessed using the QAS-99 
coding system. The commonalities between the two populations were manifested in this study by the 
similarity of issues raised when assessing the LRRC-QoL, thus demonstrating item equivalence. The 
issues identified by the QAS-99 were multifactorial, identifying three key areas of potential for 
responder error, these included the categories of clarity, assumptions and recurring questions. The 
majority of the issues related to the clarity of the questionnaire, with difficulties identified within the 
subcategories of wording, technical terms and vagueness. Problems relating to the clarity of a 
question are often associated with the respondents meaning and use of words and the context in which 
they are used in the questionnaire. Words that are familiar to one group may not be to another or they 
may have a different meaning [312].  This is illustrated in the pretesting of the LRRC-QoL, as the 
British cohort of patients understood the meaning of the technical term urostomy, whereas the 
Australian cohort were not familiar with this technical term and preferred the use of the colloquial 
term, urine bag. This issue arose due to an overestimation of the understanding of medical 
terminology by the target population [312]. To ensure the cross-cultural equivalence both terms were 
retained within the final version of the LRRC-QoL. The other main issue identified in both population 
groups was the number of recurring questions on similar themes, which required amalgamation to 
streamline the questionnaire, reduce respondent burden and improve patient comprehension. Other 
issues related to the assumption category with the item in question assuming that recovery is a 
constant and not a dynamic continuum which begins in the post-operative phase and therefore will not 
be applicable in the pre-operative phase. The presence of this question led to considerable confusion 
amongst participants as it was unclear whether the question referred to the recovery from the initial 
surgery for the primary rectal cancer or the recovery from the second recurrent rectal cancer surgery.  
 
The use of a coding system enabled a transparent and robust method of identifying and correcting 
arising issues within the framework of the LRRC-QoL questionnaire to ensure item equivalence 
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between the two population groups. The use of the QAS-99 coding system ensured data was 
interpreted in a structured and systematic manner thus reducing the potential for measurement error in 
both cohorts and enhancing the overall validity of the data acquired [312]. Furthermore, the QAS-99 
provided an efficient and effective manner of dealing with a relatively large volume of data [319, 
320]. The limitations of a coding system include identifying issues that lie outwith the predefined 
categories of the system, to circumvent this limitation it is essential to select a flexible system which 
enables all identified categories to be recognised. The advantage of using the QAS-99 system is that it 
offers flexibility within its structure through the incorporation of the ‘other’ category, this enables the 
researcher to identify and categorise issues that do not fall within the structure of the coding system.  
 
When conducting cross-national research a number of procedural and pragmatic issues must be 
consider. Procedural issues relate to target country teams, data analysis, translation, data 
documentation and evaluative criteria [317]. Procedural issues were not encountered in this study due 
to the involvement of two countries alone, both with the common language of English, with teams 
that had worked together in Phase I of the development of the LRRC-QoL. To minimise issues of data 
analysis, data documentation and evaluative criteria, a study format (Figure 6.1) was decided by 
teams within both countries prior to study commencement. Data analysis was undertaken at a local 
level in both countries by the same researcher (DH) to minimise interpreter bias. The British 
interviews and analysis was conducted first. Upon completion of the Australian analysis, a second 
round of analysis was undertaken across both population cohorts to minimise bias and ensure all 
appropriate issues were highlighted and captured. To ensure objectivity in data documentation and 
evaluative criteria a standardised topic guide, data collection sheets and systems (QAS-99) were 
employed. Pragmatic issues relate to the interviewers skills and experience, respondents 
characteristics, topic sensitivity and communication style, which can arise due to potential variations 
between participating countries [317]. To overcome the issue of variations amongst interviewers 
standardised probes and scripts were employed during the interview process. Furthermore, the British 
researcher (DH) conducted and oversaw interviews in Australia as well as in the UK to ensure 
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standardisation across all cognitive interviews. Respondent characteristics are important for extracting 
pertinent data from the participants. To encourage an open and comfortable environment local 
interviewers led or oversaw all cognitive interviews, with appropriate modification of interview 
probes as necessary. Topic sensitivity was determined during Phase I of the development of the 
LRRC-QoL which involved both British and Australian patients, this in turn informed this study, 
subsequently no issues with topic sensitivity were encountered in this study. Besides the logistic 
difficulties of conducting interviews and analysing data in two different countries no other procedural 
or pragmatic issues were encountered in this study, this is primarily due to the commonality of the 
English language and the similarities in cultural and social norms between the two population cohorts.  
Despite the issues involved in conducting cross-national research and the logistical difficulties of 
conducting studies sequentially in Britain and Australia, it was deemed appropriate to include the 
Australian cohort within this project. The Australian team have a longstanding interest in researching 
QoL in patients with advanced pelvic malignancy, including LRRC [191, 321, 322] and expressed an 
interest in developing a LRRC specific PROM. In addition to this, the Australian team has a leading, 
international reputation in performing ultra-radical surgery in this cohort of patients with good clinical 
outcomes [22, 24]. By including the Australian cohort ensures the opinions, thoughts and experiences 
of  patients with advanced disease requiring an ultra-radical resection are appropriately captured. This 
will ensure the LRRC-QoL is applicable to all patients with LRRC.  
Cognitive interviews are a commonly used method of pretesting HrQoL instruments. There are a 
number of cognitive interview techniques available; this study employed the think-aloud and verbal 
probing techniques. Think aloud techniques encourage respondents to verbalise their thoughts during 
questionnaire completion, thus enabling an insight into the respondents’ memory, comprehension and 
problem-solving strategies. The limitations to this method of cognitive interviewing include difficulty 
to articulate thought processes by some respondents during questionnaire completion, with thought 
processes being affected by this technique thus leading to an assumption that problems may exist 
within the questionnaire when they do not. The combination of the think aloud technique with verbal 
probing can help overcome some of these limitations. However, cognitive interviews have a number 
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of common limitations irrespective of technique. Cognitive interviews are often criticised for the 
artificial environment in which they are conducted and the ‘cognitive load’ they confer on 
respondents using techniques such as think-aloud and verbal probing when completing a 
questionnaire. The presence of a researcher contributes further to the artificiality of the situation and 
may introduce bias into the cognitive process. A further limitation of cognitive methods is the reliance 
on respondents’ verbal responses, when not all cognitive processes can be verbalised (e.g. gender). 
The overarching limitation of cognitive interviews is that they are qualitative in nature and therefore 
they can only identify problems, they cannot provide information with regards to the extent or the size 
of the impact on survey estimates [314]. Cognitive methods enable the pre-testing of existing 
questions and enable the testing of proposed revisions to the original question, however, they cannot 
provide quantitative evidence on whether proposed revisions are better than the original question 
[314]. To supplement the qualitative methodology there are new emerging quantitative methods such 
as Rasch analysis and Item-response theory which can assess how well items address the entire 
continuum of patient experience of the concept, thus potentially corroborating and expanding with 
qualitative data. However, these quantitative methods should not be used in isolation but in 
combination with recognised qualitative methodology, as in the absence of prior knowledge, 
frameworks and qualitative data, a theoretical instrument can be developed producing scores with 
unknown meaning.  
 
6.8 Conclusions 
 
This study documents the content validity of the LRRC-QoL as it is extended from a conceptual 
framework to a preliminary version ready for psychometric testing. It reports the process of 
instrument and item crafting, achieving consensus on format and structure and documents respondent 
understanding and acceptability through structured cognitive interviews, thus providing on-going 
evidence for the LRRC-QoL’s content validity.  
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7 Chapter 7 – Psychometric Evaluation of the LRRC-QoL – Methodology and 
Recruitment  
 
7.1 Background 
 
For any PROM to be applied in clinical practice and research its scientific validity, rigour and 
credibility must be established prior to its use.  The development of PROM is a complex 
methodological process, consisting of a number of key steps which help ensure its overall robustness, 
validity and credibility. This process must be transparent and accurately documented. To ensure a 
PROM is developed in a systematic fashion a number of regulatory authorities have produced a series 
of guidelines which outline the process of PROM development [212, 274, 283, 323]. Thus far, the 
LRRC-QoL has been developed in accordance with these guidelines by establishing the content 
validity of the LRRC-QoL in Phase I (Chapter 2-4), development of a conceptual framework (Chapter 
4) and pre-testing and refinement of the provisional questionnaire in Phase II (Chapter 6). The final 
phase of developing any PROM prior to its wider dissemination in academic and clinical practice 
involves assessing and measuring its psychometric properties using quantitative measures. Key 
properties of a PROM are measured including reliability and validity during the final field testing. 
Reliability refers to the extent to which the PROM is free from random error, whereas validity 
assesses whether the instrument measures what it purports to measure. These are required 
prerequisites for psychometrically validating a PROM as it gives meaning to the results and scores 
obtained from the instrument.  
 
7.2 Classical Test Theory 
 
Classical Test Theory (CTT) is a traditional quantitative psychometric approach employed to test the 
reliability and validity of a scale based on its items. CTT consists of a number of key principles and 
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statistical tests for developing and assessing measures including PROMS to determine how successful 
they are at estimating unobservable variables of interest such as HrQoL.  
 
Underpinning CTT is the assumption that each observed score (X) on a PROM is a combination of 
the underlying true score (T) and random error (E).  
X = T + E 
CTT assumes that each person has a true score (T), which can be observed if there are no errors in 
measurement. A person’s true score is defined as the expected score over an infinite number of repeat 
measurements of the scale, as this is not practical T is essentially a hypothetical measure. Therefore, 
CTT assumes the average of the observed score (x̅) is the best estimate of the true score. The second 
assumption of CTT is that the random error (E) found is normally distributed and therefore the 
expected value of theses fluctuations (i.e. mean of the distribution of errors over a hypothetical 
infinite number of administrations for the same subject) is taken to be 0. Furthermore, random errors 
are assumed to be uncorrelated with a true score, with no systematic relationship between a true score 
and whether a person has positive or negative errors.  
Reliability  
CTT enables the reliability of an individual item (i.e. the magnitude of error) to be calculated. A good 
item should yield a score that is a close and accurate reflection of the true score. The assumption that 
the true score varies across and within individuals during repeated measurements suggests the 
observed score should also mirror this variation. The equation for this process is:  
VAR(X) = VAR(T) + VAR(E) 
The proportion of variance between the true and observed scores should provide information 
regarding how well the item in question serves as a proxy for the true score i.e. the proportion of the 
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item’s variation that was shared with the true score. This is defined as the item’s reliability (R).  
VAR(T)/VAR(E) = R 
When the variance of the true score is high relative to the variance of the observed score the reliability 
(R) will be high. Conversely, if the variance of the true score is low relative to the variance of the 
observed score the reliability will be low.  Reliability values usually range from 0.00 – 1.00, thus 
rearranging the above equation to:  
R = 1 - (VAR(E)/VAR(X)) 
Reliability is equal to 1 – the ratio of random error variance to total score variance.  
The items within a scale must be unidimensional i.e. they must be indicative of the same underlying 
variable and thus associated with the true score of that variable. The error associated with each item 
must be independent of the true score and of the errors arising from the other items within the scale. 
Each item within the scale must be a good indicator of the true score i.e. item covariances with true 
score must be equal across the items and the magnitude of the respective error contributions to the 
total variance of each item must be equal across items. According to these criteria, the correlation 
between any two items is equal to the product of correlation of each item with the true score. The 
correlation between two items, A and B (Rab) will equal the product of the correlation of item A with 
the true score (Rat) times the correlation of item B with the true score (Rbt). As the item-with-true-
score correlations are assumed to be equal for all items, the products of Rat and Rbt is equal to the 
square of the item-with-true-score correlation for either of the items in question.  
Rab= (Rat)(Rbt) = R2at = R2bt 
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These expressions denote the reliabilities of item A and B. The correlation of the scores for the two 
items (Rab) provides a method of estimating the reliabilities of Ra and Rb respectively. These 
interitem correlations help establish item reliability. Items which strongly correlate with one another 
are also more likely to strongly correlated with the true score of the unobserved variable of interest. 
These items are deemed to have greater discrimination. Discrimination is the defined as the strength 
of association between items and the true score. It is expressed as the correlation between items and 
the set of items as a whole i.e. item-to-total correlation.  
 
CTT extends the concept of item reliability to that of scale reliability. Unidimensional items which 
measure the same underlying constructs form a scale. Scale reliability is measured by Cronbach’s 
Alpha coefficient; this is the proportion of variance in a set of scores that can be attributed to a 
common influence on the scores of the individual items. The alpha coefficient emphasises the 
difference between the common variance and unique variance. When items are correlated with one 
another they share a commonality which gives rise to a correlation. Part of what determines the 
numeric value of one variable is related to part of what determines the numeric value of the other – 
that is the proportion of variability in each item that is associated with the variability in the other. This 
is the shared or common portion of each items variability. However, there is always some variation 
within items that is unrelated to other items; this is its unique variation. The greater the proportion of 
shared variation between two items the more they have in common and the more strongly they reflect 
a common true score.  Cronbach’s coefficient alpha is referred to as a measure of internal consistency 
reliability as it quantifies the degree to which a set of items share a common core of information about 
the same true score. A good Cronbach’s Alpha value is considered to be higher than 0.7.  
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Temporal stability is also used to determine scale reliability using the test-retest measure. According 
to the principles of CTT if the stability of the true score of the variable of interest i.e. questionnaire 
item can be assumed, then changes in the observed score over time must be attributable to error. 
Therefore, a high correlation for scores across a specified time period would be indicative of low error 
and high reliability and conversely a low correlation for scores across a specified time period would 
indicate low reliability and substantial error.  
 
Validity  
Scale reliability is a precursor to scale validity. Scale reliability refers to the proportion of variance in 
a measure that can be ascribed to a common characteristic or theme shared by a group of items, 
whereas validity refers to whether that characteristic or theme is actually what is intended to be 
measured.  The goals of determining scale validity are to provide evidence that the scope of the 
scale’s items corresponds to the scope of the variable of interest and to demonstrate that the scores 
yielded by the scale are consistent with the broader understanding of how the phenomenon of interest 
varies in the real world.  
 
There are a number of different ways in which validity can be measured during the development and 
assessment of a PROM, including, content validity and construct validity which includes convergent 
validity and known-groups comparison. Content validity ensures the PROM measures the concept of 
interest. This is usually established by patient and clinician testimony using qualitative methods. The 
content validity of LRRC-QoL was determined in Phase I of this project (Chapters 2-4).  
179 
Construct validity is tested by examining evidence the that scores on the PROM of interest conform to 
a priori hypotheses concerning logical relationships that are expected to exist with related measures 
such as existing PROMS or clinical measures. Convergent validity is a type of construct validity and 
assesses the extent to which a PROM relates to other measures based on theoretical content or the 
expected relationship with a chosen variable. Known groups validity is a second form of construct 
validity. Known groups validity statistically evaluates the differences between PRO scores and for 
groups of patients that differ by a known disease indicator i.e. disease severity.  
 
7.3 Aims and Objectives 
 
The overall aims of Phase III of this study were to determine the scale structure of the LRRC-QoL 
and to measure its psychometric properties, including:  
• To test the hypothesised scale structure of the LRRC-QoL using the principles of multi-trait 
scaling analysis. This determined whether the items grouped together within the current, 
hypothesised scale were unidimensional and were therefore appropriately grouped.  
 
• To identify any new potential scales, not previously identified using the principles of 
exploratory factor analysis. 
 
• If new scales were identified, the scale structure of the LRRC-QoL was revised to incorporate 
the new scales. The unidimensionality of the revised scale structure of the LRRC-QoL was 
confirmed using the principles of multi-trait scaling analysis.  
 
180 
• To assess the psychometric properties of the finalised LRRC-QoL including reliability and 
validity.  
 
The specific aims of this chapter are:  
• To outline the methodology employed to determine scale structure of the LRRC-QoL 
• To outline the psychometric methods employed to determine the reliability and validity of the 
LRRC-QoL  
• To quantitatively assess the monthly recruitment rates for Phase III, including screened and 
recruited patients 
• To determine the sociodemographic and clinical details of all responders.  
• To determine any clinical differences between responders and non-responders 
 
7.4 Methods 
7.4.1 Cross-Sectional Observational Study  
 
To assess the psychometric properties of the LRRC-QoL a cross-sectional observational study was 
undertaken. All eligible patients from participating centres were identified and invited to participate in 
the study. A self-complete questionnaire pack was sent to eligible patients. The pack included a 
Patient Information leaflet explaining the premise of the study, a consent form to agree to 
participation, a baseline demographics questionnaire, the LRRC-QOL tool, as well as additional 
quality of life measures including the EORTC QLQ-CR29 and FACT-C. A self-addressed stamped 
envelope was provided to return the questionnaire back to the clinical centre.  
 
All patients were invited to participate in completing a second questionnaire pack 10-14 days 
following the return of the first questionnaire pack, thus enabling the investigators to carry out the 
test-retest test. This time interval between the two questionnaire packs was deemed sufficiently short 
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enough to ensure that clinical change in LRRC is unlikely to occur, but long enough to ensure that 
participants do not recall their responses from their first assessment. A short test retest interval is 
necessary to ensure stability is being evaluated, and not clinical change, which will underestimate 
reliability. 
  
There is no formal sample size calculation for the development of PRO measures, however, 
recommended guidelines state 5-10 patients should be recruited per item within the questionnaire 
[212]. The proposed LRRC-QoL consists of 32 questions, therefore a sample size of 160 patients is 
deemed sufficient. With an estimated annual incidence of 700 new cases of LRRC in the UK [5], a 
sample of 160 is feasible to recruit.  
 
Patients were sampled ensuring representation of patients with all patterns of disease recurrence 
(Table 7.1). Patient were identified from each LRRC pattern subset and approached to participate.   
 
Table 7-1 Patient Sampling Representation For Field Testing 
 
 
 
 
No of patients per disease pattern of LRRC 
(Male: Female) 
Anterior 
Recurrences 
Central 
Recurrences 
Lateral 
Recurrences 
Posterior 
Recurrences 
 
Completed Questionnaires 
 
20:20 
 
20:20 
 
20:20 
 
20:20 
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7.4.2 Recruitment  
 
7.4.2.1 Eligibility 
 
Inclusion Criteria 
Patients were included in the study if the following criteria were fulfilled:  
• aged ≥ 18 years 
• with an existing resectable LRRC undergoing neoadjuvant treatment(s) or 
• surgically treated for a LRRC within the last five years or 
• had undergone non-surgical palliative treatment of LRRC and 
• able to provide informed written consent to participate and 
• able to read and write in English. 
 
Exclusion Criteria  
 
Patients were excluded from the study in any of the following criteria applied. They: 
• had cognitive impairment 
• are in remission from treatment of primary rectal cancer with no evidence of local 
recurrence 
• receiving treatment for distant metastatic disease (i.e. liver, lung) following 
previous treatment of rectal cancer with no evidence of local recurrence. 
7.4.2.2 Patient Recruitment  
 
Patients were recruited from the UK and Australia from the following sites:  
• St James’s University Hospital, Leeds, UK 
• Royal Victoria Infirmary, Newcastle, UK 
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• Morriston Hospital, Swansea, UK 
• St Marks Hospital, London, UK 
• Southampton University Hospital, Southampton, UK 
• The Royal Prince Alfred Hospital, Sydney, Australia 
• Peter MacCallum Cancer Centre, Melbourne, Australia. 
The principle investigator at each participating site identified potential patients using through three 
sources:  
• Existing clinical registries 
• New patient referrals through LRRC multidisciplinary team meetings 
• Outpatient clinic setting.  
7.4.2.3 Recruitment Log  
 
A central recruitment log was kept at the two lead centres, Leeds and Sydney. This allowed for the 
regular review of screened, eligible and recruited patients  
 
7.4.3 Data Collection  
 
Data were collected on socio-demographic details, clinical details and PROMs.  
Socio-demographic Data 
Socio-demographic data fields were collected on patients’ age, ethnicity, marital status, education and 
employment status. This data was captured utilising a self-complete baseline questionnaire by 
participants.  
 
Clinical Data  (Appendix 13)  
The principal investigator for each site provided the following clinical details for each patient:  
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• Primary cancer details (location, neoadjuvant/adjuvant treatments, date of operation, operative 
and histological detail) 
• Mode of detection of LRRC (symptomatic or surveillance) 
• Pattern of recurrence (i.e. Anterior, Central, Lateral, Posterior) 
• Treatment Intent (Curative/Palliative) 
• Treatment plan of LRRC (pre-operative treatment, operative detail and histological detail, details 
of chemotherapy/radiotherapy) 
• Presence of concurrent metastatic disease (i.e. lung, liver)  
 
PROMs 
Alongside the LRRC-QoL the EORTC QLQ-CR29 and FACT-C measures of HrQoL were included 
in the questionnaire pack. To minimise the potential for response bias the order of questionnaires was 
randomised on a 1:1:1 bias using a random sequence allocation.  
• The LRRC-QoL (Appendix 12) 
The LRRC-QoL consists of 32 items and 5 proposed domains of symptoms, psychological 
well being, sexual function, future perspective and healthcare services.  
 
• EORTC QLQ-CR29  
The EORTC QLQ-CR29 consists of 29 items making up 4 domains of urinary frequency, 
blood or mucus in stools, frequency of defaecation, body image and 29 single items. The 
EORTC QLQ-CR29 has been validated in patients with primary colorectal cancer undergoing 
a range of treatments and has displayed acceptable psychometric properties [285]. This 
measure has been used to document outcomes in patients with LRRC despite not being 
designed or validated for use in this cohort of patients[198, 324]. Previous work carried out as 
part of the LRRC-QoL Project identified the EORTC QLQ-CR29 covered 50% of the LRRC-
specific domains (symptoms, sexual function, future perspective) and 33% of the LRRC-
specific subdomains (pain and discomfort, urological symptoms, gastrointestinal symptoms, 
185 
sexual intercourse, mood, appearance and body image), thus making it a suitable PROM to 
use in this validation study.  
 
• FACT-C  
The FACT-C consists of five subscales Physical Well-Being, Social Well-Being, Emotional 
Well-Being, Functional Well-Being and Colorectal Cancer Subscale. The measure has been 
widely validated for use in primary colorectal cancer and demonstrates acceptable 
psychometric properties [143]. It has been used in a number of studies to document outcomes 
in patients with LRRC [188, 191]. Previous work carried out as part of the LRRC-QoL 
Project identified the FACT-C covered 4 (66.6%) of the LRRC-specific domains (symptoms, 
psychological impact, role functioning and future perspective) and 7 (38.8%) subdomains 
(pain and discomfort, gastrointestinal symptoms, mood, work, social and relationships and 
future treatments), thus making it a suitable PROM for use in this validation study.  
 
7.4.4 Data Analysis  
 
All data were analysed using SPSS for Mac, version 22 (Statistical Package for Social Sciences, SPSS 
Inc., Chicago, IL). Data analysis was undertaken in a step-wise approach (Figure 7.1). Descriptive 
analyses of the demographic and clinical characteristics of all participants were performed.  
 
7.4.4.1 Data Completeness 
 
The completeness of data were analysed for LRRC-QoL to identify missing data at item and scale 
level, distribution of responses and floor/ceiling effects and descriptive analyses of items. Data 
completeness concerns the extent to which items are completed by the target population and the total 
number of available data sets from which total scores are computable [325]. The criteria for 
acceptable levels of missing data is <10% for items, <50% for computable total scale scores and for 
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maximum endorsement frequencies is <80% (floor/ceiling effects <80%) [326, 327].  Items which did 
not meet these predetermined criteria were discarded as it was deemed unlikely that these items would 
make valuable contributions to the underlying scale and the questionnaire overall, and would 
potentially contribute to a ceiling effect.  Handling of missing data for each scale was conducted using 
simple imputation using half-mean imputation. If half or more of the items within the scale are 
complete, the missing items within the scale can be imputed with the mean of the remaining items. 
This is a valid and robust manner of missing data imputation for validating multi-item, multi-scale 
questionnaires [328, 329].  
 
7.4.4.2 Scale Structure 
 
The unidimensionality of the items within the proposed scales of the LRRC-QoL was assessed using 
the principles of multi-trait analysis and exploratory factor analysis. The combined results from these 
analyses informed the final structure of the LRRC-QoL.  
 
Multi-Trait Analysis 
Multi-trait scaling was used to determine whether the hypothesised items of the LRRC-QoL fit within 
the proposed scale structure.  Pearson’s correlation co-efficient of an item with its own scale and other 
scales was calculated. The grouping of items into subscales and scales and the calculation of 
summated scores was based on four scaling assumptions [330]:  
1. Each item should have substantial correlation with the sum score computed from all 
the other items in that particular scale (item internal consistency).  
2. Each item should have substantially higher correlation with the sum score of the rest 
of the items in the scale than with scales measuring other concepts (item discriminant 
validity).  
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3. For items in the same scale, the correlation between one item and the sum of the 
other items should be of similar magnitude for all items (equal item-to-total 
correlation).  
4. Items in the same scale should have equal variance.  
If the first and second criteria are fulfilled the current grouping of items is supported [331].  If the 
third and fourth criteria are fulfilled the items can be summed without weighting; if not, weighting is 
normally suggested to achieve equal item-to-total correlations and equal variances [331-333].  
 
The multitrait/multi-item correlation matrix was used to examine the relationships of each item of the 
LRRC-QoL to its hypothesised scale. Each row in the matrix contains correlations between the score 
for one item and all hypothesised item groupings. Each column contains correlations between the 
score for one scale and all items in the matrix, including those items hypothesise to be part of that 
scale and those items hypothesised to be part of another scale. The multi-trait/ multi-item correlation 
matrix allows a number of assumptions to be examined simultaneously, including the assumption that 
items are substantially linearly related to the total scale score (item internal consistency) and that the 
items are stronger measures of their hypothesised constructs than of other constructs (item 
discriminant validity).  
 
The item internal consistency was determined by measuring the item intercorrelation and the item-to-
total correlation. The item intercorrelation measures the extent to which the items are related and 
should be between 0.3 and 0.7. The item-to-total correlations are a measure of the item convergent 
validity and indicate the strength of the relationship between the individual items and the construct 
being measured. The recommended value of item-to-total correlation values is 0.3.  
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Item discriminant validity gauges the extent to which items correlate more highly with the concept 
they are hypothesised to represent than with other concepts. Item discriminant validity is supported 
and a scaling success declared when the correlation for an item and its hypothesised scale is more 
than two standard errors higher than its correlations with another scale [332, 333]. Item discriminant 
validity is also supported when correlations of <0.4 are observed between an item and other scales in 
the questionnaire. 
 
 A definite scaling error occurs when the correlation of an item with another scale exceeded the 
correlation with its own scale by two standard errors. A probable scaling error was considered to be 
present when a correlation between an item and another scale exceeded the correlation with its own 
scale, but by less than two standard errors.  
 
Exploratory Factor Analysis 
The aim of running an exploratory factor analysis (EFA) on the LRRC-QoL questionnaire was to test 
the scale structure and stability by identifying clusters of items which were not previously 
hypothesised into a scale. EFA summarises the correlations amongst items in terms of underlying 
dimensions or factors. Items which correlate highly together will load onto the same factor. There are 
two main components to EFA, which include, estimating the number of underlying dimensions and 
rotating the number of factors to identify which items cluster on the same factor. 
 
EFA will be conducted in a step-wise fashion. Firstly, the suitability of the data for EFA will be 
determined using the Kaiser-Meyer-Olkin (KMO) Measure of Sampling Adequacy and Bartlett's Test 
of Sphericity. The KMO index ranges from 0 to 1, with an index measure of 0.50 and above 
considered suitable for factor analysis. The Bartlett’s Test of Sphericity should be significant (p 
<0.05) for factor analysis to be suitable. 
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On determining the suitability of the data for EFA the next stage of the analysis was to determine how 
the factors were extracted. For the LRRC-QoL principal component factor analysis with oblique 
rotation was used. The oblique rotation method was chosen as it allows for correlation between 
factors. Factors were extracted based on the following pre-requisites:  
• A eigenvalue of greater than 1.00 
• Cumulative percentage of variance – each component has to account for at least 5% of the 
variance amongst items. 
• Appropriate examination and interpretation of Scree plots. The scree plot is a graphical 
representation of the eigenvalues for all the extracted factors. The plotted eigenvalues are 
examined to determine where a natural break point occurs in the data and the curved line 
flattens out. The number of data points above the break are indicative of the number of factors 
which should be retained.  
 
7.4.4.3 Scale Reliability  
 
Reliability is the degree to which the questionnaire is free from random error this is measured by the 
internal consistency of a scale and reproducibility of the questionnaire using the test-retest measure.  
 
Internal consistency measures the homogeneity of a scale ensuring all items are sufficiently similar, 
thus ensuring scale reliability using alpha coefficients (Cronbach’s Alpha). Cronbach’s Alpha 
indicates the extent to which items in a scale are interrelated by comparing the variance of the total 
score to the sum of the variances of the individual items. As the correlations between the items 
increase, the variance for the total score increases and alpha coefficients approximate unity. Internal 
consistency is considered to be good when Cronbach’s alpha co-efficient exceeds 0.70. Cronbach’s 
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Alpha were calculated for all the finalised scales of the LRRC-QoL, along with 95% confidence 
interval values. 
 
The results from exploratory analysis were used to determine whether the sample size used to conduct 
the psychometric analysis was appropriate to conduct Cronbach’s Alpha. The eigenvalues from the 
principle component analysis were examined, if the first eigenvalue was >3 the sample size was 
deemed satisfactory [334]. Similarly, if the component pattern for the factor loadings was stable, with 
factor loadings of >0.6 for at least four variables within each factor [335], the sample size was 
deemed adequate to conduct reliability analysis using Cronbach’s Alpha.  
 
The test-retest measure assesses the stability of the questionnaire over a period of time during which 
the patients clinical state remains stable. The Intraclass coefficient (ICC) was used to measure the 
strength of agreement between repeated measures, by assessing the proportion of total variance of an 
observation that is associated with the in-between patient variability. If the ICC is large this suggests 
the random variability is low and a high proportion of the variance is attributable to the variation 
between patients. The measurements are thus described to have high reliability. Conversely, if the 
ICC is low, the random error variability dominates and the measurements have low reliability. An 
ICC score of 0.7 or above is recommended to ensure good test-retest reliability. The ICC was 
calculated using a fixed effects analysis of variance (ANOVA) model[336] and reported along with 
95% confidence interval values.  
7.4.4.4 Validity 
 
Construct Validity 
Construct validity can be assumed when the second round of multitrait scaling analysis on the LRRC-
QoL produces the same or similar underlying factor structure.  
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Convergent Validity  
Convergent validity reflects the correlation between individual assessment tools measuring the same 
phenomenon. Convergent validity was evaluated by making comparisons between the LRRC-QOL 
and the FACT-C and EORTC QLQ CR-29 questionnaires.  Both of these questionnaires have been 
used in previously in studies in patients with LRRC. Pearson’s product moment correlation was used 
to analyse correlation between the items and scales of the LRRC-QoL, EORTC QLQ CR29 and 
FACT-C. Pearson’s values of greater than 0.45 are considered to be highly correlated. It was 
hypothesised that the scales in the LRRC-QoL will not correlate with the FACT-C and EORTC QLQ-
CR29 unless they address similar themes.  
 
Known-Groups Comparison 
The method of known-groups comparison was used to assess the ability of the LRRC-QoL to 
distinguish between patients differing in clinical status. The clinical parameters hypothesised to form 
mutually exclusive patients for subgroup comparison included disease stage (local recurrence versus 
local recurrence and metastatic disease), recurrent disease location (central, anterior, lateral or 
posterior), treatment intention (curative versus palliative) and pre-operative treatments 
(chemoradiation versus none). The independent student t-test was used to examine differences in 
mean scores in 2 groups and the one way analysis of variance (ANOVA) for more than 2 groups.  
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Figure 7-1 Overview of Step-Wise Data Analysis Plan 
 
 Assessment of Data Completeness 
Descriptive analyses 
Missing Data 
Floor/Ceiling Effects 
Assessment of Scale Structure: Multitrait Scaling Analysis on provisional 
hypothesised scales of LRRC-QoL 
Item internal consistency 
Item intercorrelations criteria of 0.30 – 0.70 
Item discriminant validity 
 Item-to-total correlation for item and scale >2 SD higher than other scales.  
Equal Item-To-Total Correlation 
Items within a scale have equal item-to-total correlation 
Equivalent item means and variances within a scale 
Assessment of Scale Structure: Exploratory Factor Analysis to identify potential 
scales not previously hypothesised 
Kaiser-Meyer-Olkin (KMO) Measure of Sampling Adequacy 
Value of 0 – 1 
Bartlett's Test of Sphericity 
P<=0.05 
Principal Component Factor Analysis with Oblique rotation  
Eigenvalue >1.00 
Cumulative percentage of variance 
Scree plots 
Revised Scale Structure  
Further Multitrait Scale Analysis on new scale structure 
 
Finalised Scale Structure – Reliability 
Internal Consistency Cronbach’s Alpha >0.70 
Test-Retest Measure  Intra-class Correlation >0.70 
 
Finalised Scale Structure - Validity  
Construct Validity 
Multitrait scaling analysis produces the same underlying factor structure in different population samples. 
Convergent Validity  
Correlation between LRCC-QoL and FACT-C and EORTC QLQ CR29 when measuring the same 
phenomenon.  
Known Groups Comparison  
Statistical evaluation of the differences between PRO scores for groups of patients that differ by a 
known disease indicator 
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7.4.4.5 Sample Size Justification  
 
The sample size for the LRRC-QoL was based on previous guidance from the EORTC, which 
recommends a subject to item ratio of 5-10 participants per item [212].  Based on the 
hypothesised LRRC-QoL having 32 items a sample size of 160 was calculated, however, for 
the purposes of this thesis, an interim analysis on the British cohort was conducted in a 
sample size of 80 patients.  A number of analyses were conducted to determine whether the 
results obtained from the psychometric analysis from the British LRRC-QoL cohort were 
reliable given the potential limitations engendered by our small sample size.  
 
Key components of exploratory factor analysis were examined to determine whether the 
sample size included in the final analysis was adequate.  This includes assessing the 
following:  
• Communality of the variables 
The communality measures the percentage of variance in a given variable explained 
by all the factors jointly and may be interpreted as the reliability of the indicator. 
High communalities indicate that the recovery of population factors in the sample 
data is good, irrespective of the sample size [337, 338]. It is recommended that the 
communalities should all be greater than 0.6 or the mean level should be at least 0.7 
[339]. 
 
• Degree of overdetermination of the factor 
Overdetermination is the factor to variable ratio. Six variables per factor combined 
with a small number of factors is considered to be high overdetermination of factors 
if the majority of communalities are <0.50 [339]. A minimum of 3 variables is 
required per factor, a factor with fewer variables than this is considered to a weak 
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factor [337, 338].  
 
• Size of Loading 
Factor loading is the correlation between a specific observed variable and a specific 
factor. Factor loadings of >0.6 are considered to be high.  Five or more strongly 
loading items (>0.50) are desirable and indicate a robust factor. However, if factors 
possess four or more variables with loadings above 0.60, this is also acceptable. 
There should be few item crossloadings. A crossloading is when an item loads at 0.32 
or higher on two or more factors [337]. A low number of crossloadings enables each 
factor to be defined by a distinct set of interrelated variables.  
 
To interpret estimates of reliability and validity 95% confidence intervals were reviewed for 
all Cronbach’s Alpha, IntraClass correlation and Pearson product moment correlation co-
efficient values. The size of the confidence intervals indicates the precision of the underlying 
value, with narrow confidence intervals associated with greater precision. The range of values 
included in the confidence intervals indicate plausible values for the true reliability and 
validity values. 
 
7.5 Results 
 
7.5.1 Recruitment 
 
A total of 206 questionnaire packs were sent to 5 UK centres over a 22 month period between 
January 2015 and September 2016. Two centres failed to recruit any patients, one due to non-
engagement in the recruitment phase and the second due to lengthy internal R&D set-up.  
Two of our five sites were open within the first 7 months of the study, with our third and 
fourth sites opening at 8 and 11 months following the opening of the first site. Due to 
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significant delays and difficulties at local level we failed to open our 5th site. The original 
recruitment target was 10 patients per month with a total recruitment period of 8 months, 
however, we failed to achieve this target in a timely fashion achieving 80 patients in 21 
months.  
 
There were significant difficulties with the Australian recruitment. This included significant 
delays in obtaining ethical approval in Australia.  Furthermore, a number of concurrent 
studies were identified by the Australian investigators examining PROs in patients with 
locally advanced pelvic oncology, including LRRC, which employed a number of 
questionnaires. This unfortunately led to a patient complaint regarding high responder burden 
due to the co-enrolment into multiple studies. Consequently, an executive decision was made 
by the clinical research team to delay the commencement of LRRC-QoL until the completion 
of conflicting studies. Given these constraints the recruitment of Phase III did not start at the 
same time as the British recruitment. Therefore, a pragmatic decision was made to delay the 
Australian recruitment until the completion of the current, on going clinical studies, in order 
to maximise recruitment and to conduct an initial interim analysis on the UK cohort, followed 
by a complete analysis upon completion of the Australian recruitment. The results from this 
chapter concentrate primarily on the UK recruitment of Phase III.  
 
Ten patients were screened per month on average, during the first half of the recruitment 
phase however, this fell to half during the second half of the study as demonstrated by the 
recruitment chart (Figure 6.2). There were three spikes in the screening rates of patients in 
August 2015, October 2015 and September 2016. The first two screening spikes corresponded 
with the opening of two new sites during the course of the study. The first spike in screening 
rates in August 2015 failed to convert to a spike in the recruitment phase. This was due to the 
non-engagement with recruitment by the clinical team and the principal investigator at this 
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site. The second spike in screening rates in October 2015 led to an increase in recruitment 
rates for that month. However, following this increase recruitment fell back to recruiting 1-3 
patients/month. The final spike in screening was due to a targeted screening strategy 
employed at two centres, Leeds and Newcastle, to help identify potentially eligible patients. 
During this month patients’ were personally identified by the Chief Investigator by examining 
MDT records, outpatient clinic lists and theatre operating lists. Access to in-house clinical 
registries was provided during this timeframe which further helped identify potential patients. 
During this final screening spike patients were personally approached for participation of the 
study. This targeted recruitment strategy led to an increase in recruitment rates and enabled 
the study team to reach the final recruitment target.  
 
Figure 7.2 Recruitment Graph for Phase III LRRC-QoL 
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7.5.2 Patient Demographics 
 
Responder Demographics 
Of the 206 questionnaires sent 80 (38.8%) patients responded to the LRRC-QoL 
questionnaires. Of these 80 patients, 54 (67.5%) participated in the second round of the 
LRRC-QoL questionnaire testing. All patient demographics and clinical details are 
highlighted in Table 7.2. Sixty-one male and 19 female patients, with a median age of 66 
years participated in the study. Forty patients with a gastrointestinal stoma and 6 patients with 
a urostomy participated in the study. Thirty seven patients were treated with curative intent 
and 21 patients were treated with palliative intent. A total of 35 (43.8%) of patients underwent 
operative intervention, of which only one patient underwent surgical intervention for 
palliation of symptoms. The current disease status was disease free in 22 (27.5%) patients, 
distant disease recurrence in 3 (3.8%) patients and local disease recurrence in 12 (15%). The 
disease status is unknown in 43 (53.8%) of patients.  
 
Responder vs. Non-Responders: Patient and Clinical Demographics 
The rate of missing data for the clinical categories was variable, ranging from 3.9-20.9% in 
the responder group and 5.6-43.7% in the non-responder group. Personal information 
regarding ethnic group, marital status, educational status was unavailable for the non-
responder group as this is data that is not routinely captured in clinical practice and was 
obtained using a self-completed form in the LRRC-QoL questionnaire pack. On comparing 
patient and clinical variables between responders and non-responders it was noted that 
responders were older in age (62 vs. 58, p=0.01) and male (61 versus 46, p=0.01) (Table 7.2). 
Non-responders were more likely to have their LRRC treated with palliative intent (19.9% vs. 
10.2%, p=0.03) and to have distant metastatic disease (3.4% vs. 1.5%, p=0.02). A range of 
operation types were undertaken in both groups, with no demonstrable differences between 
the two cohorts. However, despite the heterogeneous nature of the operative interventions 
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undertaken, both groups of patients were similar with regards to LRRC disease subsite. 
Furthermore, there were no differences between the two groups with regards to mode of 
detection of LRRC and presence of concurrent metastatic disease.  
 
Table 7-2 Patient and Clinical Demographics 
Variable 
Responders Non - Responders  
P Value 
N = 80 N=126  
Patient Demographics 
Gender       
Male: Female : Unknown 60:20:00 46:34:46 0.01 
Mean Age (SD) 66 (8.05) 58 (12.27) 0.01 
Ethnic Group        
White 69 (86.3) Unknown N/A 
Black  5 (6.3) Unknown   
Asian 1 (1.3) Unknown   
Unknown  5 (6.3) Unknown   
Marital Status        
Married 62 (77.5) Unknown N/A 
Living Common Law 5 (6.3) Unknown   
Widowed 3 (3.8) Unknown   
Separate 2 (2.5) Unknown   
Divorced 1 (1.3) Unknown   
Single  1 (1.3) Unknown   
Unknown 6 (7.5) Unknown   
Education Status       
Secondary School 30 (37.5) Unknown N/A 
College 20 (25.0) Unknown   
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University  20 (25.0) Unknown   
Other 3 (3.8) Unknown   
Unknown 7 (8.8) Unknown   
Employment Status        
Self-employed 12 (15.0) Unknown N/A 
Home maker 0 (0.0) Unknown   
Full Time Employment 2 (2.5) Unknown   
Part Time Employment 4 (5.0) Unknown   
Unemployed 1 (1.3) Unknown   
Sick Leave 9 (11.3) Unknown   
Retired 44 (55.0) Unknown   
Unknown 8 (10.0)   
Years Between diagnosis of Primary Rectal Cancer and LRRC 
1 12 (15.0) 15 (11.9) 
0.72 
2 20 (25.0) 26 (20.6) 
3 12 (15.0) 19 (15.0) 
4 5 (6.25) 11 (8.7) 
5 4 (5.0) 1 (0.79) 
6 7 (8.75) 8 (6.3)  
Unknown  20 (25.0) 46 (36.5%) 
Primary Rectal Cancer Details 
 
Neoadjuvant Treatment       
None 31 (15.0) 36 (17.5)   
Chemoradiation 22 (10.7) 36 (17.5)   
Short Course Radiotherapy  3 (1.5) 4 (1.9) 0.3 
Contact Radiotherapy 1 (0.5) 0 (0.0)   
Unknown 23 (11.2) 50 (24.3)   
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Operation        
Anterior Resection 37 (18.0) 42 (20.4)   
APER 9 (4.4) 15 (7.3)   
Composite Abdominosacral Resection 2 (1.0) 1 (0.5)   
Hartmann’s 6 (2.9) 12 (5.8) 0.54 
Panproctocolectomy 0 (0.0) 3 (1.5)   
Pelvic Exenteration  1 (0.5) 2 (1.0)   
Local Excision  3 (1.5) 1 (0.5)   
Unknown 22 (10.7) 50 (24.3)   
Dukes Stage   
 
  
A 11 (5.3) 9 (4.4)   
B 20 (9.7) 18 (8.7) 0.05 
C 26 (12.6) 41 (19.9)   
D 1 (0.5) 1 (0.5)   
Unknown 22 (10.7) 57 (27.7)   
Margin Status       
R0 50 (37.5) 63 (47.4)   
R1 8 (6.0) 11 (8.3) 0.66 
R2 0 (0.0) 1 (0.8)   
Unknown  22 (27.5) 51 (40.4)   
Adjuvant Chemotherapy       
Chemoradiation 3 (1.5) 3 (1.5)   
Chemotherapy 31 (15.0) 38 (18.4)   
Short Radiotherapy 0 (0.0) 1 (0.5) 0.33 
None 24 (11.7) 33 (16.0)   
Unknown 22 (10.7) 51 (24.8)   
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Locally Recurrent Rectal Cancer Details 
Mode of Detection       
Surveillance 46 (22.3) 62 (30.1) 0.19 
Symptomatic  12 (5.8) 14 (6.8)   
Unknown 22 (10.7) 50 (24.3)   
Pattern of Recurrence       
Anterior 5 (2.4) 12 (5.8)   
Central  22 (10.7) 22 (10.7) 0.07 
Lateral  19 (9.2) 17 (8.3)   
Posterior  12 (5.8) 26 (12.6)   
Unknown 22 (10.7) 49 (23.8)   
Presence of Metastatic Disease       
Yes 11 (5.3) 14 (6.8)   
No 47 (22.8) 62 (30.1) 0.20 
Unknown 22 (10.7) 50 (24.3)   
Treatment Intent        
Curative  37 (18.0) 36 (17.5)   
Palliative  21 (10.2) 41 (19.9) 0.03 
Unknown 22 (10.7) 49 (23.8)   
Palliative Treatment        
Chemotherapy 16 (24.2) 30 (48.4)   
Chemoradiation 4 (6.5) 8 (12.9) 0.65 
Radiotherapy  0 (0.0) 1 (1.6)   
Surgery  1 (1.6) 0 (0.0)   
Pre-operative Treatment       
None 9 (12.5) 19 (26.4)   
Chemotherapy 1 (1.4) 2 (2.8)   
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Chemoradiation 18 (25.0) 12 (16.7) 0.09 
Radiotherapy  2 (2.8) 0 (0.0)   
Unknown 5 (6.9) 4 (5.6)   
Margin Status        
R0 21(29.6) 19 (26.8)   
R1 13 (18.3) 15 (21.1) 0.75 
R2 1 (1.4) 2 (2.8)   
Post-Operative Treatments        
Chemotherapy 8 (10.5) 8 (10.5)   
None  27 (35.5) 27 (35.5) 1.00 
Unknown 3 (3.9) 3 (3.9)   
Current Disease Status        
Disease Free 22 (10.7) 21 (10.2)   
Distant Disease Recurrence 3 (1.5) 7 (3.4) 0.02 
Local Disease Recurrence 12 (5.8) 8 (3.9)   
Unknown 43 (20.9) 90 (43.7)   
Operation Type        
Composite Abdominosacral Resection  6 (7.8) 5 (6.2)   
Anoproctectomy 1 (1.3) 3 (3.9)   
Abdominoperineal Excision of Rectum  7 (9.2) 4 (5.3)   
Abdominoperineal Excision of Rectum with 
partial vaginectomy  0 (0.0) 2 (2.6)   
Resection of mass 5 (6.5) 8 (10.4)   
Resection of mass with en bloc small bowel 
resection  1 (1.3) 1 (1.3)   
Resection of mass en bloc hysterectomy/BSO 1 (1.3) 1 (1.3)   
Resection of mass with en bloc small bowel, and 
proctectomy 0 (0.0) 1 (1.3)   
Resection of mass with en bloc vaginectomy 1 (1.3) 1 (1.3)   
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Excision of mass with partial cystectomy, distal 
uretectomy and reimplantation 0 (0.0) 1 (1.3) 0.07 
Excision of neorectum and segment 6 
metastatectomy  1 (1.3) 0 (0.0)   
Hartmann’s 3 (3.9) 1 (1.3)   
Hartmann’s with en bloc hysterectomy, bilateral 
salphino-oopherectomy, left ureterectomy and 
resection of pelvic side wall mass with 
reimplantation of ureter 
0 (0.0) 1 (1.3) 
 Laparotomy and bypass of recurrent rectal cancer 1 (1.3) 1 (1.3) 
 Pelvic Exenteration 1 (1.3) 3 (3.9) 
 Proctectomy  0 (0.0) 2 (2.6) 
 Proctectomy with en bloc resection of cervix  1 (1.3) 0 (0.0) 
 Resection of neorectum 1 (1.3) 0 (0.0)  
Resection of neorectum and en bloc hysterectomy 0 (0.0) 1 (1.3)   
Resection of recurrent mass with en bloc psoas 
muscle and iliacus 1 (1.3) 0 (0.0)   
Transacral excision of mass 3 (3.9) 1 (1.3)   
Ultralow AR with loop ileostomy with en bloc 
resection of R obturator node 1 (1.3) 0 (0.0)   
 
 
7.6 Discussion 
 
Conducting multi-centre research has a number of challenges at a number of different time 
points during the course of a study, which are further amplified on an international platform. 
Recruitment to the LRRC-QoL has been long, difficult and challenging. We were unable to 
recruit to LRRC-QoL in the pre-specified timeframe. However, due to the constant review of 
recruitment strategies the target recruitment was eventually reached for the British cohort of 
patients.  
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Delays during the initial phases of site set up were attributable to the difficulties in obtaining 
local Research and Development approval from each individual participating NHS trust, most 
of which have individualised and lengthy review processes [340-342] Further ethical approval 
had to be sought from the Australian Ethics Committee and the local ethics approval board 
which led to significant delays in commencing the final phase of the LRRC-QoL in Sydney 
and Melbourne.  Furthermore, a number of on going, competing studies were identified at the 
Australian centres. Co-enrolment of patients into studies can be employed as a strategy to 
maximise recruitment in difficult disease settings [343]. Although, there are no regulatory 
prohibitions on co-enrolment of patients into more than one study, there are ethical and 
statistical concerns regarding co-enrolment [344]. From an ethical perspective there are often 
concerns regarding patient burden when participating in multiple studies. From a statistical 
perspective co-enrolment into two studies can potentially lead to interactions between the two 
studies, which can have an impact on the obtained results. Given these ethical and statistical 
concerns of co-enrolment and the patient complaint, co-enrolment was not pursued as a 
recruitment strategy for LRRC-QoL. The concept of co-enrolment was not pursued in the UK, 
as there were no other conflicting studies identified during the study period.   
 
Timely and adequate recruitment of eligible participants is often a key challenge when 
conducting research in the advanced malignancies and rare disease settings due to a multitude 
of reasons. The key contributing factor for this is that the overall pool of potentially eligible 
patients in these complex disease settings are often small, which is further attenuated when 
applying stringent eligibility criteria. Further compounding this is the comparatively higher 
refusal rate by eligible patients and greater professional ‘gate-keeping’ of access to patients 
[345]. This can potentially have an impact on the results obtained as high refusal rates have an 
effect on sample bias, which can limit the generalisability of the results. A further barrier to 
recruitment in advanced cancer is patient illness, with severity of illness correlating with 
reduced research participation [346].  Amongst, this cohort of patients, there is also a higher 
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rate of attrition due to their unpredictable health status. Our study reflects this as a 
significantly higher proportion of patients who were treated with palliative intent and patients 
who went on to develop metastatic disease declined participation into the study.  
 
LRRC is a relatively rare occurrence in the modern management of primary rectal cancer, 
occurring in 5-10% of patients treated for primary rectal cancer, with approximately 700 
patients a year treated operatively within the UK [5].  Due to this relatively small patient 
population, a number of strategies were employed in a bid to maximise recruitment. The 
LRRC-QoL was designed as a multi-centre collaborative project in a bid to maximise the 
potential pool of eligible patients across the UK and Australia. Centres with an established 
practice in LRRC, a track record of research in this setting, and an established clinical registry 
were approached and recruited to the study prior to the commencement of Phase III. The 
overall eligibility criteria was kept broad to include all patients with LRRC, irrespective of 
disease recurrence subsite, current disease status or treatment strategy. The overall burden of 
participation was kept to a minimum and patients were specifically asked whether they 
wanted to continue their participation in the project by completing a second questionnaire.  
 
Often within the context of multicentre research there are a number of healthcare 
professionals involved, including surgeons, oncologists, nurse specialists and clinical research 
fellows, who act as ‘gatekeepers’ for patients. This can make access to potential participants a 
convoluted process requiring multiple communication systems to ensure appropriate access to 
potentially eligible patients.  Furthermore, the involvement of multiple teams, both central 
and locally can make it difficult to monitor the project overall to identify practical and 
logistical difficulties and appropriate solutions. In an attempt to reduce professional gate-
keeping and to reduce local investigator burden, the central research team kept in regular 
contact with all participating sites attempting to identify any potential problems and to offer 
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solutions and support. Furthermore, the central research team attempted to obtain access to 
the LRRC clinical registries at each site to help identify potentially eligible patients and to 
coordinate this centrally. Of the 4 participating sites, only 2 sites (Leeds and Newcastle) were 
able to provide on-site access to the clinical registries following local approval. Open access 
to these registries allowed for the rapid identification of potentially eligible patients, the 
acquisition of relevant clinical and operative data and improved overall recruitment rates.  
 
The use of clinical registries and patient advocacy groups have been utilised in aiding 
recruitment, developing and validating PROMs in rare disease settings [347-350]. However, 
gaining access to such registries is a long and difficult process, requiring further local 
approvals. The use of a patient advocacy group was not employed to help aid the recruitment 
to phase III, as there are no established patient groups specifically for LRRC. Although the 
use of such groups may potentially increase the overall recruitment pool, it may cause 
potential issues, with regards to the acquisition of relevant clinical details to enable 
appropriate context in which to interpret any obtained PROs. The use of patient advocacy 
groups may not be appropriate to recruit patients during the validation phase of a PROM 
however it would be ideally suited to promote the use of a future PROM.  
 
To help maximize recruitment a number of strategies were employed. Personalised letters 
addressing the patient themselves from the lead PIs were sent to all patients from 
collaborating centers. In combination with this centers were emailed for monthly updates to 
identify screened and recruited patients. Site visits were arranged to help engage local 
investigators at the three main recruiting sites, Leeds, Newcastle and Swansea. To reduce 
local investigator burden a pragmatic decision was made not to send reminder letters. This 
was primarily due to the fact that some of the local investigators found it difficult to send out 
207 
a second questionnaire at the two week interval following the receipt of the first questionnaire 
from responders as well as sending out a reminder questionnaire to the non-responders.  
 
A number of recruitment strategies have been investigated previously in a bid to identify 
methods of improving response rates to postal questionnaires. The use of monetary 
incentives, shorter questionnaires, coloured ink, personalised letters, the use of stamped 
addressed envelopes, questionnaires sent by first class post, contacting participants prior to 
sending questionnaires providing non-respondents with follow up questionnaires are all 
strategies associated with improved response rates [351-353].  The LRRC-QoL employed a 
number of these strategies in an attempt to maximise recruitment, this included designing the 
project as a multi-centre, collaborative project, employing broad eligibility criteria, regular 
communication between the coordinating site and peripheral sites, local site visits, the use of 
stamped addressed envelopes, the use of first class postage and sending out personalised 
letters from the PIs to patients. However, despite these efforts our overall response rate was 
low. 
 
Our response rate of 38.8% is much lower than previous reported response rates of 52.5 – 
74.9% in studies collecting PROs and HrQoL data in patients with primary colorectal cancer 
[354, 355]. However, our response rates are similar to observed response rates of 40-46.7% in 
patients with metastatic colorectal cancer [356, 357].  It is likely these lower response rates in 
metastatic and recurrent colorectal cancer are a reflection of the disease status of this cohort 
of patients, making them less likely to engage in research due to ill health.  This is further 
reflected in the patient and clinical demographics of the patients who refused participation in 
this study, with a higher proportion of patients treated with palliative intent and disease re-
recurrence refusing participation. Other key differences between the responder and non-
responder group were gender and age, with a higher proportion of male and older patients 
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consenting to participate in the study. These key differences between the responder and non-
responder groups have important implications on the validation of the LRRC-QoL, as the 
study population does not accurately reflect the patient and clinical demographics of the wider 
population affected with LRRC, thus potentially reducing the generalisability of the obtained 
results. As this study only validates the results obtained from the UK cohort of patients, it will 
be essential to appropriately monitor the sample characteristics of the Australian cohort to 
ensure a more broad and wider range of patients are targeted. This should include female 
patients, younger patients and those treated with palliative intent, to ensure the overall sample 
is representative of the intended population  
 
There are no formal sample size calculations for the development and validation of PROMS 
[358]. There are however, a number of methods which have been employed in determining a 
sample size in the validation of PROMS, this includes an arbitrary minimum sample size, a 
subject to item ratio and a subject to item ratio with a posteriori justification [358].  The 
subject to item ratio is the most frequently recommended method of sample size 
determination when employing exploratory factor analysis. However, there are a number of 
conflicting guidelines on the optimal sample size when conducting exploratory factor 
analysis, with values ranging from 100 – 1000 [359-361]. These arbitrary guidelines have been 
appropriately criticised as they do not reflect the often complex dynamics of factor analysis. It 
is the underlying strength of the data, which determines the robustness of the exploratory 
factor analysis. The strength of the data is assessed by high item communalities and several 
variables loading onto each factor [338]. Using these principles small sample sizes of 50 are 
appropriate for exploratory factor analysis in determining the scale structure of a PROM 
[362].  To mitigate the impact of having a relatively small sample size key components of 
exploratory factor analysis were analysed in an attempt to justify the sample size used and 
ensure potentially meaningful data had been obtained from the analysis. By closely examining 
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the communality of the items, degree of overdetermination of the factor and the size of the 
loading, we were able to determine whether our sample size was adequate.   
 
The overall small sample size can limit the generalisibility of the results and the precision of 
the estimates of reliability and validity of the measure overall.  Previous sample size 
requirements stipulated to provide reliable and precise estimates of Cronbach’s Alpha include 
Nunally’s recommendation of a minimum sample of 300 patients [363]. However, in practice, 
such sample sizes are often not achieved. Recent works have focused on the use of smaller 
sample sizes and determining precise measures of reliability by using the eigenvalue values of 
principal component analysis and through the reporting of confidence intervals [334, 364]. 
Yurdugul et al demonstrated that if the value of the first eigenvalue is >6 the observed value 
of Cronbach’s alpha is a robust estimate of the population Cronbach’s Alpha, even when the 
sample size is limited to 30 patients [334]. Similarly, if the first eigenvalue is 3-6 a required 
minimum sample size of 100 patients is adequate to demonstrate an unbiased estimate of 
reliability [334].  
 
To determine the precision of the results obtained from the measures of reliability 
(Cronbach’s Alpha and Intra-class coefficient) and validity (Pearson’s product moment 
correlation) the 95% confidence intervals were reported. Narrow confidence intervals indicate 
a more precise estimate for the observed value compared to wider confidence intervals. On 
assessing confidence intervals for reliability, in particular for Cronbach’s Alpha, the 
confidence intervals are wider for observed values which are low, and narrow as the value 
gets closer to 1.0, irrespective of the number of items included in the scale [364]. The sample 
size impacts upon the confidence intervals obtained for both Cronbach’s Alpha and the 
IntraClass correlation, with wider values observed in smaller sample sizes [365]. The 
precision of the value of Cronbach’s Alpha is affected by the sample size, the number of 
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items within a scale and the individual item intercorrelations. As the number of items increase 
within a scale, the strength of the Cronbach’s Alpha value increases, with the narrowing of 
the associated confidence intervals. A similar relationship is observed for item 
intercorrelations. As the strength of the item intercorrelations increase, the Cronbach’s Alpha 
value increases and the width of the confidence interval decreases. The relationship between 
sample size and the precision of Cronbach’s Alpha is slightly more complex. Confidence 
intervals are wide for small sample sizes, however, confidence intervals are also affected by 
the value for item intercorrelation and number of items so that confidence interval widths can 
be similar for example when sample sizes range from small (n=30) to large (n=200) when the 
value for item intercorrelation is >0.6 in a scale consisting of 2 items, or a item 
intercorrelation value of >0.4 in a scale consisting of 5 items [364, 365]. Similar principles 
apply to determining the precision of validity by examining the associated confidence 
intervals reported with Pearson’s product moment coefficient. Wider confidence intervals are 
observed with low validity irrespective of sample size [365].  
 
7.7 Conclusion  
 
This chapter outlines the methodology employed to determine the scale structure of the 
LRRC-QoL and the psychometric methods to assess the reliability and validity of the LRRC-
QoL. The chapter highlights the recruitment of Phase III for the UK cohort and compares 
clinical characteristics between responders and non-responders
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8 Chapter 8 – Psychometric Analysis of the LRRC-QoL  
8.1 Introduction 
 
Chapter 7 highlights the methodology employed to validate the LRRC-QoL and documents 
the recruitment rate to Phase III in the UK cohort. This chapter reports on the results of the 
psychometric analysis of the LRRC-QoL; reporting on the final scale structure and the overall 
reliability and validity of the LRRC-QoL in the UK patient cohort. 
 
8.2 Aims and Objectives 
 
The overall aims of Phase III of this study were to determine the scale structure of the LRRC-
QoL and to measure its psychometric properties. The specific aims and objectives are 
outlined in Chapter 7.3.  
 
8.3 Results 
8.3.1 Data Completeness 
 
Table 8.1 and 8.2 present the descriptive analyses of the data at an item and scale level 
respectively.  Overall, the quality of the collected data was good, with total computable score 
range of 88.7 – 100%. Missing data were higher for questions of a personal nature. The sexual 
function scale had the lowest computable score and the highest missing data rate at item level. 
Similarly, questions regarding gynaecological symptoms (items 5 and 6) had a higher missing 
data rate of 15%.   
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The criteria for acceptable levels of missing data is <10% for items and < 50% for 
computable total scale scores, with maximum endorsement frequencies of <80% (floor/ceiling 
effects <80%) [326, 327]. A number of the LRRC-QoL items did not fulfil these criteria 
(Table 8.2). For the symptoms scale, items 5 and 6 regarding gynaecological symptoms had a 
missing data rate of 20% at item level however, the total computable scale score for the scale 
was 100%. The sexual function scale also had considerably higher levels of missing data at 
item level compared to the other scales of LRRC-QoL, with a range of 15-26.3%. All these 
items address a range of issues which are of a personal nature and therefore the rate of 
missing data is not unsurprising. Given the importance of these items identified during the 
qualitative phase of the project a pragmatic decision was made to include all these items 
within their relevant scale.  
 
The only item which failed to meet a maximum endorsement rate of <80% for a response 
category was item 14, regarding management of a urostomy, having a maximum endorsement 
rate of 100% for the response category option 3. Consequently, this item was excluded from 
the LRRC-QoL, due to potential ceiling effects.  
 
The psychological function scale, future perspective scale and healthcare services scale all 
fulfilled the pre-requisite criterion at an item and scale level and were therefore appropriately 
included for further analyses. 
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Table 8-1 Item Level Descriptive Analyses for Hypothesised LRRC-QoL 
Symptom Scale N 
Missing 
(%) Mean 
Std. 
Deviation 
Response Value Frequency 
1 2 3 4 
1. Abdominal Pain  80 2 (2.5) 1.62 0.669 37 (46.3) 35 (43.8) 5 (6.3) 1 (1.3) 
2. Back Pain 80 0 (0.0) 1.89 0.900 32 (40.0) 30 (37.5) 13 (16.3) 5 (6.3) 
3. Perianal/Buttock Pain 80 1 (1.3) 1.92 0.958 31 (38.8) 31 (38.8) 9 (11.3) 10 (10.4) 
4. Rectal Bleeding/Discharge 80 1 (1.3) 1.56 0.813 1 (49.0) 18 (22.5) 10 (12.5) 2 (2.5)  
5.Vaginal Bleeding or 
discharge* 20 4  (20.0) 1.29 0.588 13 (65.0) 3 (15.0) 1 (5.0) 0 (0.0) 
6. Vaginal Irritation * 20 4  (20.0) 1.29 0.588 13 (65.0) 3 (15.0) 1 (5.0) 0 (0.0) 
7. Urinary Irritation 80 4 (5.0) 1.53 0.757 46 (57.5) 22 (27.5) 6 (7.5) 2 (2.5) 
8. Urinary Incontinence 80 0 (0.0) 1.6 0.789 44 (55.0) 27 (33.8) 6 (7.5) 3 (3.8) 
9. Lower limb weakness 80 1 (1.3) 1.7 0.806 38 (47.5) 30 (37.5) 8 (10.0) 3 (3.8) 
10. Difficulty in walking 80 0 (0.0) 1.85 0.929 34 (42.5) 31 (38.8) 8 (10.0) 7 (8.8) 
11. Lower limb numbness 80 0 (0.0) 1.87 0.973 36 (45.0) 25 (31.3) 12 (15) 7 (8.8) 
12. Pain/Discharge from 
wounds 80 1 (1.3) 1.44 0.693 53 (66.3)  17 (21.3) 9 (11.3) 0 (0.0) 
14. Problems caring for 
urostomy 6 0 (0.0) 2.00 0.000 0 (0.0) 6 (100.0) 0 (0.0) 0 (0.0) 
15. Embarrassment from 
urostomy 6 0 (0.0) 1.83 0.983 3 (50.0) 1 (16.7) 2 (33.3) 0 (0.0) 
16. Dependent on others for 
caring for urostomy  6 0 (0.0) 1.33 0.516 4 (66.7) 2 (33.3) 0 (0.0) 0 (0.0) 
18. Embarrassment from stoma 40 0 (0.0) 1.70 0.992 23 (57.5) 10 (25.0) 3 (7.5) 4 (10.0) 
19. Problems caring for stoma  40 1 (2.5) 1.41 0.715 28 (70.0) 6 (15.0) 5 (12.5) 0 (0.0) 
Psychological Impact Scale                 
20. Dependence 80 2 (2.5) 1.96 0.918 28 (35.0) 31 (38.8) 13 (16.3) 6 (7.5)  
21. Attractiveness  80 2 (2.5) 1.97 0.993 32 (40.0) 23 (28.7) 16 (20.0) 7 (8.8)  
                  
Sexual Function Scale                 
22. Pain * 80 21 (26.3) 1.44 0.815 42 (52.4) 11 (13.8) 3 (3.8) 3 (3.8) 
23. Interest * 80 11 (13.8) 1.84 0.964 32 (40.0) 22 (27.5) 9 (11.3) 6 (7.5) 
24. Erectile function * 60 9 (15.0) 2.78 1.205 11 (18.3) 10 (16.7) 9 (15.0) 21 (41.2) 
25. Ejaculatory dysfunction  * 60 12 (20.0) 2.69 1.274 14 (23.3) 6 (10.0) 9 (15.0) 19 (31.7) 
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Future Perspective Scale                 
26. Results 80 4 (5.0) 2.32 0.883 13 (16.3) 34 (42.5) 21 (26.3) 8 (10.0) 
27. Examinations and Tests 80 2 (2.5) 2.36 1.006 17 (21.3) 29 (36.3) 19 (23.8) 13 (16.3) 
28. Uncertainty 80 2 (2.5) 2.58 0.947 9 (11.3) 31 (38.8) 22 (27.5) 16 (20.0) 
                  
Healthcare Services and 
Delivery  
 
              
29. Information 80 5 (6.3) 3.11 0.847 1 (1.3) 20 (25.0) 24 (30.0) 30 (37.5) 
30. Knowledge 80 4 (5.0) 3.5 0.663 0 (0.0) 7 (8.8) 24 (30.0) 45 (56.3) 
31. Tests 80 4 (5.0) 3.18 1.016 7 (8.8) 12 (15.0) 17 (21.3) 40 (50.0) 
32. Frequency of consultations  80 4 (5.0) 3.18 0.920 4 (5.0) 14 (17.5) 22 (27.5) 36 (45.0) 
*These items failed to meet the pre-requisite criteria of <10% missing data at an item level.  
 
Table 8-2 Scalar Level Descriptive Analysis for Hypothesised Scales 
Scale Total No 
of Items 
in Scale  
Data 
Completeness 
(%) 
Possible 
Score 
Range* 
Observed 
Score Range 
Mean 
Score 
SD 
Symptoms** 16 100 11 - 68 12 - 35 19.48 5.39 
Psychological 2 98.7 2 – 8 2 – 8 3.83 1.64 
Sexual 
Function*** 
4 65.0 4 -16 4 - 15 6.03 4.13 
Future 
Perspective 
3 97.5 3 – 12 3 - 12 7.01 2.68 
Healthcare 
Services 
4 95.0 4 – 16 7 – 16 12.28 3.91 
 
* The possible score range was calculated to reflect the response category of 1 – 4. Missing data were imputed 
using the half mean imputation. **The minimum score for the symptoms scale is 11 as 5 of the items within this 
scale are for specific groups i.e. urostomy or stoma, thus leaving 12 items which are applicable to all patients with 
LRRC. ***Two of the items within the sexual function scale are gender-specific for male patients.  
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8.3.2 Scale Structure: Multi-trait Analysis on Hypothesised LRRC-QoL Scales  
 
The results for the multi-trait analysis on the hypothesised scales are presented below. The 
multi-trait, multi-item correlation matrix for the hypothesised scales is presented in Table 8.3 
and the item summary statistics are presented in Table 8.4.  
Table 8-3 Multi-trait/Multi-item Correlation Matrix for Hypothesised Scales of LRRC-
QoL 
 
Symptom Scale 
Psychological 
Function  Sexual Function Future Perspective Healthcare Services 
Symptom Scale  
1. Abdominal pain 0.604 0.374 -0.098 0.016 -0.033 
2. Back pain 0.619 0.329 -0.135 0.194 0.106 
2. Perianal/Buttock Pain 0.676 0.360 0.073 0.126 0.077 
4. Rectal Bleeding/ 
Discharge 0.450 0.204 -0.054 0.003 0.069 
5. Vaginal Bleeding/ 
Discharge 0.196 0.066 -0.465 0.090 0.003 
6. Vaginal Irritation 0.207 0.189 -0.505 0.171 -0.068 
7. Urinary Irritation  0.315 0.179 0.108 0.061 -0.001 
8. Urinary Incontinence 0.598 0.231 -0.193 0.044 -0.020 
9. Lower Limb 
Weakness 0.567 0.231 -0.153 -0.015 0.128 
10 Difficulty in walking  0.698 0.347 0.067 0.016 0.068 
11. Lower limb 
numbness 0.378 0.113 0.017 -0.159 0.139 
12. Pain/ Discharge from 
wounds 0.205 -0.016 0.098 -0.116 -0.068 
15. Embarrassment from 
urostomy  0.095 0.081 -0.014 -0.018 0.106 
16. Dependent on others 
for urostomy 0.067 0.026 0.054 -0.076 0.109 
18. Embarrassment from 
stoma 0.097 0.246 -0.055 0.210 0.089 
19. Problems caring for 
0.152 0.055 -0.053 0.066 0.135 
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stoma  
Psychological Function  
20. Dependence 0.480 0.817 -0.271 0.355 0.037 
21. Attractiveness  0.323 0.844 -0.026 0.504 -0.020 
Sexual Function 
22. Pain  -0.082 -0.188 0.546 -0.115 0.193 
23. Interest  -0.350 -0.233 0.728 -0.041 0.066 
24. Erectile Function  -0.049 -0.028 0.862 0.012 0.106 
25. Ejaculatory 
dysfunction -0.061 -0.144 0.845 0.013 0.055 
Future Perspective 
   26. Results 0.026 0.358 0.004 0.857 0.050 
27. Examination and 
Tests  0.031 0.470 -0.049 
 
0.882 
 
0.074 
28. Uncertainty 0.204 0.532 -0.026 0.880 0.159 
Healthcare Services 
29. Information 0.138 0.033 0.127 0.131 0.861 
30. Knowledge 0.041 0.055 0.153 0.177 0.885 
31. Tests  0.002 -0.036 0.081 0.047 0.869 
32. Frequency of 
consultations  0.137 -0.011 0.089 0.037 0.892 
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Table 8-4 Item Summary Statistics for all Hypothesised LRRC-QoL Scales 
Scale No 
of 
Items 
Mean Item 
Intercorrelation 
Item Discriminant Validity 
(Range of Scores) 
Item to Total 
Correlations  
 
Symptoms 16 0.170 -0.018 – 0.374 0.018  - 0.552 
Psychological 
Function  
2 0.379 -0.026 – 0.504 0.379 
Sexual Function  4 0.426 -0.082 – 0.193 0.354 – 0.674 
Future Perspective 3 0.644 -0.049 – 0.532 0.686 – 0.727 
Healthcare Services 4 0.692 -0.036 – 0.177 0.749 – 0.803 
 
8.3.2.1 Symptom Scale 
 
The hypothesised LRRC-QoL symptom scale consisted of 16 items and 2 skip questions. The 
rate of missing data at the item level was 1.3 – 15% (Table 8.1). This partly reflects the 
diversity of items within the scale, with a subset of items specific for women (Items 5-6), 
patients with a urostomy (Items 15-16) and for patients with a stoma (Items 18-19). Overall 
the proposed scale structure of the symptoms scale for the LRRC-QoL failed to demonstrate 
unidimensionality and performed poorly according to the principles of multi-trait scaling 
analysis. The scale failed to demonstrate good item internal consistency with a poor overall 
mean item intercorrelation score (Table 8.4). The scale failed to demonstrate equal item-to-
total correlations, with 8 of the 16 items failing to meet the pre-requisite criteria of an item-to-
total correlation of >0.3. Consequently, these items failed to contribute equally to the total 
score and therefore do not contribute equal proportions of information to the overall score for 
the symptoms scale. However, the scale demonstrated good item discriminant validity with 
item correlations of <0.4 with the scales.  
On examining the inter item correlation matrix for the hypothesied symptoms scale (Table 
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8.5), it becomes apparent that there are clusters of items which correlate highly and 
demonstrated high item intercorrelations. For example, all items related to pain (LRRC-QoL 
items 1-3) had item intercorrelations scores of 0.381 – 0.477. Similarly, all items related to 
gynaecological symptoms (LRRC-QoL items 5-6) had an item intercorrelation score of 0.847. 
Items related to urinary symptoms (LRRC-QoL items 8-9) had an item intercorrelation of 
0.523, items related to lower motor symptoms (LRRC-QoL items 9-11) had an item 
intercorrelation of 0.357- 0.548, items related to a urostomy (LRRC-QoL items 14-16) had an 
item intercorrelation of 0.857 – 0.939 and items related to a colorectal stoma (LRRC-QoL 
items 18-19) had an item intercorrelation of 0.63. This suggests the symptoms scale should be 
separated out to represent symptoms related to individual biological systems. Further 
evidence for this is provided by the number of items within the scale which failed to achieve 
an item intercorrelation value of >0.3, thus suggesting these items did not measure the same 
underlying construct.  
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Item  
1. 
Abdo 
pain 
2. 
Back 
Pain  
3. 
Perianal 
or 
Buttock 
Pain 
4. Rectal 
Bleeding/
discharge 
5.Vaginal 
Bleeding 
or 
discharge 
6. Vaginal 
Irritation 
7. Urinary 
Irritation 
8. Urinary 
Incontinence 
9. Lower 
limb 
weakness 
10. 
Difficulty 
in walking  
11. 
Lower 
limb 
numbne
ss 
12. 
Pain/ 
Dischar
ge from 
wounds 
15. 
Embarrass
ment from 
urostomy 
16. 
Dependen
t on others 
for caring 
for 
urostomy 
18. 
Embarrass
ment from 
stoma  
19. 
Problems 
caring for 
stoma  
1. Abdo pain 1 0.381 0.378 0.288 -0.028 0.143 0.228 0.304 0.194 0.287 0.179 0.011 -0.109 -0.029 0.038 -0.016 
2. Back pain 
 0.381 1 0.477 0.287 0.159 0.178 0.105 0.239 0.309 0.313 0.013 0.056 -0.02 -0.004 0.01 0.055 
3. Perianal/ 
Buttock Pain 0.378 0.477 1 0.492 -0.008 0.093 0.106 0.276 0.148 0.472 0 0.191 0.145 0.165 0.117 0.099 
4. Rectal 
Bleeding/discha
rge 0.288 0.287 0.492 1 -0.125 -0.086 -0.063 0.218 0.055 0.321 -0.01 0.059 0.368 0.313 -0.057 0.024 
5.Vaginal 
Bleeding or 
discharge -0.028 0.159 -0.008 -0.125 1 0.847 -0.248 -0.068 0.087 0.02 -0.016 -0.001 0.13 0.077 0.199 0.177 
6. Vaginal 
Irritation 0.143 0.178 0.093 -0.086 0.847 1 -0.218 -0.048 -0.013 -0.058 -0.046 -0.113 -0.045 -0.073 0.138 0.136 
7. Urinary 
Irritation 0.228 0.105 0.106 -0.063 -0.248 -0.218 1 0.523 0.146 0.175 -0.056 0.038 -0.257 -0.274 -0.086 -0.298 
8. Urinary 
Incontinence 0.304 0.239 0.276 0.218 -0.068 -0.048 0.523 1 0.265 0.331 0.099 0.127 -0.018 -0.119 -0.079 0.015 
9. Lower limb 
weakness 0.194 0.309 0.148 0.055 0.087 -0.013 0.146 0.265 1 0.548 0.454 -0.086 0.016 0.024 -0.092 0.044 
10. Difficulty in 
walking 0.287 0.313 0.472 0.321 0.02 -0.058 0.175 0.331 0.548 1 0.357 -0.017 0.241 0.224 0.017 0.055 
11. Lower limb 
numbness 0.179 0.013 0 -0.01 -0.016 -0.046 -0.056 0.099 0.454 0.357 1 0.023 -0.015 -0.035 0.22 0.359 
12. 
Pain/Discharge 
0.011 0.056 0.191 0.059 -0.001 -0.113 0.038 0.127 -0.086 -0.017 0.023 1 0.076 0.076 0.06 0.18 
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from wounds 
15. 
Embarrassment 
from urostomy -0.109 -0.02 0.145 0.368 0.13 -0.045 -0.257 -0.018 0.016 0.241 -0.015 0.076 1 0.857 0.18 0.164 
16. Dependent 
on others for 
caring for 
urostomy -0.029 -0.004 0.165 0.313 0.077 -0.073 -0.274 -0.119 0.024 0.224 -0.035 0.076 0.857 1 0.095 0.204 
18. 
Embarrassment 
from stoma 0.038 0.01 0.117 -0.057 0.199 0.138 -0.086 -0.079 -0.092 0.017 0.22 0.06 0.18 0.095 1 0.63 
19. Problems 
caring for stoma  -0.016 0.055 0.099 0.024 0.177 0.136 -0.298 0.015 0.044 0.055 0.359 0.18 0.164 0.204 0.63 1 
 
 
Table 8-5 Hypothesised Symptoms Scale Item Intercorrelation Matrix 
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8.3.2.2 Psychological Scale  
 
The hypothesised LRRC-QoL psychological scale consisted of two questions (LRRC-QoL 
items 20-21). The rate of missing data at item level was 2.5%.  The hypothesised 
psychological scale demonstrated good item internal consistency with a mean item 
intercorrelation value of 0.379 and equal item-to-total correlations (Table 8.4).  The item 
discriminant validity was good, with higher correlations observed between the items within 
the hypothesised psychological scale compared to the other scales (Table 8.3). However, there 
were two correlations of >0.4 between item 21 (physical attraction) and the Future 
Perspectives scale and between item 20 and the Symptoms scale, thus suggesting a degree of 
overlap between these concepts.  
 
8.3.2.3 Sexual Function Scale 
 
The hypothesised sexual function scale of the LRRC-QoL consisted of 4 questions, 2 of 
which were gender-specific for male patients. The rate of missing data at item level for this 
scale was 13.8-26.3%. Overall, the sexual function scale fulfilled the requirements of multi-
trait scaling analysis by demonstrating good item internal consistency, with a mean item 
intercorrelation value of 0.426 and equal item-to-total correlations (Table 8.4). The 
hypothesised sexual function scale demonstrated excellent item discriminant validity with low 
correlations (<0.4) between the items of the sexual function scale and the other hypothesised 
scales (Table 8.4). However, on inspecting the inter-item correlation matrix for the 
hypothesised sexual function scale it becomes apparent that not all the items within the scale 
correlate appropriately (Table 8.6). Item 22 (pain during sexual intercourse) failed to correlate 
with items 24 and 25 (erectile and ejaculatory function), thus suggesting, these items do not 
necessarily measure the same underlying construct. Consequently, the hypothesised sexual 
function scale can be further refined to ensure all the items within the scale have item 
intercorrelations of >0.3. This can be done by removing item 22, as this item did not correlate 
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with the other items within the scale. By doing this, it would ensure overall unidimensionality 
of the scale.   
Table 8-6 Item intercorrelation matrix for hypothesises Sexual Function Scale 
  22. Pain 23. Interest 24. Erectile function 25. Ejaculatory dysfunction 
22. Pain 1 0.573 0.236 0.178 
23. Interest 0.573 1 0.422 0.407 
24. Erectile function 0.236 0.422 1 0.743 
25. Ejaculatory dysfunction 0.178 0.407 0.743 1 
 
8.3.2.4 Future Perspective Scale  
 
The hypothesised future perspective scale of the LRRC-QoL consists of 3 questions (items 
26-28). The rate of missing data at item level for this scale was 2.5 – 5%. The hypothesised 
future perspective scale demonstrated good item internal consistency, with a mean item 
intercorrelation value of 0.644 (Table 8.7).  The scale also demonstrated equal item-to-total 
correlations (Table 8.4). However, the hypothesised scale failed to fulfill the item 
discriminant validity criterion for multitrait scaling, with items 27 and 28 also correlating 
with the psychological scale (Table 8.3). This suggests potential overlap in the measurement 
of underlying constructs of these items. Consequently, these items will have to be investigated 
further at exploratory factor analysis to determine whether these items measure the same 
underlying construct and whether they should be grouped within the same scale.  
 
Table 8-7 Item intercorrelation matrix for hypothesised Future Perspective Scale   
 
26. Results 27. Examinations and Tests 28. Uncertainty 
26. Results 1 0.624 0.632 
27. Examinations and Tests 0.624 1 0.676 
28. Uncertainty 0.632 0.676 1 
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8.3.2.5 Healthcare Services  
 
The hypothesised healthcare services scale of the LRRC-QoL consists of 4 questions. The 
rate of missing data at an item level was 5.0 – 6.3%. The scale demonstrated good item 
internal consistency, with a mean item intercorrelation value of 0.692 and equal item-to-total 
correlations (Table 8.4). The inter-item correlation matrix for the hypothesised healthcare 
services scale is outlined in Table 8.8. The hypothesised healthcare services and delivery 
demonstrated excellent item discriminant validity, with correlations of <0.40 with all the 
other hypothesised scales (Table 3).  
Table 8-8 Item intercorrelation matrix for hypothesised Healthcare Services Scale  
 
 
29. Information 30. Knowledge 31. Tests 32. Frequency of consultations 
29. Information 1 0.783 0.61 0.641 
30. Knowledge 0.783 1 0.639 0.715 
31. Tests 0.61 0.639 1 0.763 
32. Frequency of consultations 0.641 0.715 0.763 1 
 
8.3.2.6 Conclusions from Multitrait Scaling on Hypothesised Scales 
 
Multitrait scaling analysis on the hypothesised scales of the LRRC-QoL revealed a number of 
significant issues in terms of scale unidimensionality amongst the hypothesised scales of 
LRRC-QoL. The healthcare services scale was the only scale to fulfill all the scaling 
assumptions of multi-trait analysis and therefore establish scale unidimensionality. Analysis 
of the symptoms scale revealed poor item intercorrelations and inadequate item-to-total 
correlations, thus failing to establish the linearity of the underlying scale structure. Similarly, 
the sexual function scale failed to identify equal item intercorrelations, thus failing to 
demonstrate uniformity amongst the items of this scale. The psychological function and future 
perspective scales demonstrated items with poor item discriminant validity, with items within 
these scales correlating with each other, thus suggesting these items may measure overlapping 
or similar constructs. Due to the inconsistencies identified in the underlying scale structure of 
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the hypothesised scales, a pragmatic decision was made to conduct an exploratory factor 
analysis on all the items of the LRRC-QoL to identify any items which may cluster into scales 
that were not previously hypothesised. 
8.3.3 Scale Structure: Exploratory Factor Analysis  
 
Twenty-nine items were included in the exploratory factor analysis. The KMO measure of 
sampling adequacy was 0.552 and the Bartlett’s statistic was 1246, df=406, p<0.01. These 
statistics supported the suitability of the data for factor analysis despite a sample size of 80.  
Nine factors emerged with an eigenvalue of 1.00. This was also supported by the scree test 
criterion (Figure 8.1). These 9 factors accounted for 74.2% of the common variance. Table 
8.9 presents the factor loading of the 29 items. 
 
 
 
Figure 8-1 Scree plot of extracted number of factors based on Eigenvalue >1. 
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Table 8-9 Scales derived from Exploratory Factor Analysis  
LRRC-QoL Item Factor                 
  1 2 3 4 5 6 7 8 9 
30. Knowledge 0.884 0.127 -0.031 0.062 -0.028 -0.015 0.041 0.084 -0.111 
32. Frequency of consultations  0.883 -0.039 -0.016 0.013 0.058 0.112 0.1 0.031 0.081 
31. Tests 0.862 -0.005 -0.074 -0.059 0.081 0.038 0.044 -0.06 -0.026 
29. Information 0.843 0.078 0.041 0.076 0.028 0.048 -0.046 0.154 0.027 
28. Uncertainty 0.137 0.858 0.026 0.076 0.046 0.053 0.047 -0.019 0.114 
27. Examinations and Tests 0.055 0.847 0.045 0.041 -0.049 -0.121 -0.045 -0.05 -0.071 
26. Results 0.023 0.811 0.019 -0.023 -0.05 -0.068 0.021 -0.017 -0.079 
21. Attractiveness  -0.093 0.648 0.012 0.229 -0.061 0.073 0.291 0.016 0.195 
20. Dependence 0.007 0.422 0.116 0.391 0.193 0.357 -0.161 -0.262 0.154 
6. Vaginal Irritation  -0.069 0.15 0.898 0.127 -0.093 0.011 0.094 0.007 -0.161 
5.Vaginal Bleeding or discharge -0.007 0.049 0.89 -0.006 0.079 0.091 0.174 0.029 -0.149 
24. Erectile function 0.033 0.091 -0.685 -0.023 0.007 0.19 0.142 0.487 -0.071 
25. Ejaculatory dysfunction  -0.017 0.028 -0.67 0.072 0.002 0.105 0.215 0.432 -0.323 
3. Perianal/Buttock Pain 0.025 0.118 -0.017 0.792 0.17 0.049 0.152 0.149 0.104 
2. Back Pain 0.11 0.157 0.185 0.709 -0.076 0.157 -0.057 -0.023 0.015 
1. Abdominal Pain  -0.058 0.013 0.037 0.658 -0.17 0.179 0.029 -0.081 0.172 
4. Rectal Bleeding/Discharge 0.066 -0.031 -0.177 0.643 0.424 -0.094 -0.096 -0.224 -0.002 
15. Embarrassment from urostomy 0.06 -0.004 0.032 0.007 0.948 0.027 0.105 -0.018 -0.042 
16. Dependent on others for 
caring for urostomy  0.061 -0.067 -0.02 0.055 0.906 0.04 0.088 0.02 -0.141 
9. Lower limb weakness 0.102 -0.019 0.034 0.152 -0.006 0.802 -0.109 -0.184 0.122 
11. Lower limb numbness 0.115 -0.181 -0.109 0.007 -0.124 0.71 0.366 -0.147 -0.054 
10. Difficulty in walking -0.008 0.044 -0.041 0.393 0.299 0.686 -0.005 0.128 0.216 
18. Embarrassment from stoma 0.053 0.26 0.088 -0.069 0.079 0.023 0.823 -0.069 -0.008 
19. Problems caring for stoma  0.131 0.018 0.074 0.01 0.111 0.116 0.8 -0.137 -0.151 
12. Pain/Discharge from wounds -0.092 -0.207 -0.13 0.266 0.037 -0.275 0.44 0.052 0.146 
22. Pain during sexual intercourse 0.196 -0.141 0.014 0.089 0.027 -0.208 -0.162 0.79 0.096 
23. Interest in sex 0.048 -0.012 -0.333 -0.215 -0.054 -0.13 -0.141 0.719 -0.048 
7. Urinary Irritation -0.009 0.099 -0.159 0.05 -0.224 0.071 -0.11 0.177 0.83 
8. Urinary Incontinence -0.012 0 0.012 0.267 0.005 0.132 0.017 -0.153 0.792 
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The nine emerging factors were renamed as the following:  
Factor 1 – Healthcare Services 
Factor 2 – Psychological Impact 
Factor 3 – Sexual Function  * This is a gender specific factor – with two items specific to 
each gender.   
Factor 4- Pain and discomfort 
Factor 5 – Urostomy Related Symptoms 
Factor 6 – Lower limb symptoms 
Factor 7 – Stoma and wound related issues 
Factor 8 – Sexual Interest  
Factor 9 – Urinary Symptoms 
 
8.3.4 Scale Structure: Multitrait Scaling on Revised Scales 
 
Following the exploratory factor analysis eight new scales were identified. The only original 
scale to be retained was the Healthcare Services scale. Subsequently, further analyses were 
conducted on the 8 new scales using the principles of multi-trait scaling analysis. The multi-
trait, multi-item correlation matrix for the revised scales is presented in Table 8.10 and the 
item summary statistics are presented in Table 8.11. 
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 Table 8-10 Multi-trait/Multi-item Correlation Matrix for Revised Scales of LRRC-QoL  
 
Healthcare 
Services 
Psychological 
Impact 
Sexual 
Function 
Pain and 
Discomfort Urostomy 
Lower Limb 
Symptoms 
Stoma and 
Wound 
Sexual 
Interest 
Urinary 
Symptoms 
Healthcare Services 
29. Information 0.861 0.107 0.106 0.105 0.098 0.125 -0.006 0.153 0.043 
30. Knowledge 0.885 0.148 0.113 0.073 0.040 0.056 0.101 0.168 -0.084 
31. Tests 0.869 0.017 0.035 0.03 0.135 0.102 0.078 0.079 -0.053 
32. Frequency of consultations  0.892 0.021 0.05 0.081 0.107 0.202 0.123 0.103 0.047 
Psychological Impact 
26. Results 0.050 0.759 0.109 0.038 -0.083 -0.096 0.082 -0.066 0.011 
27. Examinations and Tests 0.074 0.825 0.022 0.087 -0.050 -0.130 0.054 -0.063 -0.010 
28. Uncertainty 0.159 0.850 0.065 0.198 0.018 0.044 0.137 -0.093 0.160 
20. Dependence 0.037 0.603 -0.178 0.437 0.159 0.377 -0.026 -0.280 0.202 
21. Attractiveness  -0.020 0.720 0.087 0.281 -0.049 0.110 0.271 -0.123 0.188 
Sexual Function  
 5.Vaginal Bleeding or discharge 0.004 0.092 0.844 0.060 0.095 0.024 0.163 -0.270 -0.183 
6. Vaginal Irritation  -0.068 0.203 0.844 0.178 -0.065 -0.063 0.067 -0.252 -0.154 
24. Erectile function 0.106 -0.003 0.739 -0.031 0.022 0.125 0.076 0.377 0.049 
25. Ejaculatory dysfunction  0.054 -0.053 0.739 0.010 0.070 0.089 0.157 0.337 -0.158 
Pain and Discomfort 
1. Abdominal Pain  -0.033 0.173 -0.033 0.658 -0.079 0.277 0.018 -0.137 0.304 
228 
2. Back Pain 0.106 0.279 -0.042 0.743 -0.014 0.257 0.049 -0.133 0.196 
3. Perianal/Buttock Pain 0.077 0.244 0.150 0.825 0.159 0.259 0.175 -0.027 0.218 
4. Rectal Bleeding/Discharge 0.069 0.090 -0.057 0.702 0.358 0.154 0.000 -0.109 0.086 
Urostomy 
15. Embarrassment from 
urostomy 0.106 0.022 0.035 0.139 0.976 0.103 0.197 -0.053 -0.159 
16. Dependent on others for 
caring for urostomy  0.109 -0.042 0.113 0.157 0.949 0.090 0.168 -0.041 -0.226 
Lower Limb Symptoms  
9. Lower limb weakness 0.128 0.089 -0.029 0.24 0.020 0.819 -0.061 -0.280 0.235 
10. Difficulty in walking 0.068 0.161 0.148 0.048 0.243 0.797 0.027 -0.077 0.289 
11. Lower limb numbness 0.139 -0.063 0.141 0.052 -0.024 0.774 0.286 -0.19 0.023 
Stoma and Wound  
12. Pain/Discharge from wounds -0.068 -0.089 0.127 0.116 0.079 -0.03 0.465 -0.001 0.094 
18. Embarrassment from stoma 0.089 0.255 0.133 0.041 0.15 0.071 0.846 -0.208 -0.094 
19. Problems caring for stoma  0.135 0.070 0.119 0.062 0.187 0.202 0.847 -0.192 -0.164 
Sexual Interest  
22. Pain 0.193 -0.162 0.21 0.04 -0.003 -0.198 -0.174 0.868 0.055 
23. Interest 0.066 -0.130 0.353 -0.253 -0.08 -0.201 -0.179 0.904 -0.061 
Urinary Symptoms  
7. Urinary Irritation -0.001 0.12 -0.018 0.122 -0.273 0.105 -0.164 0.117 0.876 
8. Urinary Incontinence -0.02 0.131 -0.234 0.349 -0.061 0.287 0.008 -0.134 0.869 
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Table 8-11 Item Summary Statistics for all Revised LRRC-QoL Scales 
 
 
Scale 
 
No of Items 
 
Mean Item 
Intercorrelation 
Item Discriminant 
Validity (Range of 
Scores) 
 
Item to Total 
Correlations 
Healthcare Services 4 0.692 -0.006 – 0.148 0.749 – 0.803 
Psychological Impact  5 0.456 -0.083 – 0.437 0.404 – 0.743 
Sexual Function  
Female 
Male 
 
2 
2 
 
0.844 
0.739 
 
-0.068 – 0.178 
-0.156 – 0.378 
 
0.847 
0.743 
Pain and Discomfort  4 0.384 -0.137 – 0.279 0.447 – 0.613 
Urostomy Related Symptoms 2 0.857 -0.226 – 0.197 0.857 
Lower Limb Symptoms 3 0.453 -0.280 – 0.289 0.458 – 0.607 
Stoma and Wound Related 
Issues 
3 0.290 -0.208 – 0.255 0.125 – 0.611 
Sexual Interest  2 0.573 -0.253 – 0.193 0.573 
Urinary Symptoms 2 0.523 -0.234 – 0.349 0.523 
 
8.3.4.1 Healthcare Services 
 
The healthcare services scale was unchanged from its initial hypothesised version, therefore 
all its original values for item intercorrelations and item-to-total correlations remain the same. 
The scale retains its item discriminant validity, with correlations of <0.4 with the other scales 
of the revised LRRC-QoL (Table 8.10). 
8.3.4.2 Psychological Impact 
 
The revised psychological impact scale consisted of 5 questions. The scale demonstrated good 
internal item consistency with a mean item intercorrelation value of 0.456 (Table 8.11). On 
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examining the item correlation matrix for the scale, item 20 (dependence) was found to have a 
low item intercorrelation value with item 26 (anxiety regarding results) (Table 8.12). Item 20 
regarding dependence was the only item within the psychological impact scale which did not 
demonstrate good item discriminate validity, as it correlated with the Pain and Discomfort 
scale (Table 8.10). All the other items within the scale displayed excellent correlations with 
the Psychological Impact scale and low correlations with the other scales. Item 20 had a lower 
item-to-total correlation score than the other items within the scale. All the other items within 
the scale had similar item-to-total correlations. As item 20 was consistently being highlighted 
as a problematic item within this scale, a pragmatic decision was made to remove this item 
from the scale.  
Table 8-12 Item intercorrelation matrix for new Psychological Impact Scale 
 
26. Results 
27. 
Examinations 
and Tests 28. Uncertainty 20. Dependence 21. Attractiveness 
26. Results 1 0.624 0.632 0.217 0.372 
27. Examinations 
and Tests 0.624 1 0.676 0.301 0.474 
28. Uncertainty 0.632 0.676 1 0.410 0.472 
20. Dependence 0.217 0.301 0.410 1 0.379 
21. Attractiveness  0.372 0.474 0.472 0.379 1 
 
8.3.4.3 Sexual Function  
 
The new sexual function scale consisted of 4 questions, which were gender specific. This 
scale was analysed individually for each gender. The mean item intercorrelation for the 
female sexual function scale was 0.844 and for the male sexual health was 0.739 (Table 8.11). 
The item discriminant validity overall was good for the scale (Table 8.10). The item-to-total 
correlations for all the items included in the scale exceeded 0.3 (Table 8.11).  
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8.3.4.4 Sexual Interest  
 
The revised sexual interest scale consisted of two questions. The scale demonstrated good 
item internal consistency with a mean item intercorrelation of 0.573 and equal item to total 
correlations (Table 8.11). The scale demonstrated good item discriminant validity with low 
correlations with the other scales (Table 8.10). 
 
8.3.4.5 Pain and Discomfort  
 
The new Pain and Discomfort scale consisted of 4 questions. The mean item intercorrelation 
was 0.384 (Table 8.11). On reviewing the item intercorrelation matrix for this scale item 4 
(rectal bleeding and discharge) had item intercorrelations of <0.3 with items 1 and 2 
(abdominal pain and back pain) (Table 8.13). Subsequently, an executive decision was made 
to remove the item from the scale and retain it as an individual item. Upon removing this item 
the mean item intercorrelation was 0.421, with item intercorrelations of >0.3 for all the 
remaining items within the scale. This scale was subsequently renamed as the pain scale.  
Table 8-13 Item intercorrelation matrix for new Pain and Discomfort Scale 
 
 
1. Abdominal 
Pain 2. Back Pain 
3. Perianal/ Buttock 
Pain 
4. Rectal Bleeding/ 
Discharge 
1. Abdominal Pain  1 0.381 0.378 0.288 
2. Back Pain 0.381 1 0.477 0.287 
3. Perianal/Buttock Pain 0.378 0.477 1 0.492 
4. Rectal 
Bleeding/Discharge 0.288 0.287 0.492 1 
 
8.3.4.6 Urostomy Related Symptoms  
 
The new Urostomy Related Symptoms scale consisted of 2 items. The scale fulfilled all the 
pre-requisite criteria of multi-trait scaling, with good item internal consistency with a mean 
item intercorrelation of 0.857 and equal item-to-total correlations (Table 8.11). Excellent item 
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discriminant validity was displayed with low correlations between the items of the urostomy 
related symptoms and the other scales within the LRRC-QoL (Table 8.10). However, the 
results for this scale must be interpreted with caution as only a total of 6 patients answered the 
items relevant to a urostomy.  
 
8.3.4.7 Lower Limb Symptoms  
 
The new Lower Limb Symptoms scale consisted of 3 items. The mean item intercorrelation 
was good at 0.453 (Table 8.11). The item intercorrelation matrix for the lower limb symptoms 
is presented in Table 8.14.  The scale demonstrated good item discriminant validity (Table 
8.10). The scale demonstrated equal item-to-total correlations (Table 8.11).  
Table 8-14 Item intercorrelation matrix for new Lower Limb Scale 
 
9. Lower limb 
weakness 
10. Difficulty in 
walking 
11. Lower limb 
numbness 
9. Lower limb 
weakness 1 0.548 0.454 
10. Difficulty in 
walking 0.548 1 0.357 
11. Lower limb 
numbness 0.454 0.357 1 
 
8.3.4.8 Stoma and Wound Related Issues  
 
The new stoma and wound related issues scale consisted of 3 items. The scale demonstrated 
poor item internal consistency with a mean item intercorrelation of 0.29 (Table 8.11). On 
examining the item intercorrelation matrix for this scale, item 12 (wound related pain and 
discharge) was identified as a problematic item (Table 8.15). Items 18 and 19 (embarrassment 
from stoma and problems caring for stoma) had good inter-item correlations of 0.63 (Table 
8.15). However, both items failed to correlate with item 12. Item 12 demonstrated a lower 
item-to-total correlation when compared to the other two items within the scale. Thus, 
suggesting non-linearity in the contribution of all the items to the overall scale score. 
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Consequently, a pragmatic decision was made to remove item 12 from the scale and retain 
this as an individual item within the framework of the LRRC-QoL. On removing item 12 the 
mean inter-item correlation was 0.788 and the item-to-total correlation was 0.630. 
Subsequently, this scale was renamed as the Stoma scale.  
Table 8-15 Inter-item correlation matrix for new Stoma and Wound Scale 
 
 
12. Pain/Discharge 
from wounds 
18. Embarrassment from 
stoma 
19. Problems caring 
for stoma 
12. Pain/Discharge from 
wounds 1 0.06 0.18 
18. Embarrassment from stoma 0.06 1 0.63 
19. Problems caring for stoma  0.18 0.63 1 
 
8.3.4.9 Urinary Symptoms  
 
The new urinary symptoms scale consisted of two items. The scale demonstrated good 
internal item consistency with a mean item intercorrelation was 0.523 and equal item to total 
correlations (Table 8.11). The item discriminant validity of the scale was excellent.  
 
8.3.5 LRRC-QoL Finalised Scale Structure  
 
Based on the combined results of the multitrait scaling analysis and the factor analysis the 
final scale structure of the LRRC-QoL was determined. The final scale structure consists of 
28 items organised into 9 scales and 2 individual items. The 9 scales were healthcare services, 
psychological impact, sexual function, pain, urostomy related symptoms, lower limb 
symptoms, sexual interest and urinary symptoms. Descriptive analyses for the finalised 
LRRC-QoL scales are presented in Table 8.16. The total computable score range for the 
finalised scales of the LRRC-QoL was 86.2 – 100%.  
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Table 8-16 Descriptive Analysis for Finalised LRRC-QoL Structure  
 
Scale Total No 
of Items 
in Scale  
Data 
Completeness 
(%) 
Possible 
Score 
Range* 
Observed 
Score Range 
Mean 
Score 
SD 
Healthcare Services 4 95.0 4 – 16 7 – 16 12.28 3.91 
Psychological Impact 5 97.5 5 – 20  5 - 20 11.15 3.56 
Sexual Function ** 
Female 
Male 
 
2 
2 
 
80.0 
86.7 
 
2 - 8 
2 – 8  
 
2 - 5 
2 - 8 
 
2.62 
4.60 
 
1.02 
3.02 
Pain  3 100 3 - 12 3 - 12 5.43 2.01 
Urostomy  2 100 2 – 8 2 – 5  3.16 1.16 
Lower Limb 3 100 2 - 12 2 - 12 5.41 2.14 
Stoma  2 98.7 2 – 8  2 – 8  3.07 1.26 
Sexual Interest 2 66.2 2 – 8  2 – 8  2.65 1.81 
Urinary Symptoms  2 95.0 2 – 8  2 – 8  3.15 1.34 
Item       
Rectal Bleeding/Discharge 1 98.8 1- 4 1 – 4 1.55 0.81 
Wound Pain/Discharge 1 98.8 1-4 1 – 3 1.44 0.69 
*The possible score range was calculated to reflect the response category of 1-4. ** This is a gender-specific scale 
and therefore only contains 2 items per gender. 
 
8.3.6 Scale Reliability 
 
Scale reliability of the LRRC-QoL was established using two different measures of reliability; 
including Cronbach’s Alpha to assess scale reliability and the intra-class correlation (ICC) 
using the test-retest method to assess temporal stability at a scalar level. The results of the 
reliability tests are outlined in Table 8.17. Overall, the LRRC-QoL demonstrated good 
reliability across both scores.  Cronbach’s Alpha values of >0.70 were fulfilled by the 
majority of the scales, except the pain and urinary symptoms scales. Temporal stability, using 
the test-retest measure, of the LRRC-QoL is good, with ICC values of >0.7. However, the 
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values obtained for both Cronbach’s Alpha and the ICC should be interpreted with caution as 
the majority of the values are associated with wide confidence intervals, thus suggesting the 
sample size is not sufficient to confirm the reliability of the LRRC-QoL. Therefore, the 
reliability of the LRRC-QoL will need to be confirmed within a larger sample.  
Table 8-17 Reliability scores of the LRRC-QoL  
 
Scale 
 
Cronbach’s Alpha          
(95% Confidence Intervals) 
 
ICC                                         
(95% Confidence Intervals) 
Healthcare Services  0.89 (0.84 – 0.92) 0.70 (0.53 – 0.81) 
Psychological Impact 0.80 (0.70 – 0.85)  0.76 (0.62 – 0.85) 
Sexual Function  
Male 
Female  
 
0.85 (0.76 – 0.90) 
0.91 (0.87 – 0.94) 
 
0.74 (0.62 – 0.82) 
0.85 (0.77 – 0.89) 
Pain  0.67 (0.52 – 0.78) 0.75 (0.57 – 0.85) 
Urostomy Related Symptoms 0.89 (0.82 – 0.92) 0.96 (0.94 – 0.97) 
Lower Limb Symptoms 0.70 (0.57 – 0.80) 0.82 (0.71 – 0.89) 
Stoma  0.76 (0.62 – 0.84) 0.85 (0.76 – 0.91)  
Sexual Interest  0.72 (0.56 – 0.82) 0.91 (0.85 – 0.94) 
Urinary Symptoms  0.68 (0.51 – 0.79) 0.71 (0.56 – 0.82) 
 
8.3.7 Scale Validity  
 
8.3.7.1 Construct Validity 
 
Construct validity of the LRRC-QoL can be assumed as the second round of multi-trait 
scaling analysis has produced 9 scales which measure the same underlying construct. The 
majority of the scales fulfilled the pre-requisite criteria of multi-trait scaling to establish 
unidimensionality and consequently, construct validity of each individual scale.  
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8.3.7.2 Convergent Validity 
  
Following the determination of the new scale structure of the LRRC-QoL based on the factor 
analysis and multi-trait scaling analysis a number of a priori hypotheses were made regarding 
convergent validity of the LRRC-QoL with the EORTC CR29 and FACT-C. 
 
The following hypotheses were made:  
• The LRRC-QoL psychological impact scale would correlate (r >0.45) with the 
EORTC CR29 body image scale and the FACT-C emotional well being scale.  
• The LRRC-QoL pain scale would correlate (r>0.45) with the FACT-C physical well 
being scale.  
• The LRRC-QoL stoma scale would correlate (r>0.45) with the EORTC frequency of 
defaecation scale.  
• The LRRC-QoL urinary symptoms scale would correlate (r>0.45) with the EORTC 
urinary frequency scale.  
• Lower correlations (<0.45) were hypothesised between the remaining LRRC-QoL, 
EORTC CR29 and FACT-C scales. 
 
The convergent validity of the LRRC-QoL and its scales were evaluated through correlational 
analyses using the Pearson’s product moment correlation (r) with the scales of the EORTC 
QLQ CR-29 and FACT-C questionnaires. Table 8.18 and 8.19 summarise the Pearson product 
moment correlations across the LRRC-QoL subscales and the EORTC CR29 and FACT-C 
scales respectively. Overall, positive correlations were moderate to high (r >0.45) in the 
hypothesised direction. As expected significant positive correlations were identified between 
the LRRC-QoL stoma scale and the EORTC frequency of defaecation scale, the LRRC-QoL 
pain scale and the FACT-C physical well-being scale and the LRRC-QoL psychological 
impact scale and the FACT-C emotional well-being scale. These identified correlations are 
statistically significant and underlie the same underlying measured themes, thus supporting 
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convergent validity. The hypothesised correlation between the LRRC-QoL urinary symptoms 
scale and with the EORTC urinary frequency scale was the only hypothesised correlation 
which failed to correlate, with a r value of -0.11, p=0.33.  
A number of interesting correlation patterns emerged between the LRRC-QoL and the 
EORTC CR29 and the FACT-C which were not hypothesised. Positive correlations between 
the LRRC-QoL pain scale and the EORTC CR29 blood and mucus in stool, the LRRC-QoL 
stoma scale and the EORTC CR29 urinary frequency scale and the EORTC body image scale, 
the LRRC-QoL lower limb symptoms scale and the FACT-C physical well being scale and 
the LRRC-QoL stoma and scale and the FACT-C physical well being scale were also 
revealed. This suggests there may be inconsistencies in the convergent validity for the LRRC-
QoL.  
 
8.3.7.3 Known-Groups Comparison  
 
A number of a priori hypotheses were made with regards to the known-groups comparison. It 
was hypothesised that the LRRC-QoL would be able to discriminate scores between clinically 
significant groups, including gender, presence of concurrent metastatic disease, recurrent 
disease location (central, anterior, lateral or posterior), treatment intention (curative versus 
palliative), pre-operative treatments (pre-operative treatment i.e. 
chemoradiation/radiotherapy/chemotherapy versus none), palliative treatments 
(chemoradiation, chemotherapy or surgery) and current disease status (recurrence versus 
recurrence and metastatic disease. Due to the small number of patients who were included in 
the LRRC-QoL with a urostomy (n=6), a pragmatic decision was made not to include the 
Urostomy-Related Symptoms scale in the known-groups comparison as it is unlikely to yield 
any meaningful results. Similarly, a pragmatic decision was made not to conduct any analyses 
for the palliative treatments group, due to the small number of patients undergoing palliative 
chemoradiation (n=4) and surgery (n=1). With regards to the current disease status clinical 
category a decision was made to combine the locally re-recurrent disease group and distant 
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disease recurrence group as a disease recurrence group and compare this to the disease-free 
group. The comparisons between LRRC-QoL scores and different clinical groups are outlined 
in Table 8.20 and 8.21.  
 
The LRRC-QoL was able to discriminate between some clinically relevant groups.  The 
sexual interest scale was able to demonstrate significant differences amongst men and 
women. The sexual function scale was able to demonstrate differences in obtained scores 
between patients treated with curative intent versus palliative intent.  The stoma scale was 
able to detect statistically significant differences between patients undergoing treatment with 
a curative intent compared to palliative intent.  
 
A number of clinically relevant trends emerged, which failed to fulfil statistical criteria 
between LRRC-QoL scores and clinical categories. The psychological impact scale revealed a 
trend towards higher LRRC-QoL scores in women and in patients with centrally and 
posteriorly located recurrent disease. The sexual function scale revealed a trend towards 
higher scores in patients undergoing no pre-operative treatment compared to those undergoing 
pre-operative treatment. The lower limb symptoms scale revealed a trend towards higher 
scores in centrally and anteriorly located recurrent disease and in patients with disease 
recurrence.  
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Table 8-18 Convergent validity between LRRC-QoL scales and EORTC CR29 scales 
LRRC-QoL Scale 
EORTC Scale  
Urinary Frequency  Blood/Mucus in Stool  Frequency of defaecation  Body Image 
r 
P 
Value 
 95%  CI 
r 
P 
Value 
95% CI 
r  
P 
Value 
95% CI 
r 
P 
Value 
95% CI 
Healthcare Services  0.205 0.07 -0.026 – 0.398 0.128 0.26 -0.085 - 0.341 0.078 0.50 -0.106 – 0.291 0.071 0.53 -0.124 – 0.272 
Psychological Impact 0.122 0.29 0.067 – 0.299 0.199 0.08 0.001 – 0.395 0.105 0.362 -0.076 – 0.365 0.481 0.01 0.270 -0.646 
Sexual Function  0.177 0.12 -0.070 - 0.418 0.118 0.30 -0.125 - 0.344 0.203 0.07 -0.052 – 0.440 0.315 0.005 0.063 – 0.522 
Pain  0.271 0.01 0.040 – 0.453 0.449 0.001 0.198 – 0.614 0.034 0.77 -0.199 - 0.235 0.364 0.01 0.141 – 0.541 
Urostomy Related 
Symptoms 0.317 0.01 
 
0.124 – 0.473 0.042 0.716 
 
-0.136 – 0.160 0.243 0.03 
 
0.011 – 0.408 0.101 0.38 
 
-0.004 – 0.201 
Lower Limb 
Symptoms 0.320 0.01 
 
0.096 – 0.486 0.204 0.075 
 
-0.022 - 0.41 0.086 0.45 
 
-0.153 – 0.280 0.212 0.06 
 
0.011 – 0.394 
Stoma  0.509 0.01 0.365 – 0.645 0.308 0.01 0.076 – 0.518 0.841 0.01 0.788 – 0.891 0.458 0.01 0.242 – 0.642 
Sexual Interest -0.204 0.07 -0.414 – 0.036 -0.123 0.28 -0.352 - .128 -0.256 0.02 -0.435 -  -0.044 -0.185 0.10 -0.388 – 0.027 
Urinary Symptoms  -0.088 0.44 -0.376 – 0.178 -0.115 0.31 -0.406 – 0.115 -0.195 0.09 -0.366 – 0.013 -0.175 0.12 -0.410 - 0.052 
r = Pearson’s product moment correlation coefficient  
 
 
 
240 
 
Table 8-19 Convergent validity between LRRC-QoL scales and FACT-C scales 
 
 
LRRC-QoL Scale 
FACT-C Scale 
Physical Well-Being 
 
Social Well Being 
 Emotional Well Being Functional Well Being Colorectal Scale 
r 
P 
Value 
95% CI 
r 
P 
Value 
95% CI 
r 
P 
Value 
95% CI 
r 
P 
Value 
95% CI 
r 
P 
Value 
95% CI 
Healthcare Services 0.157 0.19 -0.081 – 0.332 0.062 0.61 -0.170 – 0.327 -0.012 0.92 -0.223 – 0.180 0.012 0.92 -0.230 – 0.304 0.069 0.56 -0.170 – 0.327 
Psychological Impact 0.266 0.02 0.014 - 0.473 0.027 0.82 -0.193 – 0.237 0.476 0.001 0.246 – 0.655 0.098 0.41 -0.15 -0.328  0.152 0.21 -0.073 – 0.352 
Sexual Function  0.140 0.24 -0.121- 0.402 0.184 0.12 -0.066 – 0.415 0.192 0.112 -0.053 - 0.423 0.257 0.03 0.018 – 0.480 0.235 0.05 -0.009 – 0.459 
Pain  0.495 0.001 0.232 – 0.696 0.005 0.97 -0.215 – 0.218 0.268 0.01 0.029 – 0.479 -0.196 0.10 -0.388 – 0.007 0.017 0.89 -0.199 – 0.231 
Urostomy Related 
Symptoms 0.240 0.04 
 
0.079 – 0.401 0.137 0.25 
 
0.027 – 0.258 0.199 0.09 
 
0.002 - 0.363 0.076 0.53 
 
-0.077 – 0.275 0.143 0.23 
 
-0.019 – 0.336 
Lower Limb Symptoms 0.417 0.001 0.193 – 0.613 0.163 0.17 -0.050 – 0.352 0.142 0.24 -0.147 – 0.290 -0.039 0.74 -0.262  - 0.169 0.089 0.47 -0.147 - 0.290 
Stoma  0.395 0.001 0.166 – 0.589 0.342 0.01 0.163 – 0.537 0.363 0.01 0.135 – 0.578 0.360 0.01 0.189 – 0.557 0.415 0.01 0.250 – 0.566 
Sexual Interest  -0.316 0.01 -0.494 - -0.108 -0.156 0.19 -0.41 – 0.086 -0.177 0.14 -0.41 – 0.086 -0.061 0.61 -0.315 – 0.171 -0.115 0.34 -0.375 – 0.138 
Urinary Symptoms -0.088 0.46 -0.344 - 0.147 -0.346 0.003 -0.581 - -0.104 -0.211 0.08 -0.439 – 0.019 -0.366 0.002 -0.583 -  -0.109 -0.371 0.002 -0.555 - -0.159 
r = Pearson’s product moment correlation coefficient  
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Table 8-20 Known Groups Comparison for LRRC-QoL   
Scale Healthcare Services Psychological Impact Sexual Function  Pain and Discomfort 
Groups N Mean SD P Value N Mean SD 
P 
Value N Mean SD 
P 
Value N Mean SD 
P 
Value 
Gender 
 
  
 
0.48 
 
   0.06 
 
       0.30 
 
Male 60 12.47 3.64 60 10.40 3.74 60 - - - 60 5.23 1.97 
Female 20 11.75 4.70 20 12.20 3.81 20 - - 
 
20 5.78 2.22 
Presence of Concurrent Metastatic Disease 
 
  0.93    0.64 
 
       0.99 
 
No 46 12.22 4.25 46 10.87 3.64 46 3.72 2.82 0.43 46 5.33 2.04 
Yes 11 12.09 4.57 11 11.45 4.16 11 3.00 2.19 
 
11 5.30 2.11 
Recurrent Disease Location 
 
  
0.71 
   
0.07 
 
 
   
0.55 
 
   
0.28 
 
 
Central  22 12.77 4.57 22 10.95 3.84 22 3.73 2.68 22 5.86 2.60 
Anterior 5 13.20 2.77 5 9.20 2.28 5 5.00 2.24 5 5.20 1.64 
Lateral 19 11.53 3.82 19 10.11 3.45 19 3.11 2.77 19 4.61 1.33 
Posterior  12 11.58 4.94 12 13.25 3.55 12 3.33 2.84 12 5.41 1.62 
Treatment Intent 
 
  0.49    0.46 
 
   0.01 
 
   0.65 
 
Curative 37 12.43 4.45 37 11.27 3.11 37 4.22 2.94 37 5.40 2.03 
Palliative 21 11.67 3.90 21 10.52 4.58 21 2.38 1.69 21 5.15 2.03 
Pre-operative Treatments 
 
  0.60    0.99 
 
   0.08 
 
   0.72 
 
None 9 11.89 4.83 9 11.56 3.28 9 6.00 3.16 9 5.22 2.33 
Pre-operative Treatment  22 12.86 3.90 22 11.54 2.92 22 4.00 2.70 22 5.54 2.10 
Current Disease Status 
 
  0.31    0.43 
 
   0.09 
 
   0.11 
 
Disease Free 22 11.36 5.23 22 11.32 3.41 22 4.59 2.77 22 4.86 1.83 
 Disease Recurrence 15 12.86 2.77 15 12.26 3.65 15 3.00 2.67 15 5.86 1.84 
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Table 8-21 Known Groups Comparison for LRRC-QoL 
Scale Lower Limb Symptoms Stoma  Sexual Interest  Urinary Symptoms 
Groups N Mean SD P Value N Mean SD P Value N Mean SD P Value N Mean SD P Value 
Gender 
   0.90 
 
   0.44 
 
   0.01 
 
   0.50 
 
Male 60 5.38 2.27 60 2.9 1.86 60 2.91 1.81 60 3.1 1.50 
Female 20 5.45 1.87 20 3.3 2.38 20 1.85 1.63 20 2.9 1.02 
Presence of Concurrent 
Metastatic Disease 
   0.41 
 
   0.15 
 
   0.90 
 
   0.24 
 
No 46 5.32 2.04 46 3.15 2.01 46 2.56 1.64 46 3.47 1.53 
Yes 11 5.90 2.34 11 2.18 1.99 11 2.63 2.50 11 2.90 1.04 
Recurrent Disease Location 
   
0.06 
 
   
0.87 
 
   
0.29 
 
   
0.06 
 
Central  22 6 2.50 22 2.81 2.17 22 3 1.90 22 3.81 1.65 
Anterior  5 7.2 2.38 5 2.4 1.34 5 1.8 1.30 5 3.2 1.10 
Lateral  19 4.94 1.61 19 3 1.94 19 2.05 1.68 19 2.68 0.75 
Posterior  12 4.75 1.48 12 3.25 2.26 12 2.75 2.01 12 3.66 1.72 
Treatment Intent 
   0.27 
 
   0.01 
 
   0.39 
 
   0.76 
 
Curative 37 5.72 2.46 37 3.40 2.00 37 2.70 1.63 37 3.40 1.24 
Palliative 21 5.09 1.30 21 2.09 1.81 21 2.23 2.14 21 3.28 1.79 
Pre-operative Treatments 
   0.74 
 
   0.64 
 
   0.74 
 
   0.72 
 
None 9 5.22 2.94 9 3.55 1.33 9 2.44 1.94 9 3.11 1.05 
Pre-operative treatment  22 5.59 2.44 22 3.95 2.10 22 2.68 1.46 22 3.27 1.27 
Current Disease Status 
   0.09 
 
   0.69 
 
   0.08 
 
   0.56 
 
Disease Free 22 5.09 2.07 22 3.41 2.20 22 3.00 1.60 22 3.36 1.22 
Disease Recurrence 15 6.33 2.22 15 3.13 2.03 15 2.00 1.73 15 3.66 1.71 
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8.3.8 Sample Size Justification  
 
This study reports the results of an interim analysis conducted on British patients completing the 
LRRC-QoL. To mitigate the effects of having a smaller sample size and to examine whether the 
obtained results were justified and valid a number of key aspects of the analysis were further 
examined including key components of the exploratory factor analysis and confidence intervals for 
Cronbach’s Alpha, Intraclass Correlation and Pearsons product moment correlation coefficient.  
 
The communality of variables, degree of overdetermination and size of the factor loadings were 
examined for the LRRC-QoL to ensure that the scale structure had been appropriately determined by 
exploratory factor analysis. The communalities of the individual items are outlined in Table 8.22. 
Only two items (item 1 and 12) failed to meet the baseline criterion of an item communality value of 
>0.6. However, the mean overall item communality value was 0.74, which meets the minimum 
criteria of a mean overall value of >0.70.   
 
The extracted factors are outlined in Table 8.9. The factors extracted by the exploratory factor 
analysis were highly overdetermined with 4 of the 9 factors (healthcare services, sexual function, pain 
and discomfort, lower limb symptoms) consisting of more than 3 variables with high factor loadings. 
Three factors consisted of two variables (urostomy-related symptoms, sexual interest and urinary 
symptoms) however these variables had high factor loadings >0.7.  Two of the nine factors extracted 
(psychological function and stoma and wound related issues) consisted of one variable with a lower 
factor loading. Both of the variables in these factors (items 20 and items 12) were noted to be 
problematic at subsequent multitrait scaling analysis and were appropriately removed. Overall, the 
factor loadings of the variables onto the factors were high for the majority with few crossloadings of 
variables. Based on the overall communality of the variables, the degree of overdetermination and the 
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size of the factor loadings, the sample size employed in this analysis was adequate to determine the 
scale structure of the LRRC-QoL using the principles of exploratory factor analysis.  
Table 8-22 Communalities of LRRC-QoL Items 
Item  Communalities  
1. Abdominal Pain  0.536 
2. Back Pain 0.608 
3. Perianal/Buttock Pain 0.73 
4. Rectal Bleeding/Discharge 0.698 
5.Vaginal Bleeding or discharge 0.863 
6. Vaginal Irritation  0.893 
7. Urinary Irritation 0.825 
8. Urinary Incontinence 0.739 
9. Lower limb weakness 0.74 
10. Difficulty in walking 0.78 
11. Lower limb numbness 0.736 
12. Pain/Discharge from wounds 0.433 
15. Embarrassment from urostomy 0.918 
16. Dependent on others for caring for urostomy  0.862 
18. Embarrassment from stoma 0.772 
19. Problems caring for stoma  0.731 
20. Dependence 0.627 
21. Attractiveness  0.614 
22. Pain 0.77 
23. Interest 0.718 
24. Erectile function 0.777 
25. Ejaculatory dysfunction  0.803 
26. Results 0.673 
27. Examinations and Tests 0.751 
28. Uncertainty 0.782 
29. Information 0.753 
30. Knowledge 0.824 
31. Tests 0.767 
32. Frequency of consultations  0.815 
 
The reliability scores of the LRRC-QoL using Cronbach’s Alpha and Intraclass correlation and the 
associated confidence intervals are outlined in Table 17. For the Cronbach’s Alpha values the 
confidence intervals for the majority of the scales were wide. The confidence intervals for the 
Cronbach’s alpha values for the pain, stoma, lower limb symptoms, sexual interest and urinary 
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symptoms scales were wider than for the other scales. For the IntraClass correlation values the 
majority of the confidence values were of acceptable widths. The confidence intervals for the 
healthcare services, pain and urinary symptoms scales are wider than for the other scales. The scores 
for the Pearson’s product moment correlation values for the convergent validity are highlighted in 
Table 18 and 19. Overall, the confidence intervals are wide for the majority of the obtained values.  
Based on the size of the confidence intervals for reliability, the sample size of the LRRC-QoL is 
adequate. However, this is not applicable when assessing validity using Pearson’s product moment 
correlation coefficient. The width of the confidence intervals seen for the Pearson’s correlation 
coefficients are too wide for any meaningful interpretation of the obtained value, thus suggesting the 
sample study is underpowered and inadequate. Therefore, both the reliability and validity of the 
LRRC-QoL will have to be re-assessed in a larger sample size.  
 
8.4 Discussion  
 
Phase III of the LRRC-QoL project adapts and validates the measure for use in British patients with 
LRRC in a step-wise and methodical fashion.  The hypothesised scales of the LRRC-QoL failed to 
fulfil the principles of multitrait analysis during the first round of testing, with significant issues 
identified in four out of the five hypothesised scales. Subsequently, exploratory factor analysis was 
employed to identify the scale structure of the LRRC-QoL, this identified 9 scales, which performed 
well on subsequent multitrait scaling analysis. The final version of the LRRC-QoL for use in the UK 
consists of 28 items and 2 skip questions organised into 9 scales and 2 individual item.   
 
Employing a pre-specified, multi-step process ensured we developed a questionnaire which was 
reliable and valid in this group of patients.  The first step of data analysis ensured a well-balanced 
questionnaire was created with no ceiling or floor effects. This led to the removal of Item 14 
(problems regarding the care of a urostomy) during the initial analysis phase. Using the principles of 
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multitrait scaling analysis the scale structure of the hypothesised LRRC-QoL revealed a number of 
inconsistencies within the proposed structure of the questionnaire and did not support the concept of 
unidimensionality.  This was further confirmed through the use of factor analysis, which reproduced 
only one of the five hypothesised scales and produced eight new scales. Factor analysis split up the 
relatively big, hypothesised symptoms scale and separated it out into a more functional and logical 
systems based approach, by clustering items regarding the similar biological systems together. 
Overall, all of the newly proposed scales by factor analysis were logical and largely fulfilled the pre-
requisite criteria of multitrait scaling. However, the new Stoma and Wound and the Pain and 
Discomfort scales were the only two new scales not to fulfil the principles of multitrait scaling 
analysis with Item 12 within the Stoma scale and Item 4 within the Pain scale not displaying 
uniformity when compared to the other items within the scale. Subsequently, these items were 
removed from these scales. Using this combined method of multitrait analysis and factor analysis 
ensured the same underlying construct was measured by each defined scale through multiple rounds 
of testing, thus contributing to the overall robustness of the structure of the LRRC-QoL and providing 
evidence for the construct validity of the questionnaire.  
 
The LRRC-QoL demonstrated excellent temporal and scale reliability, high ICC and Cronbach’s 
Alpha values of >0.70 for the majority of the scales. The internal consistency, using the internal item 
consistency (item intercorrelations) and Cronbach’s Alpha provides further evidence for scale 
structure, by providing a further measure of homogeneity amongst the items of each scale. The ICC 
values confirm the ability of the LRRC-QoL to produce highly reproducible scores on repeated 
applications. However, given the associated size of the confidence intervals observed with these 
values, these results must be interpreted with caution and must reproduced within a larger sample size.  
 
The convergent validity of the LRRC-QoL was relatively good, with the majority of a priori 
hypotheses correctly confirmed, with moderate to high correlations demonstrated between the LRRC-
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QoL, the FACT-C and the EORTC CR29 questionnaires. This provides supporting evidence that the 
LRRC-QoL scales measure what they purport to measure. The obvious limitation in demonstrating 
the convergent validity of the LRRC-QoL was the exclusion of the use of the core EORTC QLQ-C30 
measure. This was due to an oversight on the principal investigators part in the first round of 
dispatching the questionnaires and as recruitment had already commenced by the time this was 
realised, a pragmatic decision was made to continue the study without using the EORTC QLQ-C30 
for validation purposes. Consequently, further work is required to provide further evidence for the 
convergence validity using the EORTC QLQ-C30, as well as demonstrating whether the LRRC-QoL 
can be used in conjunction with this measure. Future works should include examining a number of 
hypothetical correlations between these two measures including the following:  
• The LRRC-QoL psychological scale would correlate (r>0.45) with the EORTC QLQ-C30 
emotional scale.  
• The LRRC-QoL pain scale would correlate (r>0.45) with the EORTC QLQ-C30 pain scale.  
• The LRCC-QoL lower limb scale would correlate (r>0.45) with the EORTC QLQ-C30 
physical function scale.  
 
A further limitation of the convergence validity is the number of significant correlations that were 
revealed between the LRRC-QoL and the FACT-C and EORTC questionnaires, which were not 
previously hypothesised. A total of 5 such correlations were made, which did not make logical sense, 
this may be due to the multiple comparisons made between the LRRC-QoL, FACT-C and EORTC 
CR29 questionnaires. Consequently, further work is required regarding establishing the convergence 
validity of the LRRC-QoL. This should be carried out in an independent sample.  
 
The evidence for the known groups comparison validity of the LRRC-QoL is conflicting. Although 
the LRRC-QoL was able to discriminate scores between some clinically relevant groups of patients, 
its overall ability to demonstrate any meaningful data is limited by its relatively small sample size, 
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which is demonstrated by the few statistically significant differences observed. This is further 
compounded by the variable rate of missing data regarding a number of clinical domains, which limits 
the available sample size further. To confirm the known groups comparison validity further work is 
required in a much larger sample size.  
 
The psychometric evaluation of the LRRC-QoL was based on the traditional methods of CTT. CTT 
has been widely used in the development and validation of a number of colorectal PROMs which are 
in use in current clinical and academic practice, including FACT-C [143] and EORTC QLQ-CR29 
[285]. CTT has a number of advantages including the ease with which its methods are relatively 
traceable through the application of statistical and mathematical modelling which can be checked 
against existing criteria [366]. Furthermore, the sample sizes required to run the statistical tests 
associated with CTT do not require large numbers [367] and are therefore ideal in relatively rare 
disease states such as LRRC. A further advantage of CTT is that the underlying model is ideal for 
multi-scale instruments whereby each scale measures the same underlying construct, with each item 
equally contributing to the overall scale score, which is ideally suited for the design of the LRRC-
QoL. However, the CTT model does not require individual items to be optimal, items that relate 
modestly to the underlying variable can be used within a scale if there are a number of items which 
contribute to the same underlying variable. This was apparent in the initial Stoma and Wound care 
scale and Pain and Discomfort scales, which were formulated using the principals of factor analysis. 
Although, the items within these scales all loaded onto the same factor, these items failed to correlate 
at repeat multi-trait scaling analysis, and were therefore removed.  
 
Despite the popularity of CTT in developing PROMS, it has a number of limitations, including the 
lack of precision within the model; scales can often be long and the items can be very similar in 
nature. This is as a consequence of requiring to develop items which correlate with one another i.e. 
high inter-item correlations which can potentially lead to superficial similarities between items as 
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opposed to a true correlation reflecting the same underlying construct. For example, irrelevant item 
characteristics such as grammatical structure may be common across items. This leads to the true 
score of the scale reflecting all the characteristics of the items, including the combination of the true 
variable of interest and the superficial commonalities, without being able to accurately differentiate 
between the two. Furthermore, CTT does not rigorously scrutinise item characteristics, which can be a 
potential shortcoming. Although, this is a generic criticism of CTT methods, this was not applicable 
to the LRRC-QoL. The majority of the items within the scales of the LRRC-QoL measured different 
aspects of the same underlying construct, inter-item correlations did not represent superficial 
commonalities and there was no repetition of items within scales.  
 
CTT assumes that the measurement of random error (E) is normally distributed and identical for all 
scores and is therefore assumed to have a constant value regardless of the participants’ location on the 
range of the scale. This leads to CTT based scales being potentially prone to differential sensitivity at 
the centre relative to the extremes of the score range, which translates as differences in scores at the 
centre of a range may represent a smaller true score difference than at the extremes [366].  
 
CTT produces parameters that are dependent on the sample studied [366, 368]. This can yield 
conflicting results and impact on the measurement performance of the PROM based on its study 
sample. This means different population samples with different variances will potentially not yield 
equivalent data or data that is easily comparable across samples. This study attempts to overcome this 
limitation of CTT by studying patients with LRRC across a number of centres. 
 
The overarching limitation of this study is the relatively small sample size of the patient population, 
with only 80 patients included in this subset analysis of British patients. The patient and clinical 
demographics may not be reflective of the spectrum of patients undergoing assessment and treatment 
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of LRRC, as a greater proportion of male patients and those treated with curative intent participated in 
the study. This is potentially reflected in the study results, with the known groups comparison, 
identifying significant relationships between gender and sexual function scale and treatment intent 
and stoma scale. Furthermore, the relatively small sample size can have lead to the generation of a 
number of type II statistical errors, as was evident when trying to determine correlational relationships 
between the LRRC-QoL and the EORTC CR29 and FACT-C scales, in an attempt to establish 
convergence validity.  
 
A number of strategies were employed to mitigate the effects of a small sample size, including 
examining key aspects of the exploratory factor analysis and examining the confidence intervals for 
measures of reliability and validity. On assessing the communality of variables, degree of 
overdetermination and size of the factor loadings derived from the exploratory factor analysis, the 
values extracted for the LRRC-QoL highlighted the underlying strength of the data, which were 
adequate for determining the scale structure of the LRRC-QoL using the existing sample size of 80 
patients.  
 
The observed values derived from the measures of Cronbach’s Alpha and ICC fulfilled the pre-
requisite criteria for establishing the reliability of the LRRC-QoL. However, on assessing the 
precision of these observed values using confidence intervals revealed a number of observed values 
with wide confidence intervals. The precision of the observed value is therefore questionable, this is 
most likely due to the underlying sample size of the study. Providing the confidence intervals 
alongside the observed values for Cronbach’s Alpha and ICC values provides a more accurate 
reflection of the overall reliability of the LRRC-QoL. On applying the same principles of assessing 
the confidence intervals for the Pearson’s product correlation coefficient, the size of the confidence 
intervals were wide for the majority of observed values, with a significant proportion of the 
confidence values crossing the 0 value. Overall, the sample size used in this study to determine the 
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reliability of the LRRC-QoL was adequate, however further evidence for reliability could be provided 
by replicating this in a larger sample size to ensure precision of the observed value and to provide 
further robust evidence. The sample size used in this study to determine the validity of the LRRC-
QoL was inadequate, small sample sizes are associated with wide confidence intervals, with reduces 
the precision of the observed value. The validity of the LRRC-QoL needs to be determined within a 
larger subset of patients demonstrating statistically significant Pearson’s product moment correlations 
with narrow confidence intervals.  
 
8.5 Conclusions 
 
The proposed scale structure of the LRRC-QoL did not fulfil the principles of multi-trait scaling 
analysis and required further testing using exploratory factor analysis. This led to the extraction of 9 
factors which performed well at subsequent multitrait scaling analysis, thus confirming the scale 
structure of the LRRC-QoL. The item, scale and temporal reliability of the LRRC-QoL is good, 
however, needs to be confirmed within a larger sample size.  This study failed to establish the 
construct and convergence validity of the measure. Thus, further work is required to establish this 
within a larger sample size of patients. It is hope the combined analysis of the British and Australian 
cohorts will overcome some of the limitations discussed in this chapter.  
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9 Chapter 9 – General Discussion  
 
9.1 Overview 
 
The aims of this thesis were to establish the impact of LRRC on HrQoL with the specific aim to 
develop a LRRC specific PROM for use in clinical practice and research. This project was designed 
as a multicentre, international, three phase mixed methodological project. Phase I developed a 
conceptual framework utilising qualitative and quantitative data, Phase II focussed on design and pre-
testing of the LRRC-QoL and the final Phase III evaluated the psychometric properties of the outcome 
measure.  
 
9.1.1 Phase I: Development of a Conceptual Framework 
 
Phase I established a conceptual framework using data from two systematic reviews examining 
HrQoL outcomes in LRRC (Chapter 2) and pelvic exenteration (Chapter 3) and patient testimony 
through focus groups and expert panel review (Chapter 4). This conceptual framework underpins the 
LRRC-QoL and consists of 6 domains and 21 sub-domains including symptoms, sexual function, 
psychological impact, role functioning, future perspective and healthcare services. To ensure the 
clinical relevance of the LRRC-QoL, domains and subdomains of the LRRC-QoL were compared 
with 9 existing validated PROMs in primary rectal cancer. There was little overlap between the 
LRRC-QoL and current existing measures, with 5.5-38.8% of the LRRC-QoL domains covered by the 
existing measures. This provided evidence for the requirement of a LRRC-specific PROM given the 
inadequacy of existing PROMS for primary colorectal cancer in capturing themes relevant to this 
patient population group.  
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9.1.2 Phase II: Development and Pre-testing of the LRRC-QoL 
 
The LRRC-QoL was designed in keeping with the principles of the development of the EORTC 
questionnaires with the intention to use the LRRC-QoL as a supplementary module to the EORTC 
QLQ-C30. Using the EORTC item bank and a modified Delphi exercise, 39 items were 
operationalised into 6 scales of Symptoms, Psychological Impact, Role Function, Sexual Function, 
Future Perspective and Healthcare Services. This provisional questionnaire was pre-tested using 
cognitive interviews in 32 patients. This identified 16 items as being problematic by the British and 
Australian cohort due to issues with clarity, assumptions and other problems. The LRRC-QoL was 
modified to correct these issues. The final version of the LRRC-QoL consisted of 32 questions 
organised into 5 hypothesised scales; Symptoms, Sexual Function, Psychological Impact, Future 
Perspective and Healthcare Services. 
 
9.1.3 Phase III: Psychometric Analysis  
 
The LRRC-QoL was validated for use in British patients with LRRC, in an initial sample size of 80 
patients (with ongoing data collection in Australia). Initial multi-trait scaling on the hypothesised 
scale structure of the LRRC-QoL failed to meet the principles of unidimensionality and therefore 
exploratory factor analysis was performed to identify a potential new scale structure. Exploratory 
factor analysis retained only 1 original scale (Healthcare Services) and identified 8 new scales 
(Psychological Impact, Sexual Function, Sexual Interest, Pain and Discomfort, Urostomy-Related 
Symptoms, Lower Limb Symptoms, Stoma and Wound Related Issues, Urinary Symptoms). Further 
multi-trait scaling analysis confirmed the unidimensionality of 6 of these 8 scales, with revision of 2 
scales (Pain and Discomfort and Stoma and Wound Related Issues).  
 
The reliability of the LRRC-QoL was assessed at a scalar and temporal level using the measures of 
Cronbach’s Alpha and the Intra-class correlation. Cronbach’s Alpha values of >0.70 were fulfilled by 
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the majority of the scales, except the pain and urinary symptoms scales. Temporal stability, using the 
test-retest measure, of the LRRC-QoL is good, with ICC values of >0.7. However, the confidence 
intervals were wide for the majority of obtained values due to the small sample size. 
 
The LRRC-QoL demonstrated good construct validity as all the scales were unidimensional in 
measuring the same underlying construct with no overlapping measurement of constructs with the 
other scales, as determined by the second round of multitrait scaling analysis. The LRRC-QoL 
displayed reasonably good convergence validity, with 80% of the a priori hypotheses between the 
LRRC-QoL scales and the FACT-C and EORTC CR29 scales fulfilled. However, a number of 
correlations were seen that were not previously hypothesised. The evidence for known-groups 
comparisons is limited, with the LRRC-QoL being able to discriminate scores between a few 
clinically relevant categories, including gender and treatment intent.  However, the LRRC-QoL failed 
to discriminate scores in the following clinical categories; presence of concurrent metastatic disease, 
recurrent disease location, pre-operative treatments and current disease status.  
 
9.2 Methodological Strengths and Limitations  
 
9.2.1 Phase I 
 
The conceptual framework of the LRRC-QoL was developed using a variety of sources including 
current published literature, peer-reviewed papers, conference abstracts, unpublished grey literature, 
patient testimony and expert opinion. This ensured the developed conceptual framework appropriately 
reflected the perspectives of the LRRC population through inclusion of all potential published 
sources, thus ensuring the overall content validity of the measure. This is crucial to the future 
application of the PROM ensuring the concept of interest is truly being measured and subsequently 
ensuring the results captured are applicable and of value [369].  
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LRRC encapsulates a heterogeneous population with a variable nature of disease recurrence, both 
with regards to pelvic recurrence and extra-pelvic disease, which is reflected in the wide range of 
available treatment options including operative and oncological. To ensure the LRRC-QoL is 
representative and applicable to all patients with LRRC no exclusions were made to the inclusion 
criterion for the systematic reviews or the qualitative study with respect to clinical variables. We were 
unable to secure ethical approval for including patients who had undergone non-surgical palliation of 
their LRRC for this phase. This was due to the ethics committee being concerned about the potential 
psychological burden of participating in a focus group study for patients with end stage, palliative 
LRRC.  There was, however, some representation of this patient population in the systematic review 
of HrQoL outcomes in LRRC (Chapter 2), as 9% of patients included underwent palliative 
chemotherapy +/- radiotherapy or best supportive treatment for LRRC. By ensuring appropriate 
inclusion of all patients with LRRC and reflecting all opinions ensures the future usability of our 
PROM by ensuring it possesses content validity.  
 
However, there are some limitations to the work conducted in Phase I. The development of the 
conceptual framework is potentially limited by the quality and quantity of the current evidence base 
reporting HrQoL outcomes in patients with LRRC. A number of methodological limitations were 
common across studies included in both reviews, which included retrospective data collection, mixed 
disease populations, sampling and responder bias, long lag periods between diagnosis and/or 
treatment and collection of HrQoL data, lack of baseline data and the lack of use of validated 
measures. These limitations have obvious implications on understanding the reporting and evaluation 
of PROs and HrQoL in this complex disease group and further limits the understanding of the impact 
of LRRC on HrQoL. More importantly, these methodological limitations may have impacted upon the 
themes extracted, which may have potentially led to inadequacies within the conceptual framework.  
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Extracting PROs for patients with LRRC alone from the current evidence base was extremely difficult 
as the majority of studies included mixed study populations, including reporting outcomes in locally 
advanced primary rectal cancer, gynaecological and urological malignancy, without reporting of 
outcomes for individual cancer groups. A more purist approach to data extraction and development of 
relevant themes would have been to include studies which exclusively reported PROs in patients with 
LRRC. However, this would have limited the data collection and the subsequent generation of 
relevant themes, as only three studies would have been eligible for inclusion.  Consequently, a more 
inclusive approach was adopted including all patients with advanced pelvic malignancies, requiring a 
pelvic exenteration. Despite there being considerable overlap between the themes extracted between 
the two reviews, it is important to note, the majority of participants in both reviews did not have 
LRRC, with only 52.9%  (n = 501 patients) with LRRC in the first review (Chapter 2) and 3.4% (n = 
20 patients) in the pelvic exenteration review (Chapter 3). As well as identifying a broad range of 
disease pathology within these two reviews, patients underwent a range of treatments, including 
surgery, radiotherapy, chemotherapy and IORT with various treatment goals. Ten of the studies 
outlining HrQoL outcomes in LRRC documented treatment strategies, with a total of 403 (80.4%) 
patients included in this review undergoing some form of surgical intervention. The number of 
patients undergoing palliative treatment including best supportive care included in this review was 
small (8.9%, n = 45). Consequently, this limits the themes extracted primarily to patients who 
undergo operative treatment alone and does not truly encapsulate all relevant themes for those who 
may undergo palliation of their LRRC. It is important to understand whether there are similarities and 
differences in HrQoL themes between those who undergo surgical treatment of LRRC and those who 
undergo palliation to enable future comparison between these important disease groups. A further 
limitation of the included patient population is the high number of female patients included in both 
reviews, with 278 (41.1%) of women included in the review of HrQoL in LRRC and 473 (80.8%) of 
women included in the review of HrQoL in pelvic exenteration. The inclusion of a large proportion of 
females has an obvious impact on the themes extracted. The majority of the work regarding sexual 
function and body image in both reviews was primarily conducted in female participants, with very 
little qualitative and quantitative work regarding sexual function and body image in male patients. 
257 
There is potential that not all relevant themes applicable to male patients have been elucidated due to 
the lack of inclusion of male patients within the identified studies.  
  
 The lack of adequate representation of patient and treatment factors within the sampling population 
combined with the methodological flaws of the studies leads to obvious limitations within the 
literature that has informed the inductive (top down) approach of developing the conceptual 
framework. The themes extracted at this stage may not have be relevant to all patients with LRRC 
given the heterogeneous patient population from which the evidence has been extracted. Furthermore, 
given the potential exclusion of important clinical groups i.e. male patients and palliative patients 
relevant themes may have been missed.  
 
To overcome the limitations of relying on current evidence alone, qualitative teleconference focus 
groups were conducted. Teleconference focus groups were used to overcome the logistical difficulties 
of assembling a group due to the scattered geographical location of the majority of patients included 
in the study. The advantages of collecting qualitative data in this manner is the potential for data to be 
collected over a short time frame in a cost-effective manner [269, 370]. However, focus groups have a 
number of limitations including the potential for the group processes overall to have considerable 
influence on the consensus view expressed in the focus groups which may not be reflective of 
individual participants. Furthermore, the use of teleconference focus groups may lead to missing key 
pieces of non-verbal communication, which may potentially impact the quality of the data collect 
using this medium.  
 
Given the limitations associated with focus groups, the use of in-depth cognitive interviews may have 
been a potential alternative in collecting qualitative data from patients with LRRC to elicit relevant 
concepts and themes of HrQoL. The use of in-depth cognitive interviews was considered for use in 
258 
Phase I of the LRRC-QoL. However, given the geographical location of the majority of patients and 
the logistical difficulties of conducting face-to-face interviews, a pragmatic decision was made to 
conduct teleconference focus groups. It was felt that the convenience of holding teleconference focus 
groups would help aid recruitment in this cohort of patients.  It is acknowledged that conducting in-
depth cognitive interviews on an individual basis may have the potential advantage of identifying 
sensitive and/or personal information, which some participants may be uncomfortable sharing in a 
group setting [259]. In-depth cognitive interviews allows for the interviewer to explore topics in a 
more detailed manner, thus garnering more qualitative data which would have informed the 
development of the conceptual framework overall. This may have potentially led to slightly different 
themes being obtained. There are a number of advantages of conducting cognitive interviews over 
focus groups, including the process of data analysis. It is much easier to analyse the transcripts from 
the cognitive interviews due to the individualised nature of these interviews. Cognitive interviews 
represent the opinions, thoughts and feelings of one person alone. It is, therefore easier to identify 
themes on an individual patient basis when analysing data extracted from cognitive interviews. In 
comparison, the data analysis for focus groups includes analysing individual participant data and the 
interaction between participants. It is important that the themes extracted from focus groups are an 
aggregation of the views of individual participants and not the consensus opinion of the group overall 
[371]. Thus ensuring that participants with opposing or differing views are appropriately represented 
within the data analysis. There are disadvantages associated with conducting cognitive interviews 
including their costly and time consuming nature [259]. 
 
9.2.2 Phase II  
 
The design of the LRRC-QoL was broadly based on the EORTC questionnaires, using items from the 
EORTC item bank to operationalise the conceptual framework. Adopting this design strategy ensured 
the development of a well designed, clear and concise questionnaire using previously validated items. 
This strategy ensured that consistency was maintained between the core EORTC QLQ-C30 module 
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and the LRRC-QoL. The aim of this was to help reduce cognitive loads placed on participants whilst 
completing both questionnaires concurrently, and to enable the development of cognitive models for 
repetitive behaviours which are essential for navigating through instruments and formulating 
responses [296, 298].    
 
To maintain the content validity throughout Phase II of the LRRC-QOL a modified Delphi study was 
embedded within the study design. This Delphi study enabled patients and experts the opportunity to 
evaluate the range of items identified which could be suitably operationalised into a provisional 
questionnaire using an online survey. The use of Delphi studies in this manner is an emerging concept 
[372, 373]. This approach allows for the validation of the initial qualitative work within a second 
independent sample of patients. Using an online survey to conduct a Delphi study has a number of 
advantages including ease of access for participants, pre-set rules to ensure every question is answered 
thus limiting the amount of missing data, easy and efficient collation of survey results and prompt 
distribution of feedback. There are, however, some limitations to our Delphi study, this includes the 
small overall sample size and the subsequent potential for bias as the participants who responded to 
the survey may not be representative of the overall population with LRRC. Furthermore, the use of an 
online Delphi survey limits participation to those with Internet access alone and to those who are 
interested in participating in research.   
 
One of the greatest strengths of this study was the way in which the data analysis was conducted. The 
data analysis was conducted in the same manner in the UK and Australia, with review and analysis of 
all data after three consecutive cognitive interviews. This was followed by review by an expert panel. 
All data was coded in accordance with the QAS-99 tool. Although, the methodology employed was 
the same in both participating countries, the cognitive interviews and data analysis were conducted 
separately. The final versions of the LRRC-QoL from both countries were synthesised and reviewed 
by an international expert panel, prior to finalisation of the format and content of the LRRC-QoL. 
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This strategy ensured a systematic and robust manner of analysis was employed taking into the 
account the individual analyses from both participating countries and synthesising these to ensure the 
overall content validity of the LRRC-QoL was retained. Employing this strategy ensured the cross-
cultural equivalence of the LRRC-QoL between the UK and Australia, ensuring both operational and 
item equivalence, thus ensuring the content validity of the measure overall.  The use of a checklist, in 
the form of the QAS-99 tool, enabled the systematic analysis of the collected data, allowing for the 
easy and early identification of problematic items [312, 319, 320]. The QAS-99 has been previously 
reported to be the most productive method in identifying potential issues with surveys and 
questionnaires during the pre-testing phase, however, it has been determined to have a high sensitivity 
and a low specificity when discriminating between items [374]. In a bid to circumvent these issues 
regarding sensitivity and specificity, a dual process of analysis was employed by discussing all items 
highlighted by the QAS-99 checklist with an expert panel. The use of expert panels in pre-testing 
questionnaires has been well documented and are proven to be an effective method of identifying 
potential issues [374, 375]. This dual process of analysis ensured that appropriate items were being 
considered for revision, refinement and inclusion within the LRRC-QoL.  
 
The overarching limitation of cognitive interviews and this manner of pretesting questionnaires are 
that they are entirely reliant on qualitative methodology to assess potential measurement error. 
Qualitative methods, including cognitive interviews, are good at identifying potential difficulties in 
item wording, format and responses, however they cannot quantitatively measure the size and 
magnitude of the identified difficulty and cannot measure whether proposed revisions have the 
capacity to reduce the measurement error [314]. Consequently, there has been an emergence of 
quantitative methods, including Rasch and Item-response theory, in pretesting questionnaires. These 
modern psychometric techniques assess how well items address the entire continuum of patient 
experience of the concept and have been used increasingly in the development and pre-testing of a 
number of PROMS [376-379]. The use of quantitative methods early in instrument development is 
aimed at providing descriptive profiles and exploratory information regarding the questionnaire 
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content. In comparison, confirmatory psychometric evaluation during the latter phases of PROM 
development are used to provide definitive information regarding the measurement properties.  The 
use of Rasch analysis and Item-Response theory undoubtedly adds value and rigour to the pre-testing 
phase of questionnaire development by providing precise and accurate measures of scale performance, 
measuring scale construct and not scale content alone and by providing statistical detail on the 
measurement performance of each individual item [380, 381]. Provision of quantitative measurement 
data on scale operationalisation at the pre-testing stage enables for scale refinement, development and 
retesting in a more scientifically rigorous and robust manner than relying on qualitative methods 
alone. However, it must be acknowledged that quantitative methods should not be used alone as a 
substitute for qualitative methodology, but in tandem, in an effort to provide data which is both 
qualitatively and quantitatively meaningful. The use of qualitative and quantitative methodology 
provides the optimal foundations to fully understand the measurement performance of a questionnaire.  
 
The lack of quantitative methods during the pre-testing stage of LRRC-QoL may potentially limit the 
clinical utility of the measure overall by potentially under- or over-estimating the content validity 
provided through the use of qualitative methodology alone. However, the LRRC-QoL has been 
developed in accordance with existing guidelines on the development of PROMS [89, 212, 292], 
including guidance from the FDA, EORTC and ISPOR. These well-regarded institutions advocate the 
use of qualitative methods, in particular, cognitive interviews, when pre-testing questionnaires. 
Therefore, the LRRC-QoL fulfils current gold standard criteria in the development of PROMs. 
However, as the science of PROMs continues to evolve, quantitative methodology such as Rasch or 
Item Response theory may become a mandatory component of pre-testing of questionnaires. To be 
able to reliably incorporate this into the current algorithms of developing PROMS requires guidance 
from the regulatory authorities, appropriate training and resource. At present, due to the lack of 
guidance and regulation, it is not unsurprising that researchers follow tried and tested methods of 
questionnaire development currently advocated by the regulatory authorities.  
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9.2.3 Phase III 
Achieving the target recruitment for the UK cohort for Phase III is one of the strengths of this study. 
LRRC is a relatively rare disease outcome for primary rectal cancer, with approximately 700 patients 
a year being treated operatively within the UK. Given these relatively small numbers it is not 
unsurprising that the recruitment rate was slow and target recruitment was not met in a timely fashion, 
however, despite this the study eventually recruited its target sample size for the UK cohort. This is 
due to the regular monitoring of monthly recruitment rates, regular discussion with PIs and sites and 
continual review and revision of recruitment strategies. The constant reviewing and revision of 
recruitment strategies led to sending patients personalised letters from the lead PIs at each site, site 
visits and access to clinical registries. Employing these strategies enabled eventual achievement of the 
target sample size. The important lessons learnt from this study overall will be implemented to inform 
and modify the protocol to aid recruitment for the Phase III component of the Australian validation.  
 
The main strength of Phase III was the methodological and step-wise manner in which the 
psychometric analysis was conducted. The use of a clear and detailed analysis plan made it easier to 
identify and eliminate any poorly performing items and ensured a robust scale structure. Using a 
combined approach of multitrait scaling and factor analysis enabled testing of the a priori scale 
structure of the LRRC-QoL and allowed for the identification of any latent scales. Both multitrait 
scaling analysis and exploratory factor analysis have both been previously used in combination to 
determine the scale structure of multi-item scales, and therefore was an ideal strategy for determining 
the structure of the LRRC-QoL. Multiple rounds of testing the scale structure using this method 
ensured that any items which did not perform optimally within a scale were appropriately identified 
and reviewed. This ensured the principles of unidimensionality were maintained through the scale 
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structure of the LRRC-QoL, so that each item within a scale measured the same underlying construct. 
Employing this dual strategy of testing the scale structure of the LRRC-QoL ensured the rigor and 
robustness of the final scale structure and therefore ensured the construct validity of the measure 
overall. 
The LRRC-QoL was designed, developed and validated with a multi-national perspective, ensuring 
cross-cultural equivalence for British and Australian patients. Four areas of equivalence are required 
when conducting multinational research; this includes conceptual equivalence, operational 
equivalence, item equivalence and scalar equivalence [317]. Conceptual equivalence for the LRRC-
QoL was demonstrated in Phase I by conducting focus groups in both population groups and ensuring 
appropriate and relevant HrQoL themes were extracted. The operational and item equivalence of the 
LRRC-QoL was demonstrated in Phase II, whereby the structure, format and interpretation of each 
item of the LRRC-QoL, was assessed individually in both populations. Although, a number of steps 
have been taken to ensure the LRRC-QoL is relevant and applicable to both populations, we have 
failed to demonstrate the scalar equivalence of the LRRC-QoL thus far. This is primarily because the 
final phase of this thesis reports on the psychometric analysis of the LRRC-QoL in the UK population 
alone. Currently, recruitment is on going in Australia. We will not be able to demonstrate the scalar 
equivalence of the LRRC-QoL between the two population groups until the psychometric analysis has 
been completed for the entire group. Therefore, at present, the LRRC-QoL does not demonstrate 
complete cross-cultural equivalence, and therefore, cannot be used in the Australian population.  
  
The obvious limitation of Phase III is the sample size of the study. There are no strict rules with 
regards to determining the sample size for the validation of PROMS, however, for the purposes of this 
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study the EORTC guidance was followed [212]. This states that a subject to item ratio of 5-10 
participants per item is adequate, based on this a sample size of 160 was determined for the UK and 
Australian cohort. However, this is a preliminary analysis of the UK cohort and therefore does not 
fulfill this pre-requisite criterion. To overcome the limitations of a smaller than anticipated sample 
size a number of strategies were employed. This included examining key aspects of the exploratory 
factor analysis to ensure the underlying robustness of the data was adequate for determining scale 
structure. Confidence intervals were examined for the measures of reliability (Cronbach’s Alpha and 
ICC) and validity (Pearson’s product moment correlation) to assess the precision of the observed 
value. Employing these strategies revealed the sample size was adequate to determine the scale 
structure of the LRRC-QoL, with acceptable communality of variables, degree of overdetermination 
and size of the factor loadings. 
 
The majority of the LRRC-QoL scales were considered to be reliable according to the observed values 
of Cronbach’s Alpha and ICC with acceptable confidence intervals suggesting the sample size to 
determine reliability was adequate. However, this was not applicable for all scales with wide 
confidence intervals observed for Cronbach’s Alpha for the pain scale, lower limb symptoms scale, 
stoma scale, sexual interest scale and the urinary symptoms scale. Wide confidence intervals, which 
included the observed values were observed with the ICC for healthcare services scale, psychological 
impact scale, pain scale and urinary symptoms scale. This means that the reliability of the LRRC-QoL 
requires further testing within a larger sample size.  
The lack of inclusion of the EORTC QLQ-C30 core questionnaire in the validation of the LRRC-QoL 
limits the ability to test convergent validity. The convergent validity of the LRRC-QoL was tested 
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using the FACT-C and EORTC CR29 questionnaires alone, with a number of moderate to high 
correlations made in the hypothesised direction. As well as a number of not previously hypothesised 
correlations identified.  Including the EORTC QLQ-C30 would have potentially provided more 
evidence for the convergent validity of the LRRC-QoL, thus strengthening the evidence for this 
psychometric outcome. Future work surrounding convergent validity for the LRRC-QoL will need to 
include the EORTC QLQ C30 and will need to be conducted in an independent sample. Furthermore, 
the lack of inclusion of the EORTC QLQ-C30 limits the initial recommendation that the LRRC-QoL 
should be used as a supplementary module to the core EORTC questionnaire. The recommendation to 
use the LRRC-QoL in this manner can only be made following the validation of the measure using the 
EORTC QLQ-C30 in an independent sample.  
 
The small sample size in this study is further compounded by the relatively high rates of missing 
clinical data, which further reduces the statistical power of the study. Difficulties were encountered in 
collecting clinical and patient demographic data from participating sites, with a number of sites failing 
to provide this information to the coordinating project team. This may be due to the amount and 
complexity of the clinical data required from sites for Phase III. Furthermore, due to the lack of 
standardised referral and follow up pathways for LRRC, there is often a degree of missing clinical 
data within the registries kept by the tertiary centres. Missing data rates are often highest for details of 
the primary cancer, re-recurrent disease and adjuvant oncological treatments, as these details are held 
by the primary, referring centre and not always communicated to the tertiary hospital. The lack of 
available clinical data is reflected in the analyses and results for the known groups validity. Limited 
numbers of patients with specific characteristics i.e. urostomy, palliative chemoradiation etc. meant 
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that subset analyses were not conducted for these groups and therefore we were unable to validate 
whether the LRRC-QoL is able to determine meaningful and discriminatory scores in these cohort of 
patients at present. Furthermore, the observed values for the known groups validity analyses have 
wide confidence intervals, further reinforcing the limitations in the interpretation of the results.  
 
The results from Phase III of this study must be interpreted with caution as they report on an interim 
analysis in the UK cohort alone, which limits the generalisablity of the obtained results. Conducting 
an interim analysis has advantages and disadvantages. Within the context of conducting research in 
rare disease settings using interim analyses, within the setting of an adaptive trial design is a useful 
study design to ensure successful recruitment in a difficult disease cohort [382, 383]. This concept is 
not limited to clinical trials and has previously been explored within the context of observational 
studies [384]. The advantage of employing an interim analysis is that it allows for an evaluation of the 
study processes and its impact on data collection. Specifically, for the LRRC-QoL, we identified a 
lack of adequate representation in our patient population, with a greater proportion of male patients 
and those treated with curative intent participating in this study, with a lack of patients with a 
urostomy or treated with a palliative setting adequately represented. Consequently, we have modified 
our sampling strategy with ongoing data collection in Australia. However, there are a number of 
limitations associated with conducting an interim analysis, this includes the acquisition of immature 
results on small numbers of patients, which may provide imprecise and biased results. The results 
obtained from the interim analysis may differ greatly from the final obtained results and therefore are 
not conclusive. Furthermore, these results are not applicable or generalisable to all patients with 
LRRC, due to the lack of Australian data and the imbalances in the study population included.  
267 
One of the major drawbacks of this study is the lack of endorsement of the LRRC-QoL tool from the 
EORTC, especially given that the development and validation of this outcome measure has been 
based on the guidelines from this organisation. Initially, during project conceptualisation EORTC 
guidance and endorsement was not sought as the initial project design was broadly based on the FDA 
guidelines [89]. It was not until the commencement of the project that it was realised the EORTC 
questionnaires would make a useful template upon which to build and design the LRRC-QoL 
(Chapter 6). By this stage, it was too late to approach the EORTC, especially given the 
commencement of the work and the time constraints required to finish the thesis. The obvious 
advantages of working collaboratively with the EORTC would be the additional expertise available to 
help develop and validate the LRRC-QOL, as well as providing support in the dissemination of the 
end user outcome measure and badging the LRRC-QoL as an official EORTC module.  
 
The LRRC-QoL has been validated using the principles of CTT. CTT is a traditional psychometric 
method which consists of a number of theoretical principles and statistical models, which derive 
summated scores across multiple items. CTT assumes that each observed score on a PROM is a 
combination of the true score of the concept of interest and unsystematic random error. The strengths 
of using this model to validate the LRRC-QoL include the familiarity of the statistical model in 
developing PROMs, the relative ease of use and its ability to provide tangible statistics that can be 
checked against existing criteria [368]. However, there are a number of limitations of CTT. Firstly, 
CTT focuses on the total scale score, with its theoretic constructs operating on the summary scores of 
items, consequently individual items are not considered [367]. This was apparent during the second 
round of multitrait scaling analysis, which identified, two items regarding wound issues and rectal 
discharge that had been loaded onto two different factors, Stoma and Wound scale and Pain and 
Discomfort scale, at exploratory factor analysis, which failed to correlate on repeat multitrait scaling 
analysis. Secondly, CTT produces results that are sample and scale dependent, leading to potential 
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drawbacks if the measurement performance of the instrument is affected by the sample it is suppose to 
be measuring. Thirdly, the standard error of measurement is assumed to be a constant value 
irrespective of the person’s location of the range of the scale.  These inherent limitations associated 
with CTT have the potential to limit the psychometric validity of the LRRC-QoL, therefore it is 
important that the results obtained from this analysis are confirmed within a larger sample. If at this 
stage further issues are identified, it may be useful to repeat the psychometric validation of the LRRC-
QoL using newer psychometric techniques, such as Rasch analysis.  
Conducting this study on a multi-centre platform has both advantages and disadvantages. The main 
advantage of conducting the validation of the LRRC-QoL in this manner is obtaining a diverse sample 
which is representative of the population of interest, thus making the obtained results generalisable.  A 
further advantage of employing more than one centre which manages complex patients with LRRC is 
that it enables for faster recruitment due to the combined patient pool available. Although, the overall 
recruitment for Phase III was relatively slow, using patients from one site alone would have further 
impeded the recruitment rate further for this project. The main disadvantage of conducting multicentre 
research was the logistical aspects of coordinating a number of sites. Difficulties were encountered 
with obtaining local ethical approval for sites which led to a delay in opening the study for 
recruitment. This is a reflection of coordinating the individual processes of a number of Research and 
Development departments. A further disadvantage of the LRRC-QoL was the lack of ‘buy-in’ into the 
study by some of the centres, with non-engagement of the PI from one site. This was combined with 
difficulties encountered with gathering patient and clinical demographics from participating sites, 
which contributes to the moderately high rates of missing data within these domains and ultimately 
contributes to a reduction in the power of the study overall. As these issues were realised during the 
course of the study appropriate measures were taken from the central, coordinating centre, with site 
visits initiated, research nurses identified to help the day-to-day running of the study, regular 
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communication and updates from each site and on-site access to clinical registries.  
 
9.3 Future Applications of the LRRC-QoL  
 
The LRRC-QoL has been developed in response to a need within the colorectal fraternity to 
objectively, accurately and robustly measure HrQoL outcomes in patients with LRRC [6]. The 
development of this instrument is the first step towards achieving this.  
 
9.3.1 Clinical Application 
 
The potential clinical applications of the LRRC-QoL are vast and can provide unique insights into 
patient outcomes, processes of care and health service outcomes [250-252].   
Patient Level Outcomes 
The LRRC-QoL can be used in clinical practice to quantify patient symptoms, experience and overall 
satisfaction. Using PROMS in routine clinical practice can improve the overall reporting of 
symptoms, lead to the disclosure and identification of symptoms not routinely reported and improve 
the early detection and subsequent monitoring of symptoms. The LRRC-QoL is ideally suited for 
assessing symptoms in this manner as it encapsulates the wide range of potential symptoms patients 
can experience, and can therefore help guide clinical decision-making. 
 
Outcome Measure  
The burden of treatment for LRRC is high for patients, in particular for surgical intervention, and 
therefore utilising HrQoL as an additional outcome is of huge relevance in this cohort. By equating a 
value or a range of values to HrQoL using the LRRC-QoL and combining this data with oncological 
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and surgical outcome data, will ensure the presentation of a balanced and measured perspective when 
discussing and considering potential treatment options. The value of outcome measures and the type 
of outcome measure of most importance often differ between patients and clinicians, with HrQoL 
being of the most value to patients [385].  Consequently, combined presentation of quantitative data 
including HrQoL, oncological and surgical outcomes should be provided to patients when counselling 
for potential treatments during the decision-making process. The values derived using the LRRC-QoL 
can be integrated with established survival data to provide a dual ‘quality of survival’ measure to help 
guide clinicians and patients with clinical decision–making, including, type of treatment initiated and 
emphasis of treatment i.e. curative versus palliative.  
 
Establishing baseline QoL values is important in complex disease settings such as LRRC, as there is 
much emerging evidence to suggest baseline QoL values are associated with overall survival, with 
poor baseline scores associated with poor overall survival [386, 387]. As well as baseline QoL scores 
being prognostic in a variety of malignancies, the use of serial measurements of QoL in advanced 
cancer can be used in a similar fashion to guide prognosis [388]. 
 
Patient Satisfaction 
The use of PROMs can provide unique insights into patient satisfaction with treatment and healthcare 
services. A systematic review consisting of 16 studies reported a moderated to strong effect on patient 
satisfaction through the collection of routine PROMs in clinical practice [252]. The Healthcare 
Services domain of the LRRC-QoL is ideally suited to assess outcomes surrounding patient 
satisfaction and HrQoL in patients with LRRC.  This domain focuses on the delivery of clinical care 
and clinical processes and therefore is well placed to measure patient satisfaction to help guide service 
improvement.  
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Patient-Clinician Communication  
The use of PROMS can help identify patient concerns and subsequently guide patient-clinician 
communication [252]. There is some evidence that when clinicians are provided with PRO data there 
is improved communication with patients regarding HrQoL issues regarding emotional, social and 
sexual function [251]. Discussions of these issues in turn can lead to appropriate referral to 
psychological services and can improve the patients health status overall. A number of studies have 
reported on clinicians using PROM; concluding the use of PROMS can help confirm clinicians’ 
knowledge of patients’ clinical status, provision of a wider overall assessment, identification of 
appropriate issues for further discussion and contribution to patient management [389, 390]. 
Measuring PROMS using the LRRC-QoL in clinical practice may similarly help guide patient-
clinician communication in the clinical setting in a bid to improve the clinical care currently provided 
to patients.  
 
Processes of Care - Clinical Decision Making  
PROMs data can help aid clinical decision-making by integrating PRO data with clinical data. The 
use of supplementary PRO data can help guide treatment and aid appropriate clinical referrals through 
the provision of a more complete assessment [251]. PROMs data may help guide clinical referral, in 
particular, for emotional and psychological support [390]. Using PROMs data in this manner has been 
shown to identify and facilitate earlier referral when compared to conventional clinical practice [391, 
392]. 
 
Using PROMs in a systematic manner, over a longitudinal timeframe can provide unique insights into 
disease progression, symptom control and treatment response [393]. The LRRC-QoL can be used to 
assess the effectiveness of a variety of treatment strategies in LRRC, monitor treatment response and 
evaluate disease progression/regression by comparing baseline PROMs data to serial measurements. 
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Using the LRRC-QoL in this manner will allow clinicians to provide a tailored and individualised 
treatment strategy to all patients. 
 
9.3.2 Health Services Outcomes  
 
Use of healthcare services 
The identification of psychological and emotional distress through the use of PROMs, leading to 
appropriate referral to psychological services can help reduce the frequency of routine clinical 
services. Ganz et al reported a reduction in use of routine healthcare services in women with breast 
cancer following psychosocial referral [394]. LRRC is a complex disease process with a number of 
healthcare professionals involved, with patients often requiring referral and treatment at tertiary 
hospitals. Ensuring access to appropriate treatment facilities either locally or within a tertiary referral 
centre based on integrated clinical and PROMs data may help streamline a patients cancer journey and 
can help reduce the need for multiple clinic visits.  
 
National Health Service 
The NHS has been collecting routine PROMs in four elective surgery groups including hernia repair, 
varicose vein surgery and hip and knee replacement as part of the NHS PROMS Programme. Using 
PROMS in this manner can provide unique insights into healthcare service delivery. Black et al 
demonstrated that despite an increase in utilisation rates of surgery over a three-year period there was 
no impact on the mean pre-operative severity score of symptoms in patients participating in the NHS 
PROMS programme [395]. This data provides a patient perspective on the commissioning of 
healthcare services, demonstrating patient need using PROMS data. The same data has been used to 
outline PROMS as a more sensitive indicator of consultant outcomes when compared to elective post-
operative mortality in elective hip replacement [101]. The use of routine PROMS to inform healthcare 
policy in the NHS is still within its infancy. There are a number of challenges to overcome prior to the 
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use of PROMs to inform and develop healthcare policy and commissioning of services [396]. To 
ensure sustainable and meaningful collection of PROMS data to inform healthcare policy requires the 
appropriate measurement of data regarding on clinical practice and provider performance [397]. The 
integration of these two key features will ensure better quality data is collected, allow for better 
patient and clinician engagement and influence of healthcare policy [397]. 
 
The NHS is actively engaged in the development and measurement of PROMS for patients with 
cancer as part of the Five Year Forward View plan [398]. This plan outlines the development of a 
cancer dashboard with key outcome metrics, including PROMS, which will be used to assess patient 
and clinical outcomes. There is an emphasis on using good quality measures to measure PROs and 
QoL in patients living with and following the treatment of cancer. These outcome measures can then 
subsequently be used to appropriately target care and further treatment based on patient needs.  The 
Department of Health is keen on working with a number of key stakeholders, including patients, 
charitable organisations and carers to develop a national metric of QoL to enable long-term 
evaluation. It is anticipated that this newly developed PROM will be suitable for use by a number of 
clinical system users, including healthcare commissioners and providers.  
In the future should PROMS data be used to help measure provider performance to inform healthcare 
policy and the commissioning of healthcare services, the LRRC-QoL would be well placed to 
measure these output specifically in patients with LRRC. The Healthcare Services domain specifically 
focuses on the impact of clinical services on HrQoL and therefore would be a good tool to use in the 
assessment of clinical services and may play a role in the future in defining healthcare services for 
patients with LRRC.  
9.3.3 Clinical Research  
 
Currently, there are two population-based registries, BeyondTME Registry and the PelEx 
Collaborative, within the UK and Ireland measuring clinical outcomes in patients with advanced 
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pelvic oncology, including LRRC. The primary endpoint of these registries is to document clinical 
and oncological outcomes associated with the management of LRRC. The LRRC-QoL would be well 
placed to be incorporated within the frameworks of such established registries and could be used to 
measure HrQoL as a key secondary endpoint in this cohort of patients. The advantages of collecting 
PRO data in this way includes the potential to amass a relatively large volume of data over a short 
period of time, compare clinical demographics between responders and non-responders, and measure 
the change in HrQoL scores following treatment. This data can then be used in a variety of ways 
including prognostic modelling and in hypothesising the effectiveness and cost-effectiveness of a 
variety of treatments.   
 
9.4 Future Perspectives - Methodological Developments of LRRC-QoL 
 
9.4.1 Large Field Validation  
 
The next step in developing the LRRC-QoL from a methodological perspective is the overall 
validation of the outcome measure in the British and Australian cohort. This large-scale validation of 
the LRRC-QoL in this combined population, based on the original sample size estimation of 160 
patients, will identify whether the LRRC-QoL is a reliable and valid outcome measure. The findings 
from this combined validation of the LRRC-QoL should be further confirmed in an independent 
sample to ensure the generalisability of the results obtained.  
 
9.4.2 Responsiveness 
 
For a PROM to be used within the clinical context it must be able to accurately and appropriately 
detect a clinically meaningful change [276, 283, 399]. This is a measure of responsiveness. 
Responsiveness is an essential property of any PROM monitoring clinical changes over a longitudinal 
timeframe. The best way of assessing responsiveness for the LRRC-QoL would be through a multi-
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centre, prospective, longitudinal study with regular interval assessment of HrQoL. Measuring the 
responsiveness of the LRRC-QoL will improve its utility both in clinical practice and clinical 
research, as this would enable the precise evaluation of treatment impact on patients, determine the 
minimal clinically important difference and enable for the generation of sample size calculations for 
future studies.  
 
9.4.3 Further Psychometric Validation - Rasch Analysis 
 
The LRRC-QoL was validated using the principles of CTT. Although, widely recognised for its use in 
the development of PROMs, there are a number of associated limitations with employing this manner 
of psychometric testing. To build on the initial psychometric analysis of the LRRC-QoL, further work 
should be carried out to refine and strengthen the validity of the LRRC-QoL using newer approaches, 
such as Rasch analysis. Rasch analysis is a probabilistic, mathematical model of how participants 
respond to any given item. It assumes that the probability of a participant endorsing an item is a 
logistic function of the relative difference between the item’s location (how difficult the item is) and 
the person’s location (persons’ ability). The Rasch model constructs a line of measurement with the 
items placed hierarchically on this line according to their importance to patients. The overall objective 
of the analysis is to test the extent to which the observed pattern of item responses conforms to Rasch 
model expectations [400, 401].  
 
Rasch analysis overcomes a number of the limitations inherent to CTT by providing item level data 
through the assessment of individual item function, including to what level of the underlying trait is 
measured by the item and the extent to which the item is related to the underlying construct measured 
by the instrument. It facilitates the development of a more efficient and streamlined questionnaire by 
reducing the number of items needed to provide comparable measurement precision and reliability. 
Rasch has the ability to investigate variations in item and scale performance within different 
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population samples [402, 403]. Therefore, future analyses of employing the principles of Rasch 
analysis should include overall model fit statistics (targeting of samples to items, tests of individual 
item fit, item-trait chi-squared vales, item characteristics curves), person separation index, ordering of 
response categories and differential item functioning [404].  
 
However, the limitations of Rasch must be acknowledged prior to embarking on psychometric 
validation using this method. The main limitation of Rasch analysis is the relatively large sample size 
required to validate a multi-item PROM, with a stipulated recommendation of 10 subjects per 
response category [405]. There is emerging evidence that Rasch analysis requires sample sizes of 
between 250-500 participants to be able to ensure stable and robust estimates of item parameters [381, 
405]. Given the difficulties encountered in achieving the pre-requisite sample size for the LRRC-QoL 
it is unlikely a sample size adequate for Rasch analysis will be realised in a timely fashion for this 
cohort of patients, without collaboration from a greater number of international centres.  
 
 Using Rasch analysis to supplement the initial CTT psychometric analysis conducted will help 
further confirm the psychometric properties of the LRRC-QoL. It may potentially help refine the 
PROM further, developing a shorter more robust outcome measure. This will help enhance the 
clinical utility of the LRRC-QoL overall.  
 
9.4.4 International Collaboration, Translation and Cross-Cultural Validation  
 
A number of international groups of experts have come together through the BeyondTME 
collaborative to develop clinical guidelines in a bid to aid clinical decision-making and to improve 
clinical and PRO outcomes in LRRC [6]. To effectively identify further areas of clinical research and 
to conduct well-designed clinical studies in LRRC requires collaborative effort between a number of 
clinical bodies due to the complex nature of LRRC and its relative rare occurrence. The collaborative 
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efforts of the LRRC-QoL between the UK and Australian team have demonstrated the advantages and 
pitfalls of conducting research in this cohort of patients. This study has highlighted the importance of 
collaborative networks in ensuring high quality delivery of clinical research in complex and rare 
disease processes and therefore it is imperative that further research continues in the same 
collaborative manner.  
 
We have been approached by a number of clinicians and surgeons across Europe (Denmark, Norway, 
France, Germany) to validate the questionnaire in their respective languages and cultures. We are 
currently in the process of developing a protocol for the translation and field testing of the LRRC-
QoL into a number of languages. To improve and strengthen the utility of the LRRC-QoL, we will 
approach the EORTC organisation to help advise, endorse and incorporate the LRRC-QoL within the 
framework of the EORTC questionnaires.  
 
9.4.5 Online Administration, Social Media and Mobile Technology Applications  
 
The interface between the internet, mobile technology applications and healthcare is rapidly changing 
and gaining increasing momentum with the rapid expansion of these technologies into diagnostics, 
imaging and therapeutics. The use of mobile applications through the use of text messaging and smart 
phone applications has been demonstrated to be effective when promoting smoking cessation [406], 
medication adherence [407] and overall healthcare promotion. Furthermore, the development of 
mobile applications which enable self-monitoring have been found to be acceptable to patients. The 
gradual integration of the Internet and mobile technology into healthcare has led to the development 
of Electronic PROMS. These are PROMS which have developed to be delivered on an online or 
electronic platform. Electronic PROMs offer a number of advantages over the traditional paper-based 
methodology including the collection of a more complete data set and the minimisation of potential 
sources of errors through automated calculation of scores. It also provides a more convenient method 
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of participation and may lead to potentially higher retention rates. Electronic PROMS can be linked 
with clinical registries, thus reporting data in a more clinically meaningful manner, providing data in 
real-time, which may help inform on going treatment strategies [130, 408]. Electronic PROMS are 
ideally suited to monitoring patients over a wide geographical location at timely and regular intervals. 
Developing an electronic version of the LRRC-QoL would potentially increase the accessibility of the 
measure to a wider pool of patients and would make the PROM more easier to disseminate on an 
international platform. However, electronic PROMS are in their infancy and for them to become 
widely used and embedded within the healthcare system requires the development of sophisticated 
information technology systems alongside the appropriate training of clinicians.  
 
The use of social media to collect PROMS data is a relatively new and unique concept [409, 410]. 
Collecting PROMS data in this manner has a number of advantages including a large patient 
population pool, low costs and a relatively short latency period for data acquisition. This is ideally 
suited for measuring outcomes in rare disease groups, such as LRRC. The LRRC-QoL has the 
potential to be disseminated through social media using a targeted sampling strategy to identify 
relevant online patient groups on an international platform. Measuring PROs for LRRC in this manner 
allows for the acquisition of a large volume of data over a short period of time on an international 
platform to provide a cross-sectional representation of HrQoL in this cohort of patients. However, 
there are limitations to potentially using the LRRC-QoL in this manner, including sampling bias and 
potential lack of construct validity [410]. The potential for sampling bias occurs as participants 
engaging in social media are often self-selected, highly motivated individuals with familiarity in using 
technology and social media, and thus may not be representative of the population overall. 
Furthermore, it is difficult to elicit important information regarding clinical, operative and oncological 
outcomes and therefore has an impact on the ability to interpret the results in a clinically meaningful 
manner.  
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9.4.6 Core Outcome Set for LRRC  
 
As demonstrated in this thesis there is significant heterogeneity in reporting PROs in LRRC. This 
issue of variation in outcome reporting extends to the clinical, surgical and oncological outcomes 
reported for this cohort of patients. This outcome heterogeneity contributes to reporting bias and 
prevents adequate evidence synthesis. To overcome such issues there has been much work conducted 
on developing core outcome sets. This work was initiated and developed by the COMET (Core 
Outcome Measures in Effectiveness Trials) initiative, which aims to develop a standardised set of 
outcomes which should be measured and reported in all trials for a particular disease pathology [411]. 
A core outcome set has been developed for colorectal cancer [412-414] however, this focuses 
primarily on primary colorectal cancer and fails to encapsulate clinical and oncological detail relevant 
to LRRC. It is therefore essential that a core outcome set is specifically developed for use in LRRC. 
This core outcome set should include PROs, which makes it ideal to embed the LRRC-QoL within its 
framework. This core outcome set should be developed in collaboration with key stakeholders 
including patients, surgeons, oncologists, specialist nurses and palliative care physicians. The 
development of a core outcome set in LRRC will standardise outcome reporting, enable comparison 
between individual studies and allow for better evidence synthesis. 
 
9.5 Conclusions  
 
This thesis aimed to develop and validate a PROM of HrQoL in patients with LRRC – The LRRC-
QoL. This is the first measure to be developed exclusively in this cohort of patients. This PROM has 
been developed and validated in a methodologically robust, step-wise manner based on existing 
guidelines. Currently, the measure has only been validated in the UK cohort, with on-going validation 
in the Australian cohort. This thesis provides evidence that PROMs can be developed in complex and 
rare disease settings through multi-centre, international collaboration. There are number of further 
methodological studies which will further refine and validate the LRRC-QoL, including the 
completion of the Australian validation, further validation in an independent sample and assessment 
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of responsiveness over a longitudinal timeframe. These further studies will enhance the robustness 
and utility of the LRRC-QoL and make it a more relevant and applicable PROM for use in clinical 
practice and research. The LRRC-QoL provides a method of comprehensive assessment of the impact 
of LRRC and its subsequent treatments on patients and enables that impact to be quantified in a 
meaningful and measurable manner. It is hoped the integration of the LRRC-QoL into routine clinical 
practice will enable the documentation of PROs relevant to this cohort of patients through validated 
means. It is hoped the LRRC-QoL will be used in routine clinical practice, within the wider NHS and 
in clinical research as an end outcome measure in prospective clinical studies and trials. The LRRC-
QoL has great potential to enhance the understanding of HrQoL outcomes and subsequently improve 
the clinical outcomes in this complex cohort of patients. 
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Appendices 
Appendix 1 – Search Strategy for HrQoL in LRRC 
 
Free Text Search Terms 
Locally 
Recurrent 
Rectal  
Quality 
Life 
Quality of life 
Symptom prevention and control 
Questionnaires 
Health Related 
Physical  
Distress 
Psychological  
Psychosocial 
 
MeSH Terms 
Rectal neoplasms 
Quality of Life 
Questionnaires 
Health  
Physical examination 
 
 
Search Strategy 
1. ‘Locally’ (All Fields) and ‘Recurrent’ (All fields) and ‘Rectal Neoplasm’ (MeSH term) or Rectal (All 
fields) 
2. ‘Quality of Life’ (MeSH Term) OR (‘quality’ (All Fields) and ‘life’ (All Fields) OR ‘quality of life’ 
(All Fields) 
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3. ‘Health’ (MeSH Terms) OR ‘health’ (All Fields) AND related (All Fields) AND ‘Quality of Life’ 
(MeSH Terms) OR ‘quality’ (All Fields) AND ‘life’ (All Fields) OR ‘Quality of Life’ (All Fields) 
4. ‘Symptom’ (All Fields) AND ‘prevention and control’ (Subheading) 
5. ‘Questionnaires’ (MeSH Terms) OR ‘Questionnaires’ (All Fields) 
6. ‘Physical Examination’ (MeSH Terms) OR ‘Physical’ (All Fields) AND ‘Examination’ (All Fields) 
OR ‘Physical Examination’ (All Fields) OR ‘Physical’ (All Fields) AND ‘distress’ (All Fields).  
7. ‘Psychological’ (All Fields) AND ‘distress’ (All Fields) 
8. ‘Psychosocial’ (All Fields) AND ‘distress’ (All Fields) 
 
 
Conference Proceedings 
Association of Surgeons of Great Britain and Ireland 2000 -2012 
Association of Coloproctologists of Great Britain and Ireland 2000 -2012 
European Society of Coloproctology 2007-2012 
 
 
Internet search of web content relating to LRRC self-help and focus group: 
- www.macmilian.org 
- http://cancerchat.cancerresearchuk.org 
- www.beatingbowelcancer.org 
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Appendix 2 – Topic Guide For Phase I: Focus Groups 
LRRC-QoL PROJECT 
Topic Guide for Focus Group for the Development of a Conceptual Framework 
1. Welcome 
a. Introduction 
b. Ground rules including confidentiality, mutual respect and voluntary withdrawal of 
participation at any time 
c. Participant Introductions 
 
2. Focus Group Interview 
Opening Statements 
a. Tell me about your initial experiences of LRRC when you were first diagnosed 
b. Tell me about your experiences of your treatment of LRRC 
c. Tell me about your feelings and experiences following the treatment of LRRC 
 
For each phase of the management and treatment of LRRC the following key issues will be 
touched upon. 
i. Symptoms experienced 
1. Pain 
2. Gastrointestinal symptoms 
3. Genitourinary symptoms 
4. Sexual symptoms  
ii. How the diagnosis was obtained 
iii. Communication with health care professionals 
iv. Psychological impact 
v. Impact on relationships/finances/work 
vi. Sexual impact 
 
Cognitive probes will be used to further explore the themes and issues raised by the patients. 
 
Example cognitive probes:  
 
• Pain 
Where is the location of the pain? 
Which words would you use to describe the pain? 
When do you experience pain? What time of day? 
How often do you experience pain? 
How does pain affect your life and relationships?  
 
• Diagnosis obtained        
How were you diagnosed with LRRC? 
Did you have any symptoms? What were they? 
How did the diagnosis impact your life? 
What information did you receive about your disease from your doctor? 
 
3. Debrief 
At the end of the focus group: 
• Debrief the patient 
• Explain their role in the development of LRRC-QoL Tool 
• Thank the patients for their time and help 
• Provide them the opportunity to ask further questions and/or comment
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Appendix 3 Topic Guide for Semi-Structured Interviews with Expert Panel for the 
Development of a Conceptual Framework 
 
LRRC-QoL PROJECT 
 
1. Background 
Explanation of background to the study and the development of preliminary conceptual framework to 
LRRC-QoL questionnaire. 
 
2. Semi-structured Interview Guide 
 
For each domain:  
1) Do you think the items in this domain are relevant to patients with LRRC and should be included 
in the questionnaire? 
 
2) What factors do you think influence the items in this domain? 
 
3) Are there any relevant items that we have left out of this domain? 
 
Overview: 
1) Overall, do you think all the domains reflect the experiences of patients with LRRC. 
a. If  no, which ones? And how so? 
 
2) Are there any domains which you think might be relevant that have not been included? 
a. If yes, what are they? 
 
3) Overall, do you think the proposed conceptual framework encompasses all issues relevant to 
patients with LRRC?  
 
 
3. Additional comments and close of interview 
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Appendix 4 Provisional Item Pool for LRRC-QoL 
 
1. Have you had abdominal pain? 
2. Have you had pain in your lower back and/or pelvis? 
3. Have you had pain your back? 
4. Have you had pain in your buttocks/anal area/rectum? 
5. Have you had pain in your lower back? 
6. Has pain interfered with your daily activities? 
7. Have you been tired? 
8. Have you lacked energy? 
9. Have you had irritation or soreness in your vagina or vulva? 
10. Have you had any abnormal discharge or bleeding from your vagina? 
11. Has your vagina felt short and/or tight? 
12. Have you had pain or a burning feeling when passing water/urinating? 
13. Have you had any unintentional release (leakage) of urine? 
14. Have you had pain when you urinated? 
15. Did you have problems caring for your urostomy? 
16. Have you felt embarrassed because of your urostomy? 
17. Have you have been dependent on others for caring for your urostomy? 
18. Have you been troubled by passing wind/gas/flatulence? 
19. Have you had any abnormal bleeding or discharge from you rectum? 
20. Have you felt embarrassed because of your stoma? 
21. Have you had any problems caring for your stoma? 
22. Have you had any tingling or numbness in your feet or legs? 
23. Have you had any weakness of both legs? 
24. Have you worried about loss of mobility because of your illness? 
25. Have you had pain during sexual intercourse or other sexual activity?  
26. Have you had pain or discomfort during intercourse? 
27. Have you felt less interest in sex? 
28. Have you felt less sexual enjoyment? 
29. For men only: Did you have difficulty gaining or maintaining an erection? 
30. For men only: Did you have ejaculation problems (e.g. dry ejaculation)? 
31. Have you felt uncomfortable about being sexually intimate? 
32. Have you felt depressed? 
33. Have you felt anxious? 
34. Have you felt angry? 
35. Have you felt less confident? 
36. Do you feel dependent on others? 
37. Have you worried about becoming dependent on others because of your illness? 
38. Do you think others perception of you has changed following your medical diagnosis and treatment? 
39. Have you felt physically less attractive as a result of your disease or treatment? 
40. Have you been dissatisfied with your body? 
41. Has your physical condition or medical treatment interfered with your work (occupational) activities? 
42. Has your physical condition or medical treatment interfered with your social activities? 
43. Has your physical condition or medical treatment interfered with your family life? 
44. Have you been limited in doing either your work or daily activities? 
45. Have you been limited in pursuing your hobbies or other leisure time activities? 
46. Have you had to modify your daily activities because of your illness? 
47. Has your physical condition or medical treatment caused you financial difficulties? 
48. Do you worry about the results of examinations and tests? 
49. Do you worry about new symptoms? 
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50. Do you worry about possible future treatments? 
51. Have you been worried about your health in the future? 
52. Have you felt uncertain about the future? 
53. Have you felt you’ve had setbacks in your condition? 
54. Do you feel hopeful about your future? 
55. Have you felt isolated from those close to you (e.g. family, friends)? 
56. Were you satisfied with the information the healthcare professionals gave you about your illness? 
57. Were you satisfied with the information the healthcare professionals gave you about your medical 
tests? 
58. Were you satisfied with the information the healthcare professionals gave you about your treatment? 
59. Are you satisfied with the treatment and medical follow up provided? 
60. Are you satisfied with the diagnosis, treatment and medial follow up provided? 
61. Do you expect the treatment to be curative? 
62. Are you satisfied with your length of recovery? 
63. Were you satisfied with the knowledge and experience of your doctors? 
64. Were you satisfied with the waiting times for obtaining results of medical tests? 
65. Were you satisfied with the speed of implementing medical tests and/or treatments? 
66. Were you satisfied with the frequency of consultations? 
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Appendix 5: Revised Item Pool  
1. Have you had abdominal pain? 
2. Have you had pain in your lower back and/or pelvis? 
3. Have you had pain in your buttocks/anal area/rectum? 
4. Has pain interfered with your daily activities? 
5. Have you been tired? 
6. Have you lacked energy? 
7. Have you had irritation or soreness in your vagina or vulva? 
8. Have you had any abnormal discharge or bleeding from your vagina? 
9. Have you had pain or a burning feeling when passing water/urinating? 
10. Have you had any unintentional release (leakage) of urine? 
11. Did you have problems caring for your urostomy? 
12. Have you felt embarrassed because of your urostomy? 
13. Have you have been dependent on others for caring for your urostomy? 
14. Have you had any abnormal bleeding or discharge from you rectum? 
15. Have you felt embarrassed because of your stoma? 
16. Have you had any problems caring for your stoma? 
17. Have you had any tingling or numbness in your feet or legs? 
18. Have you had any weakness of both legs? 
19. Have you worried about loss of mobility because of your illness? 
20. Have you had pain during sexual intercourse or other sexual activity?  
21. Have you felt less interest in sex? 
22. For men only: Did you have difficulty gaining or maintaining an erection? 
23. For men only: Did you have ejaculation problems (e.g. dry ejaculation)? 
24. Have you felt depressed? 
25. Have you felt anxious? 
26. Have you worried about becoming dependent on others because of your illness? 
27. Do you think others perception of you has changed following your medical diagnosis and 
treatment? 
28. Have you felt physically less attractive as a result of your disease or treatment? 
29. Has your physical condition or medical treatment interfered with your work (occupational) 
activities? 
30. Has your physical condition or medical treatment interfered with your social activities? 
31. Has your physical condition or medical treatment interfered with your family life? 
32. Has your physical condition or medical treatment caused you financial difficulties? 
33. Do you worry about the results of examinations and tests? 
34. Do you worry about possible future treatments? 
35. Have you been worried about your health in the future? 
36. Have you felt uncertain about the future? 
37. Were you satisfied with the information the healthcare professionals gave you about your 
illness? 
38. Were you satisfied with the information the healthcare professionals gave you about your 
treatment? 
39. Are you satisfied with the diagnosis, treatment and medial follow up provided? 
40. Are you satisfied with your length of recovery? 
41. Were you satisfied with the knowledge and experience of your doctors? 
42. Were you satisfied with the speed of implementing medical tests and/or treatments? 
43. Were you satisfied with the frequency of consultations
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Appendix 6: Preliminary Generic LRRC-QoL  
 
Locally Recurrent Rectal Cancer Quality of Life Questionnaire 
 
 (LRRC-QoL) 
 
 
This questionnaire asks your views about the impact that the recurrence of rectal cancer in the 
pelvis has had on your everyday life during the past few weeks, including symptoms, sexual 
function, psychological impact, role functioning and healthcare services. 
Please answer all the questions yourself. There are no right or wrong answers.  
The information that you provide will remain strictly confidential.  
 
Thank you for taking the time to complete this questionnaire.  
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LRRC-QoL 
We are interested in some things about you and your health. Please answer all the questions 
by yourself by circling the number that best applies to you. There are no right or wrong 
answers. 
 
 
Symptoms 
During the past week: 
 
 
Not at 
all 
 
A little 
 
Quite a 
Bit 
 
Very 
much 
 
1. Have you had abdominal pain?..................................... 
 
 
1 
 
2 
 
3 
 
4 
 
2. Have you had pain in your lower back and/or pelvis?... 
 
 
1 
 
2 
 
3 
 
4 
 
3. Have you had pain in your buttocks/anal area/rectum?. 
 
1 
 
2 
 
3 
 
4 
 
4. Have you had any abnormal bleeding or discharge 
from your rectum?.......................................................... 
 
1 
 
2 
 
3 
 
4 
 
5. For women only: Have you had irritation or soreness 
in your vagina or vulva?................................................. 
 
 
1 
 
2 
 
3 
 
4 
 
6. For women only: Have you had any abnormal 
discharge or bleeding from your vagina?....................... 
 
1 
 
2 
 
3 
 
4 
 
7. Have you had pain or a burning feeling when passing 
water/urinating?..............................................................  
 
1 
 
2 
 
3 
 
4 
 
8. Have you had any unintentional release (leakage) of 
urine?.............................................................................. 
 
 
1 
 
2 
 
3 
 
4 
 
9. Have you had any weakness of both legs?..................... 
 
 
1 
 
2 
 
3 
 
4 
 
10. Have you worried about loss of mobility because of 
your illness?................................................................... 
 
 
1 
 
2 
 
3 
 
4 
 
11. Have you had any tingling or numbness in your feet or 
legs?................................................................................ 
 
 
1 
 
2 
 
3 
 
4 
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12. Do you have a urostomy? 
 
Yes...Please go to Question 13 
No....Please go to Question 16 
 
    
 
13. Did you have problems caring for your urostomy?....... 
 
 
1 
 
2 
 
3 
 
4 
 
14. Have you felt embarrassed because of your urostomy?. 
 
 
1 
 
2 
 
3 
 
4 
 
15. Have you have been dependent on others for caring for 
your urostomy?............................................................... 
 
 
1 
 
2 
 
3 
 
4 
16. Do you have a stoma? 
 
Yes...Please go to Question 17 
No....Please go to Question 19 
 
    
 
17. Have you felt embarrassed because of your stoma?..... 
 
 
1 
 
2 
 
3 
 
4 
 
18. Have you had any problems caring for your stoma?..... 
 
 
1 
 
2 
 
3 
 
4 
     
     
 
Psychological Impact 
During the past week: 
 
 
Not at 
all 
 
A little 
 
Quite a 
Bit 
 
Very 
much 
 
19. Have you worried about becoming dependent on 
others because of your illness?...................................... 
 
 
1 
 
2 
 
3 
 
4 
 
20. Do you think others perception of you has changed 
following your medical diagnosis and treatment?......... 
 
 
1 
 
2 
 
3 
 
4 
 
21. Have you felt physically less attractive as a result of 
your disease or treatment?............................................. 
 
1 
 
2 
 
3 
 
4 
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Role  Function  
During the past week: 
 
 
Not at 
all 
 
A little 
 
Quite a 
Bit 
 
Very 
much 
 
22. Has your physical condition or medical treatment 
interfered with your work (occupational) activities?.... 
 
 
1 
 
2 
 
3 
 
4 
23. Has your physical condition or medical treatment 
interfered with your work (household) activities?........ 
 
 
1 
 
2 
 
3 
 
4 
 
 
Sexual Function 
During the past 4 weeks: 
 
 
Not at 
all 
 
 
A little 
 
Quite a 
Bit 
 
Very 
much 
24. Are you sexually active? 
 
Yes...Please go to Question 25 
No....Please go to Question 29 
 
    
 
25. Have you had pain during sexual intercourse or other 
sexual activity?............................................................... 
 
 
1 
 
2 
 
3 
 
4 
 
26. Have you felt less interest in sex?.................................. 
 
 
1 
 
2 
 
3 
 
4 
 
27. For men only: Did you have difficulty gaining or 
maintaining an erection?................................................ 
 
 
1 
 
2 
 
3 
 
4 
 
28. For men only: Did you have ejaculation problems 
(e.g. dry ejaculation)?..................................................... 
 
 
1 
 
2 
 
3 
 
4 
 
Future Perspective 
During the past 4 weeks: 
 
 
Not at 
all 
 
A little 
 
Quite a 
Bit 
 
Very 
much 
 
29. Do you worry about the results of examinations and 
tests?............................................................................. 
 
 
1 
 
2 
 
3 
 
4 
 
30. Do you worry about possible future treatments?........... 
 
 
1 
 
2 
 
3 
 
4 
 
31. Have you been worried about your health in the 
future?............................................................................ 
 
1 
 
2 
 
3 
 
4 
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32. Have you felt uncertain about the future?..................... 
 
 
1 
 
2 
 
3 
 
4 
 
Healthcare Services 
During the past 4 weeks: 
 
 
Not at 
all 
 
A little 
 
Quite a 
Bit 
 
Very 
much 
 
33. Were you satisfied with the information the healthcare 
professionals gave you about your illness?.................... 
 
 
1 
 
2 
 
3 
 
4 
 
34. Were you satisfied with the information the healthcare 
professionals gave you about your treatment?.............. 
 
 
1 
 
2 
 
3 
 
4 
 
35. Are you satisfied with the diagnosis, treatment and 
medial follow up provided?........................................... 
 
 
1 
 
2 
 
3 
 
4 
 
36. Are you satisfied with your length of recovery?............ 
 
 
1 
 
2 
 
3 
 
4 
 
37. Were you satisfied with the knowledge and experience 
of your doctors?.............................................................. 
 
1 
 
2 
 
3 
 
4 
 
38. Were you satisfied with the speed of implementing 
medical tests and/or treatments?.................................... 
 
 
1 
 
2 
 
3 
 
4 
 
39. Were you satisfied with the frequency of 
consultations?................................................................. 
 
 
1 
 
2 
 
3 
 
4 
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Appendix 7 Topic Guide for Cognitive Interviews for the Pre-testing 
 
1. Welcome 
 
a. Introduction 
b. Instructions  
 
 
 
2. Cognitive Interview – Audio recorded  
 
The interviewer will read out the question to the participant and utilising the principles of the 
think-aloud technique ask the participant to vocalise their initial responses and thoughts to the 
question.  
 
Once the participant has completed the initial think-aloud phase, cognitive probes will be 
used to further explore each question.  
 
Example cognitive probes:  
 
• Pain in lower back and/or pelvis 
What do you understand by the term lower back and/or pelvis pain? 
What does that mean to you? 
Are there any other phrases you would use to describe it? 
Is this question clear? 
Is this question easy to understand? 
Was is easy to choose an answer? 
 
 
• Have you had any unintentional release (leakage) of urine? 
What do you understand by the term unintentional release? 
What do you understand by the term leakage? 
What does that mean to you? 
Are there any other phrases you would use to describe this? 
Is this question clear? 
Is this question easy to understand? 
Was it easy to choose an answer? 
 
3. Debrief 
 
Debriefing questions regarding the questionnaire.  
 
• Instructions 
 
Are the instructions to the questionnaire clear? 
 
• Recall 
 
Is the recall period too long/ too short/ just right? 
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• Response Options 
Are the response options clear? 
Are the response options easy to choose? 
• Content coverage 
 
Do the questions cover all aspects of HrQoL issues relevant to LRRC? 
 
• Format 
 
Is the format easy to follow? 
 
Are the skip questions easy to follow and understand? 
 
• Length 
 
Is the questionnaire too long or too short? 
 
What did you think of the amount of time it took to complete the questionnaire? 
 
 
 
• Debrief the patient 
• Explain their role in the development of LRRC-QoL Tool 
• Thank the patients for their time and help 
• Provide them the opportunity to ask further questions and/or comments 
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Appendix 8: Preliminary LRRC-QoL British version 2  
 
Locally Recurrent Rectal Cancer Quality of Life Questionnaire 
 
 (LRRC-QoL) 
 
 
This questionnaire asks your views about the impact that the recurrence of rectal cancer in the 
pelvis has had on your everyday life during the past few weeks, including symptoms, sexual 
function, psychological impact, role functioning and healthcare services. 
Please answer all the questions yourself. There are no right or wrong answers.  
The information that you provide will remain strictly confidential.  
Thank you for taking the time to complete this questionnaire.  
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LRRC-QoL 
We are interested in some things about you and your health. Please answer all the questions 
by yourself by circling the number that best applies to you. There are no right or wrong 
answers. 
 
Symptoms 
During the past week: 
 
 
Not at 
all 
 
A little 
 
Quite a 
Bit 
 
Very 
much 
 
1. Have you had abdominal pain?................................................... 
 
 
1 
 
2 
 
3 
 
4 
 
2. Have you had pain in your lower back and/or pelvis?................ 
 
 
1 
 
2 
 
3 
 
4 
 
3. Have you had pain in your buttocks/anal area/rectum?.............. 
 
 
1 
 
2 
 
3 
 
4 
 
4. Have you had any abnormal bleeding or discharge from your 
rectum?........................................................................................ 
 
1 
 
2 
 
3 
 
4 
 
5. For women only: Have you had irritation or soreness in your 
vagina or vulva?.......................................................................... 
 
1 
 
2 
 
3 
 
4 
 
6. For women only: Have you had any abnormal discharge or 
bleeding from your vagina?........................................................ 
 
1 
 
2 
 
3 
 
4 
 
7. Have you had pain or a burning feeling when passing 
water/urinating?................................................................... 
 
1 
 
2 
 
3 
 
4 
 
8. Have you had any unintentional release (leakage) of urine?...... 
 
 
1 
 
2 
 
3 
 
4 
 
9. Have you had any weakness of both legs?................................. 
 
 
1 
 
2 
 
3 
 
4 
 
10. Have you worried about loss of mobility because of your 
illness?....................................................................................... 
 
 
1 
 
2 
 
3 
 
4 
 
11. Have you had any tingling or numbness in your feet or legs?.... 
 
 
1 
 
2 
 
3 
 
4 
 
12. Have you had pain or discharge from your wound?.................. 
 
 
1 
 
2 
 
3 
 
4 
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13. Do you have a urostomy? 
 
Yes...Please go to Question 14 
No....Please go to Question 17 
    
 
14. Did you have problems caring for your urostomy?.................... 
 
 
1 
 
2 
 
3 
 
4 
 
15. Have you felt embarrassed because of your urostomy?............. 
 
 
1 
 
2 
 
3 
 
4 
 
16. Have you have been dependent on others for caring for your 
urostomy?................................................................................... 
 
 
1 
 
2 
 
3 
 
4 
17. Do you have a stoma? 
 
Yes...Please go to Question 18 
No....Please go to Question 20 
    
 
18. Have you felt embarrassed because of your stoma?............. 
 
 
1 
 
2 
 
3 
 
4 
 
19. Have you had any problems caring for your stoma?............ 
 
 
1 
 
2 
 
3 
 
4 
 
Psychological Impact 
During the past week: 
 
 
Not at 
all 
 
A little 
 
Quite a 
Bit 
 
Very 
much 
 
20. Have you worried about becoming dependent on others 
because of your illness?........................................................ 
 
 
1 
 
2 
 
3 
 
4 
 
21. Do you think others perception of you has changed 
following your medical diagnosis and treatment?................ 
 
 
1 
 
2 
 
3 
 
4 
 
22. Have you felt physically less attractive as a result of your 
disease or treatment?............................................................. 
 
 
1 
 
2 
 
3 
 
4 
 
Sexual Function 
During the past 4 weeks: 
 
 
Not at 
all 
 
 
A little 
 
Quite a 
Bit 
 
Very 
much 
23. Are you sexually active? 
 
Yes...Please go to Question 25 
No....Please go to Question 29 
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24. Have you had pain during sexual intercourse or other 
sexual activity?..................................................................... 
 
 
1 
 
2 
 
3 
 
4 
 
25. Have you felt less interest in sex?......................................... 
 
 
1 
 
2 
 
3 
 
4 
 
26. For men only: Did you have difficulty gaining or 
maintaining an erection?....................................................... 
 
 
1 
 
2 
 
3 
 
4 
 
27. For men only: Did you have ejaculation problems (e.g. 
dry ejaculation)?................................................................... 
 
 
1 
 
2 
 
3 
 
4 
 
Future Perspective 
During the past 4 weeks: 
 
 
Not at 
all 
 
A little 
 
Quite a 
Bit 
 
Very 
much 
 
28. Do you worry about the results of examinations and tests?. 
 
 
1 
 
2 
 
3 
 
4 
 
29. Do you worry about possible future treatments?.................. 
 
 
1 
 
2 
 
3 
 
4 
 
30. Have you felt uncertain about the future?............................. 
 
 
1 
 
2 
 
3 
 
4 
 
Healthcare Services 
During the past 4 weeks: 
 
 
Not at 
all 
 
A little 
 
Quite a 
Bit 
 
Very 
much 
 
31. Were you satisfied with the information the healthcare 
professionals gave you about your illness and treatment?.... 
 
 
1 
 
2 
 
3 
 
4 
 
32. Were you satisfied with the knowledge and experience of 
your doctors?......................................................................... 
 
1 
 
2 
 
3 
 
4 
     
 
33. Were you satisfied with the speed of implementing 
medical tests and/or treatments?........................................... 
 
 
1 
 
2 
 
3 
 
4 
 
34. Were you satisfied with the frequency of consultations?..... 
 
 
1 
 
2 
 
3 
 
4 
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Appendix 9: Preliminary Final LRRC-QoL British version 3 
 
Locally Recurrent Rectal Cancer Quality of Life Questionnaire 
 
 (LRRC-QoL) 
 
 
This questionnaire asks your views about the impact that the recurrence of rectal cancer in the 
pelvis has had on your everyday life during the past few weeks, including symptoms, sexual 
function, psychological impact, role functioning and healthcare services. 
Please answer all the questions yourself. There are no right or wrong answers.  
The information that you provide will remain strictly confidential.  
 
Thank you for taking the time to complete this questionnaire.  
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LRRC-QoL 
We are interested in some things about you and your health. Please answer all the questions 
by yourself by circling the number that best applies to you. There are no right or wrong 
answers. 
 
 
Symptoms 
During the past week: 
 
 
Not at 
all 
 
A little 
 
Quite a 
Bit 
 
Very 
much 
 
1. Have you had abdominal pain?............................................. 
 
 
1 
 
2 
 
3 
 
4 
 
2. Have you had pain in your lower back and/or pelvis?.......... 
 
 
1 
 
2 
 
3 
 
4 
 
3. Have you had pain in your buttocks/anal area/rectum?........ 
 
 
1 
 
2 
 
3 
 
4 
 
4. Have you had any abnormal bleeding or discharge from 
your rectum?......................................................................... 
 
1 
 
2 
 
3 
 
4 
 
5. For women only: Have you had irritation or soreness in 
your vagina or vulva?......................................................... 
 
 
1 
 
2 
 
3 
 
4 
 
6. For women only: Have you had any abnormal discharge 
or bleeding from your vagina?.............................................. 
 
1 
 
2 
 
3 
 
4 
 
7. Have you had pain or a burning feeling when passing 
water/urinating?................................................................... 
 
 
1 
 
2 
 
3 
 
4 
 
8. Have you had any unintentional release (leakage) of urine? 
 
 
1 
 
2 
 
3 
 
4 
 
9. Have you had any weakness of both legs?........................... 
 
 
1 
 
2 
 
3 
 
4 
 
10. Have you had any tingling or numbness in your feet or 
legs?...................................................................................... 
 
 
1 
 
2 
 
3 
 
4 
 
11. Have you had pain or discharge from your wound or scars? 
 
 
1 
 
2 
 
3 
 
4 
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12. Do you have a urostomy? 
 
Yes...Please go to Question 13 
No....Please go to Question 16 
 
    
 
13. Did you have problems caring for your urostomy?.............. 
 
 
1 
 
2 
 
3 
 
4 
 
14. Have you felt embarrassed because of your urostomy?....... 
 
 
1 
 
2 
 
3 
 
4 
 
15. Have you been dependent on others for caring for your 
urostomy?..................................................................... 
 
 
1 
 
2 
 
3 
 
4 
16. Do you have a stoma? 
 
Yes...Please go to Question 17 
No....Please go to Question 19 
 
    
 
17. Have you felt embarrassed because of your stoma?............. 
 
 
1 
 
2 
 
3 
 
4 
 
18. Have you had any problems caring for your stoma?............ 
 
 
1 
 
2 
 
3 
 
4 
 
Psychological Impact 
During the past week: 
 
 
Not at 
all 
 
A little 
 
Quite a 
Bit 
 
Very 
much 
 
19. Have you worried about becoming dependent on others 
because of your illness?........................................................ 
 
 
1 
 
2 
 
3 
 
4 
 
20. Have you felt physically less attractive as a result of your 
disease or treatment?............................................................. 
 
 
1 
 
2 
 
3 
 
4 
 
Sexual Function 
During the past 4 weeks: 
 
 
Not at 
all 
 
 
A little 
 
Quite a 
Bit 
 
Very 
much 
     
 
21. Have you had pain during sexual intercourse or other 
sexual activity?..................................................................... 
 
 
1 
 
2 
 
3 
 
4 
 
22. Have you felt less interest in sex?......................................... 
 
1 
 
2 
 
3 
 
4 
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23. For men only: Did you have difficulty gaining or 
maintaining an erection?....................................................... 
 
 
1 
 
2 
 
3 
 
4 
 
24. For men only: Did you have ejaculation problems (e.g. 
dry ejaculation)?................................................................... 
 
 
1 
 
2 
 
3 
 
4 
 
Future Perspective 
During the past 4 weeks: 
 
 
Not at 
all 
 
A little 
 
Quite a 
Bit 
 
Very 
much 
 
25. Do you worry about the results of examinations and tests?. 
 
 
1 
 
2 
 
3 
 
4 
 
26. Do you worry about possible future treatments?.................. 
 
 
1 
 
2 
 
3 
 
4 
 
27. Have you felt uncertain about the future?............................. 
 
 
1 
 
2 
 
3 
 
4 
 
Healthcare Services 
During the past 4 weeks: 
 
 
Not at 
all 
 
A little 
 
Quite a 
Bit 
 
Very 
much 
 
28. Were you satisfied with the information the healthcare 
professionals gave you about your illness and treatment?... 
 
 
1 
 
2 
 
3 
 
4 
 
29. Were you satisfied with the knowledge and experience of 
your doctors?......................................................................... 
 
1 
 
2 
 
3 
 
4 
 
30. Were you satisfied with the speed of implementing 
medical tests and/or treatments?........................................... 
 
 
1 
 
2 
 
3 
 
4 
 
31. Were you satisfied with the frequency of consultations?..... 
 
 
1 
 
2 
 
3 
 
4 
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Appendix 10: Preliminary LRRC-QoL version 2 - Australia 
 
Locally Recurrent Rectal Cancer Quality of Life Questionnaire 
 
 (LRRC-QoL) 
 
 
This questionnaire asks your views about the impact that the recurrence of rectal cancer in the 
pelvis has had on your everyday life during the past few weeks, including symptoms, sexual 
function, psychological impact, role functioning and healthcare services. 
Please answer all the questions yourself. There are no right or wrong answers.  
The information that you provide will remain strictly confidential.  
 
Thank you for taking the time to complete this questionnaire.  
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LRRC-QoL 
We are interested in some things about you and your health. Please answer all the questions 
by yourself by circling the number that best applies to you. There are no right or wrong 
answers. 
 
Symptoms 
During the past week: 
 
 
Not at 
all 
 
A little 
 
Quite a 
Bit 
 
Very 
much 
 
1. Have you had abdominal pain?............................................. 
 
 
1 
 
2 
 
3 
 
4 
 
2. Have you had pain in your lower back and/or pelvis?.......... 
 
 
1 
 
2 
 
3 
 
4 
 
3. Have you had pain in your buttocks/anal area/rectum?........ 
 
 
1 
 
2 
 
3 
 
4 
 
4. Have you had any abnormal bleeding or discharge from 
your rectum?......................................................................... 
 
1 
 
2 
 
3 
 
4 
 
5. For women only: Have you had irritation or soreness in 
your vagina or vulva?......................................................... 
 
 
1 
 
2 
 
3 
 
4 
 
6. For women only: Have you had any abnormal discharge 
or bleeding from your vagina?.............................................. 
 
1 
 
2 
 
3 
 
4 
 
 
 
7. Have you had pain or a burning feeling when passing 
water/urinating?................................................................... 
 
 
1 
 
2 
 
3 
 
4 
 
8. Have you had any unintentional release (leakage) of urine? 
 
 
1 
 
2 
 
3 
 
4 
 
9. Have you had any weakness of both legs?........................... 
 
 
1 
 
2 
 
3 
 
4 
 
10. Have you had any difficulty in walking................................ 
 
 
1 
 
2 
 
3 
 
4 
 
 
 
11. Have you had any tingling or numbness in your feet or 
legs?...................................................................................... 
 
12. Have you had pain or discharge from your wound(s) or 
scar(s)?.................................................................................. 
 
1 
 
 
 
1 
 
2 
 
 
 
2 
 
3 
 
 
 
3 
 
4 
 
 
 
4 
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13. Do you have a urostomy, nephrostomy or urinary catheter? 
 
Yes...Please go to Question 14 
No....Please go to Question 17 
 
    
 
14. Did you have problems caring for your urostomy, 
nephrostomy or urinary catheter?........................................ 
 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
15. Have you felt embarrassed because of your urostomy, 
nephrostomy or urinary catheter?......................................... 
 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
16. Have you have been dependent on others for caring for 
your urostomy?..................................................................... 
 
 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
17. Do you have a stoma? 
 
Yes...Please go to Question 18 
No....Please go to Question 20 
 
    
 
18. Have you felt embarrassed because of your stoma?............. 
 
 
1 
 
2 
 
3 
 
4 
 
19. Have you had any problems caring for your stoma?............ 
 
1 
 
2 
 
3 
 
4 
 
 
 
 
 
 
 
 
Psychological Impact 
During the past week: 
 
 
Not at 
all 
 
A little 
 
Quite a 
Bit 
 
Very 
much 
 
20. Have you worried about becoming dependent on others 
because of your illness?........................................................ 
 
 
1 
 
2 
 
3 
 
4 
 
21. Have you felt physically less attractive as a result of your 
disease or treatment?............................................................. 
 
1 
 
2 
 
3 
 
4 
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Sexual Function 
During the past 4 weeks: 
 
Not at 
all 
 
A little Quite a 
Bit 
Very 
much 
 
22. Have you had pain during sexual intercourse or other 
sexual activity?..................................................................... 
 
 
1 
 
2 
 
3 
 
4 
 
23. Have you felt less interest in sex?......................................... 
 
 
1 
 
2 
 
3 
 
4 
 
24. For men only: Did you have difficulty gaining or 
maintaining an erection?....................................................... 
 
 
1 
 
2 
 
3 
 
4 
 
25. For men only: Did you have ejaculation problems (e.g. 
dry ejaculation)?................................................................... 
 
 
 
1 
 
2 
 
3 
 
4 
 
Future Perspective 
During the past 4 weeks: 
 
 
Not at 
all 
 
A little 
 
Quite a 
Bit 
 
Very 
much 
 
26. Do you worry about the results of examinations and tests?. 
 
 
1 
 
2 
 
3 
 
4 
 
27. Do you worry about possible future treatments?.................. 
 
 
1 
 
2 
 
3 
 
4 
 
28. Have you felt uncertain about the future?............................. 
 
 
 
1 
 
2 
 
3 
 
4 
 
Healthcare Services 
During the past 4 weeks: 
 
 
Not at 
all 
 
A little 
 
Quite a 
Bit 
 
Very 
much 
 
29. Were you satisfied with the information the healthcare 
professionals gave you about your illness?........................... 
 
 
1 
 
2 
 
3 
 
4 
 
30. Were you satisfied with the information the healthcare 
professionals gave you about your treatment?...................... 
 
 
1 
 
2 
 
3 
 
4 
 
31. Are you satisfied with the diagnosis, treatment and medial 
follow up provided?............................................................. 
 
 
1 
 
2 
 
3 
 
4 
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32. Were you satisfied with the knowledge and experience of 
your doctors?......................................................................... 
 
1 
 
2 
 
3 
 
4 
 
33. Were you satisfied with the speed of implementing 
medical tests and/or treatments?........................................... 
 
 
1 
 
2 
 
3 
 
4 
 
34. Were you satisfied with the frequency of consultations?..... 
 
 
1 
 
2 
 
3 
 
4 
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Appendix 11 Preliminary LRRC-QoL version 3 - Australia 
 
Locally Recurrent Rectal Cancer Quality of Life Questionnaire 
 
 (LRRC-QoL) 
 
This questionnaire asks your views about the impact that the recurrence of rectal cancer in the 
pelvis has had on your everyday life during the past few weeks, including symptoms, sexual 
function, psychological impact, role functioning and healthcare services. 
Please answer all the questions yourself. There are no right or wrong answers.  
The information that you provide will remain strictly confidential.  
 
Thank you for taking the time to complete this questionnaire.  
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LRRC-QoL 
We are interested in some things about you and your health. Please answer all the questions 
by yourself by circling the number that best applies to you. There are no right or wrong 
answers. 
 
Symptoms 
During the past week: 
 
 
Not at 
all 
 
A little 
 
Quite a 
Bit 
 
Very 
much 
 
1. Have you had abdominal pain?............................................. 
 
 
1 
 
2 
 
3 
 
4 
 
2. Have you had pain in your lower back and/or pelvis?.......... 
 
 
1 
 
2 
 
3 
 
4 
 
3. Have you had pain in your buttocks/anal area/rectum?........ 
 
 
1 
 
2 
 
3 
 
4 
 
4. Have you had any abnormal bleeding, discharge or faecal 
leakage your rectum?............................................................ 
 
 
1 
 
2 
 
3 
 
4 
 
5. For women only: Have you had any abnormal discharge 
or bleeding from your vagina?................................ 
 
 
1 
 
2 
 
3 
 
4 
 
6. For women only: Have you had irritation or soreness in 
your vagina or vulva?...................................................... 
 
 
1 
 
2 
 
3 
 
4 
 
7. Have you had pain or a burning feeling when passing 
water/urinating?................................................................... 
 
 
1 
 
2 
 
3 
 
4 
 
8. Have you had any unintentional release (leakage) of urine? 
 
 
1 
 
2 
 
3 
 
4 
 
9. Have you had any weakness of either/ or both legs?........... 
 
 
1 
 
2 
 
3 
 
4 
 
10. Have you had any difficulty in walking................................ 
 
1 
 
2 
 
3 
 
4 
 
 
11. Have you had any tingling or numbness in your feet or 
legs?...................................................................................... 
 
12. Have you had pain or discharge from your wound(s) or 
scar(s)?.................................................................................. 
 
1 
 
 
 
1 
 
2 
 
 
 
2 
 
3 
 
 
 
3 
 
4 
 
 
 
4 
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13. Do you have a urostomy (urine bag), nephrostomy or 
urinary catheter? 
 
Yes...Please go to Question 14 
No....Please go to Question 17 
 
    
 
14. Did you have problems caring for your urostomy (urine 
bag), nephrostomy or urinary catheter?............................. 
 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
15. Have you felt embarrassed because of your urostomy 
(urine bag), nephrostomy or urinary catheter?..................... 
 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
16. Have you have been dependent on others for caring for 
your urostomy?..................................................................... 
 
 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
17. Do you have a stoma? 
 
Yes...Please go to Question 18 
No....Please go to Question 20 
 
    
 
18. Have you felt embarrassed because of your stoma?............. 
 
 
1 
 
2 
 
3 
 
4 
 
19. Have you had any problems caring for your stoma?............ 
 
1 
 
2 
 
3 
 
4 
 
 
 
 
Psychological Impact 
During the past week: 
 
 
Not at 
all 
 
A little 
 
Quite a 
Bit 
 
Very 
much 
 
20. Have you worried about becoming dependent on others 
because of your illness?........................................................ 
 
 
1 
 
2 
 
3 
 
4 
 
21. Have you felt physically less attractive as a result of your 
disease or treatment?............................................................. 
 
 
 
 
 
1 
 
2 
 
3 
 
4 
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Sexual Function 
During the past 4 weeks: 
 
 
Not at 
all 
 
 
A little 
 
Quite a 
Bit 
 
Very 
much 
 
22. Have you had pain during sexual intercourse or other 
sexual activity?..................................................................... 
 
 
1 
 
2 
 
3 
 
4 
 
23. Have you been interested in sex?......................................... 
 
 
1 
 
2 
 
3 
 
4 
 
24. For men only: How difficult is it for you to gain or 
maintain an erection?....................................................... 
 
 
1 
 
2 
 
3 
 
4 
 
25. For men only:  Have you had ejaculation problems (e.g. 
dry ejaculation)?................................................................... 
 
 
 
1 
 
2 
 
3 
 
4 
 
Future Perspective 
During the past 4 weeks: 
 
 
Not at 
all 
 
A little 
 
Quite a 
Bit 
 
Very 
much 
 
26. Do you worry about the results of examinations and tests?. 
 
 
1 
 
2 
 
3 
 
4 
 
27. Do you worry about possible future treatments?.................. 
 
 
1 
 
2 
 
3 
 
4 
 
28. Have you felt uncertain about the future?............................. 
 
 
 
1 
 
2 
 
3 
 
4 
 
Healthcare Services 
During the past 4 weeks: 
 
 
Not at 
all 
 
A little 
 
Quite a 
Bit 
 
Very 
much 
 
29. Were you satisfied with the information the healthcare 
professionals gave you about your illness and treatment?.. 
 
 
1 
 
2 
 
3 
 
4 
 
30. Were you satisfied with the knowledge and experience of 
your specialist team (Doctors/ Nurses/Specialist Nurses/ 
Physiotherapists)?.................................................... 
 
1 
 
2 
 
3 
 
4 
 
31. Were you satisfied with the speed of implementing 
medical tests and/or treatments?........................................... 
 
1 
 
2 
 
3 
 
4 
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32. Were you satisfied with the frequency of consultations?..... 
 
 
1 
 
2 
 
3 
 
4 
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Appendix 12 Preliminary Final LRRC-QoL - Generic 
 
Locally Recurrent Rectal Cancer Quality of Life Questionnaire 
 
 (LRRC-QoL) 
 
 
This questionnaire asks your views about the impact that the recurrence of rectal cancer in the 
pelvis has had on your everyday life during the past few weeks, including symptoms, sexual 
function, psychological impact, role functioning and healthcare services. 
Please answer all the questions yourself. There are no right or wrong answers.  
The information that you provide will remain strictly confidential.  
 
Thank you for taking the time to complete this questionnaire.  
 
 
 
 
 
 
 
335 
LRRC-QoL 
We are interested in some things about you and your health. Please answer all the questions 
by yourself by circling the number that best applies to you. There are no right or wrong 
answers. 
 
 
Symptoms 
During the PAST WEEK: 
 
 
Not at 
all 
 
A little 
 
Quite a 
Bit 
 
Very 
much 
 
1. Have you had abdominal pain?............................................. 
 
 
1 
 
2 
 
3 
 
4 
 
2. Have you had pain in your lower back and/or pelvis?.......... 
 
 
1 
 
2 
 
3 
 
4 
 
3. Have you had pain in your buttocks/anal area/rectum?........ 
 
 
1 
 
2 
 
3 
 
4 
 
4. Have you had any abnormal bleeding, discharge or faecal 
leakage your rectum?............................................................ 
 
 
1 
 
2 
 
3 
 
4 
 
5. For women only: Have you had any abnormal discharge 
or bleeding from your vagina?................................ 
 
 
1 
 
2 
 
3 
 
4 
 
6. For women only: Have you had irritation or soreness in 
your vagina or vulva?...................................................... 
 
 
1 
 
2 
 
3 
 
4 
 
7. Have you had pain or a burning feeling when passing 
water/urinating?................................................................... 
 
 
1 
 
2 
 
3 
 
4 
 
8. Have you had any unintentional release (leakage) of urine? 
 
 
1 
 
2 
 
3 
 
4 
 
9. Have you had any weakness of either or both legs?........... 
 
 
1 
 
2 
 
3 
 
4 
 
10. Have you had any difficulty in walking?.............................. 
 
 
11. Have you had any tingling or numbness in your feet or 
legs?...................................................................................... 
 
 
1 
 
 
1 
 
2 
 
 
2 
 
3 
 
 
3 
 
4 
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12. Have you had pain or discharge from your wound(s) or 
scar(s)?.................................................................................. 
 
 
1 
 
2 
 
3 
 
4 
 
13. Do you have a urostomy (urine bag)? 
 
Yes...Please go to Question 14 
No....Please go to Question 17 
    
  
Not at 
all 
 
 
A little 
 
Quite a 
Bit 
 
Very 
much 
 
14. Did you have problems caring for your urostomy (urine 
bag), nephrostomy, or urinary catheter?............................ 
 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
15. Have you felt embarrassed because of your urostomy 
(urine bag), nephrostomy or urinary catheter?...................... 
 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
16. Have you have been dependent on others for caring for 
your urostomy (urine bag)?................................................... 
 
 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
17. Do you have a stoma? 
 
Yes...Please go to Question 18 
No....Please go to Question 20 
    
  
Not at 
all 
 
 
A little 
 
Quite a 
Bit 
 
Very 
much 
 
18. Have you felt embarrassed because of your stoma?............. 
 
 
1 
 
2 
 
3 
 
4 
 
19. Have you had any problems caring for your stoma?............ 
 
1 
 
2 
 
3 
 
4 
 
 
 
Psychological Impact 
During the PAST WEEK: 
 
 
 
Not at 
all 
 
A little 
 
Quite a 
Bit 
 
Very 
much 
 
20. Have you worried about becoming dependent on others 
because of your illness?........................................................ 
 
 
1 
 
2 
 
3 
 
4 
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21. Have you felt physically less attractive as a result of your 
disease or treatment?............................................................. 
 
 
 
1 
 
2 
 
3 
 
4 
 
Sexual Function 
During the PAST 4 WEEKS: 
 
 
 
Not at 
all 
 
 
A little 
 
Quite a 
Bit 
 
Very 
much 
 
22. Have you had pain during sexual intercourse or other 
sexual activity?..................................................................... 
 
 
1 
 
2 
 
3 
 
4 
 
23. Have you been interested in sex?......................................... 
 
 
1 
 
2 
 
3 
 
4 
 
24. For men only: How difficult is it for you to gain or 
maintain an erection?....................................................... 
 
 
1 
 
2 
 
3 
 
4 
 
25. For men only:  Have you had ejaculation problems (e.g. 
dry ejaculation)?................................................................... 
 
 
1 
 
2 
 
3 
 
4 
 
Future Perspective 
During the PAST 4 WEEKS: 
 
 
Not at 
all 
 
A little 
 
Quite a 
Bit 
 
Very 
much 
 
26. Do you worry about the results of examinations and tests?. 
 
 
1 
 
2 
 
3 
 
4 
 
27. Do you worry about possible future treatments?.................. 
 
 
1 
 
2 
 
3 
 
4 
 
28. Have you felt uncertain about the future?............................. 
 
 
1 
 
2 
 
3 
 
4 
     
 
Healthcare Services 
During the PAST 4 WEEKS: 
 
 
Not at 
all 
 
A little 
 
Quite a 
Bit 
 
Very 
much 
 
29. Were you satisfied with the information the healthcare 
professionals gave you about your illness and treatment?.. 
 
 
1 
 
2 
 
3 
 
4 
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30. Were you satisfied with the knowledge and experience of 
your specialist team (Doctors/ Nurses/Specialist Nurses/ 
Physiotherapists)?.................................................... 
1 2 3 4 
 
31. Were you satisfied with the speed of implementing 
medical tests and/or treatments?........................................... 
 
 
1 
 
2 
 
3 
 
4 
 
32. Were you satisfied with the frequency of consultations?..... 
 
 
1 
 
2 
 
3 
 
4 
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Appendix 13: Clinical Information Form for Phase III Data Collection 
Patient Identifier: ___________________________________________________________ 
1. Date of Primary Rectal Cancer Operation ____/____/____ 
2. Neoadjuvant Treatment  
None ☐ Short Course Radiotherapy ☐  Chemoradiation☐ Chemotherapy 
☐ 
 
3. Operation Type 
Local Excision ☐  Anterior Resection  ☐ Abdominoperineal Resection  ☐  
Hartmann’s Procedure  ☐ Pelvic Exenteration  ☐ Other ☐ _____________ 
4. Histology – Primary Cancer  
4.1. TNM Staging ______________ 
4.2. Dukes Classification _________ 
4.3. Margin Status ______________ 
 
5. Mode of detection of local recurrence 
Symptomatic  ☐  Surveillance  ☐ 
6. Date of diagnosis of Local Recurrence ___/___/___ 
7. Pattern of Local Recurrence  
Anterior ☐ Central ☐ Posterior ☐ Lateral ☐ 
8. Presence of Concurrent Metastatic Disease  
8.1.  Yes ☐ No ☐ 
8.2. Number of Sites of Metastatic Disease 
1  ☐ 2  ☐ 3  ☐ 4  ☐ 
8.3. Location of Metastatic Disease 
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Lung ☐ Liver ☐ Cerebral ☐ Bone☐ Other ☐ ___________________ 
9. Treatment Intent of Local Recurrence 
Curative ☐  Palliative  ☐ 
10. If palliative intent, what is the treatment plan? 
Palliative Chemotherapy ☐ Palliative Chemoradiation  ☐       
Palliative Radiotherapy ☐ Best Supportive Care ☐ 
11. If curative intent what is the treatment plan? 
11.1. Pre-operative treatment  
None  ☐ Short Course Radiotherapy ☐  Chemoradiation ☐ Chemotherapy ☐ 
12. Date of operation of LRRC ___/___/___ 
13. Operation Type _____________________________________________________ 
14. Margin Status ______________________________________________________ 
15. Post-operative Treatments  
None☐ Short Course Radiotherapy ☐  Chemoradiation ☐ Chemotherapy ☐ 
16. Current Status 
Disease Free  ☐   Local re-recurrence  ☐ Distant Metastases  
 
 
 
 
 
 
 
